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The urinary tract is lined by a barrier-forming, mitotically-quiescent urothelium, 
which retains the ability to regenerate following injury. Regulation of tissue 
homeostasis by Hippo and Sonic Hedgehog signalling has previously been 
implicated in various mammalian epithelia, but limited evidence exists as to their 
role in adult human urothelial physiology. Focussing on the Hippo pathway, the 
aims of this thesis were to characterise expression of said pathways in urothelium, 
determine what role the pathways have in regulating urothelial phenotype, and 
investigate whether the pathways are implicated in muscle-invasive bladder cancer 
(MIBC). These aims were assessed using a cell culture paradigm of Normal Human 
Urothelial (NHU) cells that can be manipulated in vitro to represent different 
differentiated phenotypes, alongside MIBC cell lines and The Cancer Genome Atlas 
resource. 
Transcriptomic analysis of NHU cells identified a significant induction of VGLL1, a 
poorly understood regulator of Hippo signalling, in differentiated cells. Activation of 
upstream transcription factors PPARγ and GATA3 and/or blockade of active 
EGFR/RAS/RAF/MEK/ERK signalling were identified as mechanisms which induce 
VGLL1 expression in NHU cells. Ectopic overexpression of VGLL1 in undifferentiated 
NHU cells and MIBC cell line T24 resulted in significantly reduced proliferation. 
Conversely, knockdown of VGLL1 in differentiated NHU cells significantly reduced 
barrier tightness in an unwounded state, while inhibiting regeneration and 
increasing cell cycle activation in scratch-wounded cultures. A signalling pathway 
previously observed to be inhibited by VGLL1 function, YAP/TAZ, was unaffected by 
VGLL1 manipulation. In MIBC, overexpression of VGLL1 was observed in a subset of 
differentiated tumours associated with significantly reduced survival, indicative of 
dysregulated VGLL1 function. 
This study reveals a novel Hippo pathway-independent function of VGLL1, with the 
protein observed to play an important role in regulating urothelial tissue 
homeostasis. Consequently, these findings contribute to the current understanding 
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1.1 The urinary system 
The mammalian urinary tract is a contiguous system consisting of two kidneys, two 
ureters, a bladder and urethra (Figure 1.1). Urine is produced in the kidneys 
through the process of glomerular filtration, where excess water and waste product 
(urea) is filtered from circulating blood. This is subsequently transported from the 
kidneys to the bladder (via the renal pelvis and ureters) through peristaltic 
contractions (reviewed by Hickling et al., 2015). The physiological function of the 
bladder is to store urine at low pressure until the point of voiding (secretion of 
urine through the urethra; reviewed by Elbadawi, 1996).  
Figure 1.1: Diagram of the male mammalian urinary system 




The regions of the urinary tract ranging from the renal pelvis to the proximal 
urethra are lined by a unique epithelial tissue known as the urothelium. This is 
separated from the underlying connective tissue of the lamina propria by a laminin 
and collagen-based basement membrane. The lamina propria is vascularised and 
innervated, while also containing stromal cell types such as smooth muscle cells 
and the extracellular matrix (ECM)-producing fibroblasts (Dixon et al., 1983). The 
lamina propria is surrounded by smooth muscle bundles which orchestrate the flow 
of urine through each section of the system (Fig. 1.2). Despite the urothelium of 
each organ being highly similar to one another morphologically, the bladder and 
ureters are in fact derived from different embryological derivations, with the 
bladder arising from the urogenital sinus (endoderm) while the ureters arise from 
the intermediate mesoderm (Saxén et al., 1987; Baskin et al., 1996). 
Figure 1.2: Cross section of human ureter 
Haematoxylin & eosin stained tissue section of a normal ureter, with the location of the 
morphologically distinct tissue layers (the fibrous connective adventitia, smooth muscle, 
lamina propria and urothelium) labelled. Scale bar = 500 µm. 
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1.2 Urothelium  
1.2.1 Urothelial morphology and function 
The urothelium is a transitional epithelium, denoting that it is a stratified 
epithelium which contains characteristics of both simple columnar and stratified 
squamous epithelia. Human urothelium is typically composed of between 3-6 layers 
of cells, with a layer of cuboidal basal cells anchored to the basement membrane 
separated from the lumen-facing superficial cells by a variable amount of 
intermediate cell layers (Fig. 1.3; Jost et al., 1989). The superficial (or “umbrella”) 
cells are larger than the underlying basal cells and are often bi-nucleate (reviewed 
by Hicks, 1975). Superficial cells reside in the most highly specialised cell zone of the 
urothelium and express rigid plaques on their luminal surface known as the 
asymmetric unit membrane (AUM; Hicks, 1965). Production of AUM and expression 
of specific tight junction proteins by superficial urothelial cells result in the 
constitution of the tightest barrier created by any known mammalian epithelium, as 
measured by transepithelial electrical resistance (TEER; Negrete et al., 1996). The 
para-cellular and trans-cellular barriers created by tight junction proteins and AUM, 
respectively, thus grant urothelia the ability to provide a permeability barrier 
against the reabsorption of urinary-excreted toxins and are therefore vital for 

























The human urothelium does not contain a resident lymphocyte population (Jost et 
al., 1989), nor does it regularly participate in mitosis under normal conditions. 
Initial studies into the mitotic turnover of the urothelium in mice and rats found the 
tissue to have a mitotic index of <1% (Messier et al., 1960; Walker, 1960). Later 
molecular studies demonstrated widespread expression of cell cycle-associated 
Ki67 in the basal and intermediate cells of rat urothelium (Chopra et al., 2008) but a 
labelling index of S-phase marker BrdU <1% (Dominick et al., 2006), indicative of a 
non-proliferating tissue. In comparison, a near absence of Ki67 positivity has been 
observed in multiple studies of human urothelium, thus confirming the human 
urothelium to be a mitotically quiescent tissue (Varley et al., 2005; Chopra et al., 
2008). Despite this characteristic, the adult mammalian urothelium retains a 
formidable capacity for regenerative proliferation following injury-induced stress. 
Damage to rodent urothelium by chemical insult was found to result in the 
Figure 1.3: Haematoxylin stain of normal human bladder urothelium 
Large, AUM-expressing superficial urothelial cells border the bladder lumen, 
situated above variable layers of intermediate cells and a single layer of basal cells 
attached to a basement membrane (with approximate localisation highlighted with 
a black dotted line). Basal cells are separated by the basement membrane from a 
lamina propria containing stromal cells attached to an ECM. Histology image 
courtesy of Dr. Jennifer Hinley. Scale bar = 20 µm. 
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Figure 1.4: The regenerative phenotype of the urothelium 
The urothelium is notable for its ability to rapidly proliferate and repair itself following 
physical, chemical or bacterial injury. An inability to completely repair damaged 
urothelium compromises barrier function and is indicative of chronic conditions such as 
interstitial cystitis (Southgate et al., 2007). Unrestrained regeneration results in an 
inactivation of quiescence, urothelial hyperplasia and potentially tumorigenesis. 
Diagram adapted from review by Balsara et al., 2017. 
activation of mitosis in all cell layers (Levi et al., 1969) and a rapid recovery of 
barrier function (Lavelle et al., 2002). This observed switch between a mitotically 
quiescent (but proliferation capable) and an actively regenerating state forms the 
primary tenet behind urothelial tissue homeostasis; and as such needs to be tightly 















1.2.2 Molecular markers of urothelial cells in situ 
The cell layers of the urothelium have been shown to express different protein 
markers which correspond to their state of differentiation within the tissue 
(reviewed by DeGraff et al. 2013). AUM produced at the apical surface of superficial 
cells is composed of integral membrane proteins known as uroplakins. First 
discovered in bovine urothelium (Wu et al., 1990), it was subsequently determined 
uroplakin proteins UPK1a, UPK1b, UPK2 and homologues UPK3a/UPK3b are 
expressed in humans. Uroplakin proteins are expressed exclusively by superficial 
cells with the exception of UPK1b which has also been found in some intermediate 
cell layers (Lobban et al., 1998). Due to their unique status as being expressed only 
by superficial urothelial cells, expression of UPK1a, UPK2 and UPK3a/b are 
considered to be markers of a highly differentiated, mature urothelium. The 
importance of uroplakin expression to urothelial phenotype is supported by gene 
knockdown studies in mice that demonstrate that loss of UPK3A is responsible for a 
significant elevation in bladder permeability (Hu et al., 2002) while knockdown of 
UPK2 resulted in mice with proliferating urothelium (Kong et al., 2004).  
Alongside uroplakins, components of intercellular tight junctions are also important 
in maintaining urothelial barrier integrity. Tight junctions act  to limit paracellular 
movement of water and solutes and are located at the interface of adjacent 
epithelial cells. The multi-protein complexes are primarily composed of zonular 
occludens (ZO) and tetra membrane-spanning proteins such as occludin and 
members of the claudin family. ZO proteins were determined to play a role in 
stabilising and crosslinking the tight junction proteins to the actin cytoskeleton 
(Fanning et al., 1998), while claudins are the fibrils which provide the principle 
physical seal (Furuse et al., 1998). Multiple tight junction proteins have been 
confirmed histologically to be expressed by human urothelium, including claudin 3, 
claudin 4, claudin 5, claudin 7, ZO-1 and its alternatively spliced variant ZO-1α+ 
(Varley et al., 2006; Smith et al., 2015).  
The urothelium also expresses a number of cytokeratins (CKs), a family of twenty 
cytoskeletal intermediate filament isotypes which are expressed by most epithelial 
cell types. Distribution of CK expression in urothelium is dependent on the cell zone 
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the cell inhabits, with alterations in the level of stratification or differentiation of 
the tissue resulting in atypical expression patterns (reviewed by Southgate et al., 
1999). For example, in normal urothelium CK5 and CK17 are examples of proteins 
that are localised to basal urothelial cells only, while CK20 is localised exclusively to 
superficial cells (Schaafsma et al., 1989; Moll et al., 1992). In comparison, CK13 
localises to both basal and intermediate cell zones, while CK7, CK8, CK18 and CK19 
are expressed abundantly in all layers of the urothelium (Moll et al., 1988). Changes 
in the normal pattern of CK expression in urothelium is a common diagnostic 
marker of high-grade malignancy (Moll et al., 1988; Schaafsma et al., 1990).  
1.3 Normal Human Urothelial (NHU) cells in vitro 
1.3.1 NHU cell phenotype 
One method for investigating human urothelial cell physiology in vitro was achieved 
by separating urothelial cell sheets from the underlying stroma and growing the 
isolated cells in culture as non-immortalised, finite cell lines (Southgate et al., 
1994). When cultured in low calcium (0.09 mM), serum-free medium environment, 
Normal Human Urothelial (NHU) cells adopt a sub-basal phenotype that lacks the 
expression of differentiated urothelial markers such as CK20. Instead, NHU cells 
express CK14 and CK16, markers of squamous metaplasia not typically found in 
native urothelium but are upregulated in bladder cancer (Southgate et al., 1994; 
Harnden et al., 1997). In comparison to urothelium in situ, NHU cells are highly 
proliferative and grow as a dispersed monolayer; with the majority of cells 
expressing nuclear Ki67 antigen and exhibiting an average doubling time of around 
15 hours (Southgate et al., 1994, 2002).  
NHU cultures do not require exogenous epidermal growth factor (EGF) to 
proliferate or survive, but in fact were found to produce their own amphiregulin 
ligand which powers cell proliferation through an autocrine EGF receptor (EGFR) 
loop. Autocrine activation of EGFR was found to subsequently instigate cell cycle 
progression through the activation of downstream RAS/RAF/MEK/ERK signalling via 
a protein phosphorylation cascade (Varley et al., 2005). The importance of this 
pathway to NHU cell proliferation was highlighted following treatment of NHU 
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cultures with EGFR receptor tyrosine kinase (RTK) inhibitor PD153035 or mitogen-
activated protein kinase kinase (MEK1/2) inhibitor UO126, which were found to 
completely curtail cell growth and cause G1 arrest (Varley et al., 2005). NHU cells 
treated with PD153035 or U0126 were able to reactivate phosphorylated 
extracellular signal-regulated kinase (ERK1/2) and regain a proliferative phenotype 
once said inhibitors were removed from the growth medium, demonstrating that 
urothelial cells retain a degree of plasticity to switch between a quiescent and 
regenerative state in culture (MacLaine et al., 2008).  
1.3.2 NHU cytodifferentiation  
1.3.2.1 Induction of cytodifferentiation in vitro 
When cultured NHU cells were seeded onto de-epithelialised urothelial stroma, the 
cells regained their stratified, transitional phenotype and inhibited proliferation 
(Scriven et al., 1997). This discovery indicated that NHU cells retained the capacity 
to re-differentiate when given the right signalling cues, even if the identity of the 
paracrine “differentiation-inducing“ molecules presumably released by the stroma 
was unknown. Later studies optimised two distinct methods to induce 
differentiation in NHU cells in an in vitro, stroma-free environment. One method 
involves pharmacologically inducing differentiation through activation of the 
nuclear receptor Peroxisome Proliferator-Activated Receptor γ (PPARγ; section 
1.3.2.2) with the thiazolidinedione PPARγ agonist troglitazone (TZ)  alongside 
concurrent blockade of autocrine EGFR signalling by PD153035 (Varley et al., 2004a; 
Varley et al., 2004b). In this “TZ/PD differentiated” state in vitro, NHU cultures have 
been shown to express multiple differentiation-associated targets, including various 
tight junction proteins and transcript expression of uroplakins UPK1B and UPK2 
(Varley et al., 2004a; Varley et al., 2006). However, differentiation via 
pharmacological means alone was unable to induce stratification of the NHU 
cultures (Varley et al., 2006). 
In contrast, earlier studies had demonstrated that the application of a high calcium 
medium to NHU cultures resulted in some evidence of stratification but was not 
sufficient to induce cytodifferentiation or functional barrier formation (Southgate et 
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al., 1994). By growing NHU cells in a physiologically relevant concentration of 
calcium in addition to the presence of serum, this was found to produce a fully 
stratified, barrier-forming, “biomimetic” urothelium (Cross et al., 2005). Evidence of 
the barrier forming potential of the serum-differentiated cells was provided 
through the measurement of the TEER of the tissue, with readings of >3000 Ω.cm2 
designating a significantly tighter barrier than the accepted >500 Ω.cm2 threshold 
for a “tight” epithelial barrier (Fromter et al., 1972; Cross et al., 2005). This 
differentiation method was similarly demonstrated to reverse the CK14-high/CK13-
low NHU phenotype alongside induction of claudin 1, claudin 3, claudin 4, occludin 
and ZO-1 in a similar localisation to that found in situ (Cross et al., 2005; Smith et 
al., 2015). The similarities in phenotype between differentiated NHU cells and 
native urothelium have therefore fostered the use of in vitro NHU cells as a robust 
and accurate proxy for predicting human urothelial biology in situ.  
1.3.2.2 PPARγ 
Functional differentiation of the highly specialised superficial cells is predicated on 
the activation of a complex and specific network of transcription factors that induce 
the mature phenotype (Varley et al., 2009; Fishwick et al., 2017). Initially implicated 
in the terminal differentiation of adipocyte cells (Rosen et al., 1999), multiple 
studies have since provided evidence for the role of PPARγ as a ‘master regulator’ 
of urothelial cytodifferentiation (Varley et al., 2004a; Varley et al., 2006; Varley et 
al., 2009). PPARγ is a member of the PPAR family of nuclear receptors that require 
ligand binding to activate function (Issemann et al., 1990), although the identity of 
the natural ligand to PPARγ in native human urothelium is currently undetermined. 
Studies by Stahlschmidt et al. initially proposed the lipid compound 15-deoxy-
Δ12,14-prostaglandin J2 (15d-PGJ2) as a potential natural ligand of PPARγ due to its 
previously defined presence in urine (Hirata et al., 1988). However, analysis of 
bladders from long term dialysis patients discovered that PPARγ was still expressed 
in the nuclei of urothelial cells, while addition of 15d-PGJ2 to NHU cells was unable 
to induce differentiation in vitro, suggestive of activation of the nuclear receptor by 
a PPARγ-specific ligand produced by the urothelium or other surrounding cell types 
(Stahlschmidt et al., 2005). Upon ligand activation PPARγ heterodimerises to a 
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different nuclear receptor, Retinoid X Receptor α (RXRα), in the nucleus. The active 
PPARγ complex can subsequently bind to specific PPAR Response Elements (PPRE) 
that are located in the promoter region of various genes to induce gene 
transcription (Kliewer et al., 1992).  
 
Active, phosphorylated ERK1/2 has previously been shown to inhibit PPARγ activity 
in HEK293T cells by phosphorylating the protein at its serine 82 site (Camp et al., 
1997). Active MEK1/2 signalling has also been demonstrated to bind directly to 
PPARγ in HEK293 cells and inhibit its function independently of ERK1/2 activity 
through export from the nucleus in HeLa cells (Burgermeister et al., 2007). This 
evidence suggests that the process of TZ/PD differentiation could work by activating 
dormant PPARγ in NHU cells while simultaneously blocking the activation of PPARγ 
inhibitors, thus amplifying the effects of cytodifferentiation in EGFR-blockaded cells. 
Treatment with the potent PPARγ antagonist T0070907 (T007) or genetic 
knockdown of PPARγ using small interfering RNA (siRNA) was found to abrogate the 
differentiation-inducing effect of TZ/PD in NHU cells, thereby confirming the 
specific role that PPARγ plays in the differentiation process (Varley et al., 2006).  
1.3.2.3 Other transcription factors involved in urothelial differentiation 
Investigation into the specific timeframe in which certain urothelial differentiation-
associated genes were induced determined that expression of the UPK2 gene took 
place several days after the onset of TZ/PD treatment in NHU cells. Additionally, no 
PPRE binding sites where found in or upstream of the promoter site of the UPK2 
gene, suggesting that activation of PPARγ was regulating or inducing the expression 
of one or multiple intermediary transcription factors that controlled late 
differentiation (Varley et al., 2004a). Studies in mice supported this hypothesis by 
identifying grainyhead-like protein 3 (GRHL3) and Kruppel-like transcription factor 5 
(KLF5) as two transcription factors which were important for murine urothelial 
differentiation (Yu et al., 2009; Bell et al., 2011). Primarily noted for its role in 
epidermal differentiation, GRHL3 was not only found to be vital for barrier 
formation in mouse urothelium, but it was also found to directly bind to the UPK2 
promoter in the RT4 bladder cancer cell line (Yu et al., 2009). Deletion of KLF5 was 
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found to induce incomplete stratification of the developing murine urothelium 
upon deletion, with corresponding losses of Pparg and Grhl3 transcript suggestive 
of the existence of a hierarchy of TFs that are all required in order to induce 
urothelial differentiation in mice (Bell et al., 2011). 
Gene microarray analysis of NHU cells treated with TZ/PD identified Forkhead Box 
A1 (FOXA1) and Interferon Regulatory Factor-1 (IRF-1) as transcription factors that 
were induced as early as 12h post treatment and were confirmed to possess high-
affinity PPRE sites in their respective promoter regions  (Varley et al., 2009). Foxa1 
had previously been implicated as an important transcription factor in the 
development of murine urothelium (Oottamasathien et al., 2007), with knockout of 
Foxa1 in female mice found to result in CK14-high squamous metaplasia (Reddy et 
al., 2015). The role of FOXA1 and IRF-1 in mediating the human urothelial mature 
differentiation phenotype was confirmed following siRNA knockdown of the 
respective transcription factors, as this resulted in reduced claudin 3 and CK13 
protein in addition to reduced UPK2 and UPK3a transcript expression in TZ/PD 
differentiated NHU cells (Varley et al., 2009).  
 
Zinc finger transcription factor GATA3 was an example of another gene found to be 
upregulated after TZ/PD treatment in a similar timeframe to FOXA1 and IRF-1 
(Varley et al., 2009). GATA3 can act upstream of FOXA1 (Kouros-Mehr et al., 2006), 
and due to their roles as “pioneer” transcription factors, both proteins are known 
to act by binding to areas of heterochromatin to access silenced genes (Cirillo et al., 
2002). A study in oestrogen receptor α+ breast cancer demonstrated that the two 
transcription factors bind to many of the same sites (Jiang et al., 2019), which was 
consistent with a study that used Formaldehyde-Assisted Isolation of Regulatory 
Elements coupled with next-generation sequencing (FAIREseq) to identify areas of 
open chromatin in NHU cells differentiated with TZ/PD for different periods of time. 
The resulting open chromatin regions identified by FAIRE-seq were found to be 
enriched by co-occurring FOXA1 and GATA3 transcription factor-binding site motifs 
in cells differentiated for either 24h or 144h (Fishwick et al., 2017). In comparison, 
enrichment of PPARγ transcription factor-binding site motifs were found only at the 
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24h time-point, strengthening the previous observation that PPARγ serves to 
initiate urothelial differentiation and not to directly control expression of late 
differentiation-associated genes. As with FOXA1, siRNA knockdown of GATA3 
resulted in a loss of CK13 protein and UPK2 transcript, although expression of 
FOXA1 was not affected (Fishwick et al., 2017). 
Analysis of gene microarray data of a different time course of NHU cells undergoing 
differentiation via both methods (TZ/PD and serum/Ca2+) separately  uncovered 
that ETS-related transcription factor 3 (ELF3) was the top ranking transcription 
factor that was significantly induced by both differentiation methods (Böck et al., 
2014). A transcription factor previously found to be lost in the urothelium of Klf5-
null mice (Bell et al., 2011), ELF3 expression was subsequently confirmed to be 
PPARγ-mediated in NHU cells, while also negatively affecting UPK3A expression and 
barrier function when knocked down by siRNA (Böck et al., 2014). This added to a 
body of evidence that suggests that in fact a heterarchy of transcription factors 
exists to modulate urothelial differentiation; with some defined directionality to the 
order in which the transcription factors operate (e.g. PPARγ as an instigating factor) 
but also cooperativity/redundancy between some intermediary factors to drive a 
differentiated phenotype (Fig. 1.5).  
One protein negatively affected by in vitro urothelial differentiation in NHU cells is 
p63, a transcription factor found to directly induce markers of a normal basal 
urothelial cell phenotype, such as KRT5, in tissues such as skin (Romano et al., 
2009). p63 has previously been suspected to mark a population of stem cell-like 
basal cells in developing mouse urothelium (Pignon et al., 2013), although this 
observation has yet to be validated in human urothelium, where it is primarily 
localised to the basal and intermediate cell zones (Fishwick et al., 2017). Analysis of 
p63 expression in NHU cells determined that the transcription factor was abundant 
in undifferentiated NHU cultures but reduced following TZ/PD differentiation. 
Expression of p63 could subsequently be recovered in differentiated cells with 
GATA3 knockdown (Fishwick et al., 2017). Increased expression of GATA3 and 
FOXA1 protein in p63 siRNA knockdown NHU cultures further points to an opposing 
relationship between induction of p63 targets and differentiation-associated 
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Figure 1.5: Previously proposed transcriptional network of PPARγ-mediated urothelial 
differentiation  
PPARγ is constitutively expressed in urothelial cells (Varley et al., 2004a), with KLF5 
expression vital to maintain expression in murine urothelium. Activation of PPARγ by 
TZ/PD induces the upregulation of intermediary transcription factors through binding of 
PPARγ to PPRE sites. Knockdown of ELF3 in NHU cells significantly inhibits GRHL3 and 
FOXA1 expression, suggesting that ELF3 lies upstream of these markers (Böck et al., 2014). 
Multiple days after the initiation of differentiation, a combination of the intermediary 
transcription factors are able to induce transcription of genes associated with late 




Figure 1.6: Mechanism of NHU cytodifferentiation 
In undifferentiated NHU cells, autocrine stimulation of EGFR activates the 
RAS/RAF/MEK/ERK signalling axis via a protein kinase phosphorylation cascade. Active 
phosphorylated ERK1/2 (Thr202/Tyr204) has been shown to be able to inactivate PPARγ 
activation through phosphorylation at Ser82. The RAS/RAF/MEK/ERK pathway is able to 
contribute to progression through the cell cycle by expression of Cyclin D1 and 
inactivation of retinoblastoma protein (RB; Weber et al., 1997). Tyrosine kinase 
inhibitor PD153035 binds to EGFR, blocks RAS/RAF/MEK/ERK activity and inhibits cell 
cycle progression. TZ binds to inactive nuclear PPARγ, which heterodimerises with RXRα 
and binds to PPRE sites in the DNA. Intermediary transcription factors such as ELF3, 
GATA3 and FOXA1 are expressed, which subsequently bind to their motifs in the DNA 
and induce expression of markers of late differentiation, including uroplakins and 
components of tight junctions. The basal marker p63 is expressed in NHU cells in an 
undifferentiated state but inhibited following cytodifferentiation, with expression of the 
TF appearing to be regulated by the induction of GATA3 (Fishwick et al., 2017). AR= 
amphiregulin; yellow circles = phosphorylation sites. 
45 
 
1.3.3 NHU cell growth regulation 
Despite a clear role for EGFR-mediated ERK1/2 activation in the proliferation of 
NHU cells (Section 1.3.2.1); other studies have demonstrated that the cells can 
employ alternative growth regulatory pathways (in both the presence and absence 
of ERK signalling) to power growth under certain physiological conditions. One 
example of this is the Phosphoinositide 3-Kinase (PI3K)/protein kinase B (PKB or 
AKT) pathway, which has been implicated as important in processes such as cell 
metabolism, growth and survival (Roche et al., 1994; Kauffmann-Zeh et al., 1997). 
In a similar fashion to PD153035 and U0126, the PI3K inhibitor LY294002 was 
demonstrated to initially inhibit undifferentiated NHU cell proliferation. However, 
the drug only succeeded in inhibiting cell growth of sub-confluent cultures 
transiently, with cultures eventually regaining similar growth rates to control 
despite repeat administrations of the drug (MacLaine et al., 2008). This delayed 
response points to a potential reprogramming of mitogenic signalling by NHU cells 
whereby the cells can switch to other pathways to propagate growth once 
PI3K/AKT signalling is compromised.  
PI3K/AKT signalling has been found to be strongly activated in cells that are in 
contact (Nelson et al., 2002) and have created cell-cell adherens junctions with one 
another, which can be achieved by cell confluence or addition of a physiological 
concentration of calcium to the medium. A primary component of adherens 
junctions is E-cadherin, a transmembrane glycoprotein that is dependent on 
calcium to create adhesion between adjacent cells but can also regulate growth 
signalling through modulation of RTK activity (Shapiro et al., 1995; Takahashi et al., 
1996). E-cadherin function is closely associated with β-catenin, a multifunctional 
protein that stabilises adherens junctions by binding to the cytoplasmic tail of E-
cadherin while also acting as a primary signal transducer of the WNT pathway 
(McCrea et al., 1991; Behrens et al., 1996). Investigation into the interplay between 
E-cadherin expression, PI3K/AKT and WNT signalling in NHU cells determined that 
in a high calcium environment, phosphorylated (active) AKT was induced in the 
nuclei of adhered cells concurrent to the translocation of E-cadherin and β-catenin 
from the cytoplasm and nucleus, respectively, to a intercellular localisation 
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(Georgopoulos et al., 2010). Treatment of NHU cells with LY294002 increased 
nuclear expression of β-catenin (Georgopoulos et al., 2014), while short hairpin 
RNA (shRNA) knockdown of β-catenin in NHU cells resulted in an induction of E-
cadherin and phosphorylated AKT expression (Georgopoulos et al., 2010). β-catenin 
knockdown cells were highly sensitive to PI3K/AKT inhibition and  displayed 
significantly reduced proliferation compared to control cells treated with LY294002 
in both low and high calcium (Georgopoulos et al., 2010), thereby supporting the 
existence of a mutually exclusive relationship between PI3K/AKT and β-catenin in 
supporting cell growth in urothelium. While their effect on undifferentiated NHU 
cell proliferation is well-defined, the role that PI3K/AKT and β-catenin signalling 
play in the maintenance of differentiated NHU tissue homeostasis (or their effect 






Figure 1.7 Convergence of signal transduction pathways to drive NHU cell proliferation 
The primary signal transduction molecules of the RAS/RAF/MEK/ERK, PI3K/AKT and 
WNT/β-catenin pathways are represented by teal, yellow and green rectangles, 
respectively. Natural extracellular pathway ligands are represented by red circles while 
pharmacological small molecule inhibitors of specific components of each pathway are 
represented by blue circles. For the purposes of the illustration, each pathway is 
represented in its activated “ON” state. PI3K can be activated through a range of 
mechanisms, including binding to activated tyrosine kinase residues on a RTK such as 
EGFR, or activation by RAS (Rodriguez-Viciana et al., 1997). PI3K catalyses the addition of 
a phosphate group to cell membrane-localised phospholipid component PIP2, generating 
PIP3. PIP3 has a high affinity for AKT, which translocates to the membrane, undergoes 
conformational changes and is activated by phosphorylation (Boudewijn et al., 1995). 
Similarly to ERK1/2, activated AKT can enter the nucleus and affect numerous cellular 
processes. In the absence of WNT ligands, β-catenin is an integral component of E-
cadherin-mediated adherens junctions. The remaining cytosolic β-catenin is targeted by 
co-ordinated phosphorylation by the destruction complex (APC, AXIN, GSK3β and CK1) 
which leads to eventual ubiquitination and proteasomal degradation (Aberle et al., 
1997). Binding of WNT ligands to the G protein-coupled receptor frizzled results in the 
transduction of signal to membranous dishevelled (DVL) in the presence of frizzled co-
receptor lipoprotein receptor-related protein (LRP) 5/6. AXIN binds to the cytoplasmic 
tail of LRP5/6 and is inactivated while DVL is phosphorylated and inactivates 
GSK3β/destruction complex activity (Li et al., 1999). β-catenin is free to translocate to 
the nucleus, where it can influence gene expression through binding to transcription 
factors TCF and LEF (Behrens et al., 1996). As demonstrated in previous studies, NHU 
cells utilise all three pathways, which all exhibit a degree of crosstalk between one 









An added layer of complexity arises following the reprogramming of dominant 
signal transduction pathways that occurs when urothelial cells become 
differentiated. Analysis of gene microarray data comparing undifferentiated versus 
TZ/PD differentiated NHU cultures determined that differentiated NHU cells had 
significant transcriptional alterations in the canonical TGFβ pathway, a signalling 
pathway with known roles in tissue repair and migration (Postlethwaite et al., 1987; 
Montesano et al., 1988). Analysis of TGFβ pathway activation in confluent NHU 
cultures following scratch wounding revealed that differentiated cells exhibited 
decelerated migration in the presence of TGFβ receptor I (TGFβRI) inhibitor 
SB431542, while treatment with exogenous TGFβ1 retarded undifferentiated cell 
migration (Fleming et al., 2012). Activation of endogenous TGFβ signalling in 
wounded differentiated NHU cells was manifested through the appearance of 
nuclear phosphorylated SMAD3 (canonical TGFβ pathway effector) in the cells 
immediately proximal to the wound edge, with a lack of Ki-67 positive cells 
indicative of a migratory, rather than proliferative, wound response (Fleming et al., 
2012). The results of the preceding study therefore suggested that differentiated 
urothelial cells utilise alternative signal transduction pathways to undifferentiated 
cells and by extension, highlights a possible alternative pathway that 












1.4 Bladder cancer 
1.4.1 Epidemiology 
Bladder cancer is the 10th most common cancer in the UK, accounting for 10,187 
new cases and 5,407 deaths per year based on the latest statistics (Cancer Research 
UK, 2019). Approximately 60% of new bladder cancer cases are observed in people 
aged 75 or over, with a higher incidence observed in men but an average survival 
rate of 10 years or longer for both genders currently at 50% (Cancer Research UK, 
2019). Although the incidence rates of bladder cancer have decreased year-on-year 
in the Western world, the mortality rate remains relatively stable (Siegel et al., 
2019). Prior to approval of anti-PD-L1 immune checkpoint blockade therapy in cases 
of advanced bladder cancer (Rosenberg et al., 2016), little progress had been made 
in recent history in producing a treatment for bladder cancer beyond cisplatin-
based chemotherapy (Yagoda, 1979), intravesical administration of the Bacillus 
Calmette-Guérin (BCG) vaccine (Morales et al., 1976) or radical cystectomy 
(Marshall et al., 1949). 
1.4.2 Pathology 
Bladder cancer is caused by a variety of environmental factors, most notably 
smoking and occupational exposure to carcinogenic materials (Jiang et al., 2012; 
Kogevinas et al., 2003). Urothelial carcinomas make up 90% of all bladder cancers, 
with squamous cell carcinoma and adenocarcinoma accounting for two rarer forms 
of the disease (reviewed by Dahm et al., 2003). Cases of urothelial carcinoma, the 
vast majority of which originate in the bladder, can progress through one of two 
routes. 80% of total cases are hyperplastic superficial papillary tumours of a non-
muscle invasive (NMIBC) nature. NMIBC is rarely life-threatening, but it is one of 
the most costly cancers to treat on average (Riley et al., 1995) and is highly 
recurrent, with up to 70% of patients found to experience a recurrence after 5 
years (Chamie et al., 2013). 20-30% of recurrent NMIBC tumours are found to 
progress to a higher stage/grade, with 10% progressing to Muscle-Invasive Bladder 
Cancers (MIBC). Only 15% of all MIBC patients are assumed to progress from NMIBC 
however, with the remaining 85% progressing through a non-papillary route where 
urothelial cells first exhibit carcinoma in situ (CIS), a more aggressive, flat superficial 
50 
 
lesion (Schrier et al., 2004). While NMIBC is usually managed by transurethral 
resection and/or intravesical chemotherapy, MIBC is harder to treat and is 
associated with a poor survival rate (reviewed by Pang et al., 2019). 
As with other epithelial malignancies, urothelial carcinoma is a highly 
heterogeneous disease at the molecular level. MIBC was calculated to have one of 
the highest somatic mutational burdens of all human cancers, behind only non-
small cell lung cancer and melanoma (Lawrence et al., 2013). Mutational analysis of 
MIBC in humans found that the most mutated gene was the TP53 tumour 
suppressor in 49% of cases (The Cancer Genome Atlas Research Network, 2014), 
while the most frequently altered genes in NMIBC were the TERT promoter (73%), 
fibroblast growth factor receptor 3 gene (FGFR3; 49%) and the PI3K gene (PI3KCA; 
26%) (Pietzak et al., 2017).  
The genetic diversity displayed by MIBC tumours offers a potential rationale as to 
why traditional chemotherapeutic treatments have been ineffective in a large 
percentage of bladder cancer patients. A primary goal of bladder cancer 
researchers over the past twenty years has therefore been to identify 
transcriptional differences between MIBC samples. The transcriptional and 
mutational signatures of tumours could be used to subgroup MIBC (independent of 
pathologic stage) into clinically relevant subtypes based on expression of specific 
genes, with the goal of highlighting potential candidate proteins which could be 










1.4.3 Molecular subtyping of muscle-invasive bladder cancer 
The first study to demonstrate the use of gene microarrays to distinguish between 
different molecular subtypes of an epithelial malignancy was undertaken by Perou 
et al., who compared the gene expression patterns from 65 breast tumours and 
identified the genes with the highest variation in expression. Unsupervised 
hierarchical clustering was then used to group genes and tumours based on their 
similarity of expression, thereby creating four clusters of breast tumours with 
distinct gene expression profiles (Perou et al., 2000). Of these clusters, two were 
classified as “luminal” and “basal” due to their molecular similarities to the two 
types of epithelial cell found in normal mammary epithelium: luminal and basal. 
Similarly to the cells of the urothelium, luminal and basal mammary epithelial cells 
have distinct expression profiles based on their level of differentiation, with basal 
cells expressing CK5 and luminal cells expressing CK8/CK18 (Perou et al., 2000).  
This study inspired a similar application of gene microarrays to samples of bladder 
cancer, which was initially used to delineate non-recurring from frequently 
recurring cases of NMIBC whilst confirming that NMIBC and MIBC have two distinct 
patterns of expression (Blaveri et al., 2005; Dyrskjøt et al., 2003).  Numerous 
studies since have attempted to create a definitive molecular taxonomy of MIBC 
based on cohorts of tumours analysed by RNA sequencing (RNAseq), with each 
approach (and cohort) providing a similar outcome (Sjödahl et al., 2012; Choi et al., 
2014a; Damrauer et al., 2014; The Cancer Genome Atlas Research Network, 2014; 
Robertson et al., 2017; Marzouka et al., 2018; Kamoun et al., 2020).  
Whole genome mRNA expression profiling of 73 MIBC samples from the MD 
Anderson Cancer cohort revealed three distinct molecular subtypes: luminal, basal 
and ‘p53-like’. Interestingly, the luminal and basal subtypes expressed many of the 
same targets as the corresponding breast cancer subtypes, while there was a 
significant difference in disease-specific survival between luminal and basal cancers 
(Choi et al., 2014a). A comprehensive study of analysis of 131 MIBC tumours by The 
Cancer Genome Atlas (TCGA) determined that their dataset could be split into four 
clusters by splitting luminal tumours based on FGFR3 expression (The Cancer 
Genome Atlas Research Network, 2014). A later TCGA study further discriminated 
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between subtypes by creating a ‘neuronal’ classification based on neuroendocrine-
like features to give five expression subtypes (Robertson et al., 2017). The most 
recent consensus taxonomy has expanded MIBC into six distinct groups with 
identifiable gene expression profiles: Luminal Papillary (LumP), Luminal Non-
Specified (LumNS), Luminal Unstable (LumU), Basal/Squamous (Ba/Sq), 
Neuroendocrine-like (NE-like) and Stroma-rich (Kamoun et al., 2020; Table 1.1). A 
demonstration of how transcriptional subtyping of MIBC could be clinically 
beneficial was performed by using unsupervised hierarchical clustering to identify 
luminal/basal gene markers that could also be labelled in fixed tissue samples using 
immunohistochemical techniques. Immunohistochemical analysis of protein 
markers in MIBC samples demonstrated that GATA3 and KRT5/6 (genes identified 
as being associated to luminal and basal MIBC, respectively) expression could be 
used to differentiate between luminal and basal subtypes of MIBC with over 90% 
accuracy (Dadhania et al., 2016). 
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 LumP LumNS LumU Ba/Sq NE-like Stroma-rich 
Common copy number 
alterations of oncogenes/ 
tumour suppressor genes  



















Common mutations  


















Stromal cell infiltration (cell 
type) 
N/A Fibroblasts Fibroblasts Fibroblasts N/A Extensive smooth muscle 
and fibroblast infiltration 
Immune cell infiltration (cell 
type) 
N/A N/A N/A CD8 T cells; NK cells N/A B cells 
Median overall survival (years) 4 1.8 2.9 1.2 1 3.8 
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Table 1.1: Consensus MIBC subtypes 
Summary of core features inherent to each MIBC subtype according to the latest consensus 
classifications. Table and accompanying data on copy number alterations, mutation rates 
and evidence of stromal and immune cell infiltration in each tumour subtype was adapted 






























1.4.4 Molecular targets in muscle invasive bladder cancer 
Overexpression of EGFR is one of the hallmarks of basal/squamous tumours, a 
subset with one of the worst survival rates in MIBC (Kamoun et al., 2020). Basal 
tumours were found to exhibit a  higher proportion of tumours with EGFR copy 
number amplifications compared to non-basal MIBC, while basal/squamous-like cell 
lines were found to be sensitive to treatment with the EGFR inhibitor Erlotinib, 
highlighting the marker as a potential drug target in basal/squamous MIBC 
(Rebouissou et al., 2014). Despite being a feature of normal urothelium, high 
expression of TP63 in tumours was associated with an adverse overall survival  
(Choi et al., 2012) and exhibited an enriched gene signature in EGFR-high basal 
tumours, with six of the top ten most upregulated genes in basal tumours found to 
be direct targets of p63 isoform ΔNp63α (Choi et al., 2014a). EGFR expression was 
low in luminal MIBC and NMIBC tumours, where instead increased expression of 
fellow EGFR RTK family members ERBB2 and ERBB3 was observed; (Choi et al., 
2014a; Dadhania et al., 2016) perhaps indicative of the switch from an EGFR to a 
ERBB2/ERBB3 expressing phenotype found in NHU cells upon onset of quiescence 
(Varley et al., 2005). ERBB2 and ERBB3 were mutated in 12% and 10% of MIBC 
cases, respectively, while mutations in ERBB2 were found in a mutually exclusive 
pattern with FGFR3 mutations in NMIBC, with ERBB2 mutations only associated 
with higher grade tumours (Pietzak et al., 2017; Robertson et al., 2017).  
FGFR3 (encoding Fibroblast Growth Factor Receptor Protein 3) is one of the most 
frequently mutated genes in bladder cancer, with activating mutations found in 
48.6% of NMIBC and 40% of luminal papillary MIBC tumours, primarily located at 
mutational hotpots S249C and Y373C (Bernard-Pierrot et al., 2006; Tomlinson et al., 
2007; Pietzak et al., 2017; Robertson et al., 2017; Kamoun et al., 2020). The most 
common gene-gene fusion event in MIBC is that of the intrachromosomal 
translocation of FGFR3 fused to transforming acidic coiled-coil-containing protein 3 
(TACC3), leading to constitutive activation of the kinase domain of FGFR3 
(Robertson et al., 2017; The Cancer Genome Atlas Research Network, 2014). In its 
role as a RTK, FGFR3 is expressed by normal urothelium and is speculated to bind to 
FGF ligands produced by the stroma to modulate differentiation (Tomlinson et al., 
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2005), although the identity of the specific ligand FGFR3 binds to in this context is 
currently undetermined. Previous studies have confirmed the ability of NHU cells to 
express FGFR3 transcript and protein under certain physiological conditions, with 
the primary isoform of the protein expressed being FGFR3b (Tomlinson et al., 2005; 
Williams et al., 2013). However, no study has yet elucidated what signalling 
pathways are required to induce FGFR3 expression in NHU cells, nor have described 
the effect of its expression on normal human urothelial phenotype.  
Initial studies into the characterisation of PPARγ incidence in bladder cancer 
determined that expression of the nuclear receptor was inhibited in high-grade 
MIBC samples, suggesting that loss of PPARγ is an important step in MIBC 
progression (Nakashiro et al., 2001). Independent component analysis of 198 MIBC 
tumours found that high expression of PPARG is associated with the luminal 
phenotype, with PPARγ-overexpressing tumours displaying an oncogenic addiction 
which affected viability upon PPARγ inhibition (Biton et al., 2014). This observation 
is supported by meta-analysis of MIBC cohorts performed by other groups (Choi et 
al., 2014a; Dadhania et al., 2016; Damrauer et al., 2014; Rebouissou et al., 2014; 
Robertson et al., 2017). FOXA1 and GATA3 have been speculated to help drive the 
luminal MIBC phenotype (Warrick et al., 2016), suggesting that PPARγ could control 
the expression of several genes in luminal tumours via the same mechanisms 
present in normal, differentiated urothelium. Indeed, siRNA knockdown of PPARγ in 
the SD48 cell line resulted in a significant deregulation of 198 genes, including 18 
genes with known associations to urothelial differentiation (Biton et al., 2014).  
 
While its mutation rate in NMIBC is relatively low, heterodimer partner RXRα was 
found to experience recurrent gain of function mutations in luminal MIBC tumours 
that resulted in ligand-independent activation of PPARγ (Halstead et al., 2017; 
Rochel et al., 2019).  Luminal-associated overexpression of PPARγ has also been 
attributed to gain-of-function mutational hotspots in PPARγ that were found in 
residues at the PPARγ/RXRα binding interface and was predicted to affect 




Downstream targets of PPARγ activation have similarly been implicated in the 
maintenance of a luminal MIBC phenotype. FOXA1 is mutated in 5% of MIBC, with 
loss of the TF typically associated with high grade MIBC (DeGraff et al., 2012; The 
Cancer Genome Atlas Research Network, 2014). GATA3, like FOXA1, is a commonly 
used marker of luminal MIBC (Dadhania et al., 2016; Robertson et al., 2017). 
Expression of the protein was decreased in cases of high-grade MIBC when 
compared to matched non-neoplastic urothelium, where it was expressed in 98% of 
samples (Miyamoto et al., 2012). Histologically, GATA3 expression in cases of MIBC 
was correlated to CK20 expression but negatively correlated with Ki67 positivity 
(Wang et al., 2019). Found in 12% of MIBC cases, ELF3 is one of the most commonly 
mutated genes in MIBC (Dadhania et al., 2016). ELF3 mutations were significantly 
enriched in the luminal non-specified group, with 35% of tumours harbouring a 
mutation. Tumours with ELF3 mutations were commonly found in tumours with 
altered PPARG expression, with 76% of luminal non-specified tumours carrying 
PPARG amplifications or gene fusions (Kamoun et al., 2020). ELF3 mutational sites 
in luminal tumours were found to be particularly enriched in the DNA binding ETS 
domain site, with 20 out of the 22 mutations screened in this domain determined 
to be luminal tumours (Dadhania et al., 2016).  
 
The preceding observations therefore suggest that the mechanisms of PPARγ-
mediated urothelial differentiation are present in a subset of MIBC, yet important 
transcription factors in this process are often mutated and therefore exhibit 
aberrant function in comparison to normal urothelium. Loss of the PPARγ-regulated 
transcriptional machinery is a marker of highly aggressive, EGFR-overexpressing 
basal/squamous MIBC, a disease state which is associated with a low survival rate. 
A greater understanding of the mechanistic relationship between differentiation-
promoting factors and a re-activation of proliferative pathways in normal 
urothelium may thus aid attempts to produce specific therapeutic treatments for 
subsets of MIBC based on molecular profiling.  A summary of studies that have 
investigated the phenotype of commonly mutated markers of luminal and basal 
MIBC in MIBC cell lines in vitro is collated in Table 1.2. 
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Marker Luminal-like MIBC cell lines Basal/squamous-like MIBC cell lines Other MIBC cell lines 
EGFR RT4 and UM-UC-9 cells resistant to Erlotinib treatment 
(Rebouissou et al., 2014). 
Erlotinib significantly reduced 5637 and ScaBer cell growth 
(Rebouissou et al., 2014). 
 
p63 Treatment of UM-UC-9 cells with PPARγ agonist 
rosiglitazone induced expression of PPARγ targets 
while inhibiting p63 target genes (Choi et al., 2014a). 
shRNA knockdown of p63 in UM-UC-14 cells resulted in 
increased expression of FOXA1, UPK1A, UPK2, ERBB2 and 
ERBB3 (Choi et al., 2014a). 
 
FGFR3 RT4 and RT112 cell lines considered to be 'FGFR3-
driven', due to expression of activating oncogenic 
FGFR3 gene fusion proteins (Williams et al. 2013). 
These FGFR3-dependent cell lines display lower 
genomic instability and share similarities to the NMIBC 
phenotype when compared to other MIBC lines (Earl 
et al., 2015). 
  
PPARγ RT4 cells harbour an activating mutation in the PPARG 
gene, with siRNA depletion of the gene reducing 
viability in said cells (Rochel et al., 2019). 
5637 cells have low, wild-type expression of PPARG 
(Rochel et al., 2019). 
 
FOXA1 shRNA knockdown of FOXA1 in FOXA1-high RT4 cells 
resulted in increased proliferation and decreased E-
cadherin expression (DeGraff et al., 2012). 
5637 cells were FOXA1-negative (DeGraff et al., 2012). FOXA1 overexpression in T24 cells 
resulted in decreased proliferation and 
invasiveness (DeGraff et al., 2012). 
GATA3  shRNA knockdown of GATA3 in 5637 cells results in 
significantly increased migration and invasion. GATA3 
overexpression in GATA3-negative UM-UC-3 cell line 
resulted in decreased migration and invasion, attributed 
to a decrease in N-cadherin and MMP2/MMP9 expression 
(Li et al., 2014). 
 
ELF3 High ELF3 expression observed in RT112 cells (Gondkar 
et al., 2019). 
Overexpression of ELF3 reduced N-cadherin expression 
and cell invasiveness in UM-UC-3 cells (Gondkar et al., 
2019). 
Overexpression of ELF3 inhibitory 
lncRNA ELF3-AS1 in T24 cells contributed 
to increased viability and invasiveness of 
the cell line (Guo et al., 2019). 
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Table 1.2: Summary of studies investigating commonly mutated MIBC markers in MIBC 
cell lines   
Studies were separated based on whether the cell line(s) exhibited a luminal-like or basal-
like MIBC phenotype. The high-grade MIBC cell line T24 exhibit neither luminal nor basal 
































1.5 Thesis aims 
Exploiting the reversible phenotypic shifts that NHU cells can undertake between 
proliferation, differentiation and regeneration has resulted in the discovery of 
PPARγ as a master regulator of urothelial differentiation, whilst determining that 
transcription factors downstream of PPARγ such as FOXA1, GATA3 and ELF3 are 
also important in this process. Context-dependent expression of these transcription 
factors highlights the sensitive balance of tissue homeostasis in the urothelium, and 
studying this plasticity in NHU cells has previously been demonstrated to provide 
insight into the events that accompany urothelial tumorigenesis and progression to 
an invasive phenotype. Stratification of MIBC into subtypes based on their 
transcriptomic signature has so far provided a limited clinical benefit to patients 
through a lack of successful drug treatments based on molecular targets. In order to 
improve treatment of MIBC, a more focussed elucidation of how various signalling 
pathways could moderate cancer progression in different subtypes of MIBC is 
therefore required.  
This study highlights two candidate signalling pathways that were hypothesised to 
modulate urothelial tissue homeostasis and potentially interact with the previously 
identified signalling machinery that regulate urothelial phenotype: the Hippo and 
Sonic Hedgehog (SHH) pathways. The role of the SHH pathway in proliferation, 
regeneration and intercellular paracrine signalling between urothelial and stromal 
cells in foetal human and adult murine bladder is well established, but its role in 
adult human urothelium is not understood. Conversely, Hippo pathway signalling 
has not been studied in mammalian urothelium, but studies in other organ types 
implicate the pathway in the maintenance of tissue homeostasis. The aim of this 
thesis was therefore to utilise well-characterised in vitro systems (alongside 
transcriptomic analysis of normal and malignant bladder tissue) to understand how 
these two pathways affect urothelial physiology through their influence on 





The role that Hippo and SHH pathway signalling plays in urothelial phenotype was 
investigated by meeting the following three key objectives: 
 Using a combination of in-house and publically available RNAseq datasets to 
characterise transcript expression of Hippo and SHH pathway components 
in normal urothelium (in situ and in vitro NHU cells) and bladder cancer 
(MIBC tumours and cell lines; Chapter 3, 4 & 5). 
 
 Investigating what function Hippo pathway signalling plays in the onset of 
urothelial cytodifferentiation, the maintenance of tissue homeostasis and 
regulation of urothelial cell propagation in NHU cells (Chapter 3) and 
bladder cancer cell lines (Chapter 4). 
 
 
 Determining whether a SHH-mediated paracrine signalling loop between 
human urothelium and the underlying stroma exists, can be reconstituted in 


















2. Materials and methods 
2.1 General 
Practical work for this project was primarily undertaken at the Jack Birch Unit of 
Molecular Carcinogenesis, Department of Biology, University of York. Selected 
experiments were performed at the Technology Facility, Department of Biology, 
University of York or St. James’s University Hospital, University of Leeds. Details of 
suppliers of reagents used in this study can be found in Appendix i. 
 
2.2 H2O  
Recipes of stock buffers are detailed in Appendix ii. All water used in experiments 
and to make up stock solutions and buffers was purified using an ultrapure water 
deionisation unit (SUEZ Water). SUEZ-purified water (dH2O) and buffers used for 
tissue culture purposes were autoclaved (121 oC for 20 minutes) prior to use.  
To produce water that was nuclease-free (and therefore suitable for molecular 
biology-based experiments), dH2O was treated with diethylpyrocarbonate (DEPC) to 
a final concentration of 0.1%. DEPC-treated dH2O was subsequently autoclaved (as 
above) prior to use. 
 
2.3 Ethical approval 
NHS Research Ethics Committee and the University of York Biology Ethics 
Committee approved collection and use of discarded samples of human urothelial 
tissue. Tissue was sought from patients with no previous history of urological 
neoplasia, with informed consent obtained for each sample. Prior to isolation of 
cells, each anonymised sample was given a sequential, unique “Y” number (e.g. 
Y1947) and the age, gender and operation of the patient were recorded. Each Y 
number used in this thesis, along with age, gender and operation details can be 




2.4 Tissue culture 
2.4.1 General  
All cell/tissue culture work was performed aseptically in either class II recycling 
laminar air flow safety cabinets (Medical Air Technology), or an externally ducted 
cabinet (Envair) when working with retroviruses. Cabinets used for tissue culture 
work were cleaned with 70% (v/v) ethanol before and after use. Cell cultures were 
maintained in Heracell™ 240 Incubators (Heraeus®) at a temperature of 37oC in a 
humidified atmosphere of either 5% CO2 in air (NHU cells) or 10% CO2 in air (all 
other cell types used). Waste medium from cultures was aspirated into Buchner 
flasks containing 10% (w/v) Virkon® (Fisher Scientific) disinfectant prior to disposal. 
Fresh medium was applied to cultures every 2-3 days, unless otherwise stated. NHU 
cells were grown in Cell+ culture plasticware (Sarstedt) to promote attachment and 
growth of primary cells. Other cell types were grown in Primaria® (BD Bioscience) 
plasticware. 
Cell culture centrifugation steps were undertaken in a benchtop centrifuge (Sigma) 
at 360 x g for 4 minutes unless otherwise stated. To count cells, 10 µl of suspended 
cells were pipetted onto an Improved Neubauer haemocytometer (VWR) to 
determine the concentration of cells/mL of medium. An EVOS XL Core (Thermo 
Fisher) phase-contrast microscope was used to both count cells and take images of 
cells in culture. 
2.4.2 Tissue sample collection  
Samples of ureter and bladder were obtained from St. James’s University Hospital, 
Leeds or Pinderfields Hospital, Wakefield. Following surgery, sample biopsies were 
collected in sterile polystyrene Universal tubes containing sterile transport medium 
(Appendix ii). Upon arrival at the Jack Birch Unit, samples were stored at 4 oC for up 




2.4.3 Cell isolation 
2.4.3.1 Urothelial cell isolation  
The established method of growing primary urothelial cells from patient biopsies 
was used exactly as previously described (Southgate et al., 1994; Southgate et al., 
2002). Tissue samples were dissected to remove excess connective tissue and fat 
using sterile, autoclaved scissors and forceps. A small representative piece of each 
sample (~0.5 cm2) was cut and placed into 10% (v/v) formalin (Appendix ii) for a 
period of 24-48h to fix the tissue. The tissue was subsequently stored in 70% 
ethanol in preparation for later histological analysis (Section 2.9.1). 
The remaining tissue was cut into sections of approximately 1 cm2 and placed in 
Universal tubes containing stripper medium (Appendix ii). Tissue sections were 
maintained in stripper medium for either 4 hours at 37 oC or 16 hours at 4 oC before 
urothelial cells were separated from the underlying stroma through gentle scraping 
of the sample with forceps. Urothelial cells were collected by centrifugation and 
resuspended in 2 mL (400 U) of collagenase IV (Appendix ii) at 37 oC for 20 minutes 
to disaggregate the cells. Following collagenase IV treatment, cells were counted, 
centrifuged, resuspended in Keratinocyte Serum-Free Medium (KSFM; Gibco®; 
Thermo Fisher) and seeded at a minimum density of 4 x 104 cells /cm2 in Cell+ 
plasticware.  
2.4.3.2 Stromal cell isolation 
Upon de-epithelialisation of ureter and bladder samples, pieces of stroma were cut 
up in transport medium into pieces of around 1 mm3 in size. The pieces were 
centrifuged and resuspended in 100 U/mL collagenase IV for 4 hours at 37 oC. 
Stromal pieces were subsequently centrifuged, washed in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Gibco®), centrifuged again and transferred to 25 cm2 
Primaria® flasks as explants with minimal (100 µL) DMEM medium containing 10% 
HyClone™ bovine calf serum (BCS; Fisher Scientific) and 1% L-glutamine (LG; 
Gibco®). After 2 days the minimal medium was removed and the explants were 
gently flooded with medium to avoid dislodging explants. Flasks were left in the 
same medium for 7 days to encourage stromal cell growth from the explants, which 
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were discarded upon passage of cells. A summary diagram of the steps required to 




Figure 2.1: Flowchart of urothelial and stromal cell isolation from ureter 
Samples in study classified as “Urothelium in situ” refer to RNA/protein lysed 
from normal urothelium that had been stripped from pieces of ureter but were 




2.4.4 Cell culture 
2.4.4.1 Maintenance of NHU cell lines 
NHU cells were grown in KSFM supplemented as standard with 5 ng/mL 
recombinant human EGF and 50 µg/mL bovine pituitary extract (both Gibco®). 
Additional supplementation with 30 ng/mL cholera toxin (Sigma) was used to create 
what is referred to as complete KSFM (KSFMc). Upon reaching approximately 90% 
confluence, NHU cells were passaged through incubation with 0.1% 
Ethylenediaminetetra-acetic acid disodium salt (EDTA) in Phosphate Buffered Saline 
(PBS; Appendix ii) at 37 oC for approximately 5 minutes to promote dissociation of 
the cells from the Cell+ plasticware. Following aspiration of EDTA, cultures were 
incubated in 0.5- 1 mL Trypsin-Versene (TV; Appendix ii) for 5 minutes, upon which 
cells would detach from the plasticware after gentle tapping. 100 µL of 20 mg/mL 
Trypsin Inhibitor (Appendix ii) mixed with 4 mL KSFMc were added to the 
suspension of detached cells in TV and centrifuged. The resulting pellet was 
resuspended in KSFMc and split into new plasticware at a ratio of 1:3. All 
experiments in this study were performed on NHU cells that were of passage 
number 1-5. Where stated, experiments were replicated using NHU cell lines from 
multiple independent donors. 
2.4.4.2 Maintenance of stromal cell lines 
Stromal cells were grown in supplemented DMEM as described in section 2.4.3.2. 
Stromal cells were passaged as in section 2.4.4.1, except treatment with EDTA 
lasted for < 1 minute as these cells rapidly dissociated from the plasticware. The 
addition of Trypsin Inhibitor was also omitted due to the presence of serum in the 
culture medium. Stromal cells were split into new plasticware at a ratio of 1:3. All 
experiments in this study were performed on stromal cells that had been passaged 
fewer than seven times. Where stated, experiments were replicated using stromal 




2.4.4.3 Culture of established cell lines 
All established cell lines were originally obtained from the American Type Culture 
Collection (Middlesex, UK) except for the RetroPack™ PT67 cell line, which was 
obtained from Takara Bio (formally Clontech; Gothenburg, Sweden). The list of cell 
lines used in this study, their origin and the growth medium used is detailed in 
Table 2.1. All cell lines were previously genotyped using a PCR-based short tandem 
repeat analysis (performed in-house) and were passaged less than 10 times since 
the genotyping date. 
 
Table 2.1: List of established cell lines used in study. 




Name Origin Medium 
HT1376 Bladder cancer DMEM + RPMI + 5% FBS 
+1% LG 
PT67 Embryonic mouse fibroblast DMEM + 10% FBS + 1% LG 
RT4  
   
Bladder cancer DMEM + RPMI + 5% FBS + 
1% LG 
ScaBer Bladder cancer DMEM + RPMI + 5% FBS + 
1% LG 
T24 Bladder cancer DMEM + RPMI + 5% FBS + 
1% LG 
UM-UC-9 Bladder cancer DMEM + RPMI + 10% FBS 
+ 1% LG 
3T3-J2 Embryonic mouse fibroblast  DMEM + RPMI + 10% BCS 
+1% LG 
5637 Bladder cancer RPMI + 5% FBS + 1% LG 
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2.4.4.4 Pharmacological agonists and antagonists  
The list of agonists and antagonists used in this study is detailed in Table 2.2. 
Compounds were solubilised in sterile tissue culture grade dimethyl sulfoxide 
(DMSO; Sigma), dH2O or enterokinase buffer (Appendix ii) and frozen at either -20 
oC or -80 oC for long term storage in individual aliquots. A 0.1% (v/v) concentration 
of DMSO was both used as a vehicle control and kept as a constant concentration in 
treatment arms of every experiment involving the use of DMSO-reconstituted 
compounds. Compounds used were initially titrated on target cells to determine 
the optimum concentration of drug to use. The optimum concentrations for use of 
LY294002, PD153035, SB431542, rSHH, TGFβ, TZ and T0070907 were determined 
prior to the start of the study. Details of the titrations performed for SAG, PD98059 
and U0126 can be found in Section 5.4.3.1 and Appendix viii.  
2.4.4.5 ABS/Ca2+ differentiation of NHU cells 
Functional differentiation of NHU cells was achieved using a previously described 
protocol (Cross et al., 2005) that results in a functional barrier producing, 
“biomimetic” urothelium. NHU cells grown to 90% confluence in Cell+ plasticware 
were incubated in KSFMc supplemented with batch selected 5% Adult Bovine 
Serum (ABS; BioIVT; formally SeraLab) for a period of 3-5 days. 180 µL CaCl2 from a 
1 M stock solution was subsequently added /100 mL 5% ABS KSFMc medium to 
raise the total [Ca2+] concentration from 0.09 mM to 2 mM. Cultures were 
maintained in this medium (referred to as ABS/Ca2+) for a further 7 days, unless 











Function Supplier Vehicle 
FR180204 
(FR180) 






LY294002 (LY) PI3K Antagonist Merck Milipore DMSO 
PD153035 (PD) EGFR Antagonist Merck Milipore DMSO 





















SB431542 TGFβRI Antagonist Sigma-Aldrich DMSO 
Troglitazone 
(TZ) 
PPARγ Agonist Tocris DMSO 
T0070907 (T007) PPARγ Agonist Tocris DMSO 
U0126  MEK1/2 Antagonist Merck Milipore DMSO 
 





2.4.4.6 Measurement of Transepithelial Electrical Resistance (TEER) 
TEER refers to the tightness of barrier produced by ABS/Ca2+ differentiated NHU 
cells grown on 0.4 μm pore Snapwell™ membranes. NHU cells at 90% confluence 
were harvested with TV and seeded onto Snapwell membranes (surface area of 
1.13 cm2) at a concentration of 5 x105 cells/membrane. Upon attachment to the 
membranes, cultures were treated as described in Section 2.4.4.5. TEER was 
measured using the cellZscope (nanoAnalytics), an instrument that measures the 
impedance of barrier-forming cell cultures at user-defined intervals. The units of 
TEER used were Ω.cm2, with a TEER barrier measurement of > 500 Ω.cm2 
considered “tight”. All elements of the cellZscope instrument (except from the base 
unit) were autoclaved prior to use to maintain sterility. Six technical replicate 
membranes were used for each experimental condition. Using sterile forceps, 
membranes (containing ABS/Ca2+ differentiated NHU cells) were placed in stainless 
steel electrode pots screwed into the base unit of the instrument. Each pot 
contained 1.6 mL medium while 700 µL medium was added to the apical 
compartment of each membrane. The electrode-containing lid was lowered 
vertically onto the base unit and sealed to ensure that each electrode was 
submerged in the medium contained in each Snapwell in a sterile environment. To 
measure TEER of the experimental cultures, the instrument was connected to its 
station contained within a 37 oC, 5% CO2 incubator. The station recorded TEER 
readings every hour and relayed the readings to a console which converted the data 
into an .xls document upon completion of the experiment. The cultures were 
medium changed every 2-3 days, requiring the removal of the instrument from the 
station and its lid in order to gain access to the membranes. For a summary diagram 
























2.4.4.7 Scratch wounding of cell cultures grown on membranes  
ABS/Ca2+ differentiated NHU cells were seeded onto Snapwell membranes and had 
TEER measurements recorded as described in section 2.4.4.6. Once relative 
stabilisation of TEER values in cultures was observed, a sterile 200 µL pipette tip 
was used to create a single, lateral wound per membrane (six technical replicates 
per condition) and the TEER readings were measured immediately after scratch 
wounding to confirm that the impedance reading of each membrane had fallen 
below the threshold of tightness. CellZScope readings were taken every 20 minutes 
after the scratch to compare the rate of recovery between experimental conditions.  
Figure 2.2: Experimental flowchart of measuring urothelial barrier tightness using the 
cellZscope  
Snapwell membranes containing ABS/Ca2+ differentiated NHU cells were transferred 
from tissue culture plasticware to medium-containing pots screwed into the cellZscope. 
Electrodes in the machine recorded barrier impedance over time and relayed TEER 
readings to a connected console.  Image of the cellZscope console was obtained from 
the technical manual provided by nanoAnalytics. 
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2.4.4.8 Lifting of cell sheets by dispase treatment 
Once cultures growing on Snapwell™ membranes had recovered from the scratch 
wound (as determined by stabilisation of TEER), intact cell sheets were detached 
from the membranes using 2% (w/v) dispase solution (Sigma-Aldrich) in PBS, 
warmed to 37 oC prior to use. Medium was aspirated from the pots before dispase 
solution was applied to the apical and basal chambers of the pot at the same 
volume as the previous medium for a period ranging from 20 minutes to 1 hour. 
After the cell sheets started to lift away from the edges of the membrane, they 
could be removed by gentle pipetting. To create a single cell suspension, the cell 
sheets of each condition were combined and pipetted into 5 mL EDTA solution at 37 
oC. Cell sheets were then transferred to 1 mL TV solution for 1 minute before the 
cells could be disaggregated by vigorous pipetting. The resultant cell populations 
were subsequently assayed by flow cytometry (Section 2.6).  
2.4.4.9 TZ/PD differentiation of NHU cells 
A previously described protocol was used to alternatively differentiate NHU cells 
using pharmacological agents (Varley et al., 2004a). NHU cells at 80% confluence 
(unless otherwise stated) were grown in KSFMc medium and treated with PPARγ 
agonist troglitazone (TZ) and EGFR tyrosine kinase inhibitor PD153035 (PD), each at 
a final concentration of 1 µM for 24 hours. After 24 hours, TZ was removed from 
the medium and the cells were grown in KSFMc + PD153035 medium for a further 
period of 48h (72h total) or 120h (144h total).  Some experiments, where noted, 
included parallel cultures of cells pre-treated with PPARγ antagonist T0070907 
(T007) for 3h prior to TZ/PD induction to inhibit PPARγ activation. Any cultures pre-
treated with T007 were subsequently treated with T007 by itself or with a 
combination of TZ, PD and T007.  
2.4.4.10 Mycoplasma spp. testing 
To avoid the problems that occur as a result of Mycoplasma spp. contamination, 
primary and established cell lines were routinely checked for extranuclear DNA 
labelling (an indication of mycoplasma contamination) using a fluorescent DNA 
labelling method. Cells were seeded onto sterile 12 well glass slides (Hendley Essex) 
at a density of 1x104 cells/well and left to grow overnight. Slides were washed in 
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PBS, fixed in a 1:1 mixture of methanol and acetone (both Fisher Scientific) for 30 
seconds and left to dry. Cultures were stained with 0.1 µg/mL of fluorescent DNA 
counterstain Hoechst 33258 (Thermo Fisher) in PBS for 5 minutes while being 
protected from light by aluminium foil. Cultures were washed in PBS, air dried and 
mounted in Prolong™ Gold Antifade Reagent (Invitrogen). Slides were subsequently 
examined for extranuclear Hoechst labelling using an Olympus BX60 microscope 
with epifluorescence illumination.  
2.5 Cell viability assay  
The alamarBlue® (Bio-Rad) assay was used to measure proliferation of NHU cell 
cultures over a period of 9-13 days. Cells were harvested and seeded at a 
concentration of 2 x 104/ mL into ten separate Primaria® 96-well culture plates at a 
volume of 200 µL/well and left to attach. Six replicate wells were assayed per 
condition. To determine cell viability, cells were medium changed to 200 µL of 10% 
alamarBlue in KSFMc at 37 oC for four hours. Absorbance readings of 570 nm and 
600 nm were subsequently measured using a Multiskan Ascent 96-well plate reader 
(Thermo Scientific). In the absence of viable cells, the active ingredient in 
alamarBlue reagent (resazurin) is blue. Metabolic activity results in the irreversible 
reduction of non-toxic, cell-permeable resazurin into resorufin, a compound that 
produces a bright red fluorescence. In the absence of a cell stress response, the 
absorbance readings are directly proportional to mitochondrial activity which is 
used as a proxy for the total number of viable cells per sample. Plates that been 
incubated with alamarBlue were subsequently discarded, resulting in a separate 
plate being read each day. The remaining unread plates were medium changed 
every 2-3 days as standard. The equation used to calculate percentage reduction of 
alamarBlue reagent per condition using the 570 nm and 600 nm absorbance values 







Percentage alamarBlue reduction =  
2.6 Cell cycle analysis 
To determine what percentage of a cell population was actively in cell cycle, 
cultures were treated with Bromodeoxyuridine (BrdU; Cambridge Bioscience), a 
thymidine analogue that is incorporated into the DNA upon replication and 
therefore serves as a marker of cells in the population that have entered S phase in 
the assayed timeframe. Cells pulsed with BrdU were subsequently harvested, fixed, 
labelled and their fluorescent intensity detected by a flow cytometer.  
Cells that were cultured for the purpose of cell cycle analysis (other than the cells 
described in Section 2.4.4.8) were seeded into 75 cm2 flasks at a concentration of 1 
x106 cells/flask. Upon reaching the desired cell density, cultures were pulsed with 
30 µM BrdU for either 1h (MIBC cell lines) or 6h (ABS/Ca2+ differentiated NHU cells) 
in order to capture a suitable population of BrdU+ cells. Following BrdU treatment, 
cultures were harvested with TV as previously described to obtain a single cell 
suspension of 1 x106 cells, washed in PBS and fixed in 70% ethanol kept on ice. 
Fixed cells were transferred into Falcon™ 15 mL Conical Centrifuge Tubes (Fisher 
Scientific) and stored at 4 oC in 70% ethanol. All subsequent pellet steps were 
performed by spinning the cells at 2500 x g for 2 minutes. Cells were pelleted and 
an acid hydrolysis step was performed by resuspending the cells in 2 N HCl with 
0.5% Triton X-100 (Sigma) for 30 minutes to denature the DNA and allow access for 
Figure 2.3: Equation used to calculate alamarBlue reduction in proliferating samples 
34798 = the molar extinction coefficient of oxidised alamarBlue (blue) reagent at 600 
nm. 80586 = the molar extinction coefficient of oxidised alamarBlue (blue) reagent at 
570 nm. 155677 = the molar extinction coefficient of reduced alamarBlue (red) 
reagent at 570 nm. 5494 = the molar extinction coefficient of oxidised alamarBlue 
(red) reagent at 600 nm. 
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the BrdU mAb to bind. Cells were resuspended in 0.1 M sodium tetraborate for 2 
minutes, washed in PBS containing 1% (w/v) Bovine Serum Albumin (BSA; Sigma), 
and resuspended in PBS/1% BSA/0.5% Tween-20. α-BrdU mAb (IIB5, Santa Cruz 
Biotechnology) was added at a concentration of 1µg antibody/106 cells for 1h at 
ambient temperature. Cells were pelleted and washed before incubation in 50 µL 
PBS/1% BSA/0.5% Tween 20 containing 5 µg/mL Goat anti-Mouse IgG (H+L) Cross-
Adsorbed Secondary Antibody, Alexa Fluor 488 (Invitrogen) for 30 minutes at 
ambient temperature. Prior to analysis, cells were resuspended in 500 µL PBS 
containing 20 µg/mL propidium iodide (PI; fluorescent DNA intercalating agent) and 
10 µL/mL RNAse A (both Sigma) and incubated at 37 oC for 30 minutes. A CyAn™ 
ADP High-speed Analyzer (Beckman Coulter) was used to quantify PI and BrdU 
fluorescence in samples by flow cytometry. A minimum of 5000 events was counted 
for each condition. Controls included cells that had incubations with the secondary, 
but not primary, antibody (Secondary only) and cells that were not incubated with 
any antibody (PI only). These cells were additionally utilised to set up the correct 
fluorescence compensation and gated regions during each analysis. The distribution 
of cells in 2N (G0/G1), S and 4N (G2/M) phases were calculated and analysed in 
FlowJo (TreeStar) software. 
2.7 Gene expression analysis 
2.7.1 General 
All RNA processing work took place on a designated, DNA amplicon-free bench that 
had been cleaned with RNaseZap® decontamination solution (Invitrogen). Similarly, 
all pipettes and gloves used during this process were cleaned in the same manner 
prior to use. DNAse/RNAse-free pipette tips (Starlab) and DNAse/RNAse-free 
microfuge tubes (Invitrogen) were also used to inhibit contamination of samples. All 
steps were performed at ambient temperature unless otherwise stated.  
2.7.2 RNA extraction  
Cells cultured for the purpose of RNA extraction were grown in 6-well plates. Upon 
reaching the completion of a time-point or the desired confluence, cultures were 
washed twice in PBS before addition of 500 µL TRIzol® (Thermo Fisher) reagent per 
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well of a 6-well plate for 5 minutes to solubilise the cells. Rubber cell scrapers 
(Sarstedt) were used to collect the sample lysates before the mixtures were 
transferred to 1.5 mL microfuge tubes and stored at -80 oC. Samples were thawed 
on ice and then left at ambient temperature for five minutes before extraction to 
allow for complete dissociation of nucleoprotein complexes. For each 1 mL of TRIzol 
used, 0.2 mL neat chloroform was added per sample before the lysates were 
vortexed for 15 seconds and incubated for a further 3 minutes. Samples were 
centrifuged at 12000 x g for 15 minutes at 4 oC to separate the mixture into a pink 
phenol-chloroform phase, a cloudy interphase and an RNA-containing aqueous 
phase. The aqueous phases were carefully collected into clean microfuge tubes 
while the protein and DNA-containing phases were discarded. The collected RNA 
was precipitated using a 1:1 ratio of isopropanol (Fisher Scientific; formally 
Honeywell), which was gently mixed with the RNA solution and left for 10 minutes. 
Samples were spun at 12000 x g  for 20 minutes at 4 oC to collect the precipitated 
RNA at the bottom of the tubes. Waste supernatant was removed by pouring 
before the RNA was washed with 1 mL 75% ethanol. After centrifuging the sample 
at 10000 x g  for 5 minutes at 4 oC, the wash process was repeated to ensure the 
removal of all salt contaminants. The RNA pellet was allowed to air dry upon 
pouring off the final 75% ethanol wash before resuspension in 30 µL DEPC-treated 
dH2O in a clean microfuge tube.  
2.7.3 DNAse treatment of RNA 
Removal of residual contaminating DNA from RNA samples was achieved using a 
DNA-freeTM DNA removal kit (Thermo Fisher; formally Invitrogen). RNA samples 
were incubated with 2 U/µL rDNase 1 and a 1:10 dilution of 10x DNase 1 buffer 
(both Invitrogen) at 37 oC for 30 minutes. A DNase inactivation reagent slurry was 
added to the mixture at a 1:10 dilution for 2 minutes at ambient temperature, with 
vortexing of samples performed every 30 seconds. The DNase inactivation reagent 
was removed by centrifuging samples at 10500 x g for 90 seconds, with the DNA-
free supernatants subsequently transferred to clean microfuge tubes. The 
concentration and quality of RNA in solution was measured using a NanoDropTM UV 
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spectrophotometer (Thermo Fisher). Clean RNA was kept at -80 oC for long term 
storage. 
2.7.4 Sodium acetate precipitation of RNA 
A 260 nm: 230 nm ratio of less than 1.5 indicates contamination of RNA samples 
with ethanol or salts. In the event that samples contained contaminants, RNA were 
cleaned with an alcohol and salt precipitation. To a 30 µL solution of RNA, 3.3 µL of 
3 M sodium acetate was added alongside 83 µL (2.5 x volume) of 100% ethanol. The 
mixture was vortexed and stored at -80 oC for at least 16 hours. The samples were 
subsequently centrifuged at 12000 x g for 30 minutes at 4 oC, the supernatant 
removed and replaced by 500 µL 75% ethanol. The centrifugation and aspiration 
were repeated before the clean RNA pellets were left to air dry. The pellets were 
once again resuspended in 30 µL DEPC-treated dH2O, the concentration quantified 
using a NanoDropTM UV spectrophotometer and stored at -80 oC. 
2.7.5 cDNA synthesis 
1 µg RNA was used in each complementary DNA (cDNA) synthesis reaction. RNA 
was mixed with 0.1 µg/µL Oligo(dT)12-18 primers (Invitrogen) and DEPC-treated dH2O 
up to a total volume of 12 µL. Each RNA sample was used to perform two cDNA 
synthesis reactions: one containing Superscript II Reverse Transcriptase (Invitrogen) 
enzyme (RT+) and one with dH2O replacing reverse transcriptase (RT-). Heating the 
mixture to 65 oC for 10 minutes before cooling on ice resulted in the annealing of 
the primers to the RNA. 7 µL of a master mix containing 4 µL 5X First-Strand buffer, 
2 µL 0.1 M dithiothreitol (DTT; both Invitrogen), and 1µL of a 10 mM dNTP mixture 
(dATP, dTTP, dCTP and dGTP; all Promega) was added to each reaction. 50 U/µL 
Superscript II Reverse Transcriptase was subsequently added to each RT+, but not 
RT-, condition. Reaction tubes were incubated at 42 oC for 50 minutes to induce 
cDNA synthesis before inactivation of the reverse transcriptase by heating to 70 oC 
for 15 minutes. Newly synthesised cDNA was diluted to 100 µL with DEPC-treated 




2.7.6 Primer design 
Genome browser Ensembl (https://www.ensembl.org/index.html) was used to 
search for protein-coding mRNA sequences of genes that were to be amplified by 
Reverse Transcription Polymerase Chain Reaction (RT-PCR). In instances where 
genes had multiple protein-coding splice variants, sequences were aligned using 
Kalign Multiple Sequence Alignment software 
(https://www.ebi.ac.uk/Tools/msa/kalign/). Primers specific to the aligned 
sequence were designed using the Primer3 v0.4.0. program 
(http://bioinfo.ut.ee/primer3-0.4.0/). For quantitative Polymerase Chain Reaction 
(RT-qPCR) targets, primers were designed using Primer Express™ v3.0.1 (Thermo 
Fisher) software. Specifications for primers used in this study included a size range 
of 18-30 base pairs (bp), GC% content between 40-60%, melting temperature (Tm) 
between 56-65 oC and an amplicon product size of between 100-450 bp (RT-PCR) or 
50-100 bp (RT-qPCR). Target specificity of primers was confirmed using the primer 
BLAST tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer 
oligonucleotides were ordered from Eurofins Genomics, diluted in DEPC-treated 
dH2O to 100mM and stored at -20 
oC. Primer sequences are detailed in Appendix iv. 
2.7.7 Primer optimisation  
The optimum annealing temperature in which to use primer sets for RT-PCR 
analysis was determined by gradient PCR using a positive control sample. Genomic 
DNA was used when primer sets were specific to a DNA sequence located in a single 
exon, while cDNA expressing the gene was used when the primer product spanned 
intronic regions. Annealing temperatures of 56-66 oC were tested to determine the 
range of temperatures where a single, specific band was formed.  
RT-qPCR primer sets were tested for efficiency and specificity prior to use. Positive 
control DNA (genomic or cDNA expressing the gene) was serially diluted (1:10, 
1:100, 1:1000) in triplicate in order to plot a standard curve of cycle threshold (Ct) 
over log2 DNA concentration. Primers that generated a single solid peak on the 
dissociation curve, a standard curve with an R2 value greater than 0.95 and a 
gradient of -3.1 (+-5%) were considered to be both specific to the gene of interest 
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and working at optimum efficiency. The dissociation curves for RT-qPCR primer sets 
used in this study can be found in Appendix v.  
2.7.8 Reverse Transcription Polymerase Chain Reaction (RT-PCR)  
Non-quantitative RT-PCR was performed in a T100™ Thermal Cycler (Bio-Rad) using 
a GoTaq® G2 Flexi kit (Promega). PCR master mixes were formulated containing 1x 
Green GoTaq® Flexi Buffer, 10 mM dNTP mixture, 25 mM MgCl2, 10 µM forward 
and reverse primers and 5 U/µL GoTaq® G2 Flexi DNA Polymerase diluted in 30% 
v/v DEPC-treated dH2O. For each gene target, 5 µL of cDNA was mixed with 15 µL 
master mix in individual wells of 8-well PCR tubes (Starlab). Each PCR reaction 
comprised of the following: an initial DNA denaturing step at 95 oC for 2 minutes 
followed by 25-32 cycles of a 30 second 95 oC denaturation, annealing for 30 
seconds at 56-65 oC (determined through prior optimisation, see section 2.7.7) and 
an extension step at 72 oC for 1 minute/kb of expected PCR product. A final 5 
minute extension step at 72 oC was completed before the samples were stored at 4 
oC until ready to be analysed by agarose gel electrophoresis. For each gene target 
amplified, a genomic DNA positive control and a cDNA-negative, water only control 
was included. Expression of housekeeping gene GAPDH was used as both an 
internal loading control for RT+ samples and confirmation that RT- samples 
contained no DNA amplification.  
2.7.9 Gel electrophoresis  
A 2-3% w/v solution of agarose (Melford Laboratories) in 1x TBE buffer (Appendix ii) 
was made in order to separate PCR products based on size by electric current. The 
w/v % of agarose in buffer was determined by the amplicon size of interest. The 
solution was boiled to solubilise the agarose before addition of DNA intercalating 
agent SYBR™ Safe DNA Gel Stain (Invitrogen) at a dilution of 1:10,000. Gels were 
cast by pouring into a tray and allowing to set at ambient temperature. The set gels 
were submerged in 1x TBE buffer in a gel tank and PCR products electrophoresed 
next to a HyperLadder™ 100bp (Bioline) or GeneRuler™ 1 kb (Thermo Fisher) DNA 
ladder, depending on PCR product size. Once the DNA had been adequately 
separated, the resultant bands were visualised by UV detection using a PXi 4 
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(Syngene) imaging system and images captured with Genesys image acquisition 
software v1.5.0.0. 
2.7.10 Quantitative Reverse Transcription Polymerase Chain Reaction (RT-qPCR)  
RT-qPCR was performed using a Fast SYBR™ Green-based detection method 
(Thermo Fisher).  RT-qPCR master mixes were formulated containing 2x Fast SYBR™ 
Green Master Mix (a premade mix containing SYBR® Green I Dye, AmpliTaq Gold® 
Fast DNA Polymerase, dNTPs and optimized buffer components) and 10 µM 
forward and reverse primers made up to a total volume of 15 µL in DEPC-treated 
dH2O. A single PCR reaction used a mixture of 15 µL master mix and 5 µL cDNA 
product. Each gene target per cDNA sample was loaded in triplicate wells in a 
MicroAmp® Fast 0.1 mL 96-Well Reaction Plate (Applied Biosystems) and sealed 
with a plastic adhesive cover. The RT-qPCR reactions were undertaken in a 
QuantStudio™ 3 Real-Time PCR System and analysed in qPCR Design and Analysis 
Application software (both Thermo Fisher). Each RT-qPCR reaction comprised of the 
following: an initial DNA denaturing step at 95 oC for 20 seconds before 40 cycles of 
DNA denaturation at 95 oC for a second followed by elongation for 20 seconds at 60 
oC.  For each gene target amplified, a replicate RT- sample was included to confirm 
absence of non-specific amplification. Expression of housekeeping gene GAPDH was 
included for every RT+ sample as an internal loading control. The resultant data was 
analysed to determine an average Ct value per triplicate samples, and the 
difference in Ct value between the gene of interest and GAPDH was determined 
(ΔCt). ΔCt values were normalised to GAPDH expression (ΔΔCt) before the fold 
change in gene expression between experimental and control samples was 
calculated (2- Δ ΔCt).  
2.7.11 RNA Sequencing  
RNA extracted from experimental cultures were sequenced using the Illumina 
platform. RNA extraction and quantitation was performed in the same way as with 
samples used for PCR (section 2.7.1.1 to 2.7.1.4). RNA samples were diluted to 100 
ng/µL in DEPC-treated dH2O and sent to Oxford Genomics Centre for poly-A RNA-
Seq library preparation and Illumina HiSeq 4000 75bp paired-end sequencing.  
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2.8 Molecular biology 
2.8.1 General  
Molecular biology techniques were used to a) stably overexpress genes of interest, 
b) transiently knockdown expression of genes using small interfering RNA (siRNA) 
and c) induce stable knockdown of gene expression using short hairpin RNA 
(shRNA) constructs in NHU and MIBC cell lines. Overexpression and knockdown cell 
lines were generated through either transfection (siRNA) or transduction with 
replication-disabled retroviral particles.  
All microbiological work detailed below was performed in a separate room in 
accordance with the Good Microbiology Practice guide set out by the University of 
York Biology Department. Specifically, lab benches were swabbed with 70% (v/v) 
ethanol before and after handling bacteria, while any waste solution was 
disinfected with 2% (w/v) Virkon for 24h before disposal.  
2.8.2 Generation of overexpressing retroviral vectors   
2.8.2.1 PCR amplification of gene of interest  
Primers specific to the full length coding sequence of the genes of interest were 
designed as in section 2.7.6. Specifically, the primers were designed to incorporate 
sequences matching the forward and reverse strands, while also including 
restriction enzyme sites and a Kozak sequence (forward strand) to aid in coding 
sequence translation. NEBcutter v2.0 (http://nc2.neb.com/NEBcutter2/) software 
was used to determine appropriate restriction sites that allowed for directional 
ligation of the gene sequence into the multiple cloning sites (MCS) of pGEM®-T Easy 
and pLXSN vectors. Once designed, primers were purchased from Eurofins 
Genomics. 
To produce cDNA containing the coding sequence required for cloning, suitable 
RNA was used to synthesise 2 µg of cDNA (see section 2.7.5). The resultant DNA 
was amplified by PCR using a Phusion® Hot Start Flex kit (New England Biolabs), 
with the high fidelity DNA polymerase used in order to amplify an error-free 
product. A PCR master mix was formulated containing 1x Phusion High Fidelity 
Buffer, 200 µM dNTP mixture, 0.5 µM forward and reverse primers, 0.02 U/µL 
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Phusion Hot Start Flex II DNA Polymerase and 50 ng cDNA per reaction, diluted to a 
final volume of 20 µL with DEPC-treated dH2O. The PCR reaction comprised of the 
same protocol as detailed earlier (section 2.7.8) with a 60 oC annealing step for 30 
cycles. Ten PCR reactions were performed using the same master mix and cDNA, 
with one reaction used to verify the production of a single band product of the 
correct molecular size by agarose gel electrophoresis and the remaining nine 
pooled together and purified.  
2.8.2.2 Purification of PCR product  
To separate and concentrate the amplified sequence away from the other 
components of the PCR reaction, a QIAquick® PCR purification kit (Qiagen) was 
used. All following centrifuge steps took place at 14,000 x g for 60 seconds. For the 
volume of PCR reaction left, five times that volume was added of Buffer PB and this 
mixture was pipetted into a QIAquick column. The mixture was centrifuged to bind 
the DNA to the column, with the remaining flow-through discarded. Columns were 
washed in 750 µL Buffer PE and centrifuged twice to discard residual wash buffer. 
The purified DNA was eluted by adding 50 µL DEPC-treated dH2O to the centre of 
the column and centrifuging the solution into a clean microfuge tube. 
Concentration of the purified product was quantified using a NanoDrop™ UV 
spectrophotometer. Prior to ligation, the PCR fragment was first A-tailed to allow T-
vector cloning into the pGEM-T Easy vector. 6 µL of purified DNA was mixed with 1 
µL 25 mM MgCl2, 1 µL Taq DNA Polymerase 10X Reaction Buffer, 0.2 mM dATP, 5 U 
Taq DNA Polymerase and DEPC-treated dH2O to a final volume of 10 µL before the 
solution was incubated in a 70 oC heat block for 30 minutes.  
2.8.2.3 Ligation of PCR product into plasmid  
To determine the amount of amplified DNA required for optimal ligation with the 
linearised plasmid, the following formula was used: 





Purified DNA was ligated into the subcloning vector system pGEM-T Easy (Figure 
2.4) by overnight incubation at 4 oC using the pGEM®-T Easy Vector System II kit 
(Promega). The ligation reaction contained the following components: 100 ng of 
vector DNA, x amount of insert DNA (as determined above), 1 U T4 DNA ligase, and 
5 µL 2x Rapid Ligation buffer made up to a 10 µL solution in DEPC-treated dH2O. A 
positive control containing Insert DNA (provided with kit) and no template negative 
control ligation reactions were verified alongside the sequence of interest-
containing vectors by transformation.   
Figure 2.4: Vector map of pGEM-T Easy  
pGEM-T Easy vector was purchased from Promega, with the diagram of the plasmid (as 
seen above) provided in the data sheet. Features of note include an ampicillin resistance 
(Ampr) marker, a lacZ reporter gene, T7 and SP6 promoter regions and a MCS containing 
multiple restriction sites.  
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2.8.2.4 Bacterial transformation 
Ligated, circularised plasmid was introduced into XL1-Blue subcloning-grade 
competent E. coli bacteria (Agilent Technologies) by transformation using the 
manufacturer’s recommended protocol. XL1-Blue bacteria were defrosted on ice 
before 50 µL was pipetted into pre-chilled 15 mL Falcon centrifuge tubes. Between 
0.1-50 ng of plasmid (5 µL of ligation reaction mixture) was mixed with the bacteria 
and swirled gently before incubating on ice for 20 minutes. Controls included 
bacteria that received no plasmid and bacteria that received 1 µL of the ampicillin-
resistant, high copy number pUC18 plasmid. XL1-Blue bacteria underwent heat 
shock in a pre-warmed water bath at 42 oC for exactly 45 seconds before the tubes 
were returned to ice for a further 2 minutes. 900 µL of pre-warmed SOC medium 
(Invitrogen) was added to each tube and the bacteria was shaken for 30 minutes in 
a Model G25 Incubator Shaker (New Brunswick Scientific) at 37 oC to induce growth. 
To select based on successful uptake of plasmid, the bacterial cultures were 
pipetted and spread across Petri dishes containing Luria-Bertani (LB)-Agar 
(Appendix ii) and 100 µg/mL ampicillin (Melford Laboratories). Additionally, 100 µL 
2% (w/v in DMSO) X-gal (VWR), 100 µL SOC medium and 100 µL 10 mM IPTG 
(Formedium) were added to the LB-Agar plates for the purposes of blue/white 
screening of false positive colonies. Bacteria were incubated on inverted plates at 
37 oC for 16h and subsequently stored at 4 oC for up to a month. 
2.8.2.5 Colony PCR 
Validation of successfully ligated and transformed bacteria was performed using 
colony PCR. A PCR master mix (section 2.7.8) was produced which included primers 
specific to the T7 (forward) and SP6 (reverse) regions of the plasmid (Appendix iv). 
White-coloured (recombinant DNA-containing) colonies were picked from the 
original LB-Agar plate using a yellow pipette tip, transferred onto a new plate and 
pipetted into PCR mixes in individual wells of 8-well PCR tubes. To induce the 
growth of bacterial cultures containing the correct plasmid, the yellow tips were 
ejected into Universal tubes containing 10 mL of ampicillin-treated LB medium 
(Appendix ii) and incubated in the shaking incubator at 37 oC overnight. Ten PCR 
reactions were amplified for 30 cycles with an annealing temperature of 54 oC. 
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Products of the PCR reactions were visualised by gel electrophoresis to determine 
positive clones.  
2.8.2.6 Plasmid DNA extraction 
Plasmids containing the sequences of interest were extracted from positive 
bacterial cultures using a QIAprep® Spin Miniprep Kit (Qiagen). 10 mL cultures were 
first centrifuged at 3000 x g for 10 minutes at 6 oC before pelleted bacterial cells 
were resuspended in 250 µL RNAse A-containing resuspension solution (Buffer P1) 
and transferred to 1.5 mL microfuge tubes at ambient temperatures. An additional 
250 µL of SDS-containing Buffer P2 was added and each tube was gently mixed by 
repeated inversion to lyse the cells. When the solutions reached a viscous 
consistency, 350 µL neutralisation solution (Buffer N3) was added to each tube and 
mixed using the same method. Solutions were centrifuged for 10 minutes at 11500 
x g to separate plasmids from cellular debris. Plasmid-containing supernatant was 
applied to QIAprep spin columns and centrifuged for 60 seconds at 11500 x g, 
resulting in binding of the plasmids to the column. Plasmids were washed once with 
Buffer PB and once with Buffer PE before elution in 50 µL dH2O after 60 second 
centrifugations at 11500 x g. Concentrations of the resultant plasmids were 
subsequently quantified using a NanoDropTM UV spectrophotometer. 
2.8.2.7 DNA sequencing  
To validate the sequence orientation and fidelity in the purified plasmid solutions, 
75 ng plasmid was sequenced using a 3730xl DNA Analyzer (Applied Biosystems). 
The DNA sequencing service was provided by Eurofins Genomics and results 
analysed in Chromas v2.6.6 software.    
2.8.2.8 Restriction digest of subcloned DNA 
Restriction digests were used to cut out sequences from the subcloning vector 
pGEM-T Easy, allowing for subsequent subcloning into the retroviral mammalian 
expression vector pLXSN (Figure 2.5). 1 µg plasmid was mixed with 5 µL 10x Cut 
Smart Buffer, 1 µL each of the respective restriction enzymes required to excise the 
DNA sequence of interest (all from New England Biolabs) and dH2O to a final 
volume of 50 µL. This solution was incubated at 37 oC for 1h 45 minutes before heat 
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inactivation of the enzymes for 20 minutes at 65 oC. The pLXSN vector was similarly 
digested to linearise the plasmid in preparation for ligation with the target 






2.8.2.9 Gel extraction and purification of plasmid DNA 
Prior to gel electrophoresis of products of the restriction digest process (as 
described in Section 2.7.9), 6x gel loading dye (New England Biolabs) was added to 
each sample to a final concentration of 1x. Solutions containing linearised pLXSN 
and the products of the preceding restriction digest were pipetted into a 1% 
agarose gel and electrophoresed to separate linearised pGEM-T Easy vector 
Figure 2.5: Vector map of pLXSN 
pLXSN vector was purchased from Clontech, with the diagram of the plasmid (as seen 
above) provided in the data sheet. Features of note include an Ampr (for bacterial 
selection), a neomycin resistance (Neor) marker (mammalian cell selection), 5’ and 3’ 
long terminal repeats (LTR) for facilitation of gene transfer (and a strong promoter of 
the inserted transgene), retroviral packaging element ψ+ and a MCS.  
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backbone from the target DNA sequence by size. Solutions were pipetted into a 
well created by a wide gel comb to allow for up to 100 µL of product to be 
electrophoresed at once. Target DNA was visualised using the minimum possible 
exposure to UV before it was excised from the gel with a clean scalpel. The gel slices 
were placed into 1.5 mL microfuge tubes and weighed in preparation for extracting 
the DNA from the gel using a QIAquick® Gel Extraction Kit (Qiagen). To solubilise the 
remaining gel, three volumes of solubilisation solution (Buffer QG) was added to 
every one volume of gel for 10 minutes at 50 oC (or until complete solubilisation of 
gel was achieved), before vortexing the tubes to combine the mixture. A 1:1 ratio of 
isopropanol was added to the sample and mixed before the solution was 
transferred to a QIAquick spin column and centrifuged at 12000 x g for 1 minute to 
bind the DNA to the column membrane. 500 µL Buffer QG was added to the bound 
DNA and centrifuged before the product was washed in Buffer PE and allowed to 
stand in the column for 5 minutes. Buffer PE was removed by centrifugation and 
the DNA eluted from the column into a clean microfuge tube in 50 µL dH2O. 
Quantification of the concentration of plasmid and insert DNA was calculated using 
a NanoDropTM UV spectrophotometer. 
2.8.2.10 Dephosphorylation of plasmid 
To ensure that the ends of the linearised pLXSN plasmid did not ligate back together 
during the ligation process, the gel purified pLXSN backbone underwent 
desphosphorylation of its 5’ phosphate group using a FastAP Thermosensitive 
Alkaline Phosphatase kit (Thermo Scientific). 1 µL FastAP alkaline phosphatase, 2 µL 
10x AP reaction buffer and 17 µL linearised pLXSN were mixed and heated at 37 oC 
for 10 minutes before the enzyme was inactivated by heating the mixture for 5 
minutes at 75 oC.  Purified coding DNA sequences were subsequently ligated into 
pLXSN, transformed into XL1-Blue cells,  chosen by colony PCR, extracted using a 





2.8.2.11 Production of bacterial glycerol stocks  
Long term storage of plasmid-containing bacteria was achieved by freezing in 
glycerol (diluted in dH2O). 750 µL of a 5 mL overnight LB bacterial culture was mixed 
with 250 µL 80% (w/v) glycerol in a 1.5 mL Cryovial® (Sarstedt) and frozen at -80 oC. 
To recover frozen cells, an inoculating loop was used to scrape cells from the frozen 
Cryovial onto a LB-Agar plate containing ampicillin and left overnight in an inverted 
position at 37 oC.  
2.8.3 Generation of shRNA constructs  
2.8.3.1 Design of shRNA oligonucleotide sequences 
The full length coding sequence of interest was input into two shRNA construct 
designing packages: DSIR (http://biodev.extra.cea.fr/DSIR/DSIR.html) and siRNA 
Wizard v3.1 (https://www.invivogen.com/sirnawizard/). Three sequences of 19-21 
bp size were chosen and input into the shRNA Design Tool (Clontech) which used 
the target sequences to create 69 bp hairpin sequences, complete with BamHI, 
EcoRI and MluI restriction digest sites, an RNA Pol III terminator sequence and the 
hairpin loop sequence TTCAAGAGA. shRNA oligonucleotides were purchased from 
Eurofins Genomics.  
2.8.3.2 Annealing and ligation of shRNA oligonucleotides into pSIREN-RetroQ 
Sense and antisense oligonucleotide strands were resuspended separately in dH2O 
at a concentration of 100 µM before mixing 1 µL of each oligonucleotide. This 
mixture was then heated as follows in a T100™ Thermal Cycler to anneal the 
strands together: heated to 95 oC for 30 seconds (to disrupt the internal hairpins), 
heated at 72 oC for 2 minutes (to anneal the strands), heated at 37 oC for 2 minutes 
and heated at 25 oC for 2 minutes. Double-stranded oligonucleotides were 
subsequently stored at -20 oC until use.   
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Annealed oligonucleotides were ligated into the retroviral expression vector RNAi-
Ready pSIREN-RetroQ (Figure 2.6) with a 3h incubation process at ambient 
temperature. The ligation reaction contained the following components: 2 µL 
linearised pSIREN vector (25 ng/µL), 1 µL of double-stranded oligonucleotide 
(diluted to 0.5 µM), 10x T4 DNA Ligase Buffer, 0.5 µL T4 DNA Ligase and 0.5 µL 10 
mg/mL BSA (all Promega), diluted to a total volume of 15 µL in dH2O. A dH2O only 
negative control ligation reaction was verified alongside shRNA-containing vectors 










Figure 2.6: Vector map of pSIREN-RetroQ 
pSIREN vector was purchased from Clontech, with the diagram of the plasmid (as 
seen above) provided in the data sheet. The retroviral vector expresses shRNA 
through its human U6 promoter. Features of note include an Ampr, a puromycin 
resistance (Puror) marker (mammalian cell selection), 5’ and 3’ LTRs, packaging 





2.8.3.3 Bacterial transformation and colony PCR 
Transformation of XL1-Blue bacteria with ligated pSIREN plasmid was performed as 
described in section 2.8.2.4.  PCR of positive colonies was performed as described in 
section 2.8.2.5, using primers specific to U6 (forward) and the individual reverse 
sequence of the gene of interest (reverse) in the three shRNA constructs (Appendix 
iv). 15 PCR reactions (5 for each construct) were amplified for 30 cycles with an 
annealing temperature of 60 oC.  
Successful reactions were extracted from bacteria using a Miniprep kit and 
quantified with a NanoDropTM UV spectrophotometer, as detailed in Section 
2.8.2.6.   
2.8.3.4 MluI restriction analysis  
Confirmation that the shRNA inserts were correctly inserted into the purified 
plasmids was achieved by restriction digestion using MluI, an enzyme that does not 
have a native site in the pSIREN backbone. 500 ng plasmid was mixed with 2 µL 10x 
restriction enzyme buffer, 1 µL MluI (both New England Biolabs) and dH2O to a final 
volume of 20 µL. Samples were heated at 37 oC for 1h before mixing with 6x gel 
loading dye and visualising the bands by gel electrophoresis. Reactions that had 
been cut with MluI were compared to uncut control mixtures that received dH2O 
instead of enzyme.  
2.8.4 Genetic manipulation of NHU and MIBC cell lines 
2.8.4.1 Transfection of retroviral packaging cells 
All transfection/transduction work was performed in an externally vented tissue 
culture cabinet using level 2 containment safety practices. pLXSN and pSIREN 
plasmids containing target sequences of interest were introduced into the mouse 
NIH 3T3-derived, 3rd generation retroviral packaging cell line RetroPack™ PT67 
(Takara Bio) by transfection. PT67 cells express three genes vital for viral 
production: gag, pol and env. Transfection of PT67 cells with a retroviral vector that 
contains the packaging element ψ+ results in the production of infectious but 
replication-incompetent viral particles.  
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PT67 cells were maintained in 25 cm2 flasks until approximately 60% confluence 
was reached. A transfection mix was made using the Effectene® Transfection 
Reagent kit (Qiagen) containing the following reagents: 3 µg purified plasmid, 90 µL 
Buffer EC and 24 µL Enhancer (1 mg/mL). The solution was mixed and then 
incubated at ambient temperature for 5 minutes before 30 µL Effectene 
transfection reagent (1 mg/mL) was added and the mixture incubated for 10 
minutes. 1 mL of medium was added to the transfection solution and mixed, which 
was subsequently added to PT67 cells incubated in 4 mL of fresh medium. 
Additional flasks were used that contained PT67 cells that received a positive 
control plasmid (pLXSN overexpressing eGFP or pSIREN that produced scrambled 
shRNA) or negative control (medium only).  The pLXSN-eGFP and pSIREN-Scrambled 
control plasmids were previously generated by former Jack Birch Unit student Dr. 
Alex Mercado. Cultures were maintained as normal for 16h before a medium 
change containing no plasmid. 48h after transfection, PT67 cells were passaged into 
a 75 cm2 flask and were cultured in medium containing either 500 µg/mL of 
Neomycin analog G418 (pLXSN expressing cells) or 4 µg/mL Puromycin (pSIREN 
expressing cells). Cells were cultured and passaged as required until all the cells in 
the negative control mock transduced flask were killed by antibiotic selection.  
2.8.4.2 Transduction of cell lines with retroviral vector 
The production of replication-incompetent viral particles by transfected PT67 cells 
allowed for the collection of virus to infect cell lines of interest by transduction 
without the risk of retroviral replication.  
Virus-producing PT67 cells were cultured in 75 cm2 flasks until 100% confluency was 
reached. Cultures were washed once in Dulbecco’s PBS (dPBS) to remove antibiotic 
and medium changed to 10mL (1:1 ratio) DMEM:RPMI containing 5% FBS and 1% 
LG. Cells were incubated for 16h before the virus-containing medium was harvested 
and filtered through a 0.45 µm filter (Corning) to exclude PT67 cellular debris. 8 
µg/mL Polybrene (Sigma) was added to the medium and mixed to increase the 
efficiency of gene transfer. The viral medium was subsequently added to actively 
proliferating NHU or MIBC cells (at approximately 60-70% confluence) in a 75 cm2 
flask and incubated as normal for 6h. After 6h, cells were medium changed back to 
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their normal medium for 48h. Additional flasks were used that contained cells that 
received a positive control plasmid (pLXSN overexpressing eGFP or pSIREN that 
produced scrambled shRNA) or negative control (medium only). 48h post-
transduction, cells were passaged into two fresh 75 cm2 flasks in a 1:2 ratio split. 
Once attached, these cultures were medium changed into medium containing 100 
µg/mL G418 (pLXSN expressing cells) or 1 µg/mL puromycin (pSIREN expressing 
cells). Cells were cultured and passaged as required until all the cells in the negative 
control mock transduced flask were killed by antibiotic selection. Cell lines were 
subsequently maintained in medium containing a reduced concentration of 
antibiotic (25 µg/mL G418 or 0.25 µg/mL puromycin) until their final use in an assay 
in order to maintain selection pressure on positive cells. 
2.8.4.3 Transfection of NHU cells with siRNA 
Commercially available siRNA were used to transiently knockdown expression of 
genes of interest in NHU cells. Before use, siRNA were solubilised in DEPC-treated 
dH2O to a concentration of 10 µM. Optimal cell concentration (and thus 
transfection efficiency) was achieved by seeding NHU cells at a concentration of 4 x 
105 cells/well of a 6 well plate and leaving to attach overnight under normal 
conditions. The transfection mixture was prepared the following day by mixing 1.5 
µL Lipofectamine RNAiMAX (Thermo Fisher) with 248.5 µL supplement-free KSFM 
(as supplements can disrupt the transfection process) while mixing a further 245 µL 
KSFM with 5 µL siRNA (final concentration of 100 nM). The two solutions were 
mixed together and incubated at ambient temperature for 20 minutes, resulting in 
a final transfection mixture volume of 500 µL per well of cells. Cells were washed 
once in KSFM before adding the 500 µL transfection mixture to cells and incubating 
under normal conditions for 4h. An additional 500 µL of KSFM was added to each 
well (total volume 1 mL) after 4h, before preparing the cells to undergo TZ/PD 
differentiation by adding 1.5 µL 1 mM TZ/PD drug mixture to 500 µL KSFM, three 
times the working concentration. Three times the amount of KSFM supplements 
were also added to the 500 µL KSFM (15 ng/mL recombinant human EGF, 150 
µg/mL bovine pituitary extract and 90 ng/mL cholera toxin), which was 
subsequently added to each well and resulted in a 1x concentration of both TZ/PD 
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and supplements in the final 1.5 mL solution. 24h post TZ/PD treatment, cells were 
transferred into medium containing PD only, as detailed in section 2.4.4.9. Cells 
were harvested for RNA and protein 48h after treatment in PD alone (72h total 
drug treatment) and processed through to gene/protein expression analysis by RT-
qPCR and immunoblotting, as detailed in section 2.7.1 and 2.9.3.  
2.9 Protein analysis  
2.9.1 Immunohistochemistry  
2.9.1.1 Paraffin embedding and sectioning  
Pieces of normal ureter tissue were fixed in 10% formalin for a period of 24-48h and 
subsequently stored in Universal tubes containing 70% ethanol at ambient 
temperature until embedding. The tissues were transferred into labelled System II 
Hex™ tissue processing cassettes (Cellpath) and submerged in fresh 70% ethanol in 
a glass jar on an orbital shaker for 10 minutes. Three washes with absolute ethanol 
and two further washes in isopropanol for 10 minutes on an orbital shaker was 
required to fully dehydrate the tissue. To facilitate paraffin infiltration and remove 
the dehydrating agents, tissues underwent four 10 minute washes in xylene (Fisher 
Scientific). Excess xylene was removed by blotting cassettes with absorbent paper 
before the cassettes were submerged in a plastic pot containing paraffin wax in a 
60 oC oven for 15 minutes. Cassettes were transferred to fresh wax on three 
additional occasions, totalling 1h of submersion in wax. Samples were embedded 
by placing the biopsies in a metal embedding mould filled with wax and allowing to 
set on a 12 oC cool plate with the sample orientated as desired. Embedded samples 
could then be removed from the mould and stored at ambient temperature until 
use.  
Formalin-fixed, paraffin wax-embedded (FFPE) blocks of ureter tissue were cooled 
to 12 oC for an hour before use and cut into 5 µm sections using a RM2135 rotary 
microtome (Leica Biosystems). Cut sections were placed into a 40 oC water bath 
before being transferred onto Superfrost® Plus glass microscope slides (Thermo 
Scientific). Slides were left to air dry and stored at ambient temperature for up to a 
month until use.   
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2.9.1.2 Immunolabelling of sections  
Slides were heated to 50 oC on a heat block for 1h before undergoing a series of 
dewaxing steps: two 10 minute washes followed by two 1 minute washes (all in 
xylene). The slides subsequently underwent gradual rehydration by first submerging 
the tissue in absolute ethanol for three minute-long intervals, before a one minute 
wash in 75% ethanol and a final one minute wash in gently running tap water. To 
block the endogenous peroxidase activity of red blood cells in a sample, slides were 
submerged in 3% (v/v) Hydrogen Peroxide diluted in dH2O for 10 minutes followed 
by a 10 minute wash in running tap water.  
To reverse the effects of formalin fixation on the ability of antibodies to bind to 
epitopes of interest, different methods of Heat-Induced Epitope Retrieval (HIER) 
were used on ureter samples. The optimum HIER method for each antibody was 
determined empirically. The first method involved submerging the slides in 350 mL 
of 10 mM Citric Acid Buffer pH 6.0 (Appendix ii) in a Pyrex® dish, covering the dish 
in cling film and heating in the microwave (MW method) at 900 W for 13 minutes 
(resulting in approximately 10 minutes of boiling buffer) before placing the dish on 
ice until it had cooled down. The second method involved submerging the slides 
upright in plastic Coplin jars containing 10mM Citric Acid Buffer pH 6.0 before 
heating the jars for 10 minutes at 50 kPa in a Fast Slow ProTM pressure cooker 
(Sage®; PC method) filled with 2.5 L of water.  
After cooling down from HIER, slides were rinsed in a bath of Tris-Buffered Saline 
(TBS; Appendix ii) plus 0.1% Tween-20 (TBST) and placed in Shandon SequenzaTM 
slide racks with Shandon CoverplatesTM (both Thermo Fisher) to ensure consistent 
and sustained application of immunolabelling reagents. All immunohistochemistry 
experiments in this study used the reagents included in the ImmPRESS® Excel 
Amplified HRP Polymer Staining Kit (Vector Laboratories) to visualise antibody 
binding. Slide were blocked for non-specific secondary antibody binding with 100 µL 
2.5% (v/v) normal horse serum at ambient temperature for 20 minutes before an 
overnight incubation (16h) at 4 oC with 100 µL rodent or rabbit-derived primary 
antibody (concentration empirically determined) diluted in TBST. Each experiment 
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included negative control (antibody diluent only) and positive control (primary 
antibody previously confirmed to be urothelial positive in ureter) slides (Figure 2.7).  
Slides were washed thrice with TBST to remove excess primary antibody before 15 
minute incubation at ambient temperature with 100 µL goat anti-mouse (GaM) IgG 
or goat anti-rabbit (GaR) IgG amplifier antibody, dependent on the species the 
primary antibody has been raised in. Slides were washed twice more in TBST to 
remove unbound secondary antibody before a 30 minute incubation with a third 
antibody (ImmPRESS Excel Amplified HRP Polymer Reagent anti-goat IgG), thus 
amplifying the antibody signal. The slides were washed once in TBST and once in 
distilled water before addition of 3,3'Diaminobenzidine (DAB). Active DAB was 
produced through the 1:1 mix of ImmPACT® DAB EqV Reagent 1 and ImmPACT DAB 
EqV Reagent 2, with the mixture applied to the slides for 5 minutes before rinsing 
the slides with distilled water. When catalysed to its oxidised form DAB forms a 
brown precipitate, meaning that addition of DAB highlights the localisation of areas 
of tissue that contain HRP-conjugated antibodies and therefore proteins of interest. 
Slides were removed from slide racks and counterstained in Mayer’s haematoxylin 
(Sigma-Aldrich) for 3-5 seconds before thoroughly washing in running tap water. 
Slides underwent gradual dehydration (1x 1 minute wash in 70% ethanol, 3 x 1 
minute washes in absolute ethanol, 2x 1 minute washes in xylene) before mounting 
with DPX (Thermo Fisher) and applying a coverslip. Labelling was then visualised on 
an Olympus BX60 bright field microscope and images collected using cellSens 
Standard Micro Imaging Software (Olympus). The list of primary antibodies used in 







Target Clone Host Clonality Supplier  Dilution* HIER 
method 
E-cadherin HECD-1 Mouse mAb Abcam 1:1000 PC 
ELF3 HPA003479 Rabbit pAb  Atlas 
Antibodies 
1:1000 PC 
FOXA1 Q-6 Mouse mAb Santa Cruz 1:250 PC 
GATA3 D13C9 Rabbit mAb Cell Signalling  1:800 MW 
PPARγ 81B8 Rabbit mAb Cell Signalling  1:1000 PC 
p63 4A4 Mouse mAb Santa Cruz 1:1000 PC 
PTCH1 MAB41051 Rat mAb R&D Systems 1:100 PC 





VGLL1  HPA042403 Rabbit pAb  Atlas 
Antibodies  
1:3200 MW 
* Concentration of stock antibody vials not disclosed by manufacturers.   
 
Table 2.3: List of antibodies used for immunohistochemistry.  
mAb refers to monoclonal antibodies while pAb refers to polyclonal antibodies that were 
affinity purified prior to purchase.   
 
Figure 2.7: Example control immunohistochemistry section images 
Images of Y1870 ureter after immunohistochemical (IHC) analysis. For each IHC 
experiment, a section that received no primary antibody (-ve) and a section that 
received a positive control antibody derived from the same host species as the test 




2.9.2 Indirect immunofluorescence labelling of cells  
2.9.2.1 Preparation of fixed adherent cells on slides 
Cells were grown on sterilised glass 12-well microscope slides (Hendley-Essex) 
placed in 4-well quadriPERM® rectangular cell culture dishes (Sarstedt). Typical cell 
seeding density for cells was as follows: 5 x104 cells/mL for undifferentiated NHU 
and stromal cells, 7 x105 cells/mL for NHU cells that were to be ABS/Ca2+ 
differentiated on slides. Each well of the 12-well slide received 50 µL of cells which 
were allowed to attach for at least 2h at 37 oC before the dish was flooded with 5 
mL of appropriate medium. Immunofluorescence experiments in this study that 
feature ABS/Ca2+ differentiated NHU cells use cells that were differentiated on the 
slides, meaning cells were seeded onto the slides in an undifferentiated state and 
flooded with 5% ABS 2h post-seeding. Cultures were subsequently treated in the 
manner described in Section 2.4.4.5 until cells had reached 7 days ABS/Ca2+ 
treatment. Scratch wounding of ABS/Ca2+ differentiated NHU cells on slides was 
performed as described in Section 2.4.4.7, with cultures fixed either 30 minutes, 4h 
or 72h following wounding.  
Upon reaching the desired confluence or completion of an experimental treatment, 
cells were washed twice in PBS before fixation via one of two methods: 
i) Methanol:acetone fixation (dehydration of cells using organic solvents). 
Slides were fixed in a 1:1 ratio of methanol and acetone for 30 seconds 
in a glass Coplin jar before allowing slides to dry at ambient 
temperature.  
ii) Formalin fixation (crosslinking reagent that preserves cellular structure). 
Applied 5 mL 10% formalin per slide to the cell culture dish for 10 
minutes at ambient temperature before two 5 minute wash steps in PBS. 
Formalin-fixed slides were subsequently submerged in PBS and kept at 
4oC until use (up to one week following fixation). Formalin-fixed slides 
required an additional 30 minute incubation in PBS containing 0.5% 
(w/v) Triton™ X-100 (Sigma-Aldrich) in order to permeabilise the cells 




Prior to primary antibody application, slides were washed twice for 5 minutes with 
PBS before the areas around the cells on the slides were dried and an ImmEdge 
grease pen (Vector Laboratories) was applied to avoid merging of antibodies 
between wells. Primary antibodies (Table 2.4) were diluted in TBS containing 0.1% 
BSA and 0.1% sodium azide (NaN3) and 20-30 µL was added to their respective 
wells. Each experiment included negative control (antibody diluent only) and 
positive control (primary antibody previously confirmed to be positive in the cell 
type assayed) wells (Figure 2.8). Primary antibodies were pre-titrated on a positive 
control cell type before use with experimental samples to confirm the optimum 
antibody concentration and fixation method to use. Slides were incubated with 
primary antibodies overnight (16h) at 4 oC before removal from the wells by 
pipetting to prevent cross-contamination of antibody during wash steps. Slides 
were flushed once with PBS for 5-10 seconds before three 5 minute washes in PBS 
on the orbital shaker. Slides were fixed in fresh methanol:acetone for 30 seconds 
and allowed to dry. 20 µL fluorochrome-conjugated secondary antibodies diluted in 
TBS/0.1% BSA/0.1% NaN3 (Table 2.5) were applied to wells at ambient temperature 
for 1h, requiring slides to be protected from light sources by foil to prevent photo-
bleaching. Slides were washed twice for 5 minutes with PBS and then incubated 
with PBS containing 0.1 µg/mL Hoechst 33258, a fluorescent dye that intercalates 
with double-stranded DNA by binding to its minor groove. Slides were washed once 
in PBS and once in dH2O for 5 minutes each before a final drying step, after which 
the slides were mounted with Prolong™ Gold Antifade Reagent (Thermo Fisher) and 
covered by glass coverslips. Slides were stored at -20 oC in the dark until images 
were captured. Fluorescent labelling was visualised using an Olympus BX60 
epifluorescence microscope and digital images collected using cellSens Standard 




Target Clone Host Clonality Supplier Concentration* Dilution 
p-AKT (Ser473) #9271 Rabbit pAb Cell Signalling Unknown 1:25 
E-cadherin HECD-1 Mouse mAb Abcam Unknown 1:1000 
ELF3 HPA003479 Rabbit pAb  Atlas Antibodies Unknown 1:400 
p-ERK1/2 (Thr202/Tyr204) #9101 Rabbit  pAb Cell Signalling Unknown 1:200 
(Total) ERK1/2 #610123 Mouse mAb BD Biosciences 0.25 mg/mL 1:500 
GATA3 D13C9 Rabbit mAb Cell Signalling Unknown 1:800 
GLI1 OTI4E2 Mouse mAb Novus Biologicals Unknown 1:1600 
Ki67 MM1 Mouse mAb Leica Biosystems Unknown 1:400 
MCM2 D7G11 Rabbit mAb Cell Signalling  Unknown 1:1600 
PPARγ 81B8 Rabbit mAb Cell Signalling Unknown 1:100 
PTCH1 MAB41051 Rat mAb R&D Systems 0.5 mg/mL 1:50 
p63 4A4 Mouse mAb Santa Cruz 0.2 mg/mL 1:100 
p-SMAD3 (Ser423/Ser425) EP823Y Rabbit mAb Abcam 0.5 mg/mL 1:50 
(pan)-TEAD D3F7L Rabbit mAb Cell Signalling Unknown 1:800 
VGLL1  10124-2-AP Rabbit pAb  Proteintech Unknown 1:1600 
VGLL1 HPA042403 Rabbit pAb Atlas Antibodies Unknown 1:1600 
(Total) YAP  63.7 Mouse mAb Santa Cruz 0.1 mg/mL 1:800 
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Figure 2.8: Example control immunofluorescence images 
Images of Y886 stromal cells grown on glass slides. For each immunofluorescence experiment, a well that received no primary antibody (-ve) and a well 
that received a positive control antibody (such as vimentin in stromal cells) was included. The smaller image in each left hand corner displays the 













                                
 
 
Vimentin V9 Mouse mAb Sigma Unk.  1:800 
ZO-1 1A12 Mouse mAb Thermo Fisher 0.5 mg/mL 1:400 
ZO-1α+ Anti-ZO-1α+ Rabbit pAb Hycult Biotech 0.1 mg/mL 1:20 
ZO-2 #2847 Rabbit pAb Cell Signalling Unknown 1:25 
ZO-3 D57G7 Rabbit mAb Cell Signalling Unknown 1:800 
Table 2.4: List of primary antibodies used for immunofluorescence. 



















Target Conjugate Host Class Supplier Concentration Dilution 
Anti-mouse (IgG)  Alexa Fluor 488 (green) Goat pAb  Invitrogen 2 mg/mL 1:500 
Anti-rabbit (IgG)  Alexa Fluor 488 (green) Goat pAb  Invitrogen 2 mg/mL 1:500 
Anti-mouse (IgG)  Alexa Fluor 555 (red) Goat pAb  Invitrogen 2 mg/mL 1:500 
Anti-rabbit (IgG)  Alexa Fluor 555 (red) Goat pAb  Invitrogen 2 mg/mL 1:1000 
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2.9.3 Western blotting  
2.9.3.1 Preparation of protein lysates 
Cells cultured for the purpose of protein extraction were grown in either 10 cm 
dishes (10 mL medium per dish) or 6-well plates (2-3 mL medium per well). Upon 
reaching the completion of a time-point or the desired cell confluence, 2x Sodium 
Dodecyl Sulfate (SDS) sample buffer (Appendix ii) solution was premixed with 1 M 
DTT diluted 1:67 and a Protease Inhibitor Cocktail (both Sigma) diluted 1:100. 
Cultures were washed twice in cold PBS before 75-150 µL complete SDS sample 
buffer was added to each well of a 6 well plate to solubilise the cells. While samples 
were kept on ice, cell scrapers were used to detach and pool the cell lysates in each 
well before pipetting the solution into chilled 1.5 mL microfuge tubes. Samples 
were sonicated on ice to disrupt cellular structure using an ultrasonic processor 
(VWR; formally Jencons Scientific) for two 10 second bursts at 25 W, with 10 
seconds of rest in between bursts. Samples were left on ice for 30 minutes before 
being heated to 95 oC using a heat block for 5 minutes. Due to the negative effect 
that SDS can have on the accuracy of downstream quantification of protein content, 
samples were cooled on ice for a further 10 minutes and centrifuged at 20000 x g 
for 30 minutes at 4 oC to separate the lysate from the SDS. Protein lysates were 
subsequently pipetted into fresh microfuge tubes and stored at -20 oC until use. 
2.9.3.2 Protein quantification 
Quantification of protein concentration in lysates for the purposes of normalisation 
was performed using a Coomassie® Plus Protein Assay Reagent Kit (Thermo Fisher; 
formally Pierce). Vials containing 2 mg/mL BSA were diluted sequentially in dH2O to 
create protein standards of 1000, 750, 500, 250, 125, 25 and 0 (dH2O only) µg/mL. 
10 µL of each standard was added in duplicate to a 96-well plate in addition to 10 
µL protein samples (diluted 1:12.5 in dH2O) in duplicate. Coomassie® Reagent was 
warmed to ambient temperature before 200 µL was added to each well. The plates 
were shaken for 30 seconds in a Multiskan Ascent 96-well plate reader before 
absorbance of standards and samples were measured at 570 nm and 630 nm. The 
absorbance readings of the BSA standards were used to construct a standard curve 
which was used to determine the concentration of each test lysate, with duplicate 
103 
 
sample wells giving a final average concentration. Between 10 and 40 µg 
protein/sample was used in each immunoblot experiment, depending on the 
predicted expression of proteins of interest in the samples. 
2.9.3.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein lysates were prepared for SDS-PAGE by mixing the required concentration 
of total protein with NuPAGE 4x Lithium Dodecyl Sulfate (LDS) sample buffer (to 
replace the SDS detergent in the lysis buffer), 10x NuPAGE Sample Reducing Agent 
and dH2O to a set volume of between 36 to 46 µL. All NuPAGE reagents, gels and 
gel tanks were purchased from Invitrogen.  Samples were heated to 70 oC for 10 
minutes and briefly centrifuged, resulting in lysate mixes containing denatured, 
negatively charged proteins.  Samples were loaded into two types of pre-cast gel 
depending on target protein molecular weight: Bolt™ 4-12% Bis-Tris Plus 1.0mm x 
10/12 well (proteins < 125kDa) or NuPAGE ™ 3-8% Tris-Acetate 1.0mm x 10 well 
(proteins >125 kDa). Similarly, three different types of SDS running buffer were 
used: Tris-Acetate (Tris-Acetate gels), NuPAGE MOPS (Bis-Tris gels focusing on 
proteins > 50kDa) and NuPAGE MES (Bis-Tris gels for proteins < 50kDa). Gels were 
placed inside Mini Gel Tanks and submerged in selected running buffer diluted 1:20 
in dH2O before lysate samples were loaded alongside one well containing 5 µL 
Precision Plus Protein All Blue Standards (Bio-Rad). 200 µL NuPAGE Antioxidant was 
added to the inner chamber of the gel prior to electrophoresis to ensure that 
proteins remain in a reduced state throughout the process. SDS-PAGE was 
performed at 200 V (Bis-Tris gels) or 150 V (Tris-Acetate gels) for between 30 
minutes to 1h 15 minutes to allow the negatively-charged, linearised proteins to 
move through the gel and be separated on the basis of size.   
2.9.3.4 Electroblotting 
A protein-immobilising polyvinylidene difluoride (PVDF) membrane was cut into an 
appropriate size and activated by submerging in methanol for 30 seconds, rinsing in 
dH2O for 2 minutes and leaving to equilibrate in fresh transfer buffer (Appendix ii). 
A gel membrane “sandwich” was constructed to fit in a Mini Blot Module 
(Invitrogen) with the items arranged in the following order: cathode (-) core, 
sponge pad, filter paper, SDS-PAGE gel, PVDF membrane, filter paper, sponge pad, 
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anode (+) core. A mini rolling pin was used to ensure that no air bubbles were 
present between layers of the sandwich. The Mini Blot Module was inserted into 
the Mini Gel Tank, with the inner chamber filled with ice-cooled transfer buffer and 
dH2O added to the outer chamber. Electrotransfer was performed for between 1h 
and 3h (depending on size of protein targets) at 20 V. Upon completion of protein 
transfer, membranes were removed from Mini Blot Modules, moved to square 
plastic dishes and washed in 25 mL TBS. Membranes were reversibly stained with 
0.5% (w/v) Ponceau Red staining solution (Appendix ii) for 10 seconds and washed 
multiple times in dH2O to visualise the protein content of each lane and to confirm 
successful transfer.  
2.9.3.5 Immunoblotting  
In order to prevent nonspecific antibody binding, membranes were blocked with 20 
mL of blocking buffer at ambient temperature for 1h on an orbital shaker. 
Depending on the primary antibody used, blocking buffer consisted of either a) 1:1 
mix of TBS with a PBS-based Odyssey Blocking Buffer (Li-Cor) or b) 5% (w/v) 
A0830,0500 Non-fat Dried Milk Powder (PanReac AppliChem) solubilised in TBS. 
Primary antibodies (Table 2.6) were diluted in either a 1:1 mix of Odyssey Blocking 
Buffer and TBST, 5% (w/v) milk powder in TBST or 5% (w/v) BSA in TBST in a volume 
of 3 mL to 20 mL, depending on the dilution of antibody required. Antibody solution 
was applied to blots overnight at 4 oC on an orbital shaker. Membranes underwent 
four 5 minute wash steps with TBST to remove unbound primary antibody before 
blots were incubated for 1h at ambient temperature with fluorescent secondary 
antibodies (Table 2.7) diluted in either a 1:1 ratio of Odyssey Blocking Buffer and 
TBST or 5% (w/v) milk powder in TBST.  Blots were washed four further times for 5 
minutes (thrice in TBST, once in TBS) before scanning for fluorescent bands using 
the Odyssey Infrared Sa Imaging System (Li-Cor). Image Studio v5.2.5 software was 
used to visualise bands and, where appropriate, determine relative protein 
expression between samples using densitometry analysis of band intensity. 
Visualisation of housekeeping protein β-Actin was used for each blot to confirm 
equal protein loading for each sample. Primary antibodies were titrated on a 
positive control lysate before use with experimental samples to confirm the 
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optimum antibody concentration to use. Non-specific binding of secondary 
antibodies was tested by applying second antibodies to blots that had not received 
any primary antibody (Fig. 2.9). 
 
Figure 2.9: Secondary antibody only immunoblotting 
Example blots where 0.2 µg/mL Goat Anti-mouse (IgG) Alexa680 and 0.1 µg/mL 
Goat Anti-rabbit (IgG) DyLight 800 secondary antibody mixes were applied before 




Target Clone Host Class Supplier Conc.* Dilution Blocking buffer 
p-AKT (Ser473) #9271 Rabbit pAb  Cell Signalling  Unknown 1:1000 Both 
(Total) AKT #9272 Rabbit pAb  Cell Signalling  Unknown  1:1000 Odyssey 
β-Actin AC15 Mouse mAb Sigma 2 mg/mL 1:250000 Both 
Claudin 3 ab52231 Rabbit pAb  Abcam 1 mg/mL 1:1000 Odyssey 
Claudin 4 3E2C1 Mouse  mAb Thermo Fisher 0.5 mg/mL 1:1000 Odyssey 
Cytokeratin 13 1C7 Mouse mAb Abnova Unknown 1:1000 Odyssey 
ELF3 EPESER1 Rabbit mAb Abcam Unknown 1:20000 Odyssey 
p-ERK1/2 (Thr202/ 
Tyr204) 
#9101 Rabbit  pAb Cell Signalling  Unknown 1:1000 Both 
(Total) ERK1/2 #610123 Mouse mAb BD Biosciences 0.25 mg/mL 1:2000 Odyssey 
FABP4 D25B3 Rabbit mAb Cell Signalling Unknown 1:1000 Odyssey 
FGFR3  B-9 Mouse mAb Santa Cruz 0.2 mg/mL 1:1000 Milk 
FOXA1 Q-6 Mouse mAb Santa Cruz 0.1 mg/mL 1:500 Odyssey 
GATA3 D13C9 Rabbit mAb Cell Signalling  Unknown 1:1000 Odyssey 
GLI1  L42B10 Mouse mAb Cell Signalling Unknown 1:1000 Milk 
MCM2 D7G11 Rabbit mAb Cell Signalling  Unknown 1:1000 Odyssey 
p63 4A4 Mouse mAb Santa Cruz 0.2 mg/mL 1:500 Odyssey 
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PPARγ D69 Rabbit pAb Cell Signalling Unknown 1:1000 Odyssey 
(pan)-TEAD D3F7L Rabbit mAb Cell Signalling Unknown 1:1000 Milk 
VGLL1 10124-2-AP Rabbit pAb Proteintech Unknown 1:1000 Both 
VGLL1 HPA042403 Rabbit pAb Atlas Antibodies Unknown 1:1000 Both 
p-YAP (Ser127) #4911 Rabbit pAb  Cell Signalling Unknown 1:1000 Milk 
(Total) YAP  63.7 Mouse mAb Santa Cruz 0.1 mg/mL 1:1000 Milk 
ZO-3 D57G7 Rabbit mAb Cell Signalling Unknown 1:1000 Odyssey 
 
                             Table 2.6: List of primary antibodies used for immunoblotting. 
                             *Unknown designates that concentration of stock antibody vial was not disclosed by manufacturer. 
Target Conjugate Host Class Supplier Conc. Dilution Blocking 
buffer 
Anti-mouse 
(IgG H+L)  
Alexa680 Goat pAb  Thermo Fisher 2 mg/mL 1:10000 Both 
Anti-rabbit 
(IgG H+L)  
DyLight 800 Goat pAb  Rockland 1 mg/mL 1:10000 Both 
                                           




2.10.1 General  
The RNAseq analysis pipeline described in the following section was performed to 
analyse the data generated in section 5.4.4. All other RNAseq data was first 
converted into readable .xlsx files (using a similar pipeline) by Dr. Andrew Mason of 
the Jack Birch Unit before use in this study.  
2.10.2 RNAseq analysis pipeline 
2.10.2.1 Preprocessing of sequencing reads 
If required, raw paired-end sequencing reads (zipped in .gz files) were trimmed 
using Trimmomatic v0.36 (Bolger et al., 2014), a program that cuts reads based on 
user-defined adapter sequences and for low quality using a sliding window quality 
filtering score. The quality of the resultant reads were confirmed using FastQC 
v0.11.5 (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The shell 
scripts input to run Trimmomatic and analyse .gz files using FastQC are detailed in 
Appendix xv.  
2.10.2.2 Mapping of reads to reference transcriptome 
Preprocessing of paired-end sequences with Trimmomatic resulted in a collection of 
unpaired reads which were unsuitable for reference-based alignment. Unpaired 
reads were therefore assigned “pseudo” complementary reads prior to mapping. 
Reads were mapped to the reference Ensembl human transcriptome (GRCh38-p10) 
using Kallisto v0.44.0 (Bray et al., 2016). Samples were bootstrapped 100 times in 
order to ensure the most accurate mapping value for each read. The scripts used to 
assign pseudo reads to unpaired reads and to map the processed reads to the 
transcriptome using Kallisto are detailed in Appendix xv.  
2.10.2.3 Differential gene expression analysis 
Quantification of total read counts per gene was performed in R Studio v3.5.1 using 
tximport (Soneson et al., 2016), with transcript expression normalised as 
Transcripts per Million (TPM) then aggregated by gene using the R interface to the 
Ensembl BioMart (biomaRt v3.9; Durnick et al., 2009). The most differentially 
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expressed genes between control and treatment conditions were identified using 
either sleuth v0.30.0 (which accounts for donor-specific variation using the 
likelihood ratio test; Pimentel et al., 2017), or DESeq2 v1.28.1. The scripts used to 
run tximport, sleuth and DESeq2 are detailed in Appendix xv. 
2.10.3 Other bioinformatics tools 
Principle component analysis of variance in expression of genes of interest across 
RNAseq datasets was performed using the prcomp function of R Studio, with 
visualisation of the data performed using ggbiplot. The scripts used to run prcomp 
and ggbiplot are detailed in Appendix xv.  
DNA sequences upstream of the promoter of genes of interest were analysed using 
JASPAR (http://jaspar.genereg.net/) to identify potential transcription factor 
binding sites. 
The open-access cBioPortal for Cancer Genomics resource (Cerami et al., 2012) was 
used to analyse the mutation and copy number alteration rate of genes of interest 
in cases of MIBC. 
Expression data from RNAseq datasets were visualised as a matrix heat map using 
Morpheus software (https://software.broadinstitute.org/morpheus/) and grouped 
through hierarchical clustering. The results of DESeq2 analysis between two 
subgroups of RNAseq data was visualised using EnhancedVolcano v.1.6.0, which 
creates a volcano plot from the input data. Enrichment (or suppression) or a 
previously curated set of genes (the Molecular Signatures Database hallmark gene 
sets; https://www.gsea-msigdb.org/gsea/msigdb/index.jsp) in a differential 
expression analysis was analysed using the Gene Set Enrichment Analysis (GSEA) 
tool fgsea v.1.14.0. The scripts used to run EnhancedVolcano and fgsea are detailed 
in Appendix xv. 






2.11 Statistical Analysis   
Data that was represented graphically was created using either Prism 8 (GraphPad) 
or R studio software. Either the mean or the median value for every condition is 
displayed on each graph, with error bars on graphs referring to the ± standard 
deviation from the mean of all replicates.  Statistical analysis was performed in 
Prism 8 using experiments with at least three biological replicates. A Shapiro-Wilk 
test of normality was performed on each dataset to determine an appropriate use 
of parametric (or non-parametric) tests. Differences between two sample means 
was calculated using an unpaired (two-tailed) ’t’ test, while three or more samples 
were compared using a one-way analysis of variance (ANOVA) test, with 
appropriate post-hoc test.  The Kaplan-Meier estimator was implemented to 
determine whether identified subgroups in MIBC had a worse overall survival rate 
than others. Significance between survival rates was calculated using the Mantel-
Cox log-rank test. With the exception of RNAseq differential expression analysis 
data, a p value ≤0.05 was considered as significant in all experiments. Significance 
was represented on graphs as: p ≤0.05= *, p ≤0.01= **, p ≤0.001= ***. When 
analysing differential expression analysis datasets, a false discovery rate-adjusted p 















3. Characterisation of VGLL1 and Hippo pathway signalling in 
normal human urothelial cells  
 
3.1 Introduction 
3.1.1 Hippo signalling pathway 
A key question investigated by developmental biologists historically has been to 
understand the molecular basis for how multicellular organisms can undergo 
morphogenesis while maintaining a correct size and structure of tissues and organs. 
Studies in Drosophila melanogaster elucidated the importance of several genes, 
including Warts (wts), Salvador (sav) and Hippo (hpo), as being critically important 
to maintain tissue size due to an aberrant overgrowth of organs upon their 
mutation or deletion (Justice et al., 1995; Kango-Singh et al., 2002; Udan et al., 
2003). Conversely, deletion of a Wts-interacting protein, Yorkie (Yki), was found to 
abrogate the tissue overgrowth effect in wts, hpo and sav mutants (Huang et al., 
2005). Yki, Wts, Sav and Hpo were later grouped into a signalling pathway known as 
Hippo, which was found to be highly conserved in mammalian systems (Fig. 3.1). An 
example of this was demonstrated in mice, whereby the overexpression of the 
mammalian orthologue of Yki, Yes-associated protein (Yap), was found to inhibit 
differentiation and activate aberrant growth in primary mouse keratinocyte cells 










Figure 3.1: Mammalian Hippo pathway signalling 
Modulation of active Hippo signalling performs an important function in regulating 
mammalian cell growth and quiescence. In its “off” state, transcriptional co-activators 
YAP/TAZ are localised to the nucleus and bind to the transcription factor TEAD family to 
induce transcription of genes such as AXL, ANKRD1, CTGF and CYR61 (Zanconato et al., 
2015) in order to activate proliferative or migratory processes. Activation of the Hippo 
pathway in contact-inhibited cells results in phosphorylation of YAP at its serine 127 
(S127) site through sequential kinase activation of cytoplasmic MST1/2 and LATS1/2 
(Chan et al., 2005). Phosphorylated YAP is sequestered in the cytoplasm by the 
regulatory protein 14-3-3, unable to induce transcription of its target genes (Basu et al., 
2003). YAP/TAZ can additionally be rendered inactive through retention at the cell 
membranes by proteins such as angiomotin (AMOT), or processed for poly-
ubiquitination and proteasomal degradation after phosphorylation at its serine 381 site 
(Zhao et al., 2010; Chan et al., 2011). Transcription co-activators of the VGLL family are 
also able to bind to TEAD proteins, and have been shown to compete with YAP/TAZ to 
bind to TEAD when both co-activators are present in the same cell. Diagram adapted 
from a review of Hippo pathway signalling by Yu et al. Yellow circles = phosphorylated 
















In mammals, YAP has a closely related paralog entitled transcriptional co-activator 
with PDZ binding motif (TAZ; gene name WWTR1). Taz has been previously 
demonstrated in mice to have the ability to affect phenotype in the same manner 
as Yap, even when Yap is functionally inactivated through mutation (Nishioka et al., 
2009). YAP and TAZ are transcriptional co-activators, meaning that they do not 
activate transcriptional activity by binding directly to DNA but rather bind to 
transcription factors as part of a complex to induce transcriptional activity 
(reviewed by Hansen et al., 2015). YAP/TAZ has been reported to bind to various 
transcription factors, such as β-catenin and SMAD2/3 (Imajo et al., 2012; Varelas et 
al., 2008), but have primarily been investigated in relation to members of the family 
of TEAD transcription factors, of which there are four in humans. Binding of YAP to 
TEAD1, TEAD3 and TEAD4 was demonstrated to cause the upregulation of 
expression of genes such as CTGF and ITGB2 in immortalised human breast 
epithelial cells, resulting in a stimulation of growth (Zhao et al., 2008). Later studies 
marked both YAP and TAZ as the functional effectors of Hippo pathway regulation, 
as YAP/TAZ complex with TEAD proteins in the nucleus to induce transcription of 
various genes involved in processes such as proliferation, migration and tumour cell 
invasiveness (Stein et al., 2015; Zhao et al., 2019). Beyond the mechanisms of 
YAP/TAZ regulation highlighted in Figure 3.1, the transcriptional co-activators have 
additionally been shown to be controlled by a negative feedback loop in 
immortalised human breast epithelial cells where YAP/TAZ induces transcription of 
its own regulators such as NF2 and LATS2 (Moroishi et al., 2015). 
3.1.2 YAP/TAZ function in non-malignant mammalian cells  
Due to its regulation by multiple kinases and sequestration events, YAP/TAZ has 
been found to dynamically shift between intracellular locations in response to 
stimuli. Similar to the phenotype observed with active β-catenin signalling in NHU 
cells (Georgopoulos et al., 2014), one stimulus involved in modulating YAP/TAZ 
localisation appears to be cell density, as human immortalised breast epithelial 
MCF10A cells grown in sparse cultures exhibited nuclear localisation of YAP that 
translocated to the cytoplasm upon reaching quiescence (Zhao et al., 2007). 
Localisation of YAP/TAZ also seems to be affected by scratch wound healing, with 
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MCF10A cells exhibiting nuclear YAP at the wound edge but cells situated away 
from the wound expressing cytoplasmic YAP. In this situation, nuclear YAP 
expression was found to correlate highly with Ki67-positive cells at the wound edge 
(Zhao et al., 2007), suggesting that activation of YAP may promote re-entry into the 
cell cycle. 
In an in vivo context, Yap has been demonstrated to play an important role in tissue 
regeneration in multiple rodent models. In one particular study, Yap expression was 
shown to be transiently induced in hepatocytes upon chemical injury of the liver, a 
highly regenerative organ. When Yap expression was inactivated in conditional 
knockout mice, hepatocyte cells were found to exhibit significantly reduced 
proliferation, resulting in defective regeneration of the tissue and the occurrence of 
abnormal collagen deposition around the wound (Su et al., 2015). A study 
investigating the response of rat bladder tissue to bladder outlet obstruction 
described significant upregulation of transcript and protein expression of Ctgf and 
Cyr61. This was localised to the smooth muscle and lamina propria regions of the 
bladder and was positively correlated to areas of collagen deposition (Chaqour et 
al., 2002). Subsequent analysis of bovine bladder smooth muscle cells determined 
that CYR61 was additionally induced in vitro following externally applied mechanical 
strain, with the protein responsible for the induction of mechanotransduction-
related genes such as VEGF and ACTA2 (α-smooth muscle actin; Zhou et al., 2005). 
These results therefore suggest that CTGF and CYR61, which would later be  
confirmed as YAP/TAZ target genes (Zanconato et al., 2015), may play a role in 
promoting connective tissue synthesis and inducing fibrosis in multiple rodent 
tissues following deformation, including the morphologically compliant bladder 
stroma.  
3.1.3 Vestigial-like protein family 
The four proteins of the Vestigial-like (VGLL) protein family are the human 
homologues of Vestigial (Vg), a protein discovered in Drosophila. As reported for Yki 
(YAP orthologue), Vg has no DNA-binding domain of its own and instead binds to 
Scalloped (Sd; TEAD) to regulate gene expression. This was first determined in 
developing Drosophila embryo, as Vg/Sd binding was demonstrated to be crucial for 
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the induction of wing formation (Kim et al., 1996). The 25 amino acid binding site 
motif between Vg and Sd is highly conserved in Vestigial-like mammalian proteins, 
with VGLL1-4 in this case binding to the mammalian homologues of Sd, TEAD1-4 
(Vaudin et al., 1999).  
Initial studies of human VGLL1 (originally named TONDU) demonstrated that 
through retention of the complete Sd/TEAD binding motif, VGLL1 was able to 
partially restore Vg activity in loss-of-function mutant Drosophila (Vaudin et al., 
1999). Interestingly, despite the TEAD-interacting domains of mouse Vgll1 and Yap 
being highly dissimilar to one another at the primary sequence level (Table 3.1), 
both co-activators adopt a similar conformation when binding to Tead4 through 
hydrophobic interactions at their 41VxxHF45 and 65LxxLF69 domains, respectively 
(Pobbati et al., 2012; Fig. 3.2). Both proteins were found to compete to bind to the 
C-terminal domain of human TEAD4 and bound the transcription factor with the 
same affinity, despite the mouse-derived Vgll1 peptide lacking the Ω-loop domain 
of  human YAP (Mesrouze et al., 2014). Competition between VGLL1 and YAP for 
binding to TEAD4 was investigated in an in vitro context in human HEK293 cells, 
with a proposed switch in dominant binding of TEAD4 from YAP/TAZ to VGLL1 
speculated to induce a different collection of genes, suggesting that either the co-
activators alter TEAD activity through their specific binding mechanisms or that 
each protein recruits a unique set of co-factors which alter phenotype (Pobbati et 
al., 2012).  
Protein TEAD-interacting 
interface 1 sequence 
TEAD-interacting 
interface 2 sequence 
Vgll1 SVIFT DINSMVDEHFSRAL 
Yap HQIVHV DSETDLEALFNAVMN 
 
Table 3.1: Amino acid sequences of mouse Vgll1/Yap TEAD-interacting regions 
The 41VxxHF45 and 65LxxLF69 regions of Vgll1 and Yap that bind to Tead4 through 
hydrophobic interactions are highlighted in bold. The TEAD-interacting interface 



























Figure 3.2: Comparison of mouse Vgll1/Tead and Yap/Tead binding  
Ribbon cartoon representation of Vgll1 (A; cyan shape) and Yap (B; gold shape) 
binding to Tead. Vgll1 binds to Tead4 through hydrophobic interactions at 41VxxHF45, 
while Yap binds to Tead4 at 65LxxLF69, with both domains residing in the binding 
interface 2 of each complex. The crystal structures of each protein-protein interaction 
were determined by Pobbati et al. (A) and Chen et al. (B). Graphical representations 
of the Vgll1/Tead (5Z2Q) and Yap/Tead (3KYS) complexes were obtained from the 





3.2 Aims and hypothesis 
Control of tissue homeostasis through modulation of the Hippo pathway has been 
implicated in various mammalian tissues. However, there is currently no published 
literature that has characterised the Hippo pathway or determined its role in 
normal human urothelial biology. Furthermore, most studies detailing Hippo 
signalling in “normal” human cells in vitro make use of immortalised cell lines that 
have largely lost the ability to accurately replicate the homeostatic mechanisms 
found in vivo. Therefore, the overall aims of this chapter were to a) confirm that 
Hippo pathway signalling was present in urothelial cells, b) understand how 
activation or inhibition of the pathway is regulated in NHU cells, and c) investigate 
how the Hippo pathway affects urothelial cellular phenotype in a normal, non-
immortalised cell context. It was hypothesised that the differentiated, mitotically-
quiescent urothelial cell phenotype is maintained through an activation of Hippo 
pathway signalling and an inhibition of YAP/TAZ-mediated cell cycle re-entry, 
potentially through competitive binding of VGLL proteins to TEAD transcription 
factors.  Dysregulation of VGLL protein expression could therefore subsequently 
lead to an imbalance in urothelial tissue homeostasis and a reactivation of the 
proliferative, ‘wound healing’ phenotype. 
To investigate this hypothesis, the specific experimental objectives were to: 
 Verify the components of Hippo pathway signalling present in urothelial 
cells and determine whether expression of these components are affected by in 
vitro cell culture or differentiation state (Section 3.4.1). 
 
 Upon validating immunolabelling resources for studying components of the 
Hippo pathway, to compare expression of Hippo proteins of interest to proteins 
associated with a differentiated urothelial phenotype in fixed ureter samples by 
immunohistochemistry, in addition to differentiated and undifferentiated NHU 




 After ascertaining transcription factor binding sites upstream of the VGLL1 
gene, to determine what transcription factors control the induction of VGLL1 
expression in differentiated NHU cells (Section 3.4.3-5). 
 
 As proliferation of NHU cells is known to use the EGFR/RAS/RAF/MEK/ERK 
or PI3K/AKT signalling axes depending on context, to investigate whether these 
pathways are involved in modulating expression of VGLL1 (Section 3.4.6). 
 
 Utilise genetically modified NHU cell lines that overexpress or knockdown 
VGLL1 (Section 3.4.7) to investigate the role VGLL1 plays in modulating 
proliferation and ERK, PI3K/AKT and YAP/TAZ signalling (Section 3.4.8); 
differentiation (Section 3.4.9); and barrier maintenance, wound healing and cell 














3.3 Experimental approach 
3.3.1 Transcriptomic analysis of Hippo pathway genes 
Pre-existing data from RNAseq experiments of urothelial cells in different 
physiological contexts (Fishwick et al., 2017 and unpublished data) were used to 
compare transcript expression of genes of interest across multiple normal urothelial 
cell samples. This included gene expression from cells lysed immediately after 
isolation from ureter (Urothelium in situ) in addition to NHU cells grown in serum-
free KSFMc medium (Undifferentiated) and NHU cells differentiated using one of 
two well characterised methods: ABS/Ca2+ (Section 2.4.4.5) or TZ/PD (Section 
2.4.4.9). Genes of interest included various components of Hippo signalling, the 
VGLL family of transcriptional co-activators and genes previously cited as being 
important in regulating urothelial physiology. Upon identification of VGLL1 as a 
differentially expressed gene in urothelium, its association to various transcription 
factor genes in urothelial cells (under different states) was analysed by principal 
component analysis. The list of 35 transcription factors analysed were taken from a 
study by Fishwick et al. which identified urothelial transcription factors based on 
matched motif sequences in FAIREseq peaks (indicative of open chromatin regions) 
in undifferentiated and differentiated NHU cells (Fishwick et al., 2017). 
3.3.2 Characterisation of Hippo pathway component protein expression in 
differentiated urothelium 
Antibodies specific to VGLL1, total and phosphorylated (S127) YAP and “pan”-TEAD 
were validated for use in immunoblotting, immunofluorescence and/or 
immunohistochemistry-based assays. Additional immunohistochemistry 
experiments were performed to compare and contrast the localisation and 
expression of VGLL1 to prominent urothelial transcription factors in two ureter 
samples. 
Immunoblotting and immunofluorescence approaches were used to characterise 
protein expression of VGLL1, YAP (in an active and phosphorylated state) and TEAD 
in NHU cells in an undifferentiated state compared to cells differentiated using the 
TZ/PD and ABS/Ca2+ methods. Other targets labelled for in the experiment include a 
selection of urothelial-associated transcription factors, tight junction proteins 
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associated with late differentiation and proteins that mark cells as being actively 
proliferating. 
3.3.3 Induction of VGLL1 expression by urothelial transcription factors 
As a regulator of urothelial cytodifferentiation, PPARγ has previously been 
demonstrated to either directly or indirectly induce expression of various 
differentiation-associated genes in NHU cells (Böck et al., 2014; Varley et al., 2004a; 
Varley et al., 2006; Varley et al., 2009). To determine whether activation of PPARγ 
had any involvement in induction of VGLL1 expression, NHU cells were 
differentiated using TZ/PD but additionally pre-treated with T007 to inhibit PPARγ 
activity. Five independent cell lines were assayed by RT-qPCR for expression of 
VGLL1, ELF3 and FABP4 transcript after 72h of TZ/PD/T007 treatment while VGLL1 
protein expression was assayed in three NHU cell lines by immunoblot following the 
above treatment for periods of 24h, 72h and 144h.   
To identify potential candidates of alternative urothelial-associated transcription 
factors that could drive VGLL1 expression in a differentiated state, the DNA 
sequence upstream of the VGLL1 gene was analysed using an online transcription 
factor binding site tool (JASPAR) to uncover transcription factors predicted to bind 
in this area.  
Following this approach, GATA3 was identified as a potential regulator of VGLL1 
expression. To test this hypothesis, commercially available siRNA designed to target 
regions of the GATA3 gene sequence (Table 3.2) were used to transiently 
knockdown GATA3 expression in NHU cells. Three independent NHU cell lines were 
transfected with control siRNA or one of two GATA3 siRNA before induction of 
TZ/PD mediated differentiation. RT-qPCR and immunoblot analysis was 
subsequently performed to determine changes in transcript and protein expression 
of GATA3, VGLL1 and other proteins of interest. 
siRNA information  Nomenclature in thesis  
Silencer Select Negative Control siRNA Ctrl siRNA  
Silencer Select GATA3 siRNA (S5600) GATA3 siRNA #1 




Table 3.2: List of siRNA used in study 
GATA3 siRNA #1 and #2 were predesigned to target the human GATA3 transcript at exons 5 
and 6, respectively. The Ctrl siRNA was predesigned to not target any human genes.  The 
above siRNA were purchased from Thermo Fisher. 
3.3.4 Effect of active EGFR and downstream signal transduction pathways on VGLL1 
expression 
To understand whether expression of VGLL1 is modulated through the signalling 
pathways that power urothelial cell proliferation, the TZ/PD differentiation process 
was scrutinised through a series of immunoblot assays to determine what 
components of the treatment process were important for inducing VGLL1 protein. 
First, VGLL1 expression was analysed in NHU cells treated with PD153035 without 
concurrent treatment with TZ, with VGLL1 expression compared to that found in 
TZ/PD differentiated cells. NHU cells were additionally grown to a state of post-
confluence and treated with combinations of reagents to understand whether 
quiescence induced through non-drug means (i.e. sustained contact inhibition) 
affected the phenotype of cells upon treatment. NHU cells were subsequently 
treated with drugs specific to kinase targets downstream of EGFR to determine 
whether a downstream pathway of EGFR (namely the RAS/RAF/MEK/ERK signalling 
axis) is responsible for regulating VGLL1 expression. Finally, the importance of the 
PI3K/AKT pathway in inducing VGLL1 expression was interrogated in 
undifferentiated NHU cells grown in high calcium, a state previously demonstrated 
to induce juxtacrine AKT signalling in contacted cells (Georgopoulos et al., 2010).  
Prior to use, each reagent was (or had previously been) titrated on the basis of the 
minimum concentration required to block active ERK or AKT signalling, thereby 
eliminating the possibility of erroneous off-target effects. MEK1/2 inhibitor U0126 
had been previously utilised in studies at a concentration of 5 µM, but evidence of 
its efficacy lay in the retardation of growth of proliferating NHU cells (MacLaine et 
al., 2008) and had not previously been titrated for its specific blockade of MEK 
signalling. PD98059 (PD98) is an inhibitor of MEK1 (but not MEK2) signalling and 
was also titrated.  
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3.3.5 Modulation of NHU cell phenotype using VGLL1 overexpression and knockdown 
constructs 
To understand how the presence or absence of VGLL1 affected NHU cell phenotype, 
VGLL1 pLXSN overexpression and pSIREN shRNA knockdown constructs were 
designed and packaged into retroviral vectors for the purposes of transducing NHU 
cell lines.  
Once functional overexpression or knockdown of VGLL1 was confirmed in 
transfected cultures, cells were studied in multiple assays to determine the effect of 
VGLL1 expression on different cellular processes. To determine whether VGLL1 was 
affecting cell proliferation, the comparative differences between cell numbers in 
control and test cultures was quantified by cell counting at a single time-point or 
over a time series using the alamarBlue cell viability assay. Changes in signalling 
molecules known to play a role in NHU cell proliferation, such as EGFR, 
phosphorylated ERK1/2 and PI3K/AKT, in addition to cell cycle markers such as 
MKI67 and MCM2, were assayed using RT-PCR and immunoblotting approaches. 
Due to previously cited evidence in the literature that suggests a role of VGLL1 (as 
part of the Hippo pathway) in inhibiting YAP/TAZ-mediated proliferation, this 
inhibitory relationship was also explored in NHU cells. The ability of VGLL1 to 
modulate the expression of inactive phosphorylated YAP and the localisation of YAP 
after scratch wounding was performed using VGLL1 overexpression and knockdown 
transfected cell lines, respectively.  
Expression of differentiation-associated transcription factors and proteins involved 
in the onset of late differentiation were studied in VGLL1 knockdown transfected 
cell lines to observe whether manipulation of VGLL1 modulated expression of said 
proteins. 
To ascertain what effect inhibition of VGLL1 has on the strength of the stratified 
urothelial barrier, the TEER of ABS/Ca2+ differentiated VGLL1 knockdown NHU cells 
was measured in an unwounded state and in the 24h following scratch wounding of 
cultures, a process that temporarily abolishes barrier integrity. The time taken for 
cultures to return to a similar TEER reading as recorded pre-scratch was therefore 
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used to determine whether loss of VGLL1 confers a differential rate of barrier 
recovery compared to control.  
Immunofluorescence analysis of scratch wounded differentiated NHU cells was 
additionally carried out to uncover whether the expression and localisation of 
transcription factors, tight junctions and migration-associated signal transducers 
are modified in VGLL1 knockdown cells after wounding. Cells were fixed in the 
periods immediately following wounding (30 min or 4h post-scratch) or after the 
cultures have successfully healed the wound (72h post-scratch) to observe different 
stages of the wound healing process. Markers that label cells that have entered the 
S-phase of the cell cycle (BrdU) or any non-G0 phase of the cell cycle (Ki67 and 
MCM2) were utilised to determine whether VGLL1 knockdown cultures had a 
differential proportion of cell cycle-active cells upon concluding the wound healing 
process.  Due to a notable modulation of the wound migratory-associated TGFβ 
pathway in VGLL1 knockdown differentiated NHU cells, the expression of VGLL1 
and its association to cell cycle activity was finally studied in untransfected ABS/Ca2+ 
differentiated NHU cells pre-treated with agonists and inhibitors of TGFβ signalling 












3.4.1 RNAseq analysis of urothelium in situ and NHU cells 
3.4.1.1 Expression of differentiation-associated genes in urothelial cells 
Transcription factors PPARG, GATA3, FOXA1, ELF3 and TP63 have all previously 
been implicated in helping to regulate urothelial differentiation (Section 1.3.2). To 
contextualise Hippo pathway signalling activity in human urothelium, expression of 
these transcription factors were first analysed by RNAseq. RNAseq analysis 
confirmed that all of the aforementioned genes were expressed by urothelium in 
situ (Fig. 3.3). PPARG, GATA3, FOXA1 and ELF3 displayed consistent expression 
between urothelium in situ and differentiated NHU cell samples; with each gene 
being highly expressed. Culturing NHU cells in an undifferentiated state was found 
to cause a significant reduction in expression of all four genes when compared to 
urothelium in situ or differentiated NHU cells (p ≤0.001). Despite being expressed 
by native urothelium and having a similar amount of expression in differentiated 
NHU cells, expression of TP63 (p63) was found to be significantly higher when NHU 
cells were in an undifferentiated state compared to when differentiated (p ≤0.001). 
Uroplakin gene UPK2 was used as a marker of late differentiation, with high 
expression in urothelium in situ and differentiated NHU cells but significantly 

























Figure 3.3: Induction of urothelial transcription factor gene expression in 
differentiated urothelial cells 
RNAseq data analysis of PPARG, GATA3, FOXA1, ELF3, TP63 and UPK2 gene 
expression in urothelium in situ and NHU cells in differentiated and undifferentiated 
states in three biological replicates. Gene expression was measured in Transcripts 
per Million mapped reads (TPM), with error bars representing standard deviation of 
the mean. Due to the high expression of ELF3 transcript, TPM values were Log2 
transformed to allow for greater visualisation of the data. Significance between 
groups was determined by two-way ANOVA with Tukey’s multiple comparisons post-
hoc test. **= p≤0.01; ***=p≤0.001. Other significant changes between groups were 
omitted for clarity and are detailed in Appendix xii.  
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3.4.1.2 YAP/TAZ, YAP/TAZ target gene and TEAD expression in urothelial cells 
YAP1 and WWTR1 (TAZ) were expressed by urothelial cells in situ but expression of 
previously determined YAP/TAZ target genes AXL, ANKRD1, CTGF and CYR61 in this 
condition were either low or absent, suggesting that the conventional YAP/TAZ 
signal transduction pathway was not active in adult normal human ureteric 
urothelium (Fig. 3.4). Investigation of the TEAD family determined that TEAD1 and 
TEAD3 were expressed by urothelium in situ, but not TEAD2 or TEAD4. Expression 
of YAP/TAZ target genes AXL, CTGF and CYR61 was found to be significantly 
increased in vitro, with AXL and CYR61 expression found to be highest when NHU 
cells were undifferentiated, whereas expression of CTGF retained a consistent 
expression regardless of the differentiation state of the cells (p ≤0.001). YAP/TAZ 
target gene ANKRD1 was not found to be expressed in any urothelial cell state. 
Confirming what was found in in situ samples, TEAD1 and TEAD3 appeared to also 
be the predominant members of the TEAD family in NHU cells due to their 
expression in both undifferentiated and differentiated states. The following 
observations therefore point to potential YAP/TAZ-TEAD activity in urothelial cells 
in a proliferative, undifferentiated state that is reduced when cells are in a 



































Figure 3.4: YAP/TAZ target genes AXL, CTGF and CYR61 are induced by in vitro culture 
of urothelial cells 
RNAseq data analysis of YAP1, WWTR1, ANKRD1, AXL, CCN1, CCN2, TEAD1, TEAD2, 
TEAD3 and TEAD4 gene expression in urothelium in situ and NHU cells in differentiated 
and undifferentiated states (n=3 independent samples).  Significance between groups 
was determined by two-way ANOVA with Tukey’s multiple comparisons post-hoc test. 
*= p≤0.05; **= p≤0.01; ***=p≤0.001. Other significant changes between groups were 




3.4.1.3 Pattern of VGLL family expression in urothelial cells 
Transcript expression of VGLL1, VGLL3 and VGLL4 was present in both urothelium in 
situ and in NHU cells in both differentiated and undifferentiated states (Fig. 3.5A). 
VGLL1 was the most highly expressed member of the VGLL family, with the highest 
expression found in ABS/Ca2+ differentiated NHU cells and the lowest expression 
determined to be in undifferentiated NHU cells, with each condition having 
significant differences in expression when compared with one another (p ≤0.001). 
No significant difference in VGLL3 and VGLL4 expression was observed between 
urothelial conditions, whereas VGLL2 was found to be not expressed by any 
urothelial sample. When comparing expression of genes in a TZ/PD differentiation 
time-course, it was determined that VGLL1 was most highly expressed by NHU cells 
differentiated for 144h (p ≤0.001), while as before VGLL2 was not found to be 
expressed and VGLL3 and VGLL4 expression was consistent between conditions 






































Figure 3.5: VGLL1 is the most dominantly expressed transcript of the VGLL family in 
urothelial cells  
RNAseq analysis of VGLL family member transcript expression in urothelium in situ 
and in vitro cultured NHU cells (n=3 independent samples). Graph (A) denotes 
expression of VGLL1, VGLL2, VGLL3, and VGLL4 in RNAseq samples from urothelium in 
situ, ABS/Ca2+ differentiated NHU cells and accompanying isogeneic NHU cells 
provided with no differentiation cues. Graph (B) displays the expression of the same 
genes in NHU cells treated with either TZ/PD or DMSO control for periods of 24h or 
144h. Significance between groups was determined by two-way ANOVA with Tukey’s 
multiple comparisons post-hoc test. ***=p≤0.001.  
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Principal component analysis of various urothelial RNAseq samples was 
subsequently performed with transcript expression of VGLL1 and a list of 
predefined urothelial-associated transcription factors (n=35) to determine whether 
a correlation existed between VGLL1 and said genes in urothelium. The analysis 
revealed that the first principal component (PC1) explained 42.9% of the variance in 
gene expression, while PC2 explained 24.3% and PC3 explained 9.3% (Fig. 3.6). 
Based on the distribution of the urothelial sample types in the analysis, it appeared 
that PC1 represented the differences in the differentiation state between samples 
(with ABS/Ca2+ differentiated NHU cells at one side of the X axis and sub-confluent 
undifferentiated NHU cells on the other) whilst PC2 represented inherent 
differences in transcription factor expression between in vitro and in situ 
urothelium across the Y axis. Expression of FOXA1, RARG, POU5F1 (OCT4), IRF1, 
GATA3 and PPARG were found to associate strongly with functionally differentiated 
urothelial samples, while TP63 and E2F7 were associated with undifferentiated 
NHU samples. VGLL1 expression was also found to associate with the 
differentiation-associated genes, with expression found to closely align with that of 
FOXA1, RARG and POU5F1. Overall, the results of this section suggest that VGLL1 is 
the predominantly expressed member of the VGLL family in urothelial biology, and 
that its function is closely associated with differentiation. Moreover, a concurrent 
downregulation of YAP/TAZ target genes AXL and CYR61 potentially suggested an 
inhibition of YAP/TAZ signalling and a functional activation of the Hippo pathway in 
differentiated urothelium. A visual summary of the transcriptomic changes that 
occur in the Hippo pathway upon urothelial cytodifferentiation is provided in Fig. 








Figure 3.6: VGLL1 expression in urothelial cells aligns with expression of 
differentiation-associated transcription factors 
Unscaled principal component analysis plot of RNAseq samples lysed under different 
physiological conditions (n=3 samples of in situ, ABS/Ca2+ differentiated, TZ/PD 
differentiated and undifferentiated cells in a confluent state, n=6 samples of 
subconfluent undifferentiated cells), separated on the basis of expression of VGLL1 
and the cohort of urothelial transcription factor genes identified by Fishwick et al 
(n=35). Each dot represents a different RNAseq sample while each condition type is 




























Figure 3.7: Schematic representation of transcriptomic changes in Hippo pathway 
genes in NHU cells following ABS/Ca2+ differentiation  
Genes that experienced a log2 fold change ≤ -2 downregulation in expression after 
urothelial cytodifferentiation are coloured red while genes with a log2 fold change ≥ 2 
are coloured green. Genes which did not differ between conditions are coloured blue, 
while ANKRD1, VGLL2 and TEAD4 are coloured white due to being absent from NHU 





























STK4 (MST1) -0.034 






Table 3.3: Log2 fold change differences in Hippo pathway component transcript 
expression in ABS/Ca2+ differentiated NHU cells compared to undifferentiated NHU cells  
Genes with a log2 fold change ≥ 2 upregulation in ABS/Ca
2+ differentiated cells are 











3.4.2 Characterisation of Hippo pathway component protein expression in comparison 
to proteins associated with a differentiated urothelial phenotype 
3.4.2.1 Immunohistochemical analysis of VGLL1 and urothelial transcription factors of 
interest in native urothelium  
In order to characterise VGLL1 protein expression in urothelium, validation of two 
commercially available VGLL1 antibodies was performed on urothelial cells by 
immunoblotting, immunofluorescence and immunohistochemical approaches 
(Appendix vi). Subsequent immunohistochemical analysis of two normal FFPE 
human ureters with the HPA042403 antibody confirmed that VGLL1 was expressed 
by normal in situ urothelium, supporting the evidence found at the transcript level 
(Fig. 3.8A).  VGLL1 expression was observed to be localised solely to the urothelium, 
with no labelling found in the infiltrating lymphocytes or cells of the lamina propria. 
VGLL1 expression was found in both the nuclear and cytoplasmic compartments of 
urothelial cells, with slight differences in the intensity of cytoplasmic expression 
visualised between ureter samples. In both ureters, a gradient of nuclear VGLL1 
expression was found between the lumen-facing superficial cells and underlying 
intermediate and basal cell layers.  
Labelling of various urothelial transcription factors in the same ureter samples was 
subsequently performed to compare their expression patterns to that of VGLL1. 
Unlike VGLL1, transcription factors PPARγ (Fig. 3.8B), GATA3 (Fig. 3.8C) and FOXA1 
(Fig. 3.8D) were found to have homogeneous, nuclear expression in urothelial cells 
of all layers. Localisation of VGLL1 expression appeared most similar to ELF3 
expression, which was also found to be most highly expressed in superficial cells 
(Fig 3.8E). As per its previously cited role in helping to develop the basal urothelial 
phenotype (Section 1.3.2.3), p63 was expressed exclusively in the nuclei of basal 





































3.4.2.2 Immunoblotting of differentiation-associated markers and Hippo pathway 
components following NHU cytodifferentiation  
Expression of VGLL1, YAP and TEAD (following validation of antibodies specific to 
total and phosphorylated forms of YAP and “pan-TEAD”, as detailed in Appendix vi) 
protein in urothelial cells was examined after NHU cells had undergone 
differentiation by both TZ/PD and ABS/Ca2+ methods, with additional analysis of 
protein lysed from freshly isolated urothelium to compare to expression in situ (Fig. 
3.9A). NHU cells grew as a monolayer, with the cells closely resembling the 
“cobblestone-like” morphology of other epithelia upon reaching confluence (Fig. 
3.9B-C). Treatment of NHU cells with TZ/PD caused the cells to adopt a more 
compact morphology, alongside the occasional formation of rosette-like structures 
across the monolayer (Fig. 3.9D). Cellular stratification could be observed in cells 










Figure 3.8: VGLL1 displays both nuclear and cytoplasmic labelling in urothelium in situ 
Immunohistochemical analysis of VGLL1 (A), PPARγ (B), GATA3 (C), FOXA1 (D), ELF3 (E) 
and p63 (F) expression in sections of two normal human ureters, Y2055 and Y2442. The 
phenotype of VGLL1 expression was indicative of four independent samples of ureter, 
images of which can be found in Appendix vi and xii. Sections that were labelled with no 






















































Figure 3.9: NHU cell morphology in undifferentiated and differentiated states 
A) Experimental flowchart of Y1866 NHU cells (n=1) undergoing differentiation via both 
established in vitro methods. Cells were seeded into 6-well plastic plates and allowed to 
grow to approximately 80% confluence. Wells were split between cells receiving 
treatment with DMSO/TZ/PD (or vehicle control only) for 72h, or cells pre-treated with 
ABS (+ DMSO) for 72h. TZ/PD cells were lysed after 72h, while ABS cells were 
additionally supplemented with Ca2+ for an additional period of 7 days (10 days total in 
ABS). ABS/Ca2+ treated cells were media changed every 48h until lysis. A separate ureter 
sample, Y2640, was lysed immediately upon urothelial cell isolation and was used as a 
proxy for protein expression in urothelium in situ. B-E) Phase micrograph images of 
Y1866 cells in a state of sub-confluence or at confluence at the conclusion of TZ/PD and 
ABS/Ca2+ treatments. The white arrow indicates the appearance of rosette-like 
formations following TZ/PD treatment. 
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Immunoblot analysis of PPARγ, PPARγ target genes FOXA1 and ELF3, and markers of 
tight junction formation, namely claudin 3, claudin 4 and ZO-3, were labelled to 
confirm induction of urothelial cytodifferentiation. PPARγ, FOXA1, ELF3 and claudin 
4 were found to be expressed in Y1356 cells following both differentiation methods 
(Fig. 3.10A-B), whereas claudin 3 and ZO-3 were found to be exclusively expressed 
in NHU cells after ABS/Ca2+ differentiation (Fig. 3.10B). p63 was found to be highly 
expressed by undifferentiated and urothelium in situ, but expression was reduced 
in TZ/PD treated cells and abrogated in ABS/Ca2+ differentiated cells (Fig. 3.10A).  
VGLL1 protein expression was not found in sub-confluent cells, but similarly to 
transcription factors PPARγ, FOXA1 and ELF3 was found to be expressed following 
both 72h treatment with TZ/PD and by the 12 day ABS/Ca2+ differentiation 
procedure (Fig. 3.10C). Following densitometry analysis of the mean expression of 
VGLL1 between conditions, it was determined that there was a significant 
difference in expression between undifferentiated cells and every other condition 
(Fig. 3.10D; p ≤0.05). Comparatively, all NHU samples assayed were found to be 
labelled by the pan-TEAD antibody in at least one location in the specified region of 
TEAD protein size, which ranges from 47.9 kDa (TEAD1) to 49.2 kDa (TEAD2; Fig. 
3.10C). The most intense pan-TEAD band appeared in the ABS/Ca2+ differentiated 
cell sample, with this band found at a lower MW than the weaker bands found in 
undifferentiated and TZ/PD differentiated cells. This potentially indicated the 
dominant protein expression of the TEAD family members TEAD1 or TEAD3 in 
ABS/Ca2+ differentiated cells, consistent with the expression pattern found at the 
transcript level (Section 3.4.1.2). However, due to the close similarities in molecular 
weight between all four transcription factors labelled by the antibody, any attempt 
to definitively identify labelling of specific TEAD proteins was unfeasible without 
genetic manipulation, or further labelling with antibodies specific to individual TEAD 
proteins. Interestingly, expression of both total and phosphorylated forms of YAP 
remained consistent between all three cell conditions (Fig. 3.10C), suggesting no 

























































Figure 3.10: VGLL1 protein expression is induced by TZ/PD and ABS/Ca2+ 
differentiation in a similar manner to that of urothelial differentiation-associated 
transcription factors whilst YAP expression remains consistent 
Immunoblotting images of PPARγ, FOXA1, ELF3 and p63 (A), claudin 3, claudin 4 and ZO-
3 (B), VGLL1, pan-TEAD, and YAP (total  and phosphorylated forms; C) expression in 
Y1866 NHU cells (n=1) treated with DMSO or TZ/PD for 72h, ABS/Ca2+ for 7 days or lysed 
from freshly isolated Y2640 urothelium (n=1). TEAD expression was labelled for using a 
pan-TEAD rabbit mAb which recognises endogenous expression of all four TEAD proteins 
in the 48-50 kDa range (as demonstrated by accompanying image of protein ladder). 
Expression of housekeeping protein β-Actin was used to confirm equal loading of 
samples. Lanes marked with an asterisk represent protein samples that could not be 
assayed due to a lack of remaining lysate. D) Quantification of VGLL1 expression by 
immunoblotting densitometry analysis in biological replicates of each condition assayed 
(n=6 for DMSO, n=5 for TZ/PD and urothelium in situ, n=3 for ABS/Ca2+). The icons of the 
same shape and shading represent densitometry values from donor-matched urothelial 
samples. Differences in expression are represented as a Log10 fold change in comparison 
to the mean DMSO expression value. Significance between groups was determined by 





3.4.2.3 Immunofluorescence of differentiation-associated markers, proliferation-
associated markers and VGLL1 following NHU cytodifferentiation 
VGLL1 was expressed in the nuclei of NHU cells following both differentiation 
protocols (Fig. 3.11A). Expression of the protein appeared heterogeneous across 
cultures, with some nuclei labelled more intensely than others. As observed during 
initial validation of the HPA042043 antibody (Appendix vi), additional cytoplasmic 
labelling of VGLL1 was found in some cells following TZ/PD treatment, but a greater 
proportion of cytoplasmic localisation was observed when cells were ABS/Ca2+ 
differentiated. Expression of PPARγ (Fig. 3.11B), ELF3 (Fig. 3.11C) and GATA3 (Fig. 
3.11D) were similar found to be induced in the nuclei of cells following both 
differentiation methods. The pattern of p63 (Fig. 3.11E) expression supported the 
phenotype determined by immunoblotting, with nuclear p63 expression high in 
undifferentiated cells but reduced following treatment, with ABS/Ca2+ 
differentiated cells exhibited the lowest expression (Fig. 3.11E). Interestingly, dual 
labelling of the GATA3 and p63 antibodies together demonstrated a primarily 
mutually exclusive relationship between the two targets, with the majority of the 
differentiated NHU cell nuclei that remained p63-positive appeared to be found in 




































Figure 3.11: Induction of nuclear VGLL1 and differentiation-associated proteins after 
TZ/PD and ABS/Ca2+ treatment 
Y1356 cells were seeded onto glass slides and treated in the same manner as cells in 
section 3.4.2.2. Following formalin fixation and Triton X-100 permeabilisation, cells 
were labelled with VGLL1 (A), PPARγ (B; 81B8 antibody) and ELF3 (C), or dual labelled 
with GATA3 (D; red fluorescence) and p63 (E; green fluorescence) before visualisation.  
Images were all taken at same exposure and are shown with or without overlaid 









Expression of tight junction proteins in NHU cells were also investigated to uncover 
whether ZO-2 and ZO-3 localised to cell membranes under the same conditions 
found to induce previously observed membranous localisation of ZO-1 (Section 
1.3.2.1). All three proteins displayed very low or absent expression in 
undifferentiated NHU cells, while treatment of cells with TZ/PD induced 
cytoplasmic expression of ZO-1/ZO-1α+ (Fig. 3.12A) and ZO-2 (Fig. 3.12B), but not 
ZO-3 (Fig. 3.12C). ABS/Ca2+ differentiation was found to result in the translocation 
of all three proteins to the membranous regions of cells, with the observations 
made in this and the previous section confirming that ZO-3 was a robust marker of 










































Figure 3.12: Induction of membranous tight junction protein localisation following 
ABS/Ca2+ differentiation 
Immunofluorescence analysis of tight junction proteins ZO-1 (dual labelled with the ZO-
1α+ isoform; A), ZO-2 (B) and ZO-3 (C) expression  in Y1356 cells undergoing TZ/PD and 
ABS/Ca2+ differentiation (n=1). Images were all taken at same exposure and are shown 






To visualise the effect of blocking proliferation in differentiated NHU cells, cell 
cycle-associated proteins Ki67 and MCM2 were labelled for in each cell state. 
Expression of both proteins was high in the actively proliferating undifferentiated 
cells, but experienced a reduction in expression when cells were TZ/PD treated (Fig. 
3.13A). Sub-nuclear localisation of Ki67 between the two cell states suggested that 
the cells had switched from a predominantly S-phase population (Undifferentiated) 
to including a greater proportion of cells in G1 phase (TZ/PD Differentiated). 
Differentiation of the cells by ABS/Ca2+ was found to have the greatest effect on the 
onset of quiescence, as only a small population of cells remained positive for either 
protein. As expected, expression of active, phosphorylated ERK1/2 was lost from 
the nuclear and perinuclear regions of NHU cells upon treatment with TZ/PD due to 


























3.4.3 Expression of VGLL1 following inhibition of PPARγ-mediated differentiation in 
NHU cells  
3.4.3.1 Transcript expression of VGLL1 following selective inhibition of PPARγ in TZ/PD 
differentiated cells 
The preceding characterisation experiments had determined that VGLL1 was 
consistently up-regulated following the PPARγ-mediated TZ/PD differentiation 
process. A time-course of NHU cells receiving TZ/PD treatment alongside 
concurrent application of T007 for different periods of time was therefore 
completed to evaluate VGLL1 expression in PPARγ-inhibited cells (Fig. 3.14A). The 
cell morphology indicative of TZ/PD differentiation appeared to be maintained 
when cells were pre-treated with T007 (Fig. 3.14B). As expected, VGLL1, ELF3 and 
PPARγ target gene FABP4 transcript were significantly induced after 72h of TZ/PD 
treatment (p≤0.001; Fig. 3.14C). While ELF3 and FABP4 experienced a significant 
reduction in expression when concurrently treated with T007 (p≤0.05), no 
significant difference was found between TZ/PD and TZ/PD/T007 cultures in regards 
to VGLL1 expression. The lack of a significant inhibition of VGLL1 transcript in the 
TZ/PD/T007 condition appeared to be attributable to an large variation in 
expression between samples, as while three cell lines (Y1897, Y1947 and Y2351) 
were found to have inhibited VGLL1 to a similar extent as ELF3, Y1946 cells 
experienced no inhibition, while Y1226 cells exhibited a notably higher expression 
of VGLL1 compared to its corresponding TZ/PD condition.  
 
 
Figure 3.13: Loss of proliferation-associated protein expression after TZ/PD and 
ABS/Ca2+ treatments 
Dual labelling of MCM2 (red fluorescence) with Ki67 (green fluorescence; A) and p-
ERK1/2 (Thr202/Tyr204; red fluorescence) with Total ERK1/2 (green fluorescence; B) 
antibodies in Y1356 cells differentiated using TZ/PD and ABS/Ca2+ methods (n=1). Cells 
receiving no primary antibody (C) were used as a negative control for Figures 3.11-13. 
Images were all taken at same exposure and are shown with or without overlaid Hoechst 





















































Figure 3.14: PPARγ antagonism significantly inhibits FABP4 and ELF3, but not VGLL1, 
transcript expression following 72h TZ/PD differentiation 
A) Experimental flowchart of NHU cells undergoing a time-course of TZ/PD treatment. 
At the point of reaching 80% confluence, cells were pre-treated with T007 in order to 
inhibit any latent PPARγ activity in the undifferentiated cells. Cells were subsequently 
treated with a combination of either TZ/PD or TZ/PD/T007 and lysed after periods of 
24h, 72h, and 144h. All conditions were treated with 0.1% DMSO to control for non-
specific solvent effects. B) Phase micrograph images of Y1858 cells after treatment with 
the above conditions, with images captured immediately preceding lysis of cells at the 
72h time-point. C) RT-qPCR analysis of VGLL1, ELF3 and FABP4 expression in NHU cells 
treated with vehicle control, TZ/PD or TZ/PD/T007 for a period of 72h. Differences 
between conditions were displayed as a fold change in transcript expression compared 
to TZ/PD differentiated cells. Significant downregulation of PPARγ target gene FABP4 in 
TZ/PD differentiated NHU cells treated with T007 demonstrated the efficacy of T007 
treatment to inhibit PPARγ activity. The experiment was replicated in five independent 
cell lines, with icons of the same shape representing matched donors and icons of the 
same shading representing the different genes assayed. Significance between conditions 




3.4.4.2 VGLL1 protein expression following a TZ/PD/T007 treatment time-course in 
NHU cells  
Similar to what was observed at the transcript level, VGLL1 appeared to have  
decreased expression in TZ/PD differentiated cells pre-treated with T007, although 
unlike FABP4, expression which was not completely blocked by PPARγ inhibition 
(Fig. 3.15A). When quantifying the expression of VGLL1 protein across multiple 
timepoints and biological replicates, it was determined that there a significant 
reduction of VGLL1 after T007 treatment at the 24h time-point only, with the 
reduction in expression observed at later timepoints non-significant due to 
variability between cell lines (Fig. 3.15B). Overall, evidence at the transcript and 
protein level therefore suggested that activation of PPARγ did play a role in the 
initial induction of VGLL1 in NHU cells, with this effect seen most acutely in the 
early stages of TZ/PD differentiation. However, the less pronounced effect of T007 
on VGLL1 expression observed at later time-points (and increased variability 
between cell lines at these points) suggested the existence of other variables which 

























3.4.4 Bioinformatics analysis of the VGLL1 promoter region  
To predict the identity of alternative transcription factors that drive VGLL1 
expression in NHU cells via bioinformatics, the transcription factor binding site 
predictor program JASPAR was used to identify potential binding motifs in the DNA 
sequence up to 6000bp upstream of the VGLL1 gene. Predicted binding domains for 
PPARγ were searched for as part of the analysis, but no PPRE sites were discovered 
in the upstream sequence, or sites for transcription factors ELF3 or IRF-1. However, 
several potential binding sites were identified for GATA3, FOXA1 and KLF5 at a 
relative confidence score of at least 0.95 (Table 3.4). The urothelial differentiation-
associated transcription factor with the closest potential binding site to the VGLL1 
start codon was GATA3, found less than 30 bp away from the start codon. The 




Figure 3.15: Blockade of PPARγ activity has  a time-sensitive effect on the induction of 
VGLL1 protein in actively differentiating NHU cells 
Immunoblot analysis of VGLL1 expression in NHU cells treated with a combination of TZ, 
PD153035 and T007 for periods of 24h, 72h and 144h. All conditions were treated with 
0.1% DMSO to control for non-specific solvent effects.  Image (A) is a representative 
immunoblot image of VGLL1 and FABP4 expression in TZ/PD/T007 treated cells,  with 
FABP4  expression used to confirm, like at the transcript level, that T007 treatment was 
successful in blocking PPARγ activation. Expression of β-Actin was used to confirm equal 
loading of samples. Image (B) is immunoblot densitometry analysis of (A), with 
expression of VGLL1 from three independent biological replicates quantified. Differences 
between conditions was quantified by comparing the fold change in VGLL1 expression 
after TZ/PD treatment compared to each other condition at each timepoint. Significance 
between conditions was calculated using a two-way ANOVA with Tukey’s post-hoc test. 












Binding site start 
(bp) 




GATA3 1.0 3848 3855 AGATAAGA 
GATA3 0.99 5056 5061 AGATAG 
GATA3 0.99 5966 5971 AGATAG 
GATA3 0.99 1963 1968 AGATAG 
GATA3 0.99 2175 2182 AGATAAGG 
FOXA1 0.99 4052 4062 TGTTTGCTTTG 
KLF5 0.98 2688 2697 GCCCCTCCCA 
GATA3 0.98 3533 3538 TGATAG 
GATA3 0.97 5148 5155 TGATAAGG 
GATA3 0.97 2810 2817 TGATAAGG 
GATA3 0.97 1639 1646 TGATAACA 
GATA3 0.95 4847 4852 AGATTG 
GATA3 0.95 5585 5590 AGATTG 
GATA3 0.95 5833 5838 AGATTG 
GATA3 0.95 1218 1223 AGATTG 
GATA3 0.95 2134 2139 AGATTG 
GATA3 0.95 2399 2404 AGATTG 
GATA3 0.95 307 314 AGATAATA 
KLF5 0.95 3818 3827 TCCACTCCCC 
FOXA1 0.95 802 816 TATTTATTTACTTAT 
FOXA1 0.95 284 294 TGTTTACTCAA 
 
Table 3.4: List of potential binding sites for urothelial-associated transcription factors in 
the DNA sequence upstream of VGLL1. 
The sequence upstream of VGLL1 (starting from 6000bp upstream of the promoter) was 
inputted into JASPAR (http://jaspar.genereg.net/) to identify potential binding sites for 
PPARγ, FOXA1, GATA3, ELF3, IRF-1 and KLF5. Only hits with a relative score of 0.95 
(maximum 1) or above were searched for, ensuring that only binding sites with a prediction 
score of at least 95% accuracy are displayed. The GATA3 binding site closest to the VGLL1 
start codon is highlighted in bold. Information on potential RARγ and OCT4 binding motifs 
in the DNA region analysed was not available on JASPAR. 
Figure 3.16: Multiple sequence alignment of the GATA3 binding motif in the DNA 
sequence upstream of the VGLL1 promoter 
Sequence logo was created using the WebLogo application 
(https://weblogo.berkeley.edu/logo.cgi; Crooks et al., 2004). 
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3.4.5 Effect of siRNA knockdown of GATA3 on VGLL1 expression  
To determine the role of GATA3 transcriptional activity on the induction of VGLL1, 
NHU cells were transfected with siRNA specific to GATA3 and subsequently TZ/PD 
differentiated for a period of 72h. RT-qPCR analysis of the resultant conditions 
confirmed that TZ/PD differentiation in cells transfected with control siRNA induced 
significant increases in GATA3 and VGLL1 when compared to undifferentiated 
control (Fig. 3.17; p≤0.001). A significant reduction of GATA3 expression was found 
in TZ/PD treated cells after transfection with both GATA3 siRNA constructs 
(p≤0.001), confirming the efficacy of said reagents. Expression of VGLL1 was also 
revealed to be significantly lower in TZ/PD treated cells transfected with either 
GATA3 siRNA compared to TZ/PD differentiated cells transfected with control siRNA 
(p≤0.01). However unlike GATA3, expression of VGLL1 was not inhibited to the 
baseline expression found in control undifferentiated cells, with a significant 
difference in expression also found between undifferentiated control cells and 






































Figure 3.17: siRNA knockdown of GATA3 results in an inhibition of VGLL1 transcript 
expression 
RT-qPCR analysis of GATA3 and VGLL1 expression in undifferentiated NHU cells treated 
with 0.1% DMSO only and transfected with control siRNA (icons designated -/-), TZ/PD 
differentiated cells transfected with control siRNA (-/+) and TZ/PD treated cells 
transfected with GATA3 siRNA #1 (left sided +/+) or #2 (right sided +/+). All conditions 
were treated with 0.1% DMSO to control for non-specific solvent effects. Differences 
between conditions were displayed as a fold change in expression compared to TZ/PD 
differentiated cells transfected with control siRNA. The experiment is representative of 
three independent cell lines, with icons of the same shading representing matched 
donors. Significance between conditions was calculated using a two-way ANOVA with 
Tukey’s post-hoc test. **=p≤0.01; ***=p≤0.001. All significant values displayed on the 
graph represent the significant differences between Ctrl siRNA TZ/PD treated cells 
against the other conditions. A full list of conditions with significant differences in 
expression can be found in Appendix xii.  
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Immunoblotting analysis of samples from two additional cell lines (Y1652 and 
Y2442) supported the pattern of expression seen at the transcript level, as 
expression of GATA3 and VGLL1 were reduced when TZ/PD differentiated cells were 
transfected with GATA3 siRNA (Fig. 3.18A-B). It was additionally observed that the 
GATA3 siRNA transfected cells experienced an upregulation of p63 protein, 
consistent with the phenotype found in an earlier study (Section 1.3.2.3). One cell 
line (Y2303) was found to only experience a modest inhibition of GATA3 from both 
GATA3 siRNA constructs, which was reflected in a negligible effect on VGLL1 
expression (Fig. 3.18C). As a result of this, overall densitometry analysis of the three 
samples revealed no significant differences in expression of VGLL1 or GATA3 in 
TZ/PD differentiated NHU cells transfected with control siRNA compared to GATA3 
siRNA transfected cells (Fig. 3.18D). Analysis of phase-contrast images from each 
cell line and condition prior to protein lysis revealed that despite seeding all 
conditions at the same initial cell number, Y2303 cells had reached a noticeably 
higher final cell density when compared to Y1652 and Y2442 conditions, perhaps 
accounting for the discrepancy observed in the relative amount of VGLL1 and 
GATA3 inhibition (Fig. 3.18E). Overall, the preceding results at the transcript and 
protein level indicated that activation of PPARγ and GATA3 transcriptional 
processes both played a role in the induction of VGLL1 in NHU cells (Fig. 3.18F), 
although confounding factors such as cell density and the length of time that 

























































Figure 3.18: Loss of GATA3 results in an inhibition of VGLL1 protein expression in 
subconfluent NHU cells  
Immunoblot analysis of GATA3, VGLL1 and p63 expression in Y1652 (A), Y2442 (B) and 
Y2303 (C) TZ/PD treated NHU cells after transfection with either control siRNA or two 
siRNA specific to GATA3. Expression of β-Actin was used to confirm equal loading of 
samples. D) Immunoblot densitometry analysis of (A-C), with expression of GATA3 and 
VGLL1 from three independent biological replicates quantified. Differences between 
conditions were quantified by comparing the fold change in expression in control siRNA 
TZ/PD treated cells compared to each other condition. Significance between conditions 
was calculated using a two-way ANOVA with Tukey’s post-hoc test. E) Phase micrograph 
image from each cell line and condition preceding lysis of cells at the 72h time-point. F) 
Interpretation of the molecular events upstream of VGLL1 in differentiated NHU cells, as 
determined in Fig. 3.14-3.17. 1. Concurrent treatment of NHU cells with TZ and PD 
results in binding of TZ to inactive PPARγ and blockade of the active RAS/RAF/MEK/ERK 
signalling pathway, respectively. 2. Agonist-activated PPARγ heterodimerises with RXRα 
and binds to PPRE in DNA, inducing transcription of various PPARγ target genes, 
including GATA3. 3. GATA3 binds to one or multiple sites upstream of the VGLL1 
promoter, inducing transcription of the gene. 4. TZ/PD differentiated cells express VGLL1 
protein as quickly as 24h post-differentiation. Inhibition of PPARγ activity or siRNA 
knockdown of GATA3 were both found to inhibit VGLL1 expression, although the effect 
of either treatment became less pronounced when cells had reached confluency and/or 




3.4.6 Determination of VGLL1 expression after treatment of NHU cells with inhibitors 
of the EGFR/MEK/ERK and PI3K/AKT pathways 
3.4.6.1 Treatment of NHU cells with the standard TZ/PD protocol ± TZ 
 The results collated in Section 3.4.3-3.4.5 suggested that variables beyond agonist-
based activation of upstream transcription factors could potentially influence the 
induction of VGLL1 in NHU cells. To understand the specific role that PPARγ-
independent EGFR blockade had on VGLL1 expression, NHU cells were treated with 
TZ/PD or PD153035 alone for 72h. It was discovered that PD153035 treatment was 
sufficient to induce expression of both VGLL1 and ELF3 when compared to control 
(Fig. 3.19). However, treatment with both TZ and PD153035 appeared to be 
additive, as expression of both proteins was higher in TZ/PD treated cells when 
compared to PD153035 treated cells. Expression of PPARγ or FOXA1 was found to 
be only slightly induced by PD153035 treatment alone, with a full induction of 












Figure 3.19: Expression of VGLL1 and ELF3 can be induced through EGFR blockade of 
NHU cells 
Immunoblot analysis of Y2145 NHU cells (n=1) treated using the standard TZ/PD protocol 
as outlined in Section 2.4.4.9, in addition to a condition that consisted of cells receiving 1 
µM PD153035 only for 72h to inspect the effects of EGFR blockade alone on expression of 
proteins of interest. All conditions were treated with 0.1% DMSO to control for non-




3.4.6.2 Effect of TZ and PD153035 treatment in NHU cells grown to post-confluence 
The specific role that inhibition of proliferation in contact-inhibited cells plays on 
VGLL1 expression was determined by lysing cells in both a sub-confluent state and 
after they had been allowed to propagate to a state of post-confluence (as defined 
as cells that had been visually confirmed to reach confluence 6 days prior); at which 
point they were treated with a combination of TZ, PD153035 and T007 for 72h (Fig. 
3.20A). Expression of VGLL1 was found to be induced in DMSO-treated cells that 
reached a state of post-confluence when compared to DMSO-treated sub-confluent 
cells (Fig. 3.20B-D). However, significant differences in VGLL1 expression compared 
to sub-confluent control were only found when confluent cells were additionally 
treated with PD153035 alone or in combination with TZ or T007 (Fig. 3.20E; p 
≤0.001). Activating PPARγ with TZ was found to either have a negligible or reductive 
effect on VGLL1 expression in confluent NHU cells. In comparison, ELF3 and GATA3 
(but not FOXA1) also appeared to be induced by confluency, with expression of the 
genes further activated when cells were treated with TZ and PD153035 separately 
(ELF3) or just PD153035 (GATA3; Fig. 3.20B-D). Conversely, expression of p63 (n=2 
samples) was inhibited by TZ/PD differentiation in post-confluent NHU cells as 
observed previously, yet neither the onset of confluence nor the addition of TZ or 
PD in isolation was sufficient to affect expression of the transcription factor, 

















































Figure 3.20: Onset of EGFR blockade-mediated cell quiescence induces VGLL1 
expression  
A) Experimental flowchart of NHU cells treated with a combination of reagents upon 
reaching a state of post-confluence (n=3 independent samples). Cells were lysed at sub-
confluence in order to compare any changes in expression of proteins once cells became 
quiescent. Once cells had reached visual confluence, they were pre-treated with either 
0.1% DMSO only or 5 µM T007 for 72h to ensure inhibition of nascent PPARγ activity.  
Confluent cells were subsequently treated with a combination of TZ, PD153035 or T007 
for a further 72h before lysis. All conditions were treated with 0.1% DMSO to control for 
non-specific solvent effects.  B-D) Immunoblot analysis of VGLL1, PPARγ, FOXA1, ELF3 
GATA3 and p63 (in blots B, D) expression in the conditions outlined in (A) in Y1214 (B), 
Y1866 (C) and Y1898 (D) cells. Lanes marked with an asterisk represent protein samples 
that could not be assayed due to a lack of remaining lysate. Expression of β-Actin was 
used to confirm equal loading of samples. E) Densitometry analysis of VGLL1 expression 
in three independent NHU cell lines. Significance between groups was determined by a 
one-way ANOVA with Tukey’s multiple comparisons post-hoc test. *= p≤0.05; 
**=p≤0.01. A full list of conditions with significant differences in VGLL1 expression can 




3.4.6.3 Expression of VGLL1 and PPARγ target genes after treatment of NHU cells with 
inhibitors against EGFR, MEK1/2 and ERK1/2 
To elucidate the identity of the kinases downstream of EGFR that were responsible 
for VGLL1 expression following blockade of function, NHU cells were treated with 
various drug inhibitors ± TZ for 72h, with fresh drugs administered daily (Fig. 3.21A). 
MEK inhibitors U0126 and PD98059 and ERK inhibitor FR180204 (FR180) were 
titrated on their ability to inhibit active ERK signalling prior to this experiment 
(Appendix viii). Cells used in this experiment were specifically treated at a low 
density and had not reached visual confluence at the point of lysis, thereby 
ensuring that the final cell phenotype was not affected by confluence-mediated 
effects. Upon completion of 72h treatment, noticeable differences in cell density 
were observed in cells treated with PD153035 or UO126 (but not PD98059 or 
FR180) when compared to DMSO control (Fig. 3.21B), suggesting that these 
reagents were having a greater effect on cell proliferation or survival. Cells treated 
with TZ alongside each of the inhibitors appeared to have less dense cultures after 

















































VGLL1 and ELF3 were induced by TZ/PD and PD alone; mirroring what was observed 
when cells were grown to post-confluence (Fig. 3.22A-B). FOXA1, but not VGLL1 and 
ELF3, was additionally induced through activation of PPARγ by TZ alone in Y2467 
cells (Fig. 3.22A). VGLL1 was additionally expressed after treatment with U0126, 
PD98059 or FR180 when applied in isolation, suggesting that inhibition of the entire 
RAS/RAF/MEK/ERK pathway is required for the induction of VGLL1 in sub-confluent 
NHU cells (Fig. 3.22A-B). Interestingly, VGLL1 expression was lost in U0126, 
PD98059 and FR180-treated cells when the cells were treated concurrently with TZ, 
potentially indicative of a hitherto unknown tyrosine kinase-independent function 
of EGFR that permits VGLL1 induction when cells are TZ/PD treated. FOXA1 
expression displayed a similar pattern of expression to VGLL1 after being treated 
with the various inhibitors, while ELF3 was expressed after treatment with U0126, 
but not PD98059 or FR180 (or TZ/UO126, similar to the phenotype observed with 
VGLL1). Overall, the following results indicate that induction of VGLL1 expression in 
NHU cells is linked to the inhibition of EGFR signalling via its RAS/RAF/MEK/ERK 
kinase axis.  
 
Figure 3.21: Sub-confluent NHU cell morphology following treatment with inhibitors 
of EGFR/RAS/RAF/MEK/ERK signalling ± TZ 
A) Experimental flowchart of NHU cells undergoing treatment with PD153035, U0126, 
PD98059 or FR180 in the presence or absence of TZ for 72h (n=2 independent samples). 
Cells were seeded at a low density to ensure that they would not reach visual 
confluence before the end of the treatment program. Cells were treated with the 
different reagents 24h post-seeding, with fresh drug-containing medium replenished 
every 24h. All conditions were treated with 0.1% DMSO to control for non-specific 
solvent effects.  Cultures were lysed after 72h of treatment. B) Phase micrograph 
images of Y2467 cells before treatment (top image) or after 72h treatment with 
reagents (all other images) captured immediately preceding lysis. The morphology and 





























Figure 3.22: Active RAS/RAF/MEK/ERK signalling blocks VGLL1 expression in sub-
confluent NHU cells 
Immunoblot analysis of the conditions outlined in Figure 3.21 in Y2467 (A) and Y1914 
(B) cells. Treatment of NHU cells with U0126, PD98059 and FR180 were all found to 
induce VGLL1 expression in addition to PD153035 in sub-confluent cultures. 
Expression of β-Actin (Y2467) or Total ERK1/2 (Y1914) was used to confirm equal 
loading of samples. 
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3.4.6.4 Expression of VGLL1 in high Ca2+ medium after treatment with EGFR and 
PI3K/AKT inhibitors 
Following the observations that VGLL1 is expressed both as a result of blockade of 
EGFR/RAS/RAF/MEK/ERK signalling and in cells that are contact-inhibited, it was 
hypothesised that induction of the protein may require activation of PI3K/AKT 
signalling, a pathway previously demonstrated to be important in mediating the 
proliferation of undifferentiated NHU cells following blockade of downstream EGFR 
signalling.  
Undifferentiated Y1336 cells (n=1) were grown on glass slides in medium containing 
2 mM Ca2+ in order to induce nuclear p-AKT activity following formation of calcium-
mediated cell-cell adherens junctions, with these slides compared to cultures either 
grown in low calcium or treated with LY294002 or PD153035 (Fig. 3.23A). NHU cells 
grown in high Ca2+ were discovered to exhibit a striking increase in both nuclear and 
cytoplasmic VGLL1 when compared to cells grown in low calcium (Fig. 3.23B). Y1336 
cells grown in high Ca2+ were confirmed to have formed cell-cell adherens junctions 
through visualisation of E-cadherin in DMSO + Ca2+ and PD153035 + Ca2+ conditions 
(Fig. 3.23C). Interestingly, the intense intercellular border localisation of E-cadherin 
was lost in cells that were treated with LY294002 in high Ca2+ (Fig. 3.23C), a 
condition that was demonstrated to have weak nuclear phosphorylated AKT 
expression (Fig. 3.23D). Conditions that exhibited strong nuclear p-AKT expression 
(i.e. DMSO + Ca2+, PD153035 and PD153035 + Ca2+) were all found to have induced 
VGLL1 expression, while conditions with low/absent nuclear expression of p-AKT 
(DMSO, LY294002, LY294002 + Ca2+) correlated with low expression of VGLL1 (Fig. 
3.23B,D). The following observations therefore presented preliminary evidence for 
the potential role of active PI3K/AKT signalling in the induction of VGLL1 in 
undifferentiated NHU cells, a pathway that is activated through 
EGFR/RAS/RAF/MEK/ERK blockade and/or addition of a physiologically relevant 















































Figure 3.23: Induction of VGLL1 via Ca2+-mediated PI3K/AKT signalling in undifferentiated 
NHU cells 
A) Experimental flowchart of Y1336 cells undergoing treatment with DMSO only, 
PD153035 or LY294002 in the presence or absence of 2 mM Ca2+ for 72h (n=1 cell line). 
Cells were treated with the different inhibitors and Ca2+ 24h post-seeding; with fresh 
drug/Ca2+-containing medium replenished every 24h. All conditions were treated with 
0.1% DMSO to control for non-specific solvent effects.  Cultures were fixed after 72h of 
treatment. B-D) Immunofluorescence analysis of VGLL1 (B), E-cadherin (C) and p-AKT 
(Ser473; D) expression in Y1336 cells treated in the manner described in (A). Addition of 
Ca2+ induced the localisation of E-cadherin to the intercellular borders of cells in DMSO or 
PD153035-treated cultures, as indicated by white arrows. Images were all taken at same 
exposure and are shown with overlaid Hoechst 33258 DNA staining. Scale bar= 50µm. 
Labelling of total and phosphorylated forms of ERK (in addition to cells receiving no 
primary antibody) was additionally performed, images of which can be found in Appendix 
xii. E) Interpretation of the molecular events upstream of VGLL1 in undifferentiated NHU 
cells, as determined in Fig. 3.18-3.22. Inhibition of the EGFR/RAS/RAF/MEK/ERK pathway 
in sub-confluent NHU cells (1; n=2), culturing of the cells to the point of post-confluence 
(2; n=3) and/or the production of Ca2+-mediated adherens junctions in contacted cells (3; 
n=1) were all observed to induce expression of VGLL1 independent of PPARγ agonism in 
NHU cells (4). This mechanism appeared to be related to activation of PI3K/AKT signalling, 
as nuclear p-AKT was observed in NHU cells treated with PD153035 and/or Ca2+, thereby 
suggesting the existence of a hitherto unknown RTK in urothelium that induces PI3K/AKT 
activity in the absence of EGFR signalling. It was not determined as part of this study 
whether nuclear AKT affected the expression of VGLL1 through induction of urothelial 





Non-urothelial cell systems have previously demonstrated a change in the 
localisation of YAP/TAZ in response to physiological cues (Section 3.1.2). To 
determine whether YAP translocates in response to signal transduction pathway 
blockade and/or Ca2+ administration, dual-labelling of total YAP and pan-TEAD was 
additionally performed in Y1336 cells. In control cells, it was determined that 
expression of total YAP was predominantly nuclear, although cytoplasmic 
expression was occasionally observed in cells that were in close contact with one 
another (Fig. 3.24). Intense nuclear labelling was still observed in cultures treated 
with high Ca2+, PD153035 and/or LY294002, yet cells in these conditions were 
additionally observed to have increased cytoplasmic expression of the protein. In 
comparison, TEAD proteins labelled with the pan-TEAD antibody exhibited strong 
nuclear expression in cells in all conditions except when treated with LY294002, 
which induced increased cytoplasmic labelling (Fig. 3.24). The preceding results 
therefore suggested that while the total amount of YAP expression remains 
consistent in NHU cells following differentiation (Section 3.4.2.2), its subcellular 
localisation is sensitive to factors such as the modulation of proliferation-associated 
pathways and/or the induction of adherens junctions. However, an inverse 
correlation between the ratio of nuclear YAP and the induction of VGLL1 was not 
































Figure 3.24: Stimuli-dependent translocation of YAP expression in undifferentiated 
NHU cells 
A) Immunofluorescence analysis of total YAP (green fluorescence) and pan-TEAD (red 
fluorescence) expression in the same cell line and conditions outlined in Figure 3.23. 
Blue arrows indicate examples of control cells with exclusively nuclear YAP expression, 
while the white arrow indicates weak cytoplasmic YAP/TAZ expression in cells that were 
in close contact with one another. Images were all taken at same exposure and are 
shown with or without overlaid Hoechst 33258 DNA staining. Scale bar= 50µm. 
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3.4.7 Generation of genetically modified NHU cell lines that overexpress or 
knockdown VGLL1 expression 
3.4.7.1 Generation and verification of stable transfected VGLL1-overexpressing NHU 
cell lines 
To attempt to elucidate the function of VGLL1 in NHU cells, a retroviral vector that 
overexpresses VGLL1 in human cells was generated as detailed in Appendix ix. 
Following transduction of PT67 retroviral packaging cell lines with pLXSN-eGFP or 
pLXSN-VGLL1 and antibiotic selection with 500 µg/mL G418, NHU cell lines were 
transfected with retroviral particles and maintained in 100 µg/mL G418 until 
complete cell death in the mock-transfected NHU cultures was observed. 
Functional overexpression of VGLL1 was confirmed in transfected undifferentiated 
NHU cells by immunoblotting (Fig. 3.25). Immunoblotting of lysates in Figure 3.25 















Figure 3.25: Forced expression of VGLL1 protein in undifferentiated NHU cells 
NHU cell lines Y1588 and Y1696 were transfected with pLXSN-GFP or pLXSN-VGLL1 and 
positive cells selected for through maintenance in antibiotic-containing medium. 
Following selection, transfected NHU cells were lysed and immunoblotting analysis of 
VGLL1 expression was used to confirm overexpression of said proteins in both cell 
lines. Bladder cancer cell line RT4 was used as a positive control for VGLL1 expression. 
Expression of β-Actin was used to confirm equal loading of samples. Samples 
transfected with a pLXSN-ELF3 overexpression construct (red asterisk) were 
additionally included in this immunoblot but are not relevant to this study.  
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3.4.7.2 Generation and verification of stable transfected VGLL1 shRNA knockdown 
NHU cell lines 
VGLL1 shRNA knockdown constructs were generated as detailed in Appendix x. 
PT67 cells were transduced with pSIREN-Scrambled or pSIREN containing one of 
three shRNA constructs specific to VGLL1. Following antibiotic selection with 4 
µg/mL puromycin, NHU cell lines were transfected with the retroviral particles and 
maintained in 1 µg/mL puromycin until complete cell death in the mock-transfected 
NHU cultures was observed (Fig. 3.26A). Successful knockdown of VGLL1 by all 
three shRNA constructs was confirmed in TZ/PD differentiated transfected NHU 
cells by immunoblotting (Fig. 3.26B). VGLL1 shRNA #2 was determined to most 
effectively knockdown VGLL1 expression and was thus selected to be the construct 








































Figure 3.26: Knockdown of VGLL1 expression in differentiated NHU cells transfected 
with three VGLL1 shRNA constructs 
Y2324 cells were transfected with pSIREN-Scrambled, pSIREN-VGLL1 #1, pSIREN-VGLL1 
#2 or pSIREN-VGLL1 #3 and positive cells selected for through maintenance in 
antibiotic-containing medium. Panel (A) depicts phase micrograph images of Y2324 
cells taken 10 days after transduction (8 days of antibiotic selection). The mock-
transduced control demonstrated the efficacy of puromycin administration on 
untransduced cells. Following selection, transfected cells were grown to 80% 
confluence and treated using the standard TZ/PD differentiation method for 72h (B). 
Scrambled control cells alternatively received treatment with vehicle control as a 




3.4.8 Effect of forced expression of VGLL1 on signal transduction pathways and 
proliferation in NHU cells 
3.4.8.1 Evaluation of NHU cell proliferation after VGLL1 overexpression 
Following the creation of stable NHU cell lines that overexpressed VGLL1, it was 
observed that cells overexpressing VGLL1 appeared to be at a consistently lower 
cell density than the eGFP control transfected cell type (Fig. 3.27A). To address the 
hypothesis that forced expression of VGLL1 was resulting in a reduction of 
proliferation, transfected NHU cells were seeded at equal densities and the total 
cell numbers for each condition were counted 48h post-seeding. Despite each cell 
line having lower cell counts when overexpressing VGLL1, there was no significant 
difference between groups at this time point (Fig. 3.27B).  
Transfected cell lines were subsequently assayed with alamarBlue to track the 
proliferation rate of the cells over a period of 9-13 days. This method determined 
that cell lines overexpressing VGLL1 consistently had a slower proliferation rate 
when compared to eGFP control (Fig. 3.27C-E), with significant differences in the 
amount of time required to reach a 30% and 60% reduction of alamarBlue reagent 
(Fig. 3.27F; p ≤0.001). The observable difference in growth rate appeared to 
manifest 3-4 days after seeding; a period where the control cells consistently 

















































Figure 3.27: Overexpression of VGLL1 retards growth of proliferating NHU cells 
A-B) Three independent NHU cell lines overexpressing VGLL1 or eGFP control were 
seeded at the same density (5x105 cells/flask) and cultured for 48h to compare the rate 
of propagation. Figure (A) displays phase micrograph images of each cell lines prior to 
trypsinisation and counting. Image (B) depicts the total number of cells counted for 
each condition. The icons of the same shape represent values from donor-matched NHU 
samples. C-E) The growth rate of Y1696 (C), Y2167 (D) and Y2351 (E) cells transfected 
with eGFP or VGLL1 overexpressing vectors over 9-13 days, as analysed by alamarBlue 
assays. Image (F) depicts the significant differences in time eGFP and VGLL1 
overexpressing cells took to reach 30% and 60% reduction in alamarBlue reagent, a 
proxy for total cell density. Each data point in figures (C-E) represents the mean of six 
technical replicates ± SD. The data points in figure (F) represent the mean number of 
days from 18 technical replicates of three independent biological samples (n=6 per cell 
line). Significance between groups was calculated using a paired two-way T-Test (B) or 
multiple unpaired two-way T-tests with Holm-Sidak’s multiple comparisons post-hoc 




3.4.8.2 Effect of VGLL1 overexpression on EGFR expression and ERK1/2 activation 
After confirming that high expression of VGLL1 was having a negative effect on the 
growth rate of NHU cells, the gene expression of EGFR and MKI67 (Ki67) was 
analysed in sub-confluent VGLL1 overexpressing Y1696 cells to determine whether 
the EGFR growth signalling pathway (and subsequently activation of the cell cycle) 
was modulated by VGLL1. Non-quantitative RT-PCR analysis of transfected Y1696 
cells (n=1) found that expression of both genes was decreased in VGLL1 
overexpressing cells compared to control (Fig. 3.28A).  
However, subsequent immunoblotting analysis of two transfected NHU cell lines 
revealed no difference in phosphorylated ERK1/2 expression between eGFP and 
VGLL1 overexpressing conditions (Fig. 3.28B-C), suggestive of alternative signalling 


























3.4.8.3 Modulation of PI3K/AKT, YAP and cell cycle activity in VGLL1 overexpressing 
NHU cells 
Forced overexpression of VGLL1 in Y1696 cells was performed to uncover whether 
VGLL1 could affect the activation state of YAP (and thus potential YAP-mediated 
proliferation) in NHU cells. Due to a prior observation that suggested a modulation 
of YAP localisation through cell-cell contact (Section 3.4.6), cultures were lysed in 
both a sub-confluent state and once the cells had reached a post-confluent state to 
see whether this conferred additional changes in phosphorylated YAP expression. 
Despite overexpression of VGLL1 (and an induction of VGLL1 expression in eGFP 
control cells at the point of post-confluence), no change in the expression of p-YAP 
or total YAP/TAZ was observed (Fig. 3.29A), indicating that VGLL1 was not having an 
effect on the proportion of inactive YAP.  
Examination of phosphorylated AKT in the same cell line revealed a notable 
inhibition of expression in sub-confluent cells, alongside a concurrent inhibition of 
cell cycle-associated MCM2 expression in both sub-confluent and post-confluent 
cells (Fig. 3.29A). This result thereby implicated PI3K/AKT signalling as a possible 
pathway that is modulated downstream of VGLL1 overexpression, thus potentially 
accounting for the reduced cell cycle activity (and proliferation rate) observed in 
these cells (Fig. 3.29B).  
Figure 3.28: Overexpression of VGLL1 inhibits EGFR and MKI67 transcript but has no 
effect on activation of ERK 
A) RT-PCR analysis of EGFR and MKI67 transcript expression in Y1696 cells (n=1) 
transfected with VGLL1 or eGFP control overexpression constructs. Cells were lysed at 
sub-confluence in order to ascertain the specific role of VGLL1 in modulating expression 
of the above genes. Each cDNA synthesis used 1 µg starting template RNA, with cDNA 
undergoing PCR amplification up to 27 cycles. Housekeeping gene GAPDH was used to 
confirm equal loading between samples (25 cycles). The primers used produced positive 
gDNA bands of the same size, while a no template (H2O only) sample was used as a 
negative control for each primer set. B-C) Immunoblotting analysis of VGLL1, p-ERK1/2 
and Total ERK1/2 in Y1588 (B) and Y2167 (C) cells overexpressing VGLL1 or eGFP control 
(n=2 independent cell lines). Expression of Total ERK1/2 was used to confirm equal 











































Figure 3.29: Overexpression of VGLL1 inhibits p-AKT and MCM2 expression but has no 
effect on p-YAP expression in sub-confluent or confluent NHU cultures  
A) Immunoblot analysis of VGLL1, total and phosphorylated YAP (S127), phosphorylated 
AKT (S473) and MCM2 expression in Y1696 (n=1) cells following transfection with either 
control eGFP or VGLL1 overexpressing constructs. Cells were lysed in a sub-confluent state 
or in a state of post-confluence in order to observe the additional effects of confluency on 
the expression of the above proteins. Expression of β-Actin was used as a loading control. 
B) Interpretation of the molecular events downstream of VGLL1 overexpression, as 
determined in Fig. 3.27-3.29. Transfection of undifferentiated NHU cells with pLXSN-VGLL1 
resulted in high ectopic expression of VGLL1 protein (1). Cells overexpressing VGLL1 
exhibited a consistently reduced proliferation rate (2; n=3). This altered phenotype did not 
occur through modulation of active ERK1/2 (n=2), but possibly as a result of inhibiting 
phosphorylated AKT (3; n=1). Whether VGLL1 expression negatively affects proliferation 
through directly modulating AKT activity, or indirectly through activation of an 
intermediary factor, such as TEAD, was not determined as part of the overexpression 
study. VGLL1 overexpression was not found to have an effect on the amount of active or 






3.4.9 Modulation of differentiation and proliferation-associated protein expression by 
VGLL1 
To determine what effect that VGLL1 had on expression of proteins involved in the 
maintenance of a differentiated urothelial phenotype, NHU cell lines transfected 
with all three VGLL1 shRNA constructs (Y2324) or with the most inhibitory VGLL1 
shRNA #2 (n=3 independent cell lines) were immunoblotted to analyse expression 
of numerous proteins. It was determined that upon inhibition of VGLL1, expression 
of PPARγ, FABP4 and transitional cell marker CK13 were reduced compared to 
control in all three knockdown cell lines (Fig. 3.30A). Expression of tight junction 
protein claudin 4 was also found to be heavily inhibited in all knockdown cell lines, 
suggesting that inhibition of VGLL1 could additionally result in a loss of barrier 
integrity in differentiated cells. As observed in previous experiments using the 
VGLL1 shRNA constructs, VGLL1 shRNA #1 delivered the weakest relative 
knockdown of VGLL1, reflected in the expression of GATA3 and ELF3 which 
exhibited a greater inhibition in cells transfected with VGLL1 shRNA #2. 
Densitometry analysis of the expression of urothelial transcription factors in three 
independent cell lines transfected with scrambled shRNA or VGLL1 shRNA #2 
determined that knockdown of VGLL1 conferred a significant loss of GATA3, PPARγ 
and ELF3 expression compared to scrambled TZ/PD differentiated control (Fig. 
3.30B; p ≤0.01). A slight decrease in FOXA1 expression was observed by 
immunoblotting, but no significant change was observed after analysis. 
In comparison, analysis of p63 and phosphorylated AKT expression (two proteins 
observed to be inhibited by TZ/PD differentiation) discovered that both proteins 
exhibited an increase in expression in VGLL1 shRNA #2 transfected cells. The results 
gained using knockdown constructs therefore demonstrated that the presence of 
VGLL1 appeared to play a role in regulating the expression of proteins involved in 
the urothelial differentiation phenotype, with a loss of the protein associated with 





















































Figure 3.30: Knockdown of VGLL1 results in reduced expression of differentiation-
associated proteins 
A) Immunoblotting analysis of VGLL1, PPARγ, FABP4, GATA3, ELF3, FOXA1, CK13, claudin 
4, p63 and total and phosphorylated AKT expression in Y2324 cells transfected with 
either scrambled shRNA or three shRNA constructs specific to VGLL1 after 72h TZ/PD 
treatment. All conditions were treated with 0.1% DMSO to control for non-specific 
solvent effects. The expression pattern of VGLL1, PPARγ, GATA3, ELF3 and FOXA1 in the 
scrambled or VGLL1 k/d #2 conditions was representative of three independent cell lines 
(n=1 for FABP4, CK13, Claudin 4, p63, phosphorylated and total AKT). The asterisk 
represents protein samples that could not be assayed due to a lack of remaining lysate. 
Expression of β-Actin was used to confirm equal loading of samples. B) Quantification of 
VGLL1, GATA3, PPARγ, FOXA1 and ELF3 expression by immunoblotting densitometry 
analysis in three biological replicates of scrambled shRNA transfected NHU cells (treated 
with TZ/PD or vehicle control) and TZ/PD treated VGLL1 shRNA #2 transfected cells. 
Differences in expression are represented as a fold change in expression in comparison 
to the mean scrambled TZ/PD expression value. Significance between groups was 
determined using a two-way ANOVA with Tukey’s multiple comparisons post-hoc test. 
*=p≤0.05; **=p≤0.01. Immunoblot images from the biological replicates can be found in 




3.4.10 Role of VGLL1 in the differentiated NHU wound healing phenotype 
3.4.10.1 Analysis of barrier integrity in VGLL1 knockdown differentiated NHU cells   
After observing a reduction in expression of proteins known to be important for 
maintaining barrier function in VGLL1 knockdown differentiated NHU cells, 
measurement of the strength of the urothelial barrier was performed through 
electrophysiological analysis of NHU cells transfected with VGLL1 shRNA #2 or 
scrambled control (Fig. 3.31A). Immunoblotting analysis of lysates from each 
condition confirmed a reduction of VGLL1 expression in the VGLL1 knockdown 
ABS/Ca2+ differentiated cells (Fig. 3.31B).  
Measurement of barrier tightness using the cellZscope found that the strength of 
the barrier in both cell types increased at an almost identical rate in the 24h 
following the onset of ABS/Ca2+ differentiation (Fig. 3.31C). However upon achieving 
a stable barrier, it was observed that VGLL1 knockdown cells displayed a 
consistently weaker barrier in comparison to scrambled cells, even following spikes 
in tightness due to medium changes (p ≤0.001). Measurement of barrier integrity 
following scratch wounding of cultures revealed that VGLL1 knockdown cells 
additionally appeared to recover at a slower rate than scrambled cells and failed to 
return to the mean barrier tightness of pre-wounded cells after a 24h recovery 
period (Fig. 3.31D). Analysis of the time taken for each culture to recover to 75% of 
its pre-wounded barrier tightness confirmed that VGLL1 knockdown cells were 


























































Figure 3.31: VGLL1 knockdown results in decreased barrier tightness and ability to heal 
after scratch wounding in differentiated NHU cells 
A) Experimental flowchart of NHU cells (n=2 cell lines) that underwent ABS/Ca2+ 
differentiation while measuring the tightness of their barriers with the cellZscope. Cells 
were seeded onto Snapwell membranes and cultured in KSFMc for 24h before a 72h 
pretreatment with 5% ABS alone. Barrier tightness was measured upon adding Ca2+ to 
the medium of ABS treated cells, with measurements taken every hour for a period of 
144h. Y1811 cells (n=1) were additionally scratch wounded after 144h and barrier 
tightness measurements were recorded every 20 minutes for a period of 24h to analyse 
the ability of each cell type to recover its barrier. At the conclusion of the 24h recovery 
stage, membranes were either lysed for use in immunoblot analysis or pulsed with BrdU 
for 6h and fixed for analysis of S-phase positive cells in each culture. A description of the 
latter findings can be found in Section 3.4.10.5. B) Immunoblot analysis of the conditions 
outlined in (A), demonstrating a reduction in VGLL1 expression when knocked down 
compared to control. Expression of β-Actin was used to confirm equal loading of 
samples. C) Barrier impedance of ABS/Ca2+ differentiated Y1811 cells transfected with 
scrambled or VGLL1 #2 shRNA. The pattern of barrier tightness is representative of two 
independent cell lines, with the TEER readings for biological replicate Y2425 found in 
Appendix xii. D) Y1811 cells were scratch wounded and the recovery of barrier integrity 
was measured over a period of 24h. Six technical replicates of each condition in (C+D) 
were measured for barrier impedance, with TEER measured in Ω/cm2. E) The amount of 
hours each replicate required to recover 75% of the TEER of its last reading prior to 
scratch wounding was calculated. Significance between groups was determined using a 
two-way repeated measure ANOVA with Sidak’s multiple comparisons post-hoc test (C) 
or an unpaired T test (E). *=p≤0.05; ***=p≤0.001. 
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3.4.10.2 Immunofluorescence analysis of urothelial transcription factors in VGLL1 
knockdown differentiated NHU cells after scratch wounding  
To understand the molecular basis behind a lag in wound recovery in VGLL1 
knockdown cells, transfected NHU cell lines were ABS/Ca2+ differentiated for 7 days 
before being scratch wounded and allowed to recover for different periods of time 
(Fig. 3.32A).  
Phase micrograph images of ABS/Ca2+ differentiated NHU cells transfected with 
either construct determined that no observable differences in morphology could be 
observed between conditions prior to wounding (Fig. 3.32B). Images taken 30min 
and 4h after scratch wounding revealed that the wounds had yet to heal at either 
time-point, whereas after 72h cell lines transfected with either shRNA had 

































































Figure 3.32: Comparison of scrambled and VGLL1 knockdown ABS/Ca2+ differentiated 
NHU cell morphology following scratch wounding  
A) Experimental flowchart of NHU cells (n=2 independent cell lines) that were ABS/Ca2+ 
differentiated for 7 days on glass slides before  being scratch wounded and allowed to 
heal for different periods of time before formalin fixation. Cultures that had not received 
a scratch were fixed concurrently to provide a comparison to the expression pattern of 
proteins in cells that had undergone scratch wounding.  Additional slides fixed at periods 
of 30min and 72h (in addition to 4h) after wounding were prepared in the case of the 
Y2425 cell line. Slides fixed at 72h were additionally used to quantify expression of Ki67 
and MCM2 positivity in cultures, as described in Section 3.4.10.6. B) Phase micrograph 
images of ABS/Ca2+ differentiated VGLL1 knockdown Y2425 cells that were either scratch 
wounded and fixed 30min, 4h or 72h after wounding or fixed in an unwounded state. 
Cellular debris from the cells inhabiting the space that was scratched can be visualised in 
the images taken 30min post-scratch. White arrows in images taken 4h after wounding 
indicate the appearance of filopodia-like projections at the wound edge of recovering 





Analysis of unwounded cultures confirmed a reduction in VGLL1 expression in 
VGLL1 knockdown cells (Fig. 3.33A). Knockdown of VGLL1 was not found to 
modulate the frequency or intensity of nuclear p63 expression in unwounded cells, 
but similar to previous observations when dual-labelling GATA3 and p63, there 
appeared to be a mutually exclusive relationship between VGLL1 and p63 in regards 
to the dominant nuclear expression of each protein in a given cell. Expression of 
both proteins was found at the wound edge of 30min post-scratch cells (Fig. 3.33B), 
while increased expression of p63 was found 72h post-scratch in VGLL1 knockdown 
cells (Fig. 3.33C), suggestive of a potential increase in expression of proliferation-
associated targets following wound recovery.  
PPARγ was found to have reduced nuclear expression in the area directly behind 
the wound edge and exhibit a cytoplasmic expression pattern at the wound edge of 
scrambled cells at both time-points (Fig. 3.33E-F).  Interestingly, this translocation 
of PPARγ was not observed in VGLL1 knockdown cells, with nuclear PPARγ found to 
be consistently retained across the wound edge at either time-point (Fig. 3.33E-F). 
An initial concern was that this phenomenon was a result of non-specific 
fluorescence due to the trapping of antibody in the cell debris present at the wound 
edge immediately following scratch wounding. However, this phenotype was 
additionally consistently observed across the wound edge in scrambled (but not 
VGLL1 knockdown) cells 4h after scratching, a period of time in which most of the 






























Figure 3.33: VGLL1 knockdown affects the expression and localisation of urothelial 
transcription factors in scratch wounded NHU cells 
A-C) Immunofluorescence analysis of VGLL1 (red fluorescence) and p63 (green 
fluorescence) expression in ABS/Ca2+ differentiated VGLL1 knockdown NHU cultures 
that had been scratch wounded and fixed after different periods of time. Panels (A-C) 
display images of cells in an unwounded state (A) or 30min (B) and 72h (C) after 
wounding. D-F) Immunofluorescence analysis of PPARγ (D69 antibody) expression in 
VGLL1 knockdown NHU cultures in an unwounded state (D), or 30min (E) and 4h (F) 
after scratch wounding. White lines indicate the position of the wound edges.  Images 
were all taken at same exposure and are shown with or without overlaid Hoechst 33258 
DNA staining. Scale bar= 50µm. Cells receiving no primary antibody at all time-points 
were used as negative controls, images of which can be found in Appendix xii.  
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3.4.10.3 Analysis of tight junction integrity in VGLL1 knockdown differentiated NHU 
cells after scratch wounding  
Following its previous validation as a specific marker of stratified urothelium 
(Section 3.4.2.3), expression of tight junction protein ZO-3 was analysed in two 
independent cell lines to understand whether the maintenance of tight junctions is 
altered in wounded differentiated NHU cells with inhibited VGLL1 expression. 
Expression of ZO-3 appeared normal in unwounded VGLL1 knockdown cells, with a 
membranous expression pattern observed which was similar to that found in 
scrambled control cells (Fig. 3.34A,C). However, observation of the 4h post-scratch 
cultures revealed a reduction in membranous ZO-3 expression at the wound edge 
of scrambled Y2324 (Fig. 3.34B) and Y2425 (Fig. 3.34D) cells, indicative of a 
dissolution of tight junctions. In comparison, VGLL1 knockdown Y2324 cells 
exhibited a complete retention of ZO-3 at the wound edge (Fig. 3.34B), thereby 
implicating a failure to dissolve tight junctions at the wound edge as a potential 
reasoning behind the lag in wound recovery noted in this cell type. While some 
dissolution of ZO-3 at the wound edge was observed in VGLL1 knockdown Y2425 
cells, this cell type exhibited a comparatively stronger expression of the protein 
than the corresponding scrambled culture (Fig. 3.34D).  
ZO-1 expression was additionally analysed in this assay (n=1), but no change in the 
localisation of this protein was observed in either scrambled or VGLL1 knockdown 
cells at either time-point assayed (Fig. 3.34E-F), suggesting that ZO-1 is dissolved at 






























Figure 3.34: VGLL1 knockdown affects the dissolution of ZO-3 but not ZO-1 at the 
wound edge of scratch wounded NHU cells 
A-B) Immunofluorescence analysis of ZO-3 expression in Y2324  differentiated 
VGLL1 knockdown NHU cultures that had been scratch wounded and fixed after 
different periods of time. Panels display images of cells captured in an unwounded 
state (A) or 4h (B) after wounding. C-F) Immunofluorescence analysis of ZO-3 (C-D) 
and ZO-1 (E-F) expression in Y2425 differentiated VGLL1 knockdown NHU cultures 
that had been scratch wounded and fixed after different periods of time. Panels 
display images of cells captured in an unwounded state (C, E) or 4h (D, F) after 
wounding. White lines indicate the position of the wound edges. Images were all 
taken at same exposure and are shown with or without overlaid Hoechst 33258 
DNA staining. Scale bar= 50µm. 
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3.4.10.4 Immunofluorescence analysis of migration and proliferation-associated 
proteins in VGLL1 knockdown differentiated NHU cells following scratch wounding 
The canonical TGFβ pathway (as controlled through activation of signal mediator 
SMAD3 by phosphorylation at its Ser423 and Ser425 sites) has previously been 
shown to play an important role in the wound recovery phenotype of differentiated 
NHU cells (Section 1.3.3). To determine whether this signalling pathway is impaired 
in VGLL1 knockdown cells, expression of phosphorylated SMAD3 was analysed in 
the context of scratch wounding in two independent cell lines. Expression of p-
SMAD3 was similar in both transduced cell types in an unwounded state; with 
punctuate, sub-nuclear labelling found throughout both cultures (Fig. 3.35A). 
Immediately following wounding, this punctum-like p-SMAD3 signal was lost in the 
nuclei of cells situated away from the wound (Fig. 3.35B), but was retained in 
scrambled cells at the wound edge at both time points (Fig. 3.35C-D). In 
comparison, nuclear p-SMAD3 expression was lost both at and away from the 
wound edge in VGLL1 knockdown cells at both time points following scratch 
wounding, indicating an inhibition of the TGFβ-mediated wound recovery 
phenotype (Fig. 3.35B-D).  
Expression of cell cycle marker Ki67 was additionally analysed to understand 
whether the urothelial wound response was also mediated through activation of 
proliferation. As expected, expression of Ki67 was very low in both cell types in an 
unwounded state (indicative of a quiescent cell population); although positive 
nuclei were observed more frequently in the VGLL1 knockdown culture (Fig. 3.35E). 
Analysis of cells in the period of 4h post-scratch determined that neither cell type 
had Ki67 positive cells at the wound edge (Fig. 3.35F), thereby implying that the 












































YAP/TAZ signalling has previously been cited as an important pathway in the wound 
healing process (Section 3.1.2). To understand the role that YAP/TAZ signalling plays 
in the migratory phenotype of wounded ABS/Ca2+ differentiated NHU cells (and 
whether the presence of VGLL1 affects this), expression of YAP was observed in 
VGLL1 knockdown cells following scratch wounding. Similarly to the phenotype 
previously observed in PD153035-treated cells (Section 3.4.6.4), YAP expression in 
ABS/Ca2+ differentiated cells appeared to be localised to both nuclear and 
cytoplasmic compartments of cells in an unwounded state (Fig. 3.36A). Analysis of 
scratch wounded cultures determined that a mixture of nuclear and cytoplasmic 
YAP was also found at the wound edge of scrambled and VGLL1 knockdown cells 
(Fig. 3.36B-C), indicating that a translocation YAP to a more nuclear, active state 
does not occur as part of the migratory phenotype of wounded NHU cells. 
Furthermore, loss of VGLL1 appears to have no effect on this process, suggesting 
that other factors independent of VGLL1 are responsible for the nucleo-cytoplasmic 
shuttling of YAP.   
Figure 3.35: Phosphorylated SMAD3 expression is lost at the wound edge of mitotically 
quiescent scratch wounded VGLL1 knockdown NHU cells 
A-D) Immunofluorescence analysis of phosphorylated (Ser423/Ser435) SMAD3 
expression in ABS/Ca2+ differentiated VGLL1 knockdown NHU cultures that had been 
scratch wounded and fixed after different periods of time. Cultures that had not been 
scratched were used as unwounded controls (A), with cells transfected with either shRNA 
displaying nuclear expression of p-SMAD3. Panels (B-C) represent cells that were fixed 
30min after wounding, with images captured both away from the wound (B) and at the 
wound edge (C). Panel D represent images captured 4h post-scratch. E-F) 
Immunofluorescence analysis of Ki67 expression in Y2324 ABS/Ca2+ differentiated VGLL1 
knockdown NHU cultures (n=1) that had been fixed in an unwounded state (E) or 4h after 
scratch wounding (F). The expression pattern of p-SMAD3 is representative of two 
transfected NHU cell lines. Images from the biological replicate can be found in Appendix 
xii. White lines indicate the position of the wound edges. Images were all taken at same 
exposure and are shown with or without overlaid Hoechst 33258 DNA staining. Scale 


























Figure 3.36: Localisation of YAP is not altered following scratch wounding of 
ABS/Ca2+ differentiated NHU cells 
Immunofluorescence analysis of total YAP expression in ABS/Ca2+ differentiated 
VGLL1 knockdown NHU cultures fixed in an unwounded state (A), or 4h (B) after 
wounding. The expression pattern of the above targets is representative of two 
independent transfected NHU cell lines. Images from the biological replicate can 
be found in Appendix xii. White lines indicate the position of the wound edges. 
Images were all taken at same exposure and are shown with or without overlaid 








3.4.10.5 Quantification of VGLL1 knockdown differentiated NHU cells in S phase 
following wound closure 
The results of Section 3.4.8 demonstrated that forced expression of VGLL1 
negatively affected the proliferative potential of undifferentiated NHU cells, while 
the observational findings of the preceding section suggested that inhibition of the 
protein in differentiated (mitotically quiescent) NHU cells may have resulted in an 
increased proportion of cells that were actively proliferating. To quantify whether 
knockdown of VGLL1 in differentiated NHU cells led to a further reactivation of cell 
cycle upon conclusion of wound healing, Y1811 cells were pulsed with BrdU 24h 
after scratch wounding for 6h (cells fixed 30h post-scratch) to observe if there was a 
difference in the amount of S-phase positive cells in VGLL1 knockdown cells 
compared to control. The forward versus side scatter plots of both Y1811 
conditions revealed high amounts of debris in each sample, which could have 
resulted from insufficient disaggregation of tightly bound cells from the original cell 
sheet, or simply due to the large size of stratified differentiated NHU cells (Fig. 
3.37A). Cell populations were gated based on their propidium iodide fluorescence 
intensities (Fig. 3.37B) and BrdU positive populations quantified (Fig. 3.37C). MIBC 
cell line 5637 was processed in tandem with the Y1811 samples due to its high S-
phase activity, with 41.3% of all events confirmed to exhibit BrdU positivity. In 
comparison, only 0.82% of events from scrambled differentiated NHU cells were 
found to be BrdU positive, indicative of a negligible increase in S-phase positivity in 
the period of 30h post-wounding. Differentiated cells with VGLL1 knockdown were 
found to have a 2.41 fold increase in the amount of BrdU positive cells (1.98% of all 
events) compared to scrambled control; suggestive of VGLL1 having an effect on 




















































Figure 3.37: Scratch wounded VGLL1 knockdown cells exhibit a larger S-phase 
population upon re-activation of proliferation 
Y1811 cells (n=1) containing scrambled or VGLL1 #2 shRNA were ABS/Ca2+ 
differentiated and scratch wounded, as described in Section 3.4.10.1. 24h following 
scratch wounding, cultures were pulsed with BrdU for 6h before disaggregation and 
fixation with ethanol. Single cells were subsequently labelled with a BrdU-specific 
primary and GaM 488 secondary antibody and fluorescence detected by flow 
cytometry. A) Forward versus side scatter (FS Lin vs SS Lin, respectively) dot plots of 
samples, with relevant populations gated (gate R1).  B) Propidium iodide scatter (PE-
Texas Red Lin vs PE-Texas Red Area) plots of R1-gated events, with relevant populations 
gated (gate R2). C) Propidium iodide versus BrdU scatter (PE-Texas Red Area vs FITC 
Log, respectively) plots of R2-gated events. 5637 cells were initially processed to 
determine the area of S-phase positive events (gate R3), which was subsequently 
applied to both Y1811 samples. D) Propidium iodide versus BrdU scatter plots of R2-
gated events from samples that were antibody labelled but received no BrdU pulse. E) 
Quantification of the R3-gated events (BrdU-positive cells) in Y1811 conditions as a 
percentage of all events.  
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3.4.10.6 Quantification of Ki67/MCM2-positive VGLL1 knockdown differentiated NHU 
cells following wound closure   
Previously unpublished work from The Jack Birch Unit suggested that a peak re-
activation of cell cycle occurs 72h after scratch wounding differentiated NHU cell 
cultures, as determined by quantification of Ki67-positive cells over time. To 
uncover whether VGLL1 knockdown conferred a greater activation of cell cycle-
positive cells at the peak activation time, expression of Ki67 and MCM2 were 
analysed in transduced cultures left to heal for 72h.  
As observed previously (Section 3.4.10.4), unwounded Y2425 cells were found to 
have a small but noticeable increase in cell cycle positivity when VGLL1 was 
knocked down, with 1.3% of nuclei positive for Ki67 in VGLL1 knockdown cells 
versus 0.6% positivity in scrambled cells (Fig. 3.38A,C). A four-fold increase in Ki67 
positivity was observed in scrambled cells 72h following wounding compared to 
unwounded control (2.5% positive nuclei), but in comparison VGLL1 knockdown 
cells experienced a large increase in Ki67 positivity, with 51.6% of cells expressing 
Ki67 at the same time-point (Fig. 3.38B-C). The pattern of MCM2 positivity mirrored 
that of Ki67 in each condition and time-point, albeit with a greater percentage of 
positive cells in each culture (70.4% positivity in VGLL1 knockdown cells 72h 
following scratching). To confirm that the observed phenotype was not due to 
differences in cell density between cell types, the number of cell nuclei analysed 
per image was counted, with no significant differences found between conditions 
72h post-scratch (Fig. 3.38D). Analysis of these markers in this context therefore 
contributed to evidence that suggested that VGLL1 plays a role in modulating the 

















































Figure 3.38: Scratch wounded VGLL1 knockdown cells are predisposed to re-enter the 
cell cycle after wounding  
Immunofluorescence analysis of dual-labelled MCM2 (red fluorescence) and Ki67 (green 
fluorescence) expression in Y2425 ABS/Ca2+ differentiated VGLL1 knockdown NHU 
cultures (n=1 cell line) in an unwounded state (A) or 72h following scratch wounding (B). 
C) Quantification of Ki67 and MCM2 positive nuclei in figures (A-B). Six representative 
images were captured for each condition, with % positive nuclei for each protein marker 
calculated in ImageJ. D) The mean number of cell nuclei for each 72h post-wound 
condition (n=6 images) was calculated, with significance between groups determined 
using an unpaired T test. Images were all taken at same exposure and are shown with or 
without overlaid Hoechst 33258 DNA staining. Scale bar= 50µm. E) Summary of the 
changes in phenotype observed in unwounded, wounded and post-wounded 
differentiated NHU cells following VGLL1 knockdown, as determined in Fig. 3.30-3.38. 
Knockdown of VGLL1 resulted in cultures that exhibited a weaker barrier in an 
unwounded state (n=2 cell lines), yet were slower to recover a tight barrier following 
wounding (n=1). While actively recovering from wounding, VGLL1 knockdown cells were 
found to retain nuclear PPARγ and membranous ZO-3 expression, while expressing 
reduced migratory-associated p-SMAD3 at the wound edge (all n=2). Following 
completion of the healing process, inhibition of VGLL1 expression resulted in a greater 
increase of cell cycle activation than was observed in control cultures (n=1 cell line by flow 
cytometry, n=1 by immunofluorescence). Nuclei labelled green in diagram represent 




3.4.10.7 Immunofluorescence analysis of scratch wounded differentiated NHU cells 
treated with TGFβ signalling agonist and antagonist 
The preceding results suggested that VGLL1 plays an important role in regulating 
both the initial wound healing response (as determined by expression of p-SMAD3 
and ZO-3 at the wound edge) and the activation of proliferation following wound 
closure (as determined by BrdU labelling and Ki67/MCM2 expression) in 
differentiated NHU cells. To observe whether a similar phenotype arose following 
VGLL1-independent modulation of the TGFβ signalling pathway, untransfected 
differentiated NHU cell lines Y1837 and Y2696 were pre-treated with 2 ng/mL 
rTGFβ1 (henceforth referred to as TGFβ) or 3 µM SB431542 (a specific TGFβRI 
inhibitor) for 3h before scratch wounding of cultures and examination of proteins of 
interest 4h and 72h post-wounding. 
 As before, p-SMAD3 was found to exhibit widespread nuclear expression in 
unwounded control cells (Fig. 3.39A) but accumulated in the nuclei of cells at the 
wound edge in DMSO treated cultures 4h post-wound (Fig. 3.39B). Expression of p-
SMAD3 confirmed the efficacy of the reagents used, as TGFβ treated cells exhibited 
intense expression at the wound edge (Fig. 3.39C) while expression was abrogated 
in SB431542 treated cells (Fig. 3.39D). Interestingly, expression of p-SMAD3 was 
found to be inhibited in control cells 72h post-wound (Fig. 3.39E) when compared 
to TGFβ treated cells (Fig. 3.39F) at the same time-point, suggestive of a failure to 
regain basal activity of p-SMAD3 following activation of the TGFβ-mediated wound 



































Analysis of ZO-1 and ZO-3 expression in two wounded NHU cultures revealed that 
TGFβ treatment resulted in an accelerated dissolution of ZO-3 from the wound 
edge when compared to DMSO or SB431542 treated cells in Y2665 cells (Fig. 3.40B-
E), but not Y1837 cells (Fig. 3.40G-I), indicating (as observed previously in Section 
3.4.10.3) the inherent variability in the speeds in which different NHU cell lines 
activate wound recovery mechanisms. In comparison, ZO-1 expression was not 
found to be modulated at the wound edges of either cell line following any 






Figure 3.39: Treatment of differentiated NHU cells with TGFβ induces high nuclear 
p-SMAD3 activity at the wound edge following scratching  
Immunofluorescence analysis of p-SMAD3 (Ser423/Ser435) expression in ABS/Ca2+ 
differentiated NHU cultures that had been scratch wounded and fixed after different 
periods of time. Panels (A-D) display images of cells in an unwounded state (A) or 4h 
post-wounding following 3h pre-treatment with DMSO (B), 2 ng/mL TGFβ (C) or 3 µM 
SB431542 (D).  Panels (E-G) display images of cells that had been scratch wounded 
and fixed after 72h following pre-treatment with DMSO (E), TGFβ (F) or SB431542 
(G). All conditions were treated with 0.1% DMSO to control for non-specific solvent 
effects. The expression pattern of p-SMAD3 is representative of two transfected NHU 
cell lines. Images from the biological replicate can be found in Appendix xii. White 
lines indicate the position of the wound edges.  Images were all taken at same 


















































Figure 3.40: TGFβ treatment can induce dissolution of ZO-3 from the wound edge 
following scratch wounding 
A-E) ZO-1 (green fluorescence) and ZO-3 (red fluorescence) expression in Y2665 
differentiated NHU cultures that had been scratch wounded and fixed in an 
unwounded state (A), or after 4h following pre-treatment with DMSO (B), TGFβ (C-
D) or SB431542 (E).  TGFβ treated cultures exhibited dissolution of ZO-3 at the 
wound edge (C) but retained expression in cells situated away from the wound (D). 
F-I) ZO-1 (green fluorescence) and ZO-3 (red fluorescence) expression in Y1837 
differentiated NHU cultures that had been scratch wounded and fixed in an 
unwounded state (F), or after 4h following pre-treatment with DMSO (G), TGFβ (H) 
or SB431542 (I). White lines indicate the position of the wound edges.  Images were 
all taken at same exposure and are shown with or without overlaid Hoechst 33258 
DNA staining. Scale bar= 50µm. 
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Control and TGFβ treated wounded NHU cells were found to exhibit intense 
cytoplasmic PPARγ at the wound edge (Fig. 3.41B-C) while SB431542 treated cells 
retained a primarily nuclear localisation of the protein (Fig. 3.41D), mirroring the 
phenotype observed in scrambled control (cytoplasmic PPARγ) and VGLL1 




















Figure 3.41: Inhibition of TGFβ results in retention of nuclear PPARγ at the wound 
edge of differentiated NHU cells 
PPARγ (81B8 antibody) expression in ABS/Ca2+ differentiated NHU cultures that had 
been scratch wounded and fixed after different periods of time. Panels (A-D) display 
images of cells in an unwounded state (A) or 4h post-wounding following pre-
treatment with DMSO (B), TGFβ (C) or SB431542 (D).  The expression pattern of PPARγ 
is representative of two transfected NHU cell lines. Images from the biological replicate 
can be found in Appendix xii. White lines indicate the position of the wound edges.  
Images were all taken at same exposure and are shown with or without overlaid 








VGLL1 expression did not exhibit any notable changes in expression or localisation 
across any treatment in a post-wounded state (Fig. 3.42A-D); suggesting that 






















Figure 3.42: VGLL1 expression is not modulated in differentiated NHU cells following 
TGFβ agonism or antagonism  
VGLL1 expression in ABS/Ca2+ differentiated NHU cultures that had been scratch 
wounded and fixed after different periods of time. Panels (A-D) display images of cells in 
an unwounded state (A) or 72h post-wounding following pre-treatment with DMSO (B), 
TGFβ (C) or SB431542 (D).  The expression pattern of VGLL1 is representative of two 
transfected NHU cell lines. Images from the biological replicate can be found in Appendix 
xii. Images were all taken at same exposure and are shown with or without overlaid 








Analysis of Ki67 expression in the assayed cell lines revealed an increase in positivity 
from 2.2% to 5.5% when comparing unwounded control cells (Fig. 3.43A, E) to 
DMSO treated cells left to recover for 72h (Fig. 3.43B, E). Treatment with TGFβ 
served to inhibit cell cycle activation following recovery from scratch wounding 
(1.3% Ki67 index; Fig. 3.43C, E) while cells pre-treated with SB431542 exhibited an 
increased percentage of Ki67 expression (14.1%; Fig. 3.43D, E). As before, the 
expression pattern of MCM2 tallied with that of Ki67 but was expressed by a 
greater percentage of cells in the population (18.5% positivity in 72h DMSO cultures 
versus 29.4% positivity in SB431542 treated cultures). The preceding observations 
therefore indicated that inhibition of autocrine TGFβ signalling prior to the scratch 
wounding of differentiated NHU cells had a similar effect on cell phenotype as 
inhibition of VGLL1 via shRNA knockdown (Fig. 3.43F) thereby implicating both 
VGLL1 and TGFβ signalling as important modulators of the urothelial wound 





















































Figure 3.43: TGFβ pathway inhibition results in increased cell cycle activity in wounded 
differentiated NHU cells in a similar manner to inhibition of VGLL1 expression 
A-E) Analysis of dual-labelled Ki67 (green fluorescence) and MCM2 (red fluorescence) 
expression in ABS/Ca2+ differentiated NHU cultures (n=2). Panels (A-D) display images of 
cells in an unwounded state (A) or 72h post-wounding following pre-treatment with 
DMSO (B), TGFβ (C) or SB431542 (D). The expression pattern of the above targets is 
representative of two transfected NHU cell lines. Images from the biological replicate 
can be found in Appendix xii. Images were all taken at same exposure and are shown 
with or without overlaid Hoechst 33258 DNA staining. Scale bar= 50µm. E) Quantification 
of Ki67 and MCM2 positive nuclei in figures (A-D). Eight representative images were 
captured for each condition from two independent NHU cell lines (n=16 images for each 
condition total), with % positive nuclei for each protein marker calculated in ImageJ. F) 
Summary of the changes in phenotype observed in wounded and post-wounded 
differentiated NHU cells following activation or inhibition of TGFβ signalling with TGFβ or 
SB431542, respectively. These experiments revealed that TGFβ pathway inhibition 
resulted in a similar phenotype to wounded cells with VGLL1 knockdown, as evidenced 
by a retention of nuclear PPARγ and loss of p-SMAD3 at the wound edge of SB431542-
treated cultures, followed by a notable increase in cell cycle activity (all n=2). Nuclei 






3.5.1 Expression of Hippo pathway genes in urothelium 
This chapter provides the first systematic transcriptomic characterisation of Hippo 
pathway components in urothelium, with RNAseq analysis revealing several gene 
components (TEAD1, TEAD3, STK4, STK3, LATS1, LATS2, MOB1A, VGLL4) that were 
expressed in both in situ and in vitro urothelium regardless of differentiation state. 
However, only the predicted transcriptional co-activator VGLL1 displayed an 
association with a differentiated urothelial phenotype.  
3.5.2 Context-specific induction of VGLL1 expression in urothelial cells 
3.5.2.1 Identification of PPARγ and GATA3 as transcription factors involved in VGLL1 
induction 
The role of transcription factors PPARγ and GATA3 in the induction of VGLL1 in 
differentiated NHU cells was investigated due to the previous identification of 
PPARγ and GATA3 as pivotal regulators of normal urothelial cytodifferentiation 
(Varley et al., 2004a; Varley et al., 2004b; Varley et al., 2006; Varley et al., 2009; 
Fishwick et al., 2017). The results achieved by inhibiting said transcription factors in 
differentiating NHU cells by pharmacological or genetic means revealed that the 
induction of VGLL1 was a complex process that seemingly encompassed the 
activation of multiple transcription factors, modulation of proliferation-associated 
signalling pathways and a sensitivity to cell density.   
Inhibition of PPARγ in TZ/PD differentiated NHU cells was determined to have a 
highly variable effect on VGLL1 transcript and protein induction, with T007 
treatment resulting in inhibition of VGLL1 protein expression at an earlier time-
point (24h) which failed to be uniformly reproduced in cell lines at later stages of 
differentiation (72h), a time in which inhibition of GATA3 had a comparatively more 
potent effect on VGLL1 expression in 2/3 cell lines. While a previous study had 
highlighted a co-localisation between VGLL1 protein and GATA3 transcript at an 
early stage of human embryonic placental development (Soncin et al., 2018), this is 
the first evidence that indicates that GATA3 transcriptional activity is upstream of 
VGLL1 expression. The accumulative observations made in the preceding 
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experiments therefore pointed to a model whereby PPARγ plays an important role 
in the initial differentiation process to dictate VGLL1 transcription, but that this 
influence subsequently lessens over the process of differentiation as intermediate 
transcription factors such as GATA3 become activated, a phenotype consistent with 
the role of PPARγ as a pioneer urothelial transcription factor (Varley et al., 2009). 
That NHU cell lines exhibited such differential responses to T007 treatment/GATA3 
knockdown did not appear to be as a result of inherent differences between cell 
line origin (all cell lines used in this chapter were ureter-derived), but instead 
appeared to be related to subtle differences in cell density and the modulation of 
signalling pathways that entailed.  
Previous studies into the mechanisms that control NHU differentiation following 
treatment with TZ and PD153035 in isolation or concurrently determined that dual 
administration of the reagents produced a synergistic effect, therefore concluding 
that blockade of downstream EGFR signalling was necessary for consistent 
activation of PPARγ and expression of both immediate downstream targets (FOXA1, 
IRF1) and late differentiation markers, such as UPK2 and claudins 3, 4 and 5  (Varley  
et al., 2004a; Varley et al., 2006; Varley et al., 2009). The results collated through 
interrogation of the TZ/PD differentiation method in this study support the 
assertion that administration of TZ alone is able to induce expression of some 
differentiation-associated proteins such as FOXA1, ELF3 and PPARγ itself in post-
confluent NHU cells. However, this approach did little to induce expression of other 
differentiation-associated proteins such as GATA3 and VGLL1, which required 
inhibition of the EGFR/RAS/RAF/MEK/ERK signalling axis. This is an interesting 
observation, as the prevailing view of GATA3 is that its expression is solely 
downstream of PPARγ activation, as demonstrated in a study of PPARγ 
overexpression in PPARγ/GATA3-null normal human buccal cells (Hustler et al., 
2018). That GATA3 and VGLL1 (but not PPARγ) protein are induced in NHU cells 
following growth to post-confluence challenges this previous view, and suggests 




One possible hypothesis for this observation is that induction of GATA3 in 
PD153035-treated or post-confluent NHU cells may be as a result of an activation of 
previously labile (but present) PPARγ through inhibition of its ERK-mediated 
phosphorylation (Varley et al., 2004a), although this possibility was not explored as 
part of this study. As the onset of confluence has previously been demonstrated to 
negatively affect the activation of ERK1/2 in undifferentiated NHU cells 
(Georgopoulos et al., 2014), it is therefore possible that induction of GATA3 protein 
requires PI3K/AKT signalling activation, a pathway identified in this study to be 
active following PD153035 treatment. Treatment of AKT knockdown MCF-7 cells 
with the oestrogen receptor α ligand estradiol resulted in a differential expression 
of genes predicted to have binding sites in the GATA3 promoter compared to 
control (Bhat-Nakshatri et al., 2016), whilst PI3K/AKT signalling has previously been 
demonstrated to be required to stabilise GATA3 protein in differentiated T cells 
(Cook et al., 2010). However, whether this signalling relationship also exists in 
urothelial cells has yet to be confirmed.   
3.5.2.2 Relationship of VGLL1 induction to PI3K/AKT signalling 
Preliminary evidence in this chapter demonstrated the potential induction of VGLL1 
expression in undifferentiated NHU cells grown in high Ca2+, with expression of the 
protein lost when cells were concurrently treated with PI3K/AKT inhibitor 
LY294002. A potential relationship between VGLL1 and PI3K/AKT signalling has 
previously been observed by Kim et al. in specimens of gastric cancer, as tumours 
with high VGLL1 expression were found to correlate positively with PI3K genes 
PI3KCA and PI3KCB. Treatment with LY294002 or siRNA knockdown of 
PI3KCA/PI3KCB in gastric cancer cell line NUGCB3 resulted in an inhibition of VGLL1 
expression, which was hypothesised to be as a result of β-catenin signalling as 
inhibition of AKT signalling led to a loss of active β-catenin and a reduction in β-
catenin occupancy on the VGLL1 promoter (Kim et al., 2019a). However, this does 
not likely appear to be relevant in NHU cells as VGLL1 expression is significantly 
induced following PD153035 treatment, a phenotype that results in a reduction of 
active β-catenin in the nucleus. Additionally, treatment of undifferentiated NHU 
cells with LY294002 serves to increase nuclear β-catenin expression (Georgopoulos 
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et al., 2014), highlighting how these signalling pathways can crosstalk in a different 
manner depending on cell type. 
3.5.2.3 Other transcription factors potentially involved in VGLL1 expression 
siRNA knockdown of GATA3 was insufficient to completely inhibit VGLL1 expression 
in TZ/PD differentiated cells, implicating the existence of other differentiation-
associated transcription factors that work synergistically with GATA3 to regulate 
VGLL1 expression. Principal component analysis of VGLL1 expression in urothelium 
when compared to urothelial transcription factors revealed a close association to 
FOXA1, RARG and POUF51 (OCT4) expression. Sequence analysis performed in this 
study additionally highlighted multiple FOXA1 binding motifs in the DNA region 
upstream of the VGLL1 promoter, although care must be taken to not over-
interpret the findings of such predictive tools.  
FOXA1 is a known target gene of PPARγ activation in urothelium (Varley et al., 
2009) and its differentiation-associated expression appears to be independent of 
GATA3, as demonstrated following GATA3 siRNA knockdown in TZ/PD 
differentiated NHU cells (Fishwick et al., 2017). However, a study of mouse 
embryonic carcinoma cells revealed that the Foxa1 promoter contains a retinoic 
acid response element and that treatment of these cells with retinoic acid rapidly 
induced Foxa1 expression (Jacob et al., 1999), potentially implicating RARγ as an 
alternate regulator of key genes that drive the urothelial differentiation process.  
A close association of VGLL1 expression to POU5F1 in urothelium is interesting, as 
OCT4 protein has previously been determined to not be expressed in NHU cells 
(Wezel et al., 2013). However, the study by Wezel et al. focussed on expression of 
the pluripotency-associated OCT4A splice variant in undifferentiated NHU cells, 
meaning that the expression of OCT4 variants (such as OCT4B) in NHU cells and 
their effect on the differentiated phenotype is currently unknown. The respective 
roles of FOXA1, RARγ and OCT4 in inducing VGLL1 expression was not explored in 
this study, but future work that determines their relative importance (if any) in 
mediating expression of the transcriptional co-activator may help to increase 
understanding of the complex transcriptional machinery required to induce a fully 
differentiated urothelial phenotype.  
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3.5.3 The role of VGLL1 in differentiated urothelial tissue repair 
3.5.3.1 Effect of VGLL1 knockdown on differentiated urothelium  
Stable knockdown of VGLL1 resulted in reduced expression of a variety of 
differentiation-associated proteins following the onset of differentiation, including 
PPARγ, GATA3, ELF3, CK13 and Claudin 4. The effect that this loss of regulation had 
on the phenotype of ABS/Ca2+ differentiated NHU cells manifested as a tissue that 
exhibited a consistently weaker barrier, yet took longer to regenerate following 
scratch wounding. To understand how these seemingly contradictory observations 
were possible, the molecular changes that occurred following different stages of 
the urothelial wound repair process was interrogated in both VGLL1 knockdown 
cells and untransfected cells treated with modulators of TGFβ signalling, a pathway 
previously implicated in mediating a urothelial wound response (Fleming et al., 
2012). Affecting NHU physiology through VGLL1 knockdown or inhibition of TGFβ 
signalling resulted in a convergent phenotype, thereby further implicating autocrine 
TGFβ-mediated SMAD3 activation as a key signalling event in both the initial wound 
repair response in addition to highlighting a role in the subsequent return to 
quiescence of differentiated urothelium. The key observations made following 
analysis of scratch wounded VGLL1 knockdown and TGFβ/SB431542-treated 
ABS/Ca2+ differentiated NHU cells were summarised previously in Figures 3.37 and 
3.42, respectively.   
3.5.3.2 TGFβ-mediated dissolution of tight junctions 
Dissolution of tight junction proteins has been demonstrated to be a key event in 
the early stages of urothelial wound repair (Lavelle et al., 2002; Kreft et al., 2005), 
while activation of TGFβ signalling has previously been implicated as a key 
modulator of tight junction dissolution in non-urothelial murine and porcine cell 
models  (Ozdamar et al., 2005; Pierucci-Alves et al., 2012). The scratch wound 
experiments undertaken in this chapter indicate that a TGFβ-mediated mechanism 
appeared to affect the dissolution of tight junctions in wounded urothelium, as 
demonstrated by an accelerated loss of ZO-3 at the wound edge of TGFβ pre-
treated cells and retention of ZO-3 at the wound edge of VGLL1 knockdown cells 
when compared to their corresponding control cell lines. Furthermore, cells that 
219 
 
retained ZO-3 at the wound edge (i.e. VGLL1 knockdown cells) exhibited a 
concurrent inhibition of migration-associated p-SMAD3 activity. These observations 
therefore implicate VGLL1 as an important mediator of the TGFβ/SMAD3-mediated 
wound healing/migratory phenotype in NHU cells, and that loss of VGLL1 function 
results in an impaired wound response. In comparison, expression of fellow ZO 
family member ZO-1 was found to be retained at the leading wound edge of 
differentiated NHU cells following all time points and cell treatments; this reflected 
the phenotype previously observed in wounded mice bladders (Kreft et al., 2006). 
The expression and localisation of VGLL1 itself did not appear to change in scratch 
wounded cultures pre-treated with either TGFβ or SB431542, suggesting that the 
effect on cell phenotype mediated by VGLL1 knockdown was taking place upstream 
of TGFβ/SMAD3 signalling. 
3.5.3.3 Localisation of PPARγ following wounding 
An additional observation of wounded differentiated NHU cells was the increased 
cytoplasmic proportion of PPARγ that was consistently observed at the wound edge 
of control cells or TGFβ-treated cultures. In comparison, nuclear retention of PPARγ 
was observed at the wound edge of cultures with inhibited p-SMAD3 expression 
(i.e. VGLL1 knockdown and SB431542-treated cells). Various studies have 
demonstrated the ability of PPARγ agonism to negatively regulate TGFβ signalling 
activity (Ghosh et al., 2004; Reka et al., 2010; Liu et al., 2019), with this function 
speculated to arise in human hypertrophic scar fibroblasts following TZ treatment 
due to PPARγ-specific induction of miR-145, an inhibitor of SMAD3 expression (Zhu 
et al., 2015). Conversely, deletion of Pparγ in mouse fibroblasts resulted in 
constitutive expression of p-Smad3 that was independent of Tgfβ agonism (Ghosh 
et al., 2008) and was associated with an accelerated rate of wound healing (Sha et 
al., 2012). The observations made in this study therefore serve to suggest that 
PPARγ may play a similar role of SMAD3 regulation in urothelium, and that to 
circumvent inhibition of p-SMAD3 activity and drive the required migratory 
response in normal wounded differentiated NHU cells, the protein is sequestered 
from the nuclei of cells in an as-of-yet uncharacterised mechanism.  
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3.5.3.4 Reactivation of proliferation following wound closure 
Following successful closure of the wound and regeneration of a tight barrier, a 
modest increase in cell cycle activity was observed in control differentiated NHU 
cells throughout the population, indicative of a re-activation of proliferation that 
occurs at a later stage of recovery (i.e. 24-72h post-wounding) than the initial 
migratory response (0-10h post-wounding). Pre-treatment of cultures with TGFβ 
inhibited cell cycle activity to a greater degree than control, whilst VGLL1 
knockdown or SB431542 treatment resulted in a striking increase in BrdU, Ki67 and 
MCM2 labelling, additionally implicating VGLL1 regulation of the TGFβ/p-SMAD3 
signalling axis as an important modulator of differentiated cell proliferation. TGFβ 
has a known role in inducing cell cycle arrest through SMAD3-mediated induction of 
the cyclin-dependent kinase inhibitor p15INK4b (Hannon et al., 1994; Reynisdóttir et 
al., 1995; Frost et al., 2001), a process that was speculated to cause the cytostasis 
observed in undifferentiated NHU cells following treatment with TGFβ (Fleming et 
al., 2012). Activation of TGFβ signalling has additionally been implicated in an 
increased expression of fellow cyclin-dependent kinase inhibitor p27Kip1 through 
stabilisation of the protein and inhibition of its proteasomal degradation 
(Reynisdóttir et al., 1995; Lecanda et al., 2009). The observations recorded in this 
chapter therefore suggest that this growth arrest function of TGFβ signalling is also 
relevant in differentiated NHU cells, and creates a compelling argument to observe 
whether induction of p15INK4b and/or p27Kip1 is modified in TGFβ-treated cells 
compared to VGLL1 knockdown/SB431542-treated cells to confirm this hypothesis.  
3.5.4 Chapter conclusions 
The collated observations of NHU cells in this chapter have led to the following 
conclusions, summarised below and in Figure 3.44. Transcriptomic analysis 
identified VGLL1 as a transcriptional co-activator that is significantly induced 
following urothelial cytodifferentiation. A blockade of the constitutively active 
RAS/RAF/MEK/ERK signalling axis in undifferentiated NHU cells and the activity of 
transcription factors PPARγ and GATA3 were implicated in playing important roles 
in inducing expression of VGLL1, a process which may additionally require active 
PI3K/AKT signalling. Forced expression of VGLL1 in undifferentiated NHU cells 
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negatively affected proliferation, potentially as a consequence of inhibited 
PI3K/AKT signalling whilst appearing to have no effect on the activation of YAP. This 
led to the following chapter addressing whether these observations are reiterated 
in transfected MIBC cell lines with a VGLL1-low background. Examination of 
wounded differentiated NHU cells revealed a striking relationship between the 
expression of VGLL1 and the ability of cells to activate TGFβ-mediated p-SMAD3 
signalling, a pathway that is demonstrably important for mediating both the initial 
wound healing response in addition to regulating the ability of differentiated cells 
to reactivate proliferative processes. Inhibition of VGLL1 in differentiated NHU cells 
appeared to dysregulate the balance of SMAD3 activation in a post-wounded cell 
population, thereby resulting in a lack of control over cell cycle re-entry. Predictions 
as to how this previously unreported role of VGLL1 functions at a mechanistic level 





























Figure 3.44: The predicted phenotype of VGLL1 in differentiated urothelium 
In differentiating urothelium, the RAS/RAF/MEK/ERK signalling pathway is inhibited (1) 
and PI3K/AKT signalling is transiently activated (2). Activation of PPARγ and expression 
of fellow urothelial transcription factor GATA3 are important for inducing VGLL1 
expression, with the subsequent inhibition of PPARγ and GATA3 observed in VGLL1 
knockdown cells indicative of a potential positive homeostatic relationship between 
VGLL1 and the transcription factors in differentiated urothelium (3). Forced expression 
of VGLL1 retarded the proliferation of NHU cells, potentially through inhibition of 
phosphorylated AKT (4). In mitotically quiescent, differentiated urothelium, an absence 
of VGLL1 was demonstrated to affect both barrier tightness and the normal process of 
tissue regeneration following scratch wounding (5), where the phenotype of nuclear 
SMAD3 activation and a dissolution of membranous ZO-3 was lost. Comparatively, the 
presence or absence of VGLL1 was not found to have any effect on the active proportion 
of YAP in NHU cells (6), a finding in opposition to that of previous studies. Outstanding 
questions on the function of VGLL1 are highlighted on the diagram with question marks, 
examples of which include whether forced expression of VGLL1 reproducibly inhibits 
PI3K/AKT signalling, whether the protein binds to TEAD transcription factors to facilitate 
its function, the identity of VGLL1-specific target genes, how the presence of VGLL1 
affects autocrine TGFβ signalling following scratch wounding and in turn, how this 
process is related to the dissolution of tight junctions.  
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3.6 Summary of results   
 VGLL1 was expressed in in vivo human urothelium, with expression localised 
to both nuclear and cytoplasmic compartments of cells. VGLL1 transcript 
and protein expression was found to be differentiation-associated in 
cultured NHU cells, with significant increases in expression when cells were 
treated using the TZ/PD or ABS/Ca2+ methods.  This induction of VGLL1 
expression coincided with a loss of proliferation and a gain of tight junction 
protein expression.  
 
 Expression of VGLL1 following TZ/PD differentiation was affected 
independently by inhibition of PPARγ or GATA3 in certain physiological 
contexts. Blockade of downstream targets of EGFR signalling (MEK1/2 and 
ERK1/2) through the use of inhibitors, or the onset of cell contact-inhibition 
were also implicated in the induction of VGLL1 expression in 
undifferentiated NHU cells. 
 
 Overexpression of VGLL1 in undifferentiated NHU cells resulted in a reduced 
rate of proliferation. RAS/RAF/MEK/ERK signalling appeared unaffected by 
VGLL1 overexpression, implicating the modulation of other proliferation-
associated signalling pathways, such as PI3K/AKT.  
 
 shRNA knockdown of VGLL1 caused a reduction in the expression of 
differentiation-associated proteins. This manifested in a corresponding 
reduction in the overall barrier strength of cultures, yet cells were found to 
be slower to repair barrier integrity after scratch wounding. Analysis of this 
phenomenon determined that scratch wounding of VGLL1 knockdown cells 
resulted in a retention of nuclear PPARγ and membranous ZO-3 and a loss of 





 Mitotically quiescent ABS/Ca2+ differentiated cultures were observed to 
have greater population of cells actively in the cell cycle when VGLL1 
expression was inhibited in an unwounded state. VGLL1 knockdown 
differentiated NHU cells exhibited a greater increase in BrdU, Ki67 and 
MCM2 positivity compared to control following recovery from scratch 
wounding, implicating VGLL1 as a modulator of cell cycle re-entry.  
 
 Components of YAP/TAZ signalling, including TEAD1, TEAD3 and YAP were 
expressed in NHU cells. Overexpression of VGLL1 appeared to not induce 
inactivation of YAP through phosphorylation in undifferentiated cells, while 
knockdown of VGLL1 had no effect on the proportion of nuclear, active YAP 
in wounded differentiated cells. Localisation of YAP in NHU cells was 

















4. Effect of VGLL1 expression on bladder cancer cell phenotype 
4.1 Hippo pathway dysregulation in cancer  
Mutations in regulatory components of the Hippo pathway can affect tissue 
homeostasis and have a causal role in cancer initiation, as evidenced in numerous 
forms of human cancer. The most well documented instances of Hippo pathway 
mutations in cancer have been found in malignant mesothelioma, where 
inactivating mutations of the neurofibromin 2 (NF2) gene are found in around 23% 
of cases of tumour samples and 50% of cell lines (Murakami et al., 2011; Wang et 
al., 2018). NF2 is a cytoskeletal protein that binds directly to inhibitory kinases 
LATS1/2 and helps to regulate activation of YAP/TAZ (Plouffe et al., 2016). Cells with 
mutated NF2 therefore exhibit aberrant activation of YAP/TAZ target genes, cell 
cycle progression and increased migration (Fujii et al., 2012; Mizuno et al., 2012). 
Human lung cancer specimens were also found to exhibit reduced expression of 
inhibitory binding protein angiomoitin (AMOT) compared to healthy tissue, with a 
concurrent increase of nuclear YAP/TAZ suggestive of an additional mechanism by 
which normal regulation of YAP/TAZ is abrogated (Hsu et al., 2015). 
Of the VGLL family, VGLL4 is the best characterised in human disease, with evidence 
that it acts as a tumour suppressor in oesophageal, liver and colorectal cancer by 
competing with YAP/TAZ for binding to TEAD proteins (Jiang et al., 2015; Jiao et al., 
2017; Zhang et al., 2014). This observation led to the production of a VGLL4 
mimicking peptide which was demonstrated to suppress growth in both human 
gastric cancer cell lines and an in vivo mouse model of gastric cancer; a disease 
characterised by its aberrant YAP signalling (Jiao et al., 2014). No study has yet 
described a tumour suppressive role for VGLL1 in cases of human cancer; although 
given the sequence similarity of the Sd/TEAD binding motifs of VGLL1 and VGLL4 it 
may be predicted to have such a role through competitive inhibition of YAP/TAZ, as 
previously seen in an in vitro model of prostate cancer (Section 3.1.3).  
Reports of Hippo pathway dysregulation in urothelial carcinoma have previously 
been conflicting; with one study suggesting that YAP protein expression (detected 
immunohistochemically) was decreased in tissue samples of NMIBC and MIBC 
226 
 
compared to control (Latz et al., 2016), whilst another study used RT-qPCR, 
immunoblotting and immunohistochemistry to demonstrate an increase in YAP1 
transcript and nuclear YAP protein in MIBC samples compared to normal tissue (J. Y. 
Liu et al., 2013). One explanation for this discrepancy could be due to the choice of 
YAP antibody used in each study, with the rabbit polyclonal antibody employed by 



















4.2 Aims and hypothesis 
The results from Chapter 3 discovered that VGLL1 is differentiation-associated in 
NHU cells and suggested that the protein plays a role in tissue homeostasis. It is 
therefore axiomatic that VGLL1 function would be predicted to be somehow 
dysregulated in cases of MIBC. The overall aims of this chapter were to a) examine 
VGLL1 function through genetic manipulation of its expression in bladder cancer 
cell lines and b) characterise VGLL1 expression in MIBC using publically available 
datasets.  
Based on the previous observations of VGLL1 expression and function in normal 
urothelium, it was hypothesised that VGLL1 expression would be associated with 
luminal MIBC tumours and not with the less-differentiated basal/squamous MIBC 
tumours. It was additionally hypothesised that VGLL1 expression would be 
downregulated in MIBC unless the regulatory feedback pathways that act on VGLL1 
are dysregulated.  
The specific experimental objectives of this chapter were to: 
 Quantify VGLL1 transcript expression in bladder cancer cell lines (Section 
4.4.1) and TCGA MIBC cohort (Section 4.4.6) and compare to its expression 
in normal urothelium.   
 
 Generate VGLL1-overexpressing MIBC cell lines using cell lines identified in 
Section 4.4.1 that exhibit low/absent expression of the protein (Section 
4.4.2). Investigate the effect that VGLL1 overexpression has on the 
modulation of proliferation-associated signal transduction pathways 




 Identify subgroups of MIBC tumours with outlier expression of VGLL1 in 
order to observe whether said groups exhibit differences in tumour 
phenotype compared to other TCGA MIBC samples (Section 4.4.6). 
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4.3 Experimental approach  
4.3.1 Transcriptomic analysis of Hippo pathway genes in bladder cancer cell lines 
The transcriptomic phenotype of eight bladder cancer cell lines was analysed using 
a publically-available RNAseq dataset (BioProject Accession #PRJNA382834; MD 
Anderson Cancer Center) to elucidate whether the cell lines in question stratified 
into luminal and basal/squamous-like groups based on expression of previously 
determined luminal and basal/squamous MIBC marker genes (Choi et al., 2014b; 
Robertson et al., 2017; Marzouka et al., 2018). Expression of VGLL1 and various 
components of the Hippo pathway were subsequently quantified to observe 
whether these genes associated with specific cell line subtypes and determine 
whether expression was altered in an in vitro bladder cancer context in comparison 
to the expression found in normal urothelium in situ. VGLL1 protein expression in 
bladder cancer cell lines UM-UC-9, HT1376, RT4, ScaBer, T24 and 5637 was 
observed by immunoblotting in order to validate the phenotype observed at the 
transcript level. 
4.3.2 Modulation of bladder cancer cell line phenotype using a VGLL1 overexpression 
construct  
Following generation and validation of VGLL1-overexpressing 5637, T24 and ScaBer 
bladder cancer cell lines, the phenotype of the lines was analysed through a variety 
of different experiments. To further examine and potentially verify that VGLL1 is 
not acting in opposition to a YAP/TAZ signalling axis, the expression and localisation 
of the total and phosphorylated forms of YAP in the cell lines was observed by 
immunoblotting and immunofluorescence. Additionally, expression of previously 
cited YAP/TAZ downstream target genes ANKRD1, CTGF and CYR61 (Zanconato et 
al., 2015) was quantified by qRT-PCR to determine whether VGLL1 overexpression 
had an effect on markers of YAP/TAZ signalling.  
Expression of cell cycle marker Ki67 and key components of the 
EGFR/RAS/RAF/MEK/ERK and PI3K/AKT signalling pathways were analysed in the 
three cell lines by RT-PCR, immunoblotting and immunofluorescence. Changes to 
cell cycle activity following VGLL1 overexpression was additionally assayed by 
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quantifying the proportion of T24 and 5637 cells in S phase by flow cytometry of 
BrdU-positive cells.  
4.3.3 Investigation of VGLL1 phenotype in MIBC 
Transcript expression of VGLL1 in bladder cancer was analysed using the RNAseq 
resource of TCGA cohort of MIBC tumours (n=404; The Cancer Genome Atlas 
Research Network, 2014). The tumours of the cohort were separated into six 
molecular subtypes using a transcriptomic-based, computationally-devised 
consensus  classifier (Kamoun et al., 2020) and expression of VGLL1 was compared 
to that found in in-house RNAseq samples of normal urothelium in situ (n=6). 
Principal component analysis of VGLL1 and Hippo pathway components or 
urothelial-associated transcription factor expression (devised from a list of genes 
curated by Fishwick et al., 2017) in MIBC was subsequently performed to determine 
what genes (and in what MIBC molecular subtype) correlated with VGLL1 
expression.  
 
Descriptive statistics was used to identify an outlier group of tumours based on the 
distribution of VGLL1 expression across the overall MIBC cohort. The mutation 
status of VGLL1 and other genes that exhibited a significantly higher mutation 
frequency in the tumour subset was examined in an attempt to identify possible 
gene alterations that would result in dysregulated VGLL1 expression. Information 
regarding the somatic mutations and copy number alterations present in TCGA 
cohort for each gene analysed was obtained from cBioPortal 
(https://www.cbioportal.org/). 
 
Differential expression analysis was performed by comparing the transcriptome of 
the identified tumour subset to the remaining MIBC tumours to assess the genes 
that are affected in tumours that harbour VGLL1 dysregulation. Gene Set 
Enrichment Analysis (GSEA) of the differentially expressed genes was performed to 
confirm whether the significantly upregulated or downregulated genes appeared 
together in the previously curated Hallmark gene sets (downloaded from the 
Molecular Signatures Database; https://www.gsea-msigdb.org/gsea/index.jsp). 
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Expression of all the genes highlighted in the analysis was first confirmed in the 
MIBC cohort to ensure that the differential expression observed in the subset was 
biologically relevant.  Finally, the mortality rate of the identified tumour subset was 
assessed to determine whether VGLL1 dysregulation was associated with an altered 

























4.4 Results  
4.4.1 Transcriptomic analysis of bladder cancer cell lines  
4.4.1.1 Molecular subtyping of bladder cancer cell lines 
Hierarchical clustering of bladder cancer cell lines HT1197, HT1376, RT112, RT4, 
ScaBer, T24, UM-UC-9 and 5637 alongside in-house sequenced samples of normal 
urothelium in situ (n=3 independent urothelial samples) was performed based on 
expression of genes previously found to be associated with either luminal (n=13) or 
basal (n=6) MIBC. Cell lines RT4 and RT112 exhibited high relative expression of 
luminal MIBC-associated genes such as GATA3, ELF3, FOXA1 and FGFR3 and thus 
clustered most closely to the expression profile of normal urothelium in situ (Fig. 
4.1), marking these cell lines as being relatively well-differentiated. Conversely, cell 
lines 5637 and ScaBer had high relative expression of basal/squamous MIBC 
markers, such as KRT5, KRT6A and EGFR. UM-UC-9 cells were found to express 
several components of luminal MIBC biology, including very high expression of 
PPARγ (TPM = 2261), yet also had relatively low expression of luminal MIBC 
markers such as KRT13 and UPK1A. As a result, UM-UC-9 cells were more closely 
aligned with HT1197 and HT1376, cell lines that exhibited traits of both luminal 
(GATA3, ERBB3, CDH1) and basal (CDH3, EGFR) MIBC. The highly invasive MIBC cell 
line T24 exhibited low relative expression of both luminal and basal/squamous 




































Figure 4.1: Bladder cancer cell lines stratify based on expression of luminal and basal 
MIBC markers 
Unsupervised hierarchical clustering performed on RNAseq Log
2 
transformed expression 
of previously identified markers of luminal and basal/squamous MIBC (n=19 genes) in a 
cohort of bladder cancer cell lines (n=8) compared to normal urothelium in situ (mean 
TPM of n=3 biological replicates). Samples were clustered using the one minus 
Spearman rank correlation method with complete linkage. Clustering was performed 
using Morpheus software (https://software.broadinstitute.org/morpheus/). A summary 
of some of the previously identified mutations inherent to the eight cell lines is provided 
in Appendix xiii.    
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4.4.1.2 Transcript expression of VGLL1 and TEAD transcription factor genes in bladder 
cancer cell lines 
Five of the eight bladder cancer cell lines examined displayed an increased 
expression of VGLL1 transcript compared to the mean expression observed in 
normal urothelium in situ, including the luminal-derived RT4, RT112 and UM-UC-9 
cell lines, in addition to the HT1197 and HT1376 cell lines that displayed both 
luminal and basal MIBC characteristics (Fig. 4.2). Conversely, expression of VGLL1 in 
basal/squamous-like cell lines 5637 and ScaBer was notably lower in comparison to 
normal urothelium, while expression in T24 cells was absent. Similarly to normal 
urothelium, expression of TEAD1 and TEAD3 remained the predominantly 
expressed TEAD genes in RT4, RT112, UM-UC-9, HT1197 and HT1376 cells. 
However, increased expression of TEAD2 and TEAD4 was observed in all (TEAD4) or 
the majority (TEAD2) of cell lines when compared to the previously low expression 
observed in normal urothelium, highlighting a hitherto unknown induction of these 















Figure 4.2: VGLL1 and all four TEAD genes are expressed by bladder cancer cell lines  
RNAseq data analysis of VGLL1, TEAD1, TEAD2, TEAD3 and TEAD4 gene expression in 
eight bladder cancer cell lines and normal urothelium in situ (n=3 independent 
samples). Gene expression is measured in Transcripts per Million mapped reads (TPM), 
with TPM values Log
2
 transformed to allow for greater visualisation of the data.  
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4.4.1.3 Comparison of VGLL1 to YAP/TAZ target gene expression in bladder cancer cell 
lines 
Analysis of various YAP/TAZ target genes in bladder cancer cell lines determined 
that expression was either consistent (CYR61) or decreased (ANKRD1, AXL, CTGF) in 
luminal-derived cell lines RT4, RT112 and UM-UC-9 when compared to normal 
urothelium in situ (Fig. 4.3). In comparison, cell lines with low VGLL1 expression 
(ScaBer, 5637, T24) were found to exhibit higher expression of all four genes, 
including the normally absent ANKRD1. This descriptive analysis therefore identified 
a trend whereby the majority of bladder cancer cell lines that exhibited 
overexpression of YAP/TAZ target genes in comparison to normal urothelium (i.e. 
basal/squamous-like or other high grade MIBC cell lines) were additionally found to 
have reduced (or absent) expression of VGLL1. However, this pattern was not 
replicated in HT1197 cells, which exhibited overexpression of both VGLL1 and all 




Figure 4.3: Low expression of VGLL1 corresponds with high expression of YAP/TAZ 
target genes in basal/squamous-like bladder cancer cell lines  
RNAseq data analysis of VGLL1 expression compared to that of previously cited YAP/TAZ 
target genes ANKRD1, AXL, CTGF and CYR61 in eight bladder cancer cell lines and normal 
urothelium in situ (n=3 independent samples). TPM values were Log
2





4.4.2 VGLL1 protein expression in bladder cancer cell lines 
Expression of VGLL1 protein in six of the previously assayed bladder cancer cell lines 
(alongside lysate from normal urothelium in situ) was analysed by immunoblotting. 
The assay confirmed high expression of VGLL1 in UM-UC-9, HT1376 and RT4 cells, 
alongside a relatively low (ScaBer, 5637) or absent (T24) expression of VGLL1 
protein in the high grade MIBC cell lines compared to normal urothelium (Fig. 4.4). 
Based on the previous overall results, it was therefore concluded that ScaBer, 5637 
and T24 cells would make suitable candidates to study the effects of VGLL1 




















Figure 4.4: VGLL1 protein expression is low in basal/squamous MIBC-like bladder 
cancer cell lines  
Immunoblotting image of VGLL1 expression in six bladder cancer cell lines compared 
to lysate from freshly isolated (normal) Y2414 urothelium. Expression of β-Actin was 
used to confirm equal loading of samples. 
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4.4.3 Generation and verification of stable transfected VGLL1-overexpressing bladder 
cancer cell lines  
Following identification of 5637, T24 and ScaBer as ‘VGLL1-low’ bladder cancer cell 
lines, the three lines were transfected with pLXSN-VGLL1 overexpressing retroviral 
particles (constructs generated as described in Appendix ix) and maintained in 100 
µg/mL G418 to select for transfected cells (Fig. 4.5A). Overexpression of VGLL1 
transcript in all three cell lines was confirmed by qRT-PCR, with 5637 and ScaBer 
exhibiting a 50 and 22 fold change increase in expression, respectively, while T24 
cells exhibited a 179,906 fold increase in expression due to the near absence of 
transcript in the corresponding control cells (Fig. 4.5B). Immunoblotting analysis of 
the three transfected cell lines subsequently confirmed overexpression of VGLL1 at 








































Figure 4.5: Overexpression of VGLL1 in VGLL1-low bladder cancer cell lines transfected 
with pLXSN-VGLL1 retrovirus 
Bladder cancer cell lines 5637, T24 and ScaBer were transfected with pLXSN-GFP or 
pLXSN-VGLL1 and positive cells selected for through maintenance in antibiotic-
containing medium. Panel (A) depicts phase micrograph images of the aforementioned 
cells taken 4 days (T24) or 6 days (5637, ScaBer) following the initiation of antibiotic 
selection. The mock-transduced controls demonstrated the efficacy of G418 
administration on untransduced cells, which remained under antibiotic selection until 
complete death of the cell line was observed. B) Following selection, transfected cell 
lines were lysed and qRT-PCR analysis of VGLL1 expression was used to confirm 
overexpression of the gene in all three lines. Differences between cell lines were 
displayed as a Log
2 
fold change in VGLL1 expression (normalised against GAPDH) 
compared to each corresponding eGFP control cell line. C) Immunoblot analysis of VGLL1 
expression in 5637, T24 and ScaBer cells transfected with pLXSN-eGFP or pLXSN-VGLL1. 




4.4.4 Modulation of YAP/TAZ signalling in VGLL1-overexpressing bladder cancer cell 
lines  
4.4.4.1 Phosphorylated YAP expression in VGLL1-overexpressing bladder cancer cell 
lines 
To determine whether overexpression of VGLL1 influenced the proportion of 
inactive, phosphorylated YAP in VGLL1-low, YAP/TAZ signalling-high bladder cancer 
cell lines, transfected 5637 and ScaBer cells were lysed and analysed by 
immunoblotting. Despite confirmation that both cell lines experienced an induction 
of VGLL1 protein when transfected with pLXSN-VGLL1, no change in the expression 















Figure 4.6: Overexpression of VGLL1 had no effect on total or phosphorylated 
expression of YAP in 5637 and ScaBer cells 
Immunoblot analysis of VGLL1, total YAP and phosphorylated YAP (S127) expression in 
n=2 MIBC cell lines (5637 and ScaBer) overexpressing VGLL1 or eGFP. This experiment 
was performed prior to the generation and propagation of VGLL1 and eGFP-
overexpressing T24 cells, and as such was not included in the immunoblot. Expression 
of β-Actin was used to confirm equal loading of samples. 
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4.4.4.2 Localisation of YAP in VGLL1-overexpressing bladder cancer cell lines 
The localisation of total YAP has previously been demonstrated to be sensitive to 
variables such as treatment with PD153035 in NHU cells (Section 3.4.6.4). The sub-
cellular localisation of total YAP in 5637, T24 and ScaBer cells was thus compared 
between pLXSN-eGFP and pLXSN-VGLL1 transfected cells by immunofluorescence. 
In pLXSN-eGFP control cells, total YAP expression was observed to be solely nuclear 
in 5637 and T24 cells, while exhibiting nuclear and cytoplasmic expression in ScaBer 
cells (Fig. 4.7A). No notable changes in the localisation of YAP was observed in any 
of the three cell lines transfected with pLXSN-VGLL1, although the relative intensity 




















































Figure 4.7: Overexpression of VGLL1 had no effect on the subcellular localisation of 
YAP in VGLL1-low bladder cancer cell lines  
 MIBC cell lines overexpressing VGLL1 or eGFP (5637, T24 and ScaBer)  were seeded 
onto glass slides, fixed using formalin and Triton X-100 permeabilised. Cells were 
subsequently labelled with Total YAP antibody (A) or received no primary antibody (B) 
before visualisation. Images were all taken at same exposure and are shown with or 
without overlaid Hoechst 33258 DNA staining. Scale bar= 20µm. 
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4.4.4.3 YAP/TAZ target gene transcript expression in VGLL1-overexpressing bladder 
cancer cell lines 
Transcript expression of markers of YAP/TAZ signalling was quantified in the 
transfected cell lines to determine whether expression was affected by VGLL1 
overexpression. Of the cell lines and gene targets assayed, only ANKRD1 (2.31 fold 
increase in T24 cells only) and CTGF (2.54 fold decrease in 5637 cells only) 
expression was observed to change between control and VGLL1 overexpressing cell 
lines, with no gene found to be significantly altered between conditions  (Fig. 4.8). 
Overall, the results of this section demonstrate a negligible effect of VGLL1 
overexpression on YAP/TAZ signalling in VGLL1-low bladder cancer cell lines, with 
no change observed in the localisation of YAP in addition to weak, inconsistent 




















Figure 4.8: Overexpression of VGLL1 had no effect on transcript expression of YAP/TAZ 
target genes in VGLL1-low bladder cancer cell lines  
RT-qPCR analysis of ANKRD1, CTGF and CYR61 expression in n=3 MIBC cell lines (5637, 
T24 and ScaBer) overexpressing VGLL1 or eGFP control. The primers purchased specific 
to AXL did not produce a singular product during the initial quality control assessment 
and therefore were not used in the subsequent RT-qPCR analysis. Circle icons represent 
5637 samples, square icons represent T24 samples and triangle icons represent ScaBer 
samples. Differences between conditions were displayed as a Log
2 
fold change in 
expression compared to each corresponding eGFP control, with expression of each 
target gene normalised against housekeeping gene GAPDH. Significance between groups 
was calculated using a two-way ANOVA with Sidak’s post-hoc test.  
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4.4.5 Modulation of proliferation-associated pathways in VGLL1-overexpressing 
bladder cancer cell lines  
4.4.5.1 EGFR and MKI67 transcript expression in VGLL1-overexpressing cell lines 
To ascertain whether overexpression of VGLL1 affected the same signalling 
pathways in bladder cancer cell lines as to what was previously observed in NHU 
cells (Section 3.4.8), expression of EGFR and MKI67 in transfected 5637, ScaBer and 
T24 cells was analysed by non-quantitative RT-PCR. Similar to the phenotype 
observed in undifferentiated NHU cells, expression of EGFR and MKI67 appeared 
reduced in T24 cells overexpressing VGLL1 compared to control (Fig. 4.9). In 
comparison, VGLL1-overexpressing ScaBer cells appeared to have reduced 
expression of MKI67, but not EGFR, while expression of both genes appeared to be 




















Figure 4.9: Overexpression of VGLL1 resulted in reduced transcript expression of 
EGFR and MKI67 in T24 cells 
RT-PCR analysis of EGFR and MKI67 transcript expression in n=3 MIBC cell lines (5637, 
ScaBer and T24) transfected with VGLL1 or eGFP control overexpression constructs. 
Each cDNA synthesis used 1 µg starting template RNA, with cDNA undergoing PCR 
amplification up to 27 cycles. Housekeeping gene GAPDH was used to confirm equal 
loading between samples (25 cycles). The primers used produced positive gDNA bands 
of the same size, while a no template (H
2
O only) sample was used as a negative 
control for each primer set. 
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4.4.5.2 EGFR/ERK and PI3K/AKT signalling in VGLL1-overexpressing cell lines 
To elucidate what signalling pathways downstream of EGFR were being affected by 
VGLL1 overexpression, immunoblotting of transfected bladder cancer cell lines 
(lysed in a sub-confluent state) was performed. No change in the expression of the 
total or phosphorylated forms of EGFR was found between 5637 and ScaBer 
conditions, while expression of neither protein was observed in T24 cells (Fig. 4.10). 
Expression of total ERBB2 remained unchanged between all conditions, while 
modulation of p-ERK1/2 appeared to be cell-line dependent, as 5637 cells exhibited 
a slight increase in p44 expression while T24 cells had slightly decreased p44 when 
overexpressing VGLL1. Of the three cell lines assayed, only VGLL1-overexpressing 
T24 cells were found to inhibit phosphorylated AKT expression compared to 
control, replicating the phenotype observed in proliferating, undifferentiated NHU 



















Figure 4.10: Inhibition of p-AKT expression in VGLL1-overexpressing T24 cells 
Immunoblotting analysis of n=3 MIBC cell lines (5637, T24 and ScaBer) transfected with 
either VGLL1 or eGFP overexpressing constructs. Cell lines were compared based on 
their expression of VGLL1, EGFR (total and phosphorylated forms), total ERBB2, AKT 
(total and phosphorylated expression) and ERK1/2 (total and phosphorylated forms). 
Expression of β-Actin was used to confirm equal loading of samples. 
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4.4.5.3 Ki67 activity in VGLL1-overexpressing cell lines 
Expression of the cell cycle marker Ki67 was visualised in the three transfected 
bladder cancer cell lines by immunofluorescence. Comparison between the 
respective pLXSN-eGFP and pLXSN-VGLL1 transfected cells revealed little difference 
in the expression of Ki67 in 5637 (widespread positivity) and ScaBer (scattered 
positivity) cells (Fig. 4.11). However, overexpression of VGLL1 in T24 cells resulted in 
a notable reduction in Ki67 expression when compared to the eGFP control, 















Figure 4.11: Overexpression of VGLL1 reduces Ki67 positivity in T24 cells 
The 5637, T24 and ScaBer transfected cell lines used in Figure 4.7 were additionally 
assayed by immunofluorescence to determine cell cycle activity following VGLL1 
overexpression. Cells were labelled with an antibody specific to Ki67 prior to 
visualisation. Cell lines receiving no primary antibody were used as negative controls, 
images of which can be found in Figure 4.7B. Images were all taken at same exposure 
and are shown with or without overlaid Hoechst 33258 DNA staining. Scale bar= 20µm. 
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4.4.6 Cell cycle analysis of VGLL1-overexpressing bladder cancer cell lines  
Following the results of the previous section, transfected T24 cells (n=3 
independent experiments) were BrdU pulsed to determine whether the reduced 
cell cycle activity observed in VGLL1-overexpressing cells was reflected in the 
proportion of S-phase positive cells in the population. Fixed, BrdU-pulsed cells were 
processed by flow cytometry and gated to exclude cellular debris and doublet 
events (Fig. 4.12A-B). Analysis of BrdU fluorescence in the gated events determined 
that VGLL1-overexpressing T24 cells had a significantly higher proportion of cells in 
G0/G1 phase and a corresponding significant reduction of cells in S phase when 
compared to eGFP control (Fig. 4.12C-F; p ≤0.05). 
 
Conversely, processing of transfected 5637 cells (n=2 independent experiments) in 
the same manner revealed no significant differences in the proportion of G0/G1 or 
S-phase populations of pLXSN-eGFP and pLXSN-VGLL1 cell lines (Fig. 4.13A-F).  
Overall, the results of this (and the preceding) section demonstrate that VGLL1 
overexpression had a minimal effect on the phenotype of 5637 and ScaBer cells. In 
comparison, transfected T24 cells shared similarities in phenotype to that observed 
with VGLL1-overexpressing undifferentiated NHU cells in terms of inhibition of AKT 

















































































Figure 4.12: VGLL1 overexpression resulted in G0/G1 arrest in T24 cells  
T24 cells (n=3) transfected with either eGFP or VGLL1 overexpression constructs were 
pulsed with BrdU for 1h before trypinisation and fixation with ethanol. Single cells were 
subsequently labelled with a BrdU-specific primary (and GaM 488 secondary) antibody 
and fluorescence detected by flow cytometry. A) Representative forward versus side 
scatter (FS Lin vs SS Lin, respectively) dot plots of samples, with relevant populations 
gated (gate R1).  B) Propidium iodide scatter (PE-Texas Red Lin vs PE-Texas Red Area) 
plots of R1-gated events, with relevant populations gated (gate R2). C) Propidium iodide 
versus BrdU scatter (PE-Texas Red Area vs FITC Log, respectively) plots of R2-gated 
events. This plot was used to determine the percentage of cells in S (R3 gate) and G0/G1 
phase (R4 gate) in each sample. D) Propidium iodide versus BrdU scatter plots of R2-
gated events from samples that were antibody labelled but received no BrdU pulse. E) 
Representative propidium iodide cell cycle profile histograms of each condition. F) The 
percentage of T24 cells in G1, S and G2/M phase (as determined by BrdU fluorescence) 
were recorded across three separate experiments and quantified. Significance between 
groups was calculated using a two-way ANOVA with Sidak’s post-hoc test. *=p≤0.05; 
**=p≤0.01. The propidium iodide versus BrdU scatter plots of the two replicate 





































































Figure 4.13: VGLL1 overexpression had a negligible effect on the cell cycle profile of 
5637 cells 
Flow cytometry analysis of 5637 cells (n=2) transfected with either eGFP or VGLL1 
overexpression constructs. Cells were pulsed with BrdU for 1h before trypinisation, 
fixation with ethanol and labelling with BrdU primary and 488 GaM secondary 
antibodies. A) Representative forward versus side scatter (FS Lin vs SS Lin, respectively) 
dot plots of samples, with relevant populations gated (gate R1).  B) Propidium iodide 
scatter (PE-Texas Red Lin vs PE-Texas Red Area) plots of R1-gated events, with relevant 
populations gated (gate R2). C) Propidium iodide versus BrdU scatter (PE-Texas Red 
Area vs FITC Log, respectively) plots of R2-gated events. This plot was used to determine 
the percentage of cells in S (R3 gate) and G1 phase (R4 gate) in each sample. D) 
Propidium iodide versus BrdU scatter plots of R2-gated events from samples that were 
antibody labelled but received no BrdU pulse. E) Representative propidium iodide cell 
cycle profile histograms of each condition. F) The percentage of 5637 cells in G0/G1, S 
and G2/M phase (as determined by BrdU fluorescence) were recorded across two 
separate experiments and quantified. Significance between conditions was calculated 
using a two-way ANOVA with Sidak’s post-hoc test, with no significant differences found 
between the percentages of cells found in different phases of the cell cycle. The 




4.4.7 VGLL1 expression in MIBC  
4.4.7.1 Transcriptomic analysis of Hippo pathway components in MIBC subtypes 
Expression of VGLL1 transcript was assessed in TCGA MIBC cohort of tumour 
samples, with each tumour stratified into one of six consensus molecular subtypes. 
Compared to expression of in-house sequenced, stroma-free normal urothelium in 
situ, no significant differences in VGLL1 expression was observed in any of the 
subtypes apart from luminal unstable, which was found to have significantly higher 
expression of the gene (p ≤0.05; Fig. 4.14). Despite not exhibiting a significant 
difference in expression to normal urothelium, basal/squamous tumours were 
found to have significantly reduced expression of VGLL1 when compared to each 
luminal subtype (p ≤0.001). The basal/squamous subtype displayed a wide range of 
VGLL1 expression, as it contained three of the ten highest VGLL1 TPM values in the 
MIBC cohort yet also included a group of tumours with very low or absent 
expression of the gene.  Five of the six tumours of the neuroendocrine-like subtype 
were found to have very low/absent VGLL1 expression, although due to the low 
sample number this difference in expression was not significant. This analysis 
therefore suggested that apart from a subset of basal/squamous and 
neuroendocrine-like tumours, expression of VGLL1 was primarily retained in cases 

































Figure 4.14: VGLL1 expression is retained in a majority of MIBC tumours 
RNAseq gene expression data from TCGA MIBC cohort (n=404) was separated into the 
consensus molecular subtypes based on previously published (Kamoun et al. 2020) gene 
classification and compared to normal urothelium in situ samples processed in-house 
(n=6). Gene expression is displayed as Log
2 
transformed TPM, with the bars representing 
the median TPM value for each subtype. Significance between groups was determined by 
a Kruskal-Wallis ANOVA with Dunn’s multiple comparisons post-hoc test. *=p≤0.05; 
***=p≤0.001. Other significant changes between groups were omitted for clarity and are 
detailed in Appendix xiii.  
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The results of Section 4.4.4 suggested that an inhibitory relationship between 
VGLL1 expression and YAP/TAZ signalling did not exist in MIBC. To examine the 
possibility that VGLL1 and YAP/TAZ associated with different TEAD transcription 
factors in urothelium, a principal component analysis of TCGA cohort (separated 
into molecular subtypes) with transcript expression of VGLL1 in addition to YAP1, 
WWTR1, YAP/TAZ downstream target genes and TEAD genes was performed. The 
variance in the data was primarily split (PC1; 40.1%) between samples of luminal 
and basal origin, with VGLL1 expression associated with tumours of primarily 
luminal derivation (Fig. 4.15). Conversely, expression of YAP1 and YAP/TAZ 
signalling markers AXL, ANKRD1, CTGF and CYR61 were associated with a mixture of 
basal/squamous and stroma-rich tumours. Expression of the two TEAD transcription 
factors also found in normal urothelium, namely TEAD1 and TEAD3, were found to 
align separately to the two aforementioned tumour groups, with TEAD3 aligning 
with VGLL1 and TEAD1 correlated with YAP1 and YAP/TAZ target gene expression. 
This finding supported the assertion that VGLL1 and YAP possibly bind to different 
TEAD transcription factors in urothelial cells, which would account for the lack of 
modulation observed in YAP/TAZ signalling when VGLL1 expression was forced in 
















To elucidate what genes could potentially be induced through VGLL1-mediated 
TEAD3 transcriptional activity, analysis of genes in MIBC that were positively 
correlated to both VGLL1 and TEAD3 expression was performed. 247 genes were 
found to have a Pearson correlation coefficient ≥ +0.35 with either VGLL1 or TEAD3, 
while 35 of those genes were revealed to be positively correlated to both VGLL1 
and TEAD3 (Table 4.1). When combining Pearson correlation coefficient scores, the 
most correlated gene to a combination of VGLL1 and TEAD3 (excluding VGLL1 and 
TEAD3) was PARD6B, a gene involved in the regulation of tight junction assembly. 
Other genes of interest that correlated to both VGLL1 and TEAD3 in MIBC included 
the Ras homolog family member A (RHOA)-interacting factor PLEKHG6 and the tight 
junction-localised CGN (cingulin). All three genes were confirmed to be expressed 
by NHU cells, with an induction of expression observed following ABS/Ca2+ 
differentiation for each gene (Fig. 4.16).  
Figure 4.15: VGLL1 and YAP1/WWTR1 are associated with different TEAD genes and 
MIBC molecular subtypes 
Unscaled principal component analysis plot of TCGA MIBC samples separated on the 
basis of expression of VGLL1, YAP1, WWTR1, YAP/TAZ target genes and TEAD genes. 
Each dot represents a different RNASeq sample while each MIBC consensus molecular 
subtype is represented by a different icon colour.  
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Pearson’s r  
TEAD3 +0.382 +1 1.382 
VGLL1 +1 +0.382 1.382 
PARD6B +0.596 +0.465 1.061 
PLEKHG6 +0.537 +0.470 1.007 
SLC44A2 +0.556 +0.434 0.99 
SLC17A5 +0.561 +0.357 0.918 
AC108112.1 +0.489 +0.420 0.909 
DAG1 +0.536 +0.356 0.892 
SPINT1 +0.422 +0.464 0.886 
CREB3L2 +0.443 +0.426 0.869 
NR2F2 +0.431 +0.438 0.869 
SEPT8 +0.484 +0.371 0.855 
MSX2 +0.448 +0.405 0.853 
CGN +0.414 +0.434 0.848 
SLC37A1 +0.431 +0.406 0.837 
GATA2-AS1 +0.406 +0.429 0.835 
TMEM214 +0.441 +0.384 0.825 
SLC29A3 +0.448 +0.374 0.822 
B3GNT3 +0.377 +0.428 0.805 
RHOU +0.436 +0.366 0.802 
SLC11A2 +0.431 +0.366 0.797 
RBM47 +0.392 +0.396 0.788 
TAB3 +0.412 +0.372 0.784 
OTUD7B +0.401 +0.380 0.781 
NIPAL1 +0.371 +0.407 0.778 
PWWP2B +0.416 +0.361 0.777 
TIGD2 +0.368 +0.405 0.773 
TUFT1 +0.390 +0.381 0.771 
SOWAHB +0.383 +0.384 0.767 
TTC39A +0.395 +0.368 0.763 
RAB15 +0.396 +0.353 0.749 
AC022872.1 +0.388 +0.353 0.741 
TMEM62 +0.368 +0.370 0.738 
SMAGP +0.377 +0.356 0.733 
AC004982.2 +0.374 +0.356 0.73 
 
Table 4.1: Genes positively correlated to VGLL1 and TEAD3 in MIBC  
A Pearson correlation coefficient (r) was calculated between VGLL1/TEAD3 and every other 
gene quantified in TCGA MIBC cohort. Genes that were positively correlated (r ≥ +0.35) to 
both VGLL1 and TEAD3 were included in the list. PARD6B was found to be the gene with 



































Figure 4.16: Validation of potential VGLL1/TEAD3 target gene expression in NHU cells 
RNAseq data analysis of PARD6B, PLEKHG6 and CGN transcript expression in NHU cells 
in undifferentiated and ABS/Ca
2+
 differentiated states (n=3 independent samples).  
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4.4.7.2 Relationship of VGLL1 expression to urothelial-associated transcription factors 
in MIBC 
Investigation of VGLL1 expression in normal urothelium previously revealed a close 
association of VGLL1 transcript to FOXA1, RARG and POUF51 expression in ABS/Ca2+ 
differentiated NHU cells (Section 3.4.1), while GATA3 was additionally implicated as 
an important upstream transcription factor of VGLL1 in TZ/PD differentiated cells 
(Section 3.4.5). To analyse what transcription factors most closely correlated to 
VGLL1 expression in a MIBC context, a principal component analysis of TCGA cohort 
was performed, with tumours separated on the basis of expression of VGLL1 
alongside the list of (normal) urothelial-associated transcription factors utilised in 
Section 3.4.1.3. This analysis revealed that VGLL1 expression associated with the 
luminal papillary and luminal unstable subtypes and was highly correlated with 
POU5F1 expression, as seen in samples of normal urothelium (Fig. 4.17). In 
comparison to normal urothelium, expression of VGLL1 was more closely associated 
with GATA3, PPARG and HNF1B (genes which had previously associated with both 
in situ and ABS/Ca2+ differentiated NHU cells) in luminal MIBC, while expression was 
less correlated to FOXA1 and RARG expression. Despite being strongly associated 
with proliferative, undifferentiated NHU cells in vitro, TP63 expression aligned to a 



































Analysis of the mutational status of VGLL1 in TCGA MIBC cohort revealed that the 
gene was not mutated in any MIBC sample and exhibited copy number alterations 
in only 1.5% of samples (n=4 copy number amplifications and n=2 homo-deletions), 
suggesting that any aberrant expression of VGLL1 in MIBC was a result of 
alterations to factors that induce or interact with VGLL1 (Fig. 4.18). When 
examining the mutational status of the transcription factors closely associated with 
VGLL1 expression in MIBC, GATA3 was found to exhibit copy number amplification 
in one of the tumours with amplified VGLL1 expression, while PPARG was amplified 
in two VGLL1-amplified tumours alongside a missense point mutation in a third.  In 
comparison, alteration and mutation rates of POU5F1 and HNF1B in MIBC were 
low, with neither gene found to be altered in any of the four tumours with VGLL1 
alterations.  
Figure 4.17: VGLL1 closely correlates with POU5F1, HNF1B, GATA3 and PPARG 
expression in luminal MIBC 
Unscaled principal component analysis plot of TCGA MIBC samples separated on the 
basis of expression of VGLL1 and the transcription factors previously identified by 
Fishwick et al. to possess unique motifs in FAIREseq peaks in differentiated and 
undifferentiated NHU cells (n=35 genes). Each dot represents a different RNASeq sample 












Figure 4.18: Genetic alterations of VGLL1 and urothelial-associated transcription factors in MIBC 
Profile of genetic alterations and mutations in VGLL1, GATA3, PPARG, POU5F1 and HNF1B genes in TCGA MIBC cohort. For clarity, only a proportion of 
the tumours in the cohort are displayed, with the remaining tumours expressing wild-type versions of all five genes. Mutation data and graphic were 
obtained from the cBioPortal for Cancer Genomics (https://www.cbioportal.org/) 
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4.4.7.3 Mutation status of VGLL1-high MIBC 
To examine whether MIBC tumours with increased expression of VGLL1 collectively 
exhibited similar patterns of mutational load and/or gene expression (regardless of 
molecular subtype), all tumours of TCGA MIBC cohort were separated on the basis 
of VGLL1 transcript expression (Fig. 4.19). Of the 404 tumour samples analysed, 14 
were determined to have VGLL1 TPM values exceeding the 1.5 x interquartile range 
(IQR) value of 431.8, and thus were considered outliers in the distribution. These 
tumours were grouped to create the “VGLL1-high” subset of MIBC, which consisted 
primarily of tumours of luminal derivation (eight of which were subtyped as luminal 
unstable tumours) yet also contained three basal/squamous tumours. Further 
information on the identity of the samples in the VGLL1-high subset can be found in 





















Figure 4.19: Stratification of MIBC into VGLL1-high and VGLL1-low subsets 
Visualisation of unlogged VGLL1 expression across all TCGA MIBC samples (n=404), with 
the bars representing the median and interquartile range (IQR) values. Unlogged 
expression of VGLL1 in samples of normal urothelium in situ (n=6) were included for 
comparison. In the VGLL1-high subset, square icons represent luminal unstable tumours, 
triangle icons represent basal/squamous tumours, cross icons represent luminal non-
specified tumours and a star icon represents a luminal papillary tumour. The 1.5 x IQR 
rule was applied to confirm that the VGLL1 TPM values of each tumour in the designated 
VGLL1-high subset were outliers of the overall pattern of distribution (1.5 x IQR TPM 
















A9KW LumU 1754.0 Yes No Yes 
A2LD Ba/Sq 1471.9 Yes Yes Yes 
A3SR LumU 779.5 No Yes No 
A6TH Ba/Sq 646.5 No No No 
A6B1 LumU 636.2 No No No 
A3JV LumNS 618.7 No No Yes 
A3VY LumU 551.4 No Yes No 
A9KI LumU 522.6 No Yes No 
A3QH LumU 513.7 No No No 
A9ST Ba/Sq 488.8 No No No 
AAMX LumU 456.4 No No No 
A3PH LumP 447.1 No No Yes 
A40G LumU 440.4 No No No 
A3IT LumNS 432.5 No No No 
 
Table 4.2: List of tumours in the VGLL1-high subset of MIBC 
Tumours of the MIBC cohort (n=404) that were determined to have outlier expression of 
VGLL1 were grouped to form the VGLL1-high subset (n=14). The two samples with the 
highest VGLL1 expression (#A9KW and A2LD) were found to have alterations in VGLL1 and 
PPARG gene copy number, while the A2LD sample additionally exhibited GATA3 copy 








Analysis of the mutations inherent to the VGLL1-high subset was performed to 
determine whether any mutations were overrepresented in this group compared to 
the entire MIBC cohort. 24 genes were found to be mutated in over 25% (4/14 
tumours) of the subset, with commonly mutated tumour suppressor TP53 and 
striated muscle gene TTN found to be mutated in 9/14 tumours (Table 4.3). 
However, when applying a binomial test to observe whether the increased 
mutation frequency of the genes was significantly different to that of the frequency 
observed across the MIBC cohort, it was determined that mutations in these genes 
was not enriched in the VGLL1-high subset. The most prevalently mutated gene 
that was found to be significantly enriched in VGLL1-high tumours was the SWI/SNF 
chromatin remodelling complex gene ARID1A (AT-rich interactive domain-
containing protein 1A; p ≤0.01) which was observed in 8/14 tumours, including the 
three tumours with the highest VGLL1 expression (Table 4.4). ARID1A was 
additionally the only gene in the list that was mutated in both HT1376 and HT1197 
cell lines, the MIBC cell lines previously determined to have the highest expression 
of VGLL1 (Table 4.3; Fig. 4.1). Analysis of VGLL1 expression across all ARID1A-
mutated tumours in the MIBC cohort revealed a significant increase in expression 
when compared to tumours with wild-type ARID1A (Fig. 4.20; p ≤0.001), suggesting 
that dysregulation of this gene may be a causative factor behind instances of high 
VGLL1 expression observed in some cases of MIBC.  
The mutation status of NF2 and AMOT (components of the Hippo pathway that are 
frequently mutated in other forms of cancer, as discussed in Section 4.1) in the 
VGLL1-high subset was also examined. This analysis revealed that the VGLL1-high 
subtype contained no mutations in NF2 and two mutations in AMOT (samples 
#A6B1 and A3VY), suggesting that mutation of Hippo pathway regulatory 




















TP53 64.3% 48.3% 0.1058 Yes No 
TTN 64.3% 47.5% 0.0983 Yes No 
ARID1A 57.1% 24.8% 0.0078 Yes Yes 
FAT3 42.9% 11.0% 0.0021 No No 
MUC16 42.9% 28.7% 0.1121 No Yes 
CSMD3 35.7% 13.7% 0.0257 No No 
RB1 35.7% 17.6% 0.0592 Yes No 
SYNE1 35.7% 20.3% 0.0896 Yes No 
ABCA13 28.6% 9.1% 0.0264 No Yes 
ANKHD1-
EIF4EBP3 
28.6% N/A  No No 
ATP10A 28.6% 4.7% 0.0030 No Yes 
ATP1A2 28.6% 2.7% 0.0004 No No 
ERBB2 28.6% 12.3% 0.0617 No No 
FRY 28.6% 7.6% 0.0151 No No 
HERC2 28.6% 7.8% 0.0164 No No 
HYDIN 28.6% 6.1% 0.0074 No No 
KDM6A 28.6% 26.0% 0.2252 Yes No 
MALAT1 28.6% 11.4% 0.0504 No No 
NES 28.6% 4.7% 0.0030 No No 
RYR2 28.6% 19.1% 0.1600 No No 
SLC38A2 28.6% 3.4% 0.0009 No No 
SYNE2 28.6% 12.7% 0.0670 No No 
UBR5 28.6% 6.9% 0.0111 No No 




Table 4.3: Overrepresented mutations in the VGLL1-high subset of MIBC 
Point mutation data for the tumours in the VGLL1-high MIBC subset (n=14) and the VGLL1-
overexpressing HT1376 and HT1197 MIBC cell lines were collated to determine the most 
common mutations inherent to these tumours. The relative mutation frequencies for each 
gene across all MIBC samples was used to calculate whether the observed mutation 
frequency of the genes enriched in the subset was statistically significant, with significant p 
values highlighted in bold.  Mutation data for HT1376 and HT1197 cells were obtained from 
the Catalogue of Somatic Mutations in Cancer (COSMIC) database 
(https://cancer.sanger.ac.uk/cosmic), while additional information on the ARID1A 




















Table 4.4: Matrix of overrepresented mutations in the VGLL1-high MIBC subset  
The 14 tumours of the VGLL1-high MIBC subset were arranged in order of VGLL1 
expression, with sample #A9KW displaying the highest VGLL1 TPM value and #A3IT 
displaying the lowest VGLL1 TPM value of the subset. ARID1A was found to be mutated in 























Figure 4.20: Mutations to ARID1A result in elevated expression of VGLL1 in MIBC 
MIBC tumours were split based on expression of either the wild-type (n=296) or 
mutated versions (n=108) of the ARID1A gene and examined on the basis of (log
2 
transformed) VGLL1 expression. Significance between groups was determined by a 
Mann-Whitney test. ***=p≤0.001.  
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Examination of commonly mutated genes in MIBC revealed six genes that were not 
mutated in any sample in the VGLL1-high subset, with two of these genes (FGFR3 
and ELF3) additionally found to be highly expressed in the subset (Table 4.5). 
However, none of the aforementioned genes were found to be significantly 





















FGFR3 0% 82.3 14.2% 0.1172 No No 
FAT1 0% 3.6 12.5% 0.1542 Yes No 
ELF3 0% 305.2 12.3% 0.1592 No Yes 
RYR1 0% 0.6 12.3% 0.1592 No No 
LRP1B 0% 0.0 11.8% 0.1724 No No 
PCLO 0% 1.3 10.3% 0.2183 No No 
 
Table 4.5: Underrepresented mutations in VGLL1-high MIBC tumours 
The most common point mutations in MIBC were collated to determine if any genes were 
not mutated in the VGLL1-high basal/squamous subset (n=14). Only genes found to be 
mutated in at least 10% of all MIBC samples and in none of the VGLL1-high tumour subset 









4.4.7.4 Gene expression profile of VGLL1-high MIBC 
Differential expression analysis of the VGLL1-high MIBC subset versus the remaining 
(VGLL1-low) MIBC tumours (n=390) determined that 1047 genes had an absolute 
fold change ≥ 2 and a q value ≤0.05 (Fig. 4.21A). GSEA analysis of the differentially 
expressed genes in the comparison highlighted enrichment of cell cycle-associated 
E2F transcription factor targets, G2/M phase checkpoint markers and genes 
involved in adipogenesis in the VGLL1-high subset (Fig. 4.21B). However, 
investigation into the genes that comprise the various enriched gene sets revealed 
that only CCNE1 (cyclin E1, a member of the HALLMARK_E2F_TARGETS gene list) 
and ESPL1 (separase; HALLMARK_G2M_CHECKPOINT) were found to be 
significantly upregulated (q ≤0.01). Examples of genes found to be significantly 
upregulated in the VGLL1-high subset included E2F1 binding factor ARID3A and 
genes involved in the inhibition of apoptosis (FAM9C, CAPN6). Four of the most 
downregulated genes in the VGLL1-high subset were basal/squamous MIBC 
markers KRT5, KRT6A, KRT6B and KRT14, consistent with the primarily luminal 
MIBC-derived identity of the group. Pathways that were observed to be significantly 
suppressed in the subset included genes induced by p53 activity (CASP1, CLCA2) 
and genes involved in mediating an inflammatory response (CD55, CD69, CXCL10, 
IL1A) or apoptosis (CASP1, CD44, CD69, DPYD, FASLG, GSTM1, IGFBP6, IL1A, NEFH, 
PRF1). Signalling components of the WNT (WNT3A, WNT5A, WNT10A), TGFβ 
(TGFB2, TGFBI) and FGF (FGF5, FGF9, FGFBP1) pathways were additionally observed 
to have significantly reduced expression in VGLL1-high tumours. 
 
The expression of transcription factors PPARG, GATA3, FOXA1, ELF3, RARG, HNF1B 
and POU5F1 was examined to determine whether (the primarily luminal) tumours 
that exhibited overexpression of VGLL1 additionally had dysregulated expression of 
genes involved in urothelial differentiation. While no significant differences in 
expression for any of the aforementioned genes was observed between groups, 
expression of PPARγ target gene FABP4 was found to be significantly 
downregulated in the VGLL1-high subset, possibly indicative of a reduction in active 
















Figure 4.21: VGLL1–high MIBC tumours have decreased expression of apoptosis-
associated genes  and increased expression of cell cycle-associated genes 
A) Volcano plot of the most differentially expressed genes in VGLL1-high MIBC 
tumours (n=14) in comparison to VGLL1-low tumours (n=390). Genes that pass the 
criteria of having a q value ≤0.05 and a log
2
 fold change in expression ≥ 2 or ≤-2 are 
represented as red dots. Notable genes that pass the criteria set above are 
highlighted on the plot. A complete list of genes with a q value ≤0.05 and a log
2
 fold 


















Figure 4.21: VGLL1–high MIBC tumours have decreased expression of apoptosis-associated genes and increased expression of cell cycle-associated 
genes 
B) GSEA analysis of signalling pathways that are differentially expressed between VGLL1-high and VGLL1-low basal/squamous subsets. Each pathway 




To determine whether the altered phenotype of the VGLL1-high MIBC tumours 
affected the survival rate of patients in the group; a Kaplan-Meier survival analysis 
was performed. Comparison between VGLL1-high and VGLL1-low MIBC subtypes 
revealed that 57% of patients exhibiting the VGLL1-high phenotype had died within 
18 months of diagnosis (compared to 28% of VGLL1-low patients), resulting in 
significantly reduced overall survival (p ≤0.01; Fig. 4.22). The preceding analysis 
therefore revealed that overexpression of VGLL1 in cases of MIBC was associated 
with a suppression of apoptosis, a gain in genes involved in cell cycle progression 










Figure 4.22: VGLL1–high MIBC patients have reduced overall survival 
Kaplan-Meier survival plot of the groups created by separating MIBC tumours into 
VGLL1-high and VGLL1-low subtypes. The Log-Rank (Mantel-Cox) test was used to 
determine significance between the overall survival of groups. Median survival time of 
VGLL1-high basal/squamous subset (n=14) = 346 days, VGLL1-low basal/squamous 
group (n=390) = 1077 days. **=p<0.01.  
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4.5 Discussion  
4.5.1 VGLL1-mediated effects on cell phenotype following forced expression 
Overexpression of VGLL1 resulted in a G0/G1 arrest of T24 cells and a concurrent 
inhibition of phosphorylated AKT, reflecting the phenotype of undifferentiated NHU 
cells observed in the previous chapter. Collectively, these observations potentially 
suggest the existence of a negative feedback loop between VGLL1 and PI3K/AKT 
signalling, whereby VGLL1 is induced in normal cells following PI3K/AKT activation 
in adherens junction-forming cells (as observed in preliminary data in the previous 
chapter) which serves to subsequently inhibit PI3K/AKT signalling in an as-of-yet 
uncharacterised mechanism following induction of the protein. This hypothesis may 
serve to explain the phenotype observed in a Pten-inactive mouse model of 
prostate cancer tumorigenesis, whereby forced overexpression of Gata3 was 
observed to inhibit phosphorylated Akt expression and delay tumour progression 
(Nguyen et al., 2013). However, it must be noted that the evidence in support of 
VGLL1 requiring active PI3K/AKT signalling for induction (in NHU cells) while 
additionally inhibiting the pathway upon high expression of the protein (in NHU and 
T24 cells) is based off of evidence from single experiments, and would thus need to 
be replicated in further samples in order to confirm this phenotype. 
Another potential caveat that arises when critically evaluating the aforementioned 
results is due to the use of a retroviral cloning vector that facilitates constitutive 
expression of VGLL1 in cell types where the gene typically has low/absent 
expression. While the use of retroviral vectors to induce ectopic expression of a 
gene is a commonly accepted tool in molecular biology research (reviewed by 
Prelich, 2012), such an approach inevitably has various limitations that need to be 
considered. One such limitation is that overexpression likely results in a much 
stronger expression of the gene/protein than would commonly be found in situ, 
thus making comparisons to biologically relevant states difficult. Rather than 
fulfilling its wild-type function, overexpressing a protein in this ectopic manner may 
also instigate an abnormal phenotype, whereby the protein of interest exhibits an 
unusual localisation or binds to unnatural substrates or binding partners as a result 
of its aberrantly high expression (reviewed by Prelich, 2012).  
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The opposing effect that VGLL1 expression had on various processes when 
comparing the phenotypes of VGLL1 overexpressing (undifferentiated NHU and 
T24) and VGLL1 knockdown (differentiated NHU) cells does however suggest that 
forced expression of the gene was capable of producing biologically relevant 
inferences on VGLL1 function in this context. Examples of such observations include 
the effect that VGLL1 expression had on cell cycle, where VGLL1 overexpression 
resulted in G0/G1 arrest and reduced proliferation while VGLL1 knockdown 
increased Ki67/MCM2 activity, and on p-AKT expression, which was inhibited when 
VGLL1 was overexpressed but experienced increased expression compared to 
control when VGLL1 was inhibited. Additionally, the phenotypic changes resulting 
from VGLL1 overexpression were found to be cell line-specific, as negligible 
differences to the aforementioned variables were observed in 5637 or ScaBer cells 
when compared to their respective control cell lines. This observation therefore 
suggested that the cellular machinery required for normal VGLL1 function (and 
evidently present in differentiated urothelium) is also expressed to some degree in 
undifferentiated NHU and T24 cells, whereas phenotypic differences (such as 
mutations of select genes) resulted in the non-functionality of VGLL1 when 
ectopically expressed in 5637 or ScaBer cells.   
4.5.2 VGLL1 expression in MIBC 
The transcriptomic analysis of MIBC tumours performed in this chapter confirmed 
an association of VGLL1 with luminal MIBC, whilst identifying a subgroup of 
(primarily luminal) tumours that were found to exhibit aberrant overexpression of 
VGLL1 despite the gene possessing a low copy number alteration frequency and no 
mutations in the MIBC cohort. This observation was suggestive of a previously 
undescribed dysregulation of feedback that controls expression of the gene.   
Currently little is known about the role of VGLL1 in human disease, although 
recently published studies have implicated the protein as a prognostic marker in 
human gastric (Kim et al., 2019a; Im et al., 2020) and pancreatic (Bradley et al., 
2020) cancers. High expression of VGLL1 has previously been identified in TCGA 
breast cancer cohort, which revealed an association of the gene with the highly 
invasive triple-negative subtype. Subsequent analysis of the cohort determined that 
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FOXA1 and GATA3 were two of the most negatively regulated genes to VGLL1 
expression, VGLL1-high breast tumours had a significantly reduced rate of overall 
survival and that overexpression of VGLL1 was not as a result of copy number 
amplification (Castilla et al., 2014). It would therefore be interesting to compare the 
mutational backgrounds of VGLL1-high triple-negative breast cancer and VGLL1-
high MIBC to understand whether dysregulation of the gene in both cancer types 
arises from (and results in) a similar phenotype.   
The basal/squamous and neuroendocrine-like MIBC subtypes both contained 
groups of tumours that exhibited low or undetectable expression of VGLL1. These 
subgroups were not examined further as part of this study, but future analysis that 
determines the similarities between the gene expression profiles of VGLL1-low and 
VGLL1-high MIBC may help to elucidate specific markers of dysregulated VGLL1 
function.  
4.5.3 Phenotype of VGLL1-high MIBC subgroup  
4.5.3.1 Enrichment of ARID1A mutations in subgroup  
Analysis of the VGLL1-high MIBC tumours revealed an enrichment of mutations in 
the ARID1A gene, encoding for the SWI/SNF nucleosome remodelling complex 
subunit ARID1A. The SWI/SNF complex acts to modify the structure of chromatin 
and allow for transcription factor access to their respective enhancer or promoter 
regions (Kwon et al., 1994), whilst the specific role of ARID1A has been determined 
to be to recruit the fellow members of the complex to DNA in open regions of 
chromatin, as marked by acetylation of histone H3 K27 (H3K27ac; Hurlstone et al., 
2002; Wilsker et al., 2004; Alver et al., 2017). Inactivating mutations in the ARID1A 
gene have been demonstrated to result in aberrant transcriptional activity and a 
reduction in H2K27ac (Mathur et al., 2017), activation of PI3K/AKT signalling (Yang 
et al., 2019) and a loss of DNA damage repair processes (Watanabe et al., 2014).  
 
ARID1A is one of the most commonly occurring mutations in MIBC (Robertson et 
al., 2017) and has been associated with high-grade, highly invasive tumours (Li et 
al., 2016a). Alterations to ARID1A have previously been identified to be primarily 
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inactivating in MIBC (Robertson et al., 2017), a finding that supports the predicted 
loss-of-function phenotype observed in the ARID1A-mutated, VGLL1-high tumours. 
Additionally, these tumours were found to significantly downregulate multiple 
genes (including CASP1, CD55, CXCL10, GATM1, IGFBP6, WNT3A and WNT10A) 
previously identified to be ARID1A-dependent through microarray comparison of 
wild-type and Arid1a-null mouse uterine epithelial cells (Kim et al., 2015a), whilst 
upregulating genes such as CCNE1 which function in opposition to the predicted 
role of VGLL1 in modulating cell cycle arrest in normal urothelium. The following 
observations therefore suggest that the VGLL1-high subgroup consists of tumours 
that exhibit a loss of both ARID1A and VGLL1 normal function.  
The tumours of the VGLL1-high MIBC subset appear to share phenotypic similarities 
with the HT1376 and HT1197 MIBC cell lines as they also exhibit high expression of 
VGLL1 and mutated ARID1A, marking these cell lines as potentially suitable in vitro 
analogues of the “VGLL1-dysregulated” urothelial phenotype. In comparison, 
analysis of the mutational signature of T24 cells (Appendix xii) revealed that this cell 
line expresses wild-type ARID1A, which may explain why the cell line was similarly 
amenable to the effects of VGLL1 overexpression observed in undifferentiated NHU 
cells.  
How expression of wild-type ARID1A functions to enable VGLL1-mediated 
transcriptional activity in normal urothelium is currently undetermined and would 
require further study. Loss of enhancer/promoter accessibility following ARID1A 
inactivation is one possible rationale behind a loss in VGLL1 functionality, with 
deletion of ARID1A previously demonstrated to result in a significant depletion of 
H3K27ac in sites predicted to be bound to by TEAD4 in colorectal cancer cell line 
HCT116 (Mathur et al., 2017). Alternatively, ARID1A could bind directly to a VGLL1 
transcriptional complex at enhancer regions to facilitate gene transcription. A 
similar mechanism was demonstrated in murine liver, where Arid1a was shown to 
directly bind to Yap/Tead to regulate hepatocyte wound healing, with Arid1a-
mediated chromatin accessibility responsible for a significant enrichment of Hippo, 
TGFβ and tight junction assembly pathway genes (Li et al., 2019). That VGLL1-high 
tumours exhibit a loss of VGLL1-mediated function yet display high expression of 
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the gene would suggest that alterations to ARID1A may also serve to remove an as-
of-yet uncharacterised negative feedback loop on VGLL1 expression, resulting in a 
phenotype of overexpression.  
4.5.3.2 Effect of ARID1A alterations on PI3K/AKT signalling    
A potential rationale for the overexpression of VGLL1 observed in this tumour 
subtype may arise from the previously examined relationship between ARID1A and 
PI3K/AKT signalling in human cancer. Inactivating alterations to ARID1A are 
commonly found to co-occur with mutations in the PI3KCA and PTEN genes in 
ovarian and endometrial cancer (Liang et al., 2012; De et al., 2019), leading to 
aberrant activation of PI3K/AKT signalling. While mutations in PI3KCA and PTEN 
were not found to be similarly enriched in the VGLL1-high MIBC subtype, aberrant 
PI3K/AKT signalling may still be predicted to occur in these tumours due to the 
previously observed effects on AKT activation following knockdown of ARID1A in 
nasopharyngeal carcinoma cell lines (Yang et al., 2019), in addition to an increased 
sensitivity to PI3K/AKT pathway inhibitors in the PI3KCA/PTEN-WT fibroblast cell 
line MRC-5 following ARID1A depletion (Samartzis et al., 2014). Unrestrained 
PI3K/AKT pathway activation may therefore serve to further induce high expression 
of non-functional VGLL1 in this tumour subtype.  
4.5.3.3 Potential treatments against ARID1A-mutated tumours  
A notable gene that was found to be not mutated in the VGLL1-high subset was 
FGFR3, a gene that was similarly found to be induced in NHU cells following 
PD153035 (but not LY294002) treatment (Appendix vii). A previous study has 
highlighted that a mutually exclusive relationship exists between alterations to 
ARID1A and FGFR3 in cases of bladder cancer (Balbás-Martínez et al., 2013), while 
the identity of FGFR3 as an upstream RTK of PI3K/AKT signalling has previously 
been described (Salazar et al., 2009; Okada et al., 2019; Yin et al., 2020). The 
preceding observations therefore potentially implicate the requirement for normal 
FGFR3 signal transduction (and possible subsequent PI3K/AKT activation) in this 
tumour type and thus highlight a potential therapeutic option.  
Based on the effect that loss of ARID1A function has on human cells, treatment 
with inhibitors that target either components of the DNA damage response system 
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such as ATR kinase (Williamson et al., 2016), or histone deacetylases (HDACs; 
Fukumoto et al., 2018) have been previously hypothesised to display a potential 
therapeutic benefit to cancers that harbour ARID1A mutations. Indeed, a recent 
study that treated the ARID1A-mutated, VGLL1-high MIBC cell line HT1197 with 
pan-HDAC inhibitor panobinostat caused a downregulation of E2F target genes and 
upregulation of p53 and inflammatory pathway genes, in effect a reversal of the 
phenotype observed in the VGLL1-high MIBC tumour subtype expression profile 
(Gupta et al., 2019).  
4.5.4 Identification of potential VGLL1/TEAD3 target genes in urothelium 
Of the four TEAD genes, VGLL1 expression was confirmed to most closely correlate 
with TEAD3 in MIBC. Whilst a functional binding relationship between the 
transcription factor and co-activator in urothelial cells remains to be validated, this 
observation (in addition to the transcript and protein expression of the TEAD 
factors in normal urothelium examined in the previous chapter) suggested that 
TEAD3 is the predominant TEAD transcription factor that VGLL1 binds to in 
urothelium. Examination of the genes that both VGLL1 and TEAD3 positively 
correlated with in MIBC provided an insight into what genes could possibly be 
induced by normal VGLL1/TEAD3 transcriptional activity in urothelium, including 
PARD6B, PLEKHG6 and CGN, all targets which were confirmed to be expressed at 
the transcript level in differentiated NHU cells.  
PARD6B encodes a member of the PAR6 family that are required to regulate 
epithelial cell polarity through its role as part of the polarity complex, a complex 
that additionally contains Protein Kinase C ζ (PKCζ) and PAR3 (Joberty et al., 2000). 
PAR3 localises to tight junctions in the apical regions of cells (Ebnet et al., 2003), 
while PAR6 binds to PAR3 and acts as a scaffold protein to recruit PKCζ to the 
complex (Joberty et al., 2000). The role of the polarity complex in tight junction 
regulation was demonstrated in a study of normal murine mammary epithelium, as 
Par6 localised with Zo-1 and TgfβrI at apical tight junctions. Stimulation (and 
heterodimerisation) of the Tgfβ receptor complex resulted in Par6 phosphorylation 
by TgfβrII and a dissolution of tight junctions, with cells expressing mutated Par6 
unable to dissolve tight junctions following TGFβ treatment (Ozdamar et al., 2005).  
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This TGFβ-dependent dissolution of the tight junctions was demonstrated to result 
from Par6-mediated proteasomal degradation of Rho GTPase RhoA by the E3 
ubiquitin ligase Smurf1  (Ozdamar et al., 2005). Using non-tumorigenic MCF10A 
cells, PARD6B shRNA knockdown was additionally demonstrated to inhibit PKCζ 
phosphorylation, promote re-entry into the cell cycle and induce activation of AKT 
signalling (Marques et al., 2016). Dysregulation of the PKCζ/PARD3/PARD6B 
complex subsequently leads to loss of cell polarity and has been associated with a 
more invasive and chemoresistant phenotype in lung adenocarcinoma (Zhou et al., 
2017). 
RHOA has previously been demonstrated to play a multifaceted role in tight 
junction regulation, as depending on the induction of specific downstream effector 
proteins it can either contribute to an increase in epithelial barrier TEER (Hasegawa 
et al., 1999; Schlegel et al., 2011) or result in dissolution of cell-cell contacts (Zhang 
et al., 2013). Expression of PLEKHG6 and cingulin (CGN) appear to be important in 
regulating this activation, as demonstrated through a requirement of 
PLEKHG6/RHOA binding to induce invasiveness in MDA-MB-231 human breast 
cancer cells (D. Wu et al., 2009), and an increase in RhoA-mediated cell cycle 
activity following knockdown of Cgn in Madin-Darby canine kidney cells (Guillemot 
et al., 2006). The preceding findings therefore implicate PARD6B, PLEKHG6 and CGN 
as potential target genes of the VGLL1/TEAD3 transcriptional program, with the 
previously identified function of these genes offering a potential rationale behind 
some of the changes to cell phenotype observed when VGLL1 expression is 
genetically modified in NHU cells.  
4.5.5 Chapter conclusions 
Overall, data presented in this chapter confirmed that forced expression of VGLL1 
does little to affect expression of YAP or its downstream targets in MIBC cell lines, 
consistent with the results observed in NHU cells and indicative of a lack of 
competitive signalling between the two transcriptional co-activators in urothelial 
cells. Further discussion on the lack of a relationship observed between VGLL1 and 
YAP/TAZ signalling can be found in Chapter 6. Overexpression of VGLL1 was 
however found to inhibit PI3K/AKT signalling and contribute to cell cycle arrest in 
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T24 cells in a similar manner to that observed in undifferentiated NHU cells. The 
aforementioned alterations to cell phenotype were not replicated in the 
basal/squamous MIBC cell lines 5637 and ScaBer, suggesting that their respective 
mutational backgrounds predisposes these cells to be unresponsive to normal 
VGLL1 function. Examination of the phenotype of VGLL1 expression in the context 
of MIBC revealed a subgroup that exhibits overexpression of the gene, an enriched 
ARID1A mutational signature and a poor survival rate. This observation, alongside 
analysis of potential genes expressed through VGLL1/TEAD3 activity, has provided 
potentially fascinating insights into how VGLL1 functions to regulate tissue 
























4.6 Summary of results 
 VGLL1 transcript and protein expression was retained in luminal-derived 
bladder cancer cell lines but reduced or lost in basal/squamous-like bladder 
cancer cell lines, with low expression of VGLL1 appearing to correlate with 
high expression of YAP/TAZ target genes. However, overexpression of VGLL1 
in 5637, T24 and ScaBer MIBC cell lines had a negligible effect on YAP 
phosphorylation state, YAP localisation or expression of YAP/TAZ 
downstream target genes, supporting the observations made in NHU cells 
that VGLL1 does not directly affect YAP/TAZ signalling in urothelial cells.  
 
 VGLL1 overexpression in T24 (but not 5637 or ScaBer) cells inhibited AKT 
signalling and reduced the proportion of cells actively proliferating, similar 
to the phenotype found in VGLL1-overexpressing undifferentiated NHU 
cells.  
 
 MIBC tumours primarily retained VGLL1 expression in comparison to normal 
urothelium. While the VGLL1 gene itself was not mutated in MIBC, analysis 
of an outlier VGLL1-high subgroup revealed significant enrichment of 
mutations in the chromatin remodelling gene ARID1A. Tumours with 
aberrant expression of VGLL1 upregulated genes involved in cell cycle 
progression and suppressed expression of pro-apoptotic genes, suggestive 












5: Investigation of canonical and non-canonical Sonic Hedgehog 
pathway activity in urothelial and stromal cells  
 
5.1 Introduction 
Interactions between epithelia and the underlying fibroblasts, smooth muscle cells 
and other cells of mesenchymal origin that make up the stroma are known to play a 
pivotal role in the regulation of mammalian tissues (Howlett et al., 1986). As 
previously stated (Section 1.1),  the urothelium is supported by a layer of fibroblast-
containing connective tissue that makes up the lamina propria (Hodges et al., 
1977). Cells of the lamina propria help to mediate processes such as development, 
tissue repair and differentiation of urothelium (Jerman et al., 2020), while also 
being implicated in contributing to a neoplastic phenotype (reviewed by Southgate 
et al., 1999).  
5.1.1 Urothelial stromal cell phenotype 
Immunohistochemical analysis of adult human ureters determined that expression 
of cytoskeletal-related proteins such as α-smooth muscle (SM) actin, smoothelin, 
caldesmon and desmin were localised primarily to smooth muscle bundles, with 
low, scattered expression of said proteins in the lamina propria and blood vessels 
(Baker et al., 2008; Kimuli et al., 2004) . By contrast, SM myosin and vimentin were 
expressed primarily in the lamina propria and less so by smooth muscle bundles, 
with all layers of the stroma negative for Ki67 (Baker et al., 2008). Similarly to NHU 
cells, non-immortalised normal (ureter-derived) human stromal (NuHS) cells can be 
grown in culture, but unlike urothelial cells do not experience contact inhibition 
upon reaching confluence. These cells were unable to proliferate in a serum-free 
environment, yet expressed Ki67 and cyclin D1 while exhibiting an initial 
exponential growth rate when grown in the presence of serum, suggestive of a 
phenotypic shift away from mitotic quiescence in serum-supplemented culture 
(Baker et al., 2008). When grown in vitro, NuHS cells retained expression of stromal 
protein markers such as α-SM actin and vimentin (Baker et al., 2008; Kimuli et al., 
2004). However, delineation of the identity of stromal cell types primarily retained 
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in vitro was considered unfeasible due to the lack of markers specific to one cell 
type, alongside a significant reduction in expression of markers such as SM myosin 
and smoothelin when grown in culture (Baker et al., 2008). 
5.1.2 Stromal/urothelial interactions   
Initial attempts to expand adult epithelial cell cultures and reproduce their normal 
morphology ex vivo determined that cell types, such as epidermal keratinocytes, 
were unable to propagate in vitro without the presence of an accompanying 
fibroblast population (Rheinwald et al., 1975). Soon after, rodent urothelium was 
found to survive transiently in culture when grown from dissected bladder explants 
(Elliott et al., 1975), but exhibited poor viability following a period of over two 
weeks when grown on standard (plastic) Petri dishes (Chlapowski et al., 1979). Full 
differentiation of murine urothelium in vitro was only achieved by combining 
urothelial cells with mouse embryonic 3T3 fibroblast cells and a collagen matrix, 
whereas cells grown on a collagen substrate or alongside irradiated 3T3 cells only 
were both found to display a degree of histological abnormality. This suggested that 
both the cellular and non-cellular components of the stroma were required to 
induce a urothelial phenotype close to that found in situ, while also highlighting 
that the permissive signals produced by the stromal element could be produced by 
a non-isologous stromal cell type (originating from embryonic mouse compared to 
adult rat; Howlett et al., 1986). Culturing of urothelial cells with a three dimensional 
stromal support remained the prevailing approach in studying adult mammalian 
urothelial biology in vitro until the advances made by Southgate et al. which 
allowed for the cultivation of NHU cells in a stroma-free environment (Jennifer 
Southgate et al., 1994). 
The exchange of permissible signals between urothelium and stroma appears to 
occur in both adult and developing mammalian bladders, as demonstrated in 
studies with rat fetal bladders at a stage prior to tissue differentiation (Baskin et al., 
1996). Upon grafting onto a syngeneic adult host, bladders left intact or bladder 
mesenchyme that was recombined with urothelium were found to fully express 
smooth muscle differentiation markers. However, grafted bladder mesenchyme 
that was isolated and separated from accompanying urothelium displayed poor 
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growth and no signs of differentiation, potentially implicating signalling from the 
urothelium through the secretion of diffusible growth factors as a vital component 
of stromal differentiation (Baskin et al., 1996). However, due to the 
aforementioned advances made in studying human urothelial cells in vitro, limited 
progress has been made in intervening years to identify the molecular pathways 
involved in stromal:urothelial signalling in the adult human bladder. 
5.1.3 Sonic Hedgehog signalling pathway 
An example of a pathway that could be involved in human stromal:urothelial 
signalling is the Sonic Hedgehog (SHH) pathway, which has previously been 
implicated in rodent bladder development, homeostasis and repair (Figure 5.1; Shin 
et al., 2011; Shin et al., 2014b). SHH ligand (also entitled SHH) is the most 
commonly expressed member of the Hedgehog family of proteins in mammalian 
tissues and was first identified as being an important morphogen in the 
development and tissue patterning of the human embryo (Echelard et al., 1993). 
The 45kDa precursor SHH protein undergoes auto-proteolytic internal cleavage into 
an inactive carboxy-terminal domain and a 19kDa active amino-terminal domain 
entitled SHH-N (Porter et al., 1996a). The signalling molecule then undergoes 
further addition of cholesterol and palmitoyl moieties (at the C and N terminals, 
respectively) by the acyltransferase Skinny Hedgehog (Chamoun et al., 2001). These 
post-translational modifications assist in increasing the activity of SHH-N while 
facilitating paracrine signalling over relatively large distances, potentially via helping 
to promote association with the exoplasmic membrane (Kohtz et al., 2001; Koleva 
et al., 2015; Lewis et al., 2001).  
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Figure 5.1: Canonical mammalian SHH pathway signalling 
Canonical SHH signalling is initiated through the binding of SHH ligand to the 
extracellular region of PTCH1. In the absence of SHH, PTCH1 is localised primarily to 
the primary cilia of cells, where it can inhibit the translocation of signal regulator SMO 
from intracellular endosomes (Milenkovic et al., 2009). Microtubule-bound kinases 
PKA, GSK3β and CK1 phosphorylate GLI2 and GLI3, inducing proteolysis and generation 
of truncated, GLI-R repressor forms of the transcription factors. GLI-R can bind to DNA 
in the nucleus but lacks an activation domain, thereby rendering it unable to induce 
GLI-mediated transcription. Binding with SHH inhibits PTCH1 activity and allows SMO 
to translocate to primary cilia, thereby leaving GLI2 and GLI3 in an unprocessed, active 
(GLI-A) state. GLI-A dissociates from inhibitory SUFU protein and translocates to the 
nucleus where it can induce transcription of various target genes, including GLI1. 
Activation of GLI activity additionally induces negative regulator PTCH1, resulting in a 
subsequent inhibition of signalling in normal cells through the form of a negative 
feedback loop. Pharmacological activation or inhibition of canonical SHH signalling can 
be performed through binding of the heptahelical bundle of cilia-localised SMO by SAG 
or GDC-0449, respectively. Diagram adapted from a review of SHH pathway signalling 




SHH-N ligand is able to activate the canonical Hedgehog pathway in cells in both an 
autocrine or paracrine cell manner by binding to (and inhibiting) the 12-span 
transmembrane protein Patched-1 (PTCH1; Stone et al., 1996), a protein which 
catalytically inhibits the constitutive activity of G-protein-coupled receptor-like 
protein Smoothened (SMO) in the absence of SHH (Taipale et al., 2002). Repressed 
SMO activity inhibits SHH pathway signalling through sequential phosphorylation 
events of the glioma-associated oncogene (GLI) family of zinc finger transcription 
factors by Protein Kinase A (PKA),  Casein Kinase 1 (CK1) and GSK3β (Price et al., 
2002); a kinase observed to become itself phosphorylated (and therefore 
inactivated) by components downstream of EGFR in NHU cells (Georgopoulos et al., 
2014). These inhibitory phosphorylation events result in the processing of GLI 
family members GLI2 and GLI3 into transcriptional repressors (sometimes referred 
to as GLI-R) which possess a truncated C-terminal activation domain alongside N-
terminal repressor and DNA-binding domains (Sasaki et al., 1999). Inhibition of 
PTCH1 allows for translocation and activation of SMO in the primary cilia of cells, 
microtubule-based organelles that protrude from the cell surface (Bailey et al., 
2009). Translocation of SMO therefore activates a downstream signalling cascade 
whereby the proteolytic processing of GLI2 and GLI3 is bypassed and the proteins 
dissociate from the inhibitory Suppressor of Fused (SUFU) protein complex (Svärd 
et al., 2006). Activated GLI2 and GLI3 (GLI-A) are subsequently able to translocate to 
the nucleus and influence the transcription of various target genes, including GLI1 
and PTCH1 (Fig. 5.1; Lee et al., 1997). Upregulation of PTCH1 therefore ensures 
eventual inhibition of GLI-mediated signalling in the form of a negative feedback 
loop. Additional evidence exists for SHH/PTCH1-independent (non-canonical) 
activation of GLI signalling, whereby signal transducers such as RAS, MEK and AKT 
activate GLI in the absence of SHH/PTCH1 binding (Riobo et al., 2006; Stecca et al., 
2007) In this context, tumour suppressors such as p53 and Phosphatase and Tensin 
Homolog (PTEN; a negative regulator of PI3K/AKT signalling) negatively regulate 
non-canonical pathway activation in order to maintain tissue homeostasis (Gruber-
Filbin et al., 2013; Stecca et al., 2009). 
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Depending on the ratio of GLI1-A to GLI-R in a given cell, GLI transcription factors 
can act as either transcriptional activators or repressors, resulting in a highly 
complex, dynamic and context-specific output signal. This, alongside the type of cell 
responding to SHH ligand, the length of time in which this signal is propagated, the 
concentration of morphogen present and the environment in which the cell is 
inhabiting will all help to shape a particular cellular response to SHH activation, thus 
accounting for the apparently pleiotropic effect that SHH (and its pathway 
products) can have on multiple cellular processes (reviewed by Aberger et al., 
2014). 
5.1.4 Role of SHH signalling in bladder development and repair  
The importance of SHH signalling in bladder biology has been well characterised in 
in vivo rodent models. Evidence that SHH signalling could play a role in stromal: 
urothelial interactions was initially demonstrated in the developing metanephric 
kidney of the mouse, as urothelial precursor cells were required to produce Shh in 
order to induce development in the surrounding mesenchyme. Ptch1-expressing 
mesenchymal cells subsequently expressed Bmp4 in order to induce differentiation 
of said mesenchymal cells into smooth muscle (J. Yu et al., 2002), hence elucidating 
the potential molecular basis behind the urothelial-mediated mesenchymal cell 
differentiation process identified in earlier studies (Section 5.1.2).  When tracking 
smooth muscle differentiation in the developing mouse bladder, Shh was found to 
be expressed at an early stage, preceding expression of any smooth muscle 
differentiation-associated proteins.  The importance of Shh morphogen in the 
differentiation process was confirmed with the use of Smo inhibitor cyclopamine, 
which inhibited smooth muscle differentiation; and treatment of cultured bladder 
mesenchyme cells with recombinant Shh, which induced differentiation 
(Shiroyanagi et al., 2007). This pattern of expression was similar to that found 
during normal human urinary tract development, with precursor SHH protein 
expressed by the urothelium while expression of PTCH1, SMO and BMP4 were 





Beyond the role of the pathway in organogenesis, multiple publications by Shin et 
al. have demonstrated the importance of Shh signalling in the maintenance of 
postnatal bladder tissue homeostasis in mice. It was initially reported that mouse 
basal (Krt5+) urothelial cells produce and released Shh ligand upon tissue injury by 
bacterial or chemical means (Shin et al., 2011). Conversely, Gli1 was found to be 
exclusively expressed in the stroma, with expression of the protein (in addition to 
Ptch1) increased after injury. Evidence of an active, SHH-mediated paracrine 
signalling loop in the repairing bladder was provided through the use of Gli1-
mutant bladders which experienced a reduction in the level of urothelial 
proliferation post-injury compared to wild-type (Shin et al., 2011). These findings 
were later complemented in a study of adult rat bladder where expression of Shh, 
Gli1 and Bmp4 were found to be induced after subtotal cystectomy (Peyton et al., 
2012). Examples of the Gli1-dependent genes induced by injured stromal cells in 
mice included Wnt2, Wnt4, Fgf16 and Bmp4, while both basal urothelial and 
stromal cell types were found to upregulate expression of Wnt/β-catenin target 
gene Axin2 (Shin et al., 2011). Activation of Axin2 expression (through treatment 
with GSK3β inhibitor LiCl) in Gli1-mutant bladders was sufficient to rescue the 
proliferative phenotype of recovering urothelial cells post-injury; implicating 
Wnt/β-catenin pathway activation as an ultimate consequence of paracrine SHH 
pathway activity in this context (Shin et al., 2011).  
 
5.1.5 Dysregulation of SHH signalling in cancer  
As previously stated (Section 5.1.3), SMO can accumulate in the primary cilium and 
activate downstream GLI signalling constitutively if PTCH1 function is disabled. 
Mutations of the PTCH1 gene thus provide the most commonly cited mechanism of 
ligand-independent SHH pathway dysregulation in cancer, as seen in cases of basal 
cell carcinoma (BCC) of the skin and medulloblastoma (Gailani et al., 1996; Pietsch 
et al., 1997). Both cancer types can develop from Gorlin syndrome, a condition 
which is primarily caused by hemizygous deletion of PTCH1 at chromosome 9q22 
(Shimkets et al., 1996), a locus which is lost in ~50% of NMIBC cases (Aboulkassim 
et al., 2003). As a result of this, both BCC and medulloblastoma have been shown to 
be amenable to therapy using inhibitors of constitutive SMO activity, such as 
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Vismodegib (GDC-0449). Through binding to SMO at its heptahelical bundle domain 
in a similar fashion to cyclopamine (Chen et al., 2002a), GDC-0449 was found to 
significantly reduce the growth of BCC and medulloblastoma tumours (Amin et al., 
2010; Rudin et al., 2009) and is currently approved by the FDA for use in treatment 
of metastatic BCC (Ingram, 2012). Despite this, the efficacy of GDC-0449 treatment 
in the context of NMIBC has not yet been tested.  
Aberrant activation of SHH ligand activity (i.e. ligand-dependent tumours) has also 
been observed in various human malignancies, including pancreatic, breast and 
lung cancer (Bailey et al., 2009; Mukherjee et al., 2006; Yuan et al., 2007). 
Furthermore, aberrant expression of GLI1 and GLI2 can be induced through non-
canonical (SHH/PTCH1-independent) means, as evidenced in diseases such as renal 
cell carcinoma (J. Zhou et al., 2016). Cancers displaying a SHH/PTCH1-independent 
phenotype of SHH pathway activation remain unaffected by addition of SHH 
blocking ligands or canonical pathway antagonists, yet GLI signalling can be 
inhibited through blockade of crosstalk with other signalling cascades, such as 
RAS/MEK/ERK and PI3K/AKT (Kasiri et al., 2017; Po et al., 2017). 
Investigation into the role of SHH signalling in mouse MIBC has previously focused 
on the potential status of Shh-expressing basal cells as a stem cell-like population. 
Lineage tracing of normal mouse Shh+/Krt5+ urothelial cells after several rounds of 
bladder injury revealed that all layers of the urothelium expressed the fluorescent 
reporter protein, granting credence to the author’s hypothesis that the Shh+/Krt5+ 
basal urothelial cells can be identified as a form of progenitor stem cell population 
in mouse bladder (Shin et al., 2011). After treatment of bladders with the pro-
carcinogen N-butyl-N-4-hydroxybutyl nitrosamine (BBN), it was determined that the 
basal Shh+/Krt5+ population also inevitably contained the cell of origin for the 
subsequent MIBC that arose (Shin et al., 2014a). However, expression of Shh was 
found to be absent in the eventual invasive tumours alongside a corresponding loss 
of Gli1 and Ptch1 in the surrounding stroma (Shin et al., 2014a; Shin et al., 2014b).  
The observations compiled by Shin et al. suggest that unlike in various other cancer 
types (Thayer et al., 2003; Yuan et al., 2007), activated SHH signalling actually 
serves as a rate-limiting step in mouse urothelial carcinoma development. 
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Unbiased clustering of RNAseq analysis from TCGA cohort of human MIBC found 
that the well-differentiated luminal papillary bladder cancers could be clustered 
based on their expression of SHH and BMP5 (Robertson et al., 2017). However, 
reports of SHH pathway activity in human urothelial carcinoma are heavily 
conflicting: histological analysis of SHH pathway components in two studies 
determined that expression of SHH, PTCH1, GLI1 and GLI2 was overexpressed in 
high grade tumours and correlated with a reduced overall survival rate (He et al., 
2012; Islam et al., 2016). By contrast, other studies concluded that GLI1 expression 
was lower in MIBC samples compared to NMIBC (Sverrisson et al., 2014) and SHH 
protein expression did not correlate with tumour stage or survival rate (Nedjadi et 
al., 2018). Such notable differences in interpretation could possibly be as a result of 
the notoriously low quality antibodies (in terms of specificity) historically available 
for components of the pathway (reviewed by Van Den Brink, 2007). On the basis of 
these observations, further research is clearly required to elucidate the expression 
of SHH pathway components in normal urothelium and MIBC and to understand 
the processes by which dysregulation of SHH signalling can potentially initialise 
















5.2 Aims and hypothesis 
SHH pathway-mediated paracrine interactions between the urothelium and 
underlying stroma are reportedly essential for rodent bladder development and 
adult tissue homeostasis, yet as discussed in Section 1.3, in vitro studies of adult 
NHU cells have found the cells to be capable of autonomous growth. Furthermore, 
NHU cells power autonomous growth through various signalling pathways 
downstream of autocrine activation of EGFR, some of which have previously been 
implicated in SHH/PTCH1-independent, non-canonical SHH pathway signalling.   
Therefore, the overall aims of this chapter were to elucidate whether a SHH 
pathway signalling loop was active between human urothelium and stroma, 
determine whether this activation is affected in cases of MIBC through mutation or 
modulation in expression of key genes, and to understand whether undifferentiated 
NHU cells exhibit non-canonical SHH pathway activation through a pathway 
downstream of EGFR. It was hypothesised that, like in rodent bladder, adult human 
urothelial and stromal cells express the necessary components of the canonical SHH 
pathway to facilitate paracrine activation of GLI1 in stromal cells. This signalling axis 
would subsequently be affected in both undifferentiated NHU cells (which exhibit 
GLI activation through autocrine EGFR signalling) and a subset of MIBC tumours 
(due to dysregulated expression of canonical SHH genes).  
Based on this hypothesis, the specific experimental objectives were to:  
 Determine transcript and protein expression of SHH pathway components in 
urothelium in situ and compare to their expression in vitro in order to 
confirm that the cells express the required components needed for 
activation of the pathway (Section 5.4.1-2). 
 
 Establish whether NuHS or normal bladder-derived human stromal (NbHS) 
cells possess the ability to activate canonical SHH signalling using specific 
agonists and antagonist. Visualise whether this activation results in changes 
to the expression and localisation of SHH pathway proteins (Section 5.4.3), 
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before quantifying the most globally upregulated genes in NuHS and NbHS 
cells after canonical pathway induction (Section 5.4.4). 
 
 Ascertain what the effect of inhibiting EGFR or PI3K/AKT has on expression 
of active SHH pathway signalling (Section 5.4.5) in undifferentiated NHU 
cells. 
 
 Determine whether gene expression of SHH pathway components is 
dysregulated in the different molecular subtypes of MIBC and identify novel 
subgroups of tumours with aberrant expression of pathway components 


















5.3 Experimental approach 
5.3.1 Characterisation of SHH pathway component expression in urothelium 
Previously undertaken in-house RNAseq experiments were collated to quantify 
transcript expression of the primary gene components of the SHH pathway (SHH, 
PTCH1, SMO, GLI1, GLI2, GLI3, HHIP) in samples from undifferentiated NHU cells 
(n=6), NHU cells differentiated using the ABS/Ca2+ method (n=19) and urothelium in 
situ (n=10). Urothelium in situ samples were further separated on the basis of their 
organ of origin (n=6 ureter versus n=4 bladder samples) to determine whether 
there was a difference in expression of pathway components between tissue types.  
Sections of normal adult ureter tissue (n=1 for SHH, n=2 for PTCH1) were labelled 
using immunohistochemistry to determine whether protein expression of SHH and 
PTCH1 aligned with the urothelial in situ transcript expression described in the 
previous analysis.   
5.3.2 Activation of canonical SHH signalling in stromal cells  
Determination of whether NuHS cells possessed an inducible SHH pathway 
response was accomplished by treating cells with agonists of the pathway and 
quantifying the response using induction of reporter gene/protein GLI1 expression. 
Two canonical SHH pathway agonists were used in this study: recombinant, E. coli-
derived N-terminal mature SHH ligand (rSHH) and the synthetic 
chlorobenzothiophene-containing SAG. As in vivo, rSHH binds to membrane-
localised PTCH1 to induce pathway activation while SAG is PTCH1-independent and 
binds directly to the heptahelical bundle of SMO (Chen et al., 2002b). Similarly, 
synthetic antagonist GDC-0449 binds to the same heptahelical bundle (Fig. 5.1) and 
was used as a competitive inhibitor of SMO activity.  SAG activity was titrated on 
confluent NuHS cells (n=1) following serum starvation due to previous reports that 
determined that optimal formation of primary cilium occurred in confluent, serum-
free conditions (Spann et al., 2015). Expression of GLI1 in SAG-treated NuHS cells 
was compared to that found in mouse embryonic fibroblast 3T3-J2 cells, a 
previously validated SHH-responsive cell line (Martinez-Chinchilla et al., 2008). 
NuHS (n=3 independent cell lines) and NbHS (n=2 cell lines) were subsequently 
treated with SAG (in the presence and absence of GDC-0449) for periods of 24h and 
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48h to determine whether activation of canonical pathway signalling affected 
transcript and protein expression of other components of the SHH pathway. 
To reveal the identity of downstream targets induced by GLI1 activation in stromal 
cells, cultures were treated with 100 nM SAG for 24h and 48h and the sample RNA 
sequenced. Two NuHS and one NbHS cell line were sequenced, with Y875 and 
Y1027 derived from ureter and Y879 derived from bladder. RT-qPCR analysis was 
used to confirm that each sample displayed a ≥ 2-fold induction of PTCH1 and GLI1 
before they were sequenced. Differential expression analysis was performed to 
determine what the most upregulated/downregulated genes were after canonical 
pathway activation. Changes in expression to previously cited GLI target genes 
CCND1, CCND2, MYCN and BCL2 (Kasper et al., 2006; Yoon et al., 2002) and selected 
genes associated with WNT, FGF, BMP and Hippo signalling were additionally 
examined as part of the analysis. Gene ontology analysis of the genes found to have 
a Log2 fold change values ≥ 1 in each dataset was used to infer the biological 
functions related to GLI1 activation in stromal cells.  
5.3.3 Non-canonical induction of GLI1 expression in NHU cells 
To determine whether undifferentiated NHU cells express GLI1 through a non-
canonical mechanism, cells were treated with a combination of PD153035, SAG and 
GDC-0449 for a period of 24h (n=3 independent cell lines). Relative expression of 
PTCH1 and GLI1 was compared between samples by RT-qPCR due to their status as 
reporter genes of SHH pathway activation. The inhibition of an alternative signal 
transducing pathway active in NHU cells, PI3K/AKT signalling, was also explored in 
relation to expression of GLI1. Modulation of PI3K/AKT signalling was achieved by 
treating NHU cells with a PI3K inhibitor LY294002 in isolation or in combination with 
PD153035 (n=1 NHU cell line), before observing GLI1 transcript and protein 





5.3.4 SHH pathway dysregulation in MIBC  
To explore the possibility that the SHH pathway was dysregulated in cases of MIBC, 
RNAseq samples from TCGA MIBC cohort (n=404) were separated into previously 
defined molecular subtypes (Section 1.4.3) and expression of SHH, PTCH1, GLI1 and 
GLI2 compared to the expression of these genes in normal urothelium (using in situ 
expression data collated from previous in-house RNAseq experiments; n=6).  
The frequency of mutations in said genes in TCGA cohort was additionally analysed 
to determine whether SHH pathway genes (e.g. PTCH1) found to be commonly 
mutated in other forms of human cancer were also found to be commonplace in 
MIBC.  Information on the mutation status of TCGA MIBC samples was obtained 
from the cBioPortal for Cancer Genomics (https://www.cbioportal.org/). Following 
confirmation of urothelium-specific GLI2 upregulation in a subset of 
basal/squamous tumours, the tumours were analysed to determine the most 
common mutations inherent to this group and what the most differentially 
expressed genes were in comparison to the remaining basal/squamous tumours. 
The identity of a potential transcription factor that induced the expression of highly 
upregulated genes in the GLI2-high group was determined through use of the 
GeneHancer database of gene enhancers and their respective target genes 
(Fishilevich et al., 2017). Analysis of the changes in gene expression of previously 
identified markers of neuroendocrine-like MIBC tumours (Aine et al., 2015) was 
additionally performed to observe whether this novel subgroup also exhibited an 
increase in expression of these targets. Finally, the overall survival of patients with 
GLI2-high basal/squamous tumours was compared to the remaining 
basal/squamous tumour patients to determine whether upregulation of GLI2 was 








5.4.1 RNAseq analysis of SHH pathway genes in NHU cells 
Urothelial cells expressed multiple components of the SHH pathway, including SHH 
transcript (Fig. 5.2A). However, NHU cells (in both undifferentiated and serum 
differentiated states) had significantly lower expression of SHH compared to 
urothelium in situ (p ≤0.001). PTCH1, SMO, and GLI3 were expressed by urothelium 
in situ and NHU cells, with no significant differences in expression found when 
comparing cell conditions. Urothelium in situ (in addition to differentiated NHU 
cells) was not found to express GLI1 or GLI-mediated negative pathway regulator 
HHIP, although NHU cells cultured in an undifferentiated state were found to 
induce a 10-fold and 8-fold increase in expression of either gene, respectively. GLI2 
expression was absent in all urothelial samples.  
After separating the in situ samples on the basis of whether the sample was 
acquired from ureter or bladder tissue, it was determined that SHH expression was 
significantly higher in bladder urothelial samples (Fig. 5.2B; p ≤0.001), but no 
significant differences in expression of the other genes was observed. The above 
analysis therefore confirmed that urothelial cells expressed the necessary gene 
(SHH) required to participate in paracrine SHH signalling with another cell type, 
with a greater expression of the gene found in bladder urothelium compared to 
ureter. However, a lack of GLI1/GLI2 expression in both in vitro and in situ 
differentiated urothelium suggested the absence of autocrine SHH pathway 
signalling in these physiological contexts. A visual summary of the components of 
the SHH pathway expressed in NHU cells in an undifferentiated and ABS/Ca2+ 































Figure 5.2: Urothelial cells express key components of the SHH signalling pathway  
Bioinformatics analysis of multiple RNAseq experiments was performed to identify the 
expression pattern of SHH pathway components in urothelial cells under different 
conditions. Graph (A) denotes expression of SHH, PTCH1, SMO, GLI1, GLI2, GLI3 and 
HHIP in RNAseq samples from undifferentiated NHU cells (n=9), (ABS/Ca
2+
) 
differentiated NHU cells (n=13) and urothelium in situ (n=6). Graph (B) is a comparison 
of expression of SHH pathway genes in in situ urothelium when split by ureter (n=3) or 
bladder (n=3) derivation. Gene expression is measured in Transcripts per Million 
mapped reads (TPM), with error bars representing standard deviation of the mean. 
Significance between groups was determined by a two-way ANOVA with Tukey’s (A) or 
































Table 5.1: Log2 fold change differences in SHH pathway component transcript expression 
in ABS/Ca2+ differentiated NHU cells compared to undifferentiated NHU cells  
Genes that experienced a log2 fold change increase ≥ 1 are highlighted in green, while 
genes with a log2 fold change decrease ≤ -1 are highlighted in red. 
 
Figure 5.3: Schematic representation of expressed gene components of the SHH 
pathway in NHU cells 
Genes that have a log
2
 fold change increase in expression in the specified cell state 
compared to the other are coloured green while genes that have a log
2
 fold change 
decrease in expression are coloured red. Genes that are expressed by NHU cells in 
both undifferentiated and ABS/Ca
2+
 differentiated states are coloured blue. GLI2 is not 
expressed in any urothelial state so is coloured grey. Differences in fold change for 
each gene is detailed in Table 5.1.  
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5.4.2 SHH and PTCH1 protein expression in native urothelium  
Preliminary immunohistochemical analysis of FFPE human ureter using antibodies 
specific to N-terminal SHH (n=1 ureter) and PTCH1 (n=2 ureters) suggested that 
urothelium in situ expressed both proteins in addition to transcript. SHH was found 
to be expressed exclusively by urothelium, with an absence of expression visualised 
in the surrounding lamina propria (Fig. 5.4A). Expression of SHH appeared primarily 
cytoplasmic and was consistently expressed throughout all layers of the urothelium. 
However, additional nuclear SHH-N labelling was also observed in the intermediate 
and superficial layers of the urothelium. Intense PTCH1 expression was found 
localised to the apical membrane of superficial cells, with weaker cytoplasmic 
labelling found throughout the other urothelial cell layers (Fig. 5.4B). PTCH1 was 
also found to be expressed by cells residing in the lamina propria and smooth 
muscle which manifested itself in a distinctive, concentrated subcellular labelling 


































Figure 5.4: SHH expression in human ureter is restricted to the urothelium whereas 
both urothelial and stromal cells express SHH-binding protein PTCH1 
Labelling of N-terminal SHH (A) and PTCH1 (B) in normal human ureters (Y2397 and 
Y2055, respectively). Grey arrows highlight examples of the localisation of PTCH1 
expression in cells of the lamina propria. The phenotype of SHH expression was observed 
in one ureter, whilst PTCH1 expression was indicative of two independent samples of 
ureter (Appendix xiv). Sections that received no primary antibody were used as negative 




5.4.3 Activation of the canonical SHH pathway in stromal cells 
5.4.3.1 Titration of SAG on stromal cells 
To investigate SHH pathway activation in vitro, validation of reagents that could 
induce a canonical pathway response was required. Treatment of mouse 3T3-J2 
fibroblasts with 1 µg/mL rSHH and 250 nM SAG both succeeded in inducing GLI1 
protein expression, confirming that both reagents were capable of inducing a SHH 
pathway response in a suitable cell type (Fig. 5.5A). Immunoblotting of NuHS cell 
line Y929A determined that, unlike 3T3-J2 cells, NuHS cells expressed GLI1 protein 
in the absence of drug treatment, indicative of constitutive activity (Fig. 5.5B). 
Treatment of Y929A cells with a titration of SAG between 0-1 µM concluded that 
100 nM SAG induced the greatest up-regulation of GLI1 protein when compared to 

































































Figure 5.5: Validation of GLI1 induction in stromal cells using synthetic and recombinant 
SHH pathway agonists 
A) Immunoblot image of GLI1 expression in mouse fibroblast 3T3-J2 cells treated with 
250nM SAG, 1 µg/mL rSHH or DMSO vehicle control for a period of 24h. All conditions 
were treated with 0.1% DMSO to control for non-specific solvent effects. B) Immunoblot 
image of GLI1 expression in Y929A NuHS cells (n=1) treated with a titration of SAG (0 to 
1000 nM) for 24h. Protein from 3T3-J2 cells treated with and without 250nM SAG was 
used as a positive control for GLI1 induction in cells. Protein from in situ urothelium 
(Y2094) was used as a negative control as this cell type had previously been 
demonstrated to lack GLI1 transcript expression. C) Densitometry analysis of Y929A GLI1 
expression in (B). The fold changes in expression of GLI1 in each condition were 




5.4.3.2 Effect of SAG treatment on SHH pathway gene expression in stromal cells 
To characterise transcript expression of SHH pathway components in NuHS cells, 
non-quantitative RT-PCR analysis of said cells treated with 100 nM or 250 nM SAG 
for periods of 24h and 48h was performed. Phase contrast micrographs of NuHS 
cells grown in vitro revealed that these cells exhibited an elongated, fibroblast-like 
morphology when sparse but adopted a uniform, flattened morphology upon 
reaching confluence (Appendix xiv). Stromal cells were treated with SAG upon 
reaching visual confluence, with no notable changes in morphology observed after 
drug treatment when compared to control. Expression of GLI1 and PTCH1 
transcripts were induced in stromal cells by SAG in a concentration and time-
related manner (Fig. 5.6A). GLI2 and GLI3 were also expressed by NuHS cells, with 
expression found to be relatively consistent (GLI2) or displaying different 
phenotypes dependent on cell line or condition type (GLI3). Despite evidence that 
demonstrated that all of the primary downstream components of the pathway 
were expressed, NuHS cells were not found to express SHH transcript under any of 
the conditions assayed, consistent with earlier immunohistochemistry analysis.  
When assaying the RNA samples by RT-qPCR in independent NuHS (n=3) and NbHS 
(n=2) cell lines, a significant increase in PTCH1 and GLI1 expression was observed 
after 24h 100 nM SAG treatment (p ≤0.01) in cells from both derivations (Fig. 5.6B). 
NuHS cells treated with 100 nM SAG with a concurrent addition of GDC-0449 were 
found to significantly abrogate induction of PTCH1 and GLI1 transcript (Fig. 5.6C; p 


























































Figure 5.6: Treatment of NuHS cells with SAG induced increased expression of PTCH1 
and GLI1 transcript 
A) RT-PCR analysis of SHH, PTCH1, GLI1, GLI2, GLI3 transcript expression in Y875 NuHS 
cells (n=1). Cells were treated with 100 or 250 nM SAG for periods of 24h (lanes 1-3), or 
48h (lane 4-6) compared to DMSO only controls. All conditions were treated with 0.1% 
DMSO to control for non-specific solvent effects. Each cDNA synthesis used 1 µg starting 
template RNA, with cDNA undergoing PCR amplification up to 32 cycles (SHH, all other 
targets up to 30 cycles). The primers used for PTCH1, GLI1 and GLI2 expression were 
intron-spanning and therefore did not produce positive gDNA bands of the same size. 
Housekeeping gene GAPDH was used to confirm equal loading between samples (25 
cycles). A no template (H
2
O only) sample was used as a negative control for each primer 
set. B) qRT-PCR analysis of PTCH1 and GLI1 expression in five independent stromal cell 
lines (three derived from ureter, two derived from bladder) treated with 100 nM SAG for 
24h.  Circle icons represent data from NuHS samples while square icons represent data 
from NbHS samples. C) qRT-PCR analysis of PTCH1 and GLI1 expression in three 
independent NuHS cell lines treated with 100 nM SAG ± 10 µM GDC-0449 for 24h. Values 
shown in figures (B-C) represent the fold change in expression between DMSO control 
and treatment conditions, with all values normalised to GAPDH expression. Significance 
between groups was determined by a two-way ANOVA test performed with Tukey’s 




5.4.3.3 Expression and localisation of SHH pathway proteins in stromal cells after 
canonical pathway activation/inhibition 
By immunoblotting, Y875 stromal cells were also found to induce expression of GLI1 
protein after treatment with 100 nM SAG, with the greatest induction of protein 
found at 24h rather than 48h (Fig. 5.7).  
Immunofluorescence images of Y886 stromal cells revealed that PTCH1 localised 
intensely to cilia-like projections (Fig. 5.8A). Interestingly, this phenotype was also 
observed when cells were treated with SAG, suggesting that no internalisation of 
PTCH1 takes place when activating the canonical pathway at the level of SMO. 
Expression of PTCH1 was lost when treated concurrently with SAG and GDC-0449. 
GLI1 expression after SAG treatment was localised intensely to the nuclei of cells, 
but expression of the protein was also lost in GDC-0449 treated cells (Fig. 5.8B). 
Overall, the evidence presented in Section 5.4.3 revealed that NuHS cells did not 
express SHH, yet were amenable to exogenous activation of the canonical SHH 












Figure 5.7: Canonical SHH pathway activation induces GLI1 protein in NuHS cells 
After determining that SAG treatment induced a significant increase in GLI1 transcript, 
immunoblot analysis of GLI1 expression in Y875 stromal cells (n=1) treated with 100nM 
SAG for periods of 24 and 48h was performed. Mouse 3T3-J2 fibroblast cells treated with 
vehicle control or 250nM SAG for 48h were used as negative and positive controls for 
GLI1 induction, respectively. All conditions were treated with 0.1% DMSO to control for 



























Figure 5.8: Canonical SHH pathway activation induces nuclear GLI1 while concurrent 
inhibition of the pathway abrogates GLI1 and PTCH1 expression in NuHS cells 
Immunofluorescence imaging of PTCH1 (A) and GLI1 (B) expression in Y886 stromal cells 
treated with 100 nM SAG ± 10 µM GDC-0449 for 24h. All conditions were treated with 
0.1% DMSO to control for non-specific solvent effects. Prior to labelling, cells grown on 
glass slides had undergone formalin fixation and were Triton X-100 permeabilised. Red 
boxes in (A) images highlight area of interest in PTCH1-labelled cells magnified to display 
detail. White arrows indicate localisation of PTCH1 in stromal cells to cilia-like formations 
in DMSO and SAG treated cultures. The pattern of PTCH1 expression is representative of 
one NuHS cell line, whilst nuclear induction of GLI1 after SAG treatment was confirmed in 
two independent stromal cell lines, images of which can be found in Appendix xiv. Cells 
receiving no primary antibody (C) were used as a negative control. Images were all taken 
at same exposure and are shown with or without overlaid Hoechst 33258 DNA staining. 







5.4.4 RNAseq of stromal cells treated with SAG 
5.4.4.1 Differential expression analysis of SAG-treated stromal cells 
To determine what genes were upregulated following activation of the canonical 
SHH pathway, RNAseq analysis of NuHS and NbHS cells treated with SAG was 
performed. Quality control of samples was first undertaken by confirming 
expression of reporter genes by RT-qPCR and by validating raw sequencing read 
quality using FastQC (both Appendix xi). Examination of genes of the SHH pathway 
in the sequenced samples determined that GLI1, but not PTCH1, was significantly 
upregulated by SAG treatment at both time points assayed (Fig. 5.9; p ≤0.01). A 
significant difference was additionally found between expression of GLI2 at 24h 
DMSO and 48h DMSO (p ≤0.01), but not between DMSO and SAG-treated samples 
at either time-point. Expression of SMO, GLI3 and HHIP remained consistent 
throughout conditions, while expression of SHH was negative in all samples, 







Figure 5.9: Expression of SHH pathway target genes in NuHS and NbHS cells after 
SAG treatment 
RNAseq expression data of SHH, PTCH1, SMO, GLI1, GLI2, GLI3 and HHIP in NuHS 
(n=2) and NbHS (n=1) cells treated with SAG versus vehicle controls. All conditions 
were treated with 0.1% DMSO to control for non-specific solvent effects. Gene 
expression is measured in TPM, with error bars representing standard deviation of 
the mean (n=3 replicates). Significance between groups was determined by a two-
way ANOVA test performed with Tukey’s post-hoc test.**=≤0.01.  
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Differential expression analysis was performed to compare three different sets of 
expression data from the SAG treatment experiment: 24h DMSO versus 24h SAG 
(24h), 48h DMSO versus 48h SAG (48h) and all DMSO versus all SAG values 
(24/48h). It was determined that both 24h and 48h analyses had 84 genes with log2 
fold change values ≥1, while 24/48h had 39 genes that passed the same metric. Of 
these genes, 33 were classed as protein-coding in 24h, 16 in 48h and 10 for 24/48h 
(Tables 5.2-5.4). For each analysis, GLI1 was confirmed to be the gene with either 
the highest (48h, 24/48h) or third highest (24h) log2 fold change value while also 
exhibiting the lowest false discovery rate-adjusted p value (q value) of any gene. 
Despite this, differential expression analysis determined that no gene was found to 
have a significant q value in any of the three comparisons. When inputting the 24h 
protein-coding gene list for Gene Ontology (GO) enrichment analysis, it was 
revealed SAG treatment was significantly associated with upregulation of genes 
involved in the assembly of basement membrane (Table 5.5). The same approach 















No. Gene Mean DMSO TPM Mean SAG TPM Log2fold 
change 
pval qval 
1 ITGB4 1.82 16.20 2.203 0.067 0.971 
2 LAMC2 3.23 30.06 2.134 0.078 1 
3 GLI1 6.28 27.86 1.890 1.98E-05 0.307 
4 ACO68631.2 12.26 18.42 1.772 1 1 
5 FCRL3 2.71 7.50 1.645 0.165 1 
6 EIF3CL 2.80 7.60 1.576 0.106 1 
7 AC008393.2 44.12 53.66 1.559 0.809 1 
8 TNFRSF6B 1.70 4.31 1.516 1 1 
9 TRBJ2-4 0.00 2.67 1.473 1 1 
10 TRBJ2-3 5.78 5.10 1.448 1 1 
11 LAMA3 10.27 17.11 1.370 0.285 1 
12 BIVM-ERCC5 2.20 3.93 1.366 0.097 1 
13 SMIM11A 21.28 25.25 1.356 0.651 1 
14 AREG 13.62 43.53 1.349 0.476 1 
15 ATP8B1 2.50 10.93 1.334 0.010 0.818 
16 G0S2 28.48 46.65 1.316 1 1 
17 LAMB3 6.95 24.87 1.307 0.073 0.987 
18 AL035078.4 52.34 58.48 1.295 0.510 1 
19 PTHLH 5.19 11.14 1.187 0.285 1 
20 EIF4A3 8.08 13.20 1.155 0.173 1 
21 ANO9 1.34 3.08 1.134 0.388 1 
22 MDFI 1.40 5.30 1.133 0.046 0.915 
23 AC068547.1 1.73 4.14 1.113 0.110 1 
24 PIGY-DT 0.00 1.68 1.082 1 1 
25 PLEK2 1.26 4.82 1.079 0.107 1 
26 PWP2 1.88 3.92 1.075 0.662 1 
27 FAM83A 1.13 3.90 1.062 0.0233 0.889 
28 COL17A1 1.18 5.72 1.057 1 1 
29 BX470111.1 0.25 2.19 1.041 1 1 
30 AC012254.2 0.00 1.56 1.027 1 1 
31 SFN 26.12 35.41 1.021 0.009 0.818 
32 TEX22 0.93 3.44 1.019 0.003 0.818 
33 CARNS1 0.45 2.30 1.013 0.001 0.818 
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Table 5.2: List of protein-coding genes from the 24h analyses with the highest log2 fold 
change values. Genes are displayed in descending order, with the gene with the highest 
log2 fold change (ITGB4) shown first. 
 
 







1 GLI1 6.38 20.67 2.0396 0.006 0.378 
2 C19orf33 1.05 6.71 1.850 1 1 
3 ZACN 1.90 7.22 1.680 0.263 0.755 
4 PPP1R1B 0.07 3.49 1.582 1 1 
5 AL132780.3 1.27 6.43 1.540 0.042 0.487 
6 TRBJ2-5 2.93 3.21 1.515 1 1 
7 SLPI 3.04 5.04 1.424 1 1 
8 NRSN1 0.76 5.68 1.409 0.493 0.886 
9 S100A2 10.87 10.50 1.396 1 1 
10 GNG8 1.27 3.99 1.372 1 1 
11 MMEL1 0.02 2.08 1.247 1 1 
12 COMMD3-BMI1 3.49 5.12 1.220 1 1 
13 PACRG 2.41 6.79 1.220 1 1 
14 GNGT2 0.36 2.55 1.130 0.000 0.378 
15 CEMP1 0.03 1.72 1.071 1 1 
16 CFTR 2.17 4.19 1.008 0.094 0.610 
 
Table 5.3: List of protein-coding genes from the 48h analyses with the highest log2 fold 













1 GLI1 6.33 24.27 1.967 2.31E-05 0.118 
2 ITGB4 2.18 8.97 1.482 0.456 1 
3 LAMC2 2.63 15.94 1.436 0.201 1 
4 C19orf33 6.87 18.81 1.388 0.609 1 
5 S100A2 128.85 242.92 1.203 0.820 1 
6 TRBJ2-3 4.40 3.92 1.199 1 1 
7 AC068631.2 14.01 16.51 1.166 1 1 
8 TRBJ2-2P 1.38 2.00 1.131 1 1 
9 EIF3CL 2.75 5.26 1.034 0.158 1 
10 TNFRSF6B 1.30 2.68 1.008 0.234 1 
 
Table 5.4: List of protein-coding genes from the 24/48h analyses with the highest log2 fold 
change values.  
 
GO biological process  pval qval 
hemidesmosome assembly (GO:0031581) 2.24E-10  3.56E-06 
cell-substrate junction assembly 
(GO:0007044) 
5.28E-08  4.21E-04 
 
GO cellular component  pval qval 
laminin-5 complex (GO:0005610) 4.52E-05  4.55E-02 
laminin complex (GO:0043256) 3.34E-06  6.73E-03 
basement membrane (GO:0005604) 6.08E-05  4.09E-02 
 
Table 5.5: The list of genes with a log2 fold change increase ≥1 from the 24h analyses were 




5.4.4.2 Expression of other genes of interest in stromal cells  
Despite having determined that no gene was significantly upregulated by SAG 
treatment following a global analysis of changes between the 24h or 48h 
conditions, the RNAseq transcriptome resource was subsequently used to analyse 
expression of selected genes of interest.  Vehicle control-treated NuHS/NbHS cells 
were found to express GLI1 target genes CCND1 and MYCN, but no change in 
expression was found upon treatment with SAG (Fig. 5.10A). Previously cited GLI1 
target gene BCL2 was not expressed by NuHS/NbHS cells in any condition. Pathways 
that have previously been demonstrated to be active in rodent bladder stromal cell 
signal transduction, such as WNT, FGF and BMP signalling, were additionally 
investigated. This analysis revealed that WNT5A and WNT5B are the most 
expressed genes of the WNT ligand family in control cells (Fig. 5.10B), while FZD2 
and FZD7 are the most highly expressed genes encoding for the Frizzled trans-
membrane WNT receptor proteins (Fig. 5.10C). Other genes of interest include high 
expression of FGF7 (Fig. 5.10D) and BMP genes BMP1 and BMP4 (Fig. 5.10E). None 




























Figure 5.10: Activation of GLI1 had no effect on expression of WNT, FGF or BMP 
signalling genes in NuHS/NbHS cells  
RNAseq analysis of expression of genes involved in different signalling pathways in 
NuHS/NbHS cells after treatment with SAG for 24h or 48h. Graph (A) displays previously 
cited targets of GLI activation (CCND1, MYCN and BCL2),  graph (B) denotes gene 
expression of members of the WNT family of ligands, graph (C) denotes expression of 
Frizzled receptor genes, graph (D) denotes expression of FGF ligand genes and graph (E) 
displays expression of BMP ligand genes. No significant difference in expression of any 
gene analysed was found between conditions. Significance between groups was 





Due to its previously cited role in bladder connective tissue synthesis (Section 
3.1.2), the expression of YAP/TAZ signalling components was also examined.  
Transcript expression of YAP1 and WWTR1 (TAZ) was found to be expressed in 
stromal cells, along with high expression of YAP/TAZ target genes AXL, ANKRD1, 
CTGF and CYR61 (Fig. 5.11). As with previous targets, treatment with SAG was not 












Figure 5.11: YAP/TAZ target genes CTGF and CYR61 were highly expressed in 
NuHS/NbHS cells, but activation of canonical SHH signalling had no effect on 
expression  
Expression of YAP1, WWTR1, ANKRD1, AXL, CTGF and CYR61 expression from RNAseq 
data of NuHS/NbHS cells treated with 100 nM SAG for periods of 24h or 48h. 
Significance between groups was determined by a two-way ANOVA test performed 
with Tukey’s multiple comparisons post-hoc test. 
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As basement membrane assembly was a cell function that was implicated as being 
significantly altered upon SAG treatment, genes related to this process were 
additionally investigated. LAMA3, LAMB3 and LAMC2 (encoding for laminin 
subunits α1, β3 and γ2, respectively) experienced an increase in mean expression in 
stromal cells treated with SAG for 24h compared to control (Fig. 5.12). However, 
this phenotype was not replicated in the 48h conditions and the difference in fold 
change at 24h was primarily attributable to the NbHS Y879 cell line, with the NuHS 
Y875 and Y1027 samples experiencing little difference in expression of the above 
genes.  Overall, RNAseq analysis of stromal cells revealed that little to no consistent 
changes in the global transcriptome occurred following treatment with SAG in this 









Figure 5.12: Induction of laminin expression following SAG treatment was observed in 
bladder-derived stromal cells only 
RNAseq analysis of expression of genes involved in laminin production (LAMA3, LAMB3, 
LAMC2) in NuHS/NbHS cells after treatment with SAG for 24h or 48h. Icons of the same 
shape represent TPM values from stromal samples of the same derivation (circle icons for 
ureter-derived, square icon for bladder-derived). No significant difference in expression of 
any gene analysed was found between conditions. Significance between groups was 




5.4.5 Non-canonical SHH signalling crosstalk in NHU cells 
5.4.5.1 Effect on SHH pathway gene expression in NHU cells following treatment with 
PD153035 alongside SAG and/or GDC-0449 
RNAseq analysis of components of the SHH pathway in urothelial cells had 
previously revealed that expression of most genes was similar between urothelium 
in situ and NHU cells in vitro, with the primary exceptions observed to be a 
reduction in SHH and a gain of previously absent GLI1 expression in 
undifferentiated cells (Section 5.4.1). This observation suggested that GLI1 
expression was potentially being induced in undifferentiated cells through a non-
canonical, SHH/PTCH1/SMO-independent pathway.  
To address this hypothesis, undifferentiated NHU cells were treated with PD153035 
for 24h to determine whether blockade of downstream EGFR signalling would 
abrogate expression of GLI1, with the drug applied either in isolation or in tandem 
with canonical agonist/antagonist SAG and GDC-0449, respectively. While 
treatment of Y1756 cells with SAG or GDC-0449 appeared to have no effect on the 
expression of GLI1, treatment with PD153035 alone was sufficient to abrogate GLI1 
expression (Fig. 5.13A). In comparison, GLI2 expression remained absent and GLI3 
was consistently expressed in all conditions. Non-quantitative RT-PCR analysis of 
cells treated with PD153035 in addition to SAG revealed that expression of GLI1 
appeared to have recovered slightly compared to cells treated with PD153035 
alone. However, this was not reflected in the RT-qPCR analysis of three 
independent cell lines that showed a similar fold change loss of GLI1 expression in 
any sample treated with PD153035 (Fig. 5.13B). RT-qPCR analysis confirmed that 
treatment of NHU cells with PD153035 significantly reduced the expression of 
PTCH1 and GLI1 (p ≤0.01), while expression of both genes was unaltered by 
treatment of cells with GDC-0449 alone (Fig. 5.13B). This evidence therefore 
suggested that GLI1 expression in undifferentiated NHU cells was controlled 














































Figure 5.13: EGFR-mediated non-canonical activation of GLI1 expression in 
undifferentiated NHU cells  
A) RT-PCR analysis of undifferentiated Y1756 cells (n=1) treated with 1 µM PD153035, 
100 nM SAG or 10 µM GDC-0449 (or a combination of the above) for a period of 24h 
compared to vehicle DMSO control. All conditions were treated with 0.1% DMSO to 
control for non-specific solvent effects. Each cDNA synthesis used 1 µg starting template 
RNA, with cDNA undergoing PCR amplification up to 32 cycles. The primers used for GLI1 
and GLI2 expression were intron-spanning and therefore did not produce positive gDNA 
bands of the same size. Housekeeping gene GAPDH was used to confirm equal loading 
between samples (25 cycles). A no template (H
2
O only) sample was used as a negative 
control for each primer set. B) RT-qPCR analysis of PTCH1 and GLI1 expression in three 
independent undifferentiated NHU cell lines treated with the same conditions as in (A). 
Values shown represent the fold change in expression between DMSO control and 
treatment conditions. Significance between groups was determined by an ANOVA with 
Tukey’s multiple comparisons post-hoc test. **= ≤ 0.01; ***= ≤ 0.001. A full list of 




5.4.5.2 Effect on GLI1 expression following inhibition of PI3K/AKT signalling in NHU 
cells 
One candidate pathway that was modulating GLI1 expression in undifferentiated 
cells following modulation of EGFR was postulated to be PI3K/AKT, a signalling 
cascade that had previously been demonstrated to participate in non-canonical SHH 
pathway activation (Section 5.1.3).  
Treatment of Y1237 cells with a combination of PD153035 and PI3K/AKT inhibitor 
LY294002 revealed that GLI1 expression was reduced by PD153035 treatment 
alone, as seen previously (Fig. 5.14). However, blockade of PI3K/AKT with LY294002 
(in the presence or absence of PD153035) caused a complete abrogation of GLI1 
expression. Immunofluorescence analysis of NHU cells treated with said inhibitors 
confirmed this phenotype, as the nuclear GLI1 expression observed in control cells 
was inhibited by PD153035 or LY294002 (but not GDC-0449) treatment (Fig. 5.15). 
The preceding observations therefore suggested that PI3K/AKT signalling is a 
potential pathway involved in the induction of non-canonical SHH pathway 





































Figure 5.14: PI3K/AKT blockade abrogates GLI1 expression in undifferentiated NHU 
cells  
RT-PCR analysis of GLI1 and GLI3 expression in Y1237 (n=1) undifferentiated NHU cells 
treated with 1 µM PD153035 or 5 µM LY294002 (or a combination of the above) for a 
period of 24h compared to a vehicle control. Each cDNA synthesis used 1 µg starting 
template RNA, with cDNA undergoing PCR amplification up to 30 cycles. The primers 
used for GLI1 expression were intron-spanning and therefore did not produce positive 
gDNA bands of the same size. Housekeeping gene GAPDH was used to confirm equal 
loading between samples (25 cycles). A no template (H
2
O only) sample was used as a 
negative control for each primer set. Conditions marked with a red asterisk are not 


























Figure 5.15: Non-canonical inhibition of nuclear GLI1 in undifferentiated NHU cells 
Immunofluorescence imaging of GLI1 expression in Y1483 cells (n=1) treated with 1 µM 
PD153035, 5 µM LY294002 or 10µM GDC-0449 for 24h. Scale bar= 50 µm. Cells that 
received no primary antibody were used as negative controls, images of which can be 
found in Appendix xiv.  
322 
 
5.4.6 SHH signalling in MIBC  
5.4.6.1 Transcriptomic analysis of SHH pathway genes in MIBC subtypes 
Previous RNAseq analysis determined that normal urothelium in situ expressed SHH 
transcript but lacked expression of GLI1 and GLI2, possibly indicative of a signal-
inducing cell type in a paracrine SHH signalling loop (Section 5.4.1). To observe 
whether expression of these key pathway genes were dysregulated in MIBC, 
expression of said genes in isolated, stroma-free normal urothelium in situ was 
compared to TCGA MIBC samples. 
 No significant difference in SHH expression was observed between normal 
urothelium and luminal papillary tumours (Fig. 5.16), demonstrating that expression 
of the gene is retained in a majority of differentiated tumours rather than 
overexpressed, as suggested in previous studies (Section 5.1.5).  In comparison, 
luminal non-specified, luminal unstable and basal/squamous tumours were all 
found to have significantly reduced expression of SHH in comparison to normal 
urothelium or luminal papillary tumours (p ≤0.01).  
Whilst expression of PTCH1 was low across all samples, expression of the gene was 
significantly reduced in all MIBC subtypes (apart from the low sample-number 



































Figure 5.16:  SHH expression is retained in a majority of luminal papillary tumours but 
lost in basal/squamous MIBC 
RNAseq gene expression data from TCGA MIBC cohort (n=404) was separated into the 
consensus molecular subtypes based on previously published gene classification 
(Kamoun et al., 2020) and compared to normal urothelium in situ samples processed in-
house (n=6). Figure 5.16 depicts log
2
 (TPM+1) transformed gene expression of SHH in 
said groups, with the median value for each condition displayed. Significance between 
groups was determined by a Kruskal-Wallis ANOVA with Dunn’s multiple comparisons 
post-hoc test. ***=p<0.001. Other significant changes between groups were omitted for 


























Figure 5.17: PTCH1 expression is reduced in MIBC compared to normal urothelium 
Log
2 
transformed expression of PTCH1 in normal urothelium in situ (n=6) compared to 
the different molecular subtypes of TCGA MIBC cohort (n=404).  Significance between 
groups was determined by a Kruskal-Wallis ANOVA with Dunn’s multiple comparisons 
post-hoc test. **=p<0.01; ***=p<0.001. Other significant changes between groups 
were omitted for clarity and are detailed in Appendix xiv.  
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Expression of GLI1 was found to be significantly increased in luminal non-specified 
tumours (p ≤0.01), yet overall expression of the gene remained low across all 
subtypes (Fig. 5.18). Furthermore, the highest median expression of the gene was 
observed in the heavily infiltrated stroma-rich subtype, indicating a potential 
stromal-derived contaminating signal that accounted for any increased GLI1 
expression found in TCGA dataset compared to isolated normal urothelium.  
Median GLI2 expression was similarly highest in the stroma-rich MIBC subtype 
when compared to all other subtypes and normal urothelium in situ (Fig. 5.19). 
However unlike GLI1, GLI2 expression was significantly higher in basal/squamous 
MIBC compared to both normal urothelium and luminal papillary tumours (p 
≤0.001). Furthermore, a subset of basal/squamous tumours collectively exhibited 
approximately two-fold the expression of GLI2 compared to the next highest 
tumour sample, while the stroma-rich tumour samples with the highest GLI2 
expression (n=2; highlighted by square icons in Fig. 5.19) were determined to be 
most closely correlated to the basal/squamous classification centroid, indicative of 
heavily-infiltrated basal/squamous tumours.    
 To determine whether the increased expression of GLI2 observed in a subset of 
MIBC tumours was a result of activated autocrine SHH signalling, hierarchical 
clustering of the MIBC cohort based on SHH and GLI2 expression was used to 
determine whether the MIBC tumours were found to co-express both genes. 
Clustering analysis revealed that the tumours separated into mutually exclusive 
SHH-high (primarily luminal papillary) and GLI2-high (primarily basal/squamous) 
groups, suggesting that activation of GLI2 in a subset of basal/squamous tumours 



































transformed expression of GLI1 in normal urothelium in situ (n=6) compared to the 
different molecular subtypes of TCGA MIBC cohort (n=404). Significance between 
groups was determined by a Kruskal-Wallis ANOVA with Dunn’s multiple comparisons 
post-hoc test. *=p<0.05; **=p<0.01; ***=p<0.001. Other significant changes between 

























Figure 5.19: GLI2 is overexpressed in a subset of basal/squamous MIBC 
Log
2 
transformed expression of GLI2 in normal urothelium in situ (n=6) compared to the 
different molecular subtypes of TCGA MIBC cohort (n=404). The square icons in the 
stroma-rich subtype signify the tumours of that subtype that were found to be most 
closely correlated to the basal/squamous classification centroid. Significance between 
groups was determined by a Kruskal-Wallis ANOVA with Dunn’s multiple comparisons 
post-hoc test. ***=p<0.001. Other significant changes between groups were omitted for 








Figure 5.20: Loss of SHH and gain of GLI2 expression is a hallmark of a subset of basal/squamous MIBC 
Unsupervised hierarchical clustering performed on RNAseq Log
2 
transformed expression of SHH and GLI2 in TCGA MIBC cohort (n=404). Clustering of 
tumours using the two genes divided the samples into a primarily luminal SHH-high group, a GLI2-high group consisting mostly of basal/squamous and 
stroma-rich tumours and a mixed population of tumours that expressed neither gene. The cluster of tumours that had absent expression of both genes 
was condensed for clarity. Samples were clustered using the one minus Spearman rank correlation method with complete linkage. A colour-coded tumour 




5.4.6.2 Mutation analysis of SHH pathway effector genes in MIBC  
Examination of the mutation status of SHH, PTCH1, GLI1 and GLI2 in TCGA MIBC 
cohort revealed a relatively low (non-synonymous) mutation rate for all four genes 
(Fig. 5.21). GLI2 was found to be the most commonly mutated gene in the pathway, 
with 4.1% of all tumours carrying a non-synonymous GLI2 somatic mutation. Co-
occurring mutations between SHH pathway genes were rare in MIBC samples, with 
2/412 tumours (sample # A54R and A9T8) displaying missense mutations in both 
SHH and GLI2 genes while a single tumour (A6AW) displayed both GLI1 and GLI2 
missense mutations. PTCH1 was found to be mutated in 3.9% of samples but was 
found to have no overlap with tumours that carried GLI2 mutations. A statistical 
test for co-occurrence of mutations in the cohort revealed a lack of a significantly 
associated relationship between any two genes, indicating that mutations in 
components of SHH signalling in MIBC, when present, was predominantly mutually 























Figure 5.21: PTCH1 and GLI2 are mutated in a mutually exclusive manner in MIBC 
Profile of genetic alterations and mutations in SHH, PTCH1, GLI1 and GLI2 genes in TCGA MIBC cohort. For clarity, only a proportion of the tumours in the 
cohort are displayed, with the remaining tumours expressing wild-type versions of all four genes. Mutation data and graphic were obtained from the 
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SHH PTCH1 12 21 0 375 <-3 0.526 
SHH GLI1 12 14 0 382 <-3 0.654 
SHH GLI2 10 17 2 379 2.157 0.103 
PTCH1 GLI1 20 13 1 374 0.525 0.529 
PTCH1 GLI2 21 19 0 368 <-3 0.358 
GLI1 GLI2 13 18 1 376 0.684 0.493 
 
Table 5.6: Co-occurrence ratio of SHH, PTCH1, GLI1 and GLI2 alterations in MIBC. 
The likelihood of two genes being altered in the same cancer sample (odds ratio) was 
calculated using the equation (A x B) / (C x D), where A= samples where both genes are 
altered; B= samples where gene 1 but not gene 2 is altered; C= samples where gene 2 but 
not gene 1 is altered and D= samples where neither gene is altered. The calculated Log2 
odds ratio was used as an indicator of whether the relationship between alterations in the 
two genes is mutually exclusive or co-occurring (a ratio of >2 indicates a tendency towards 
co-occurrence). A Fisher’s Exact Test was used to calculate the significance between gene 
relationships, with no significant relationship determined between any combinations of 
SHH pathway gene mutations. Information on the mutation status of TCGA MIBC samples 












5.4.6.3 Generation of a GLI2-high basal/squamous MIBC subset   
To verify that the high expression of GLI2 observed in a subset of basal/squamous 
tumours was not as a result of expression from contaminating infiltrating cell types, 
basal/squamous tumours were split based on transcript expression of desmin (DES) 
or CD45 (PTPRC), genes expressed exclusively by stromal or immunocyte cell types, 
respectively. Four of the six tumours with the highest expression of GLI2 in the 
subtype were classed as ‘DES-low’ tumours, while five of the six GLI2-high tumours 
had low PTPRC expression, with no significant difference in GLI2 expression 
observed between DES-low/PTPRC-low and DES-high/PTPRC-high groups (Fig. 
5.22A-B). Additional evidence of GLI2 overexpression in malignant urothelial cells 
was observed in a subset of bladder cancer cell lines grown (in the absence of 
stroma or immunocytes) in vitro, with bladder cancer lines overall observed to have 
significantly increased expression of GLI2 in comparison to NHU cells, regardless of 
whether the NHU cells were exposed to serum (Fig. 5.22C; p≤0.001). Of the thirty 
cell lines analysed, five (1A6, 253JP, J82, TCCSup and UM-UC-15) were found to 
express a similar amount of GLI2 to that found in the GLI2-high basal/squamous 
subset.  
The preceding analysis therefore suggested that overexpression of GLI2 could occur 
in the urothelial cells of basal/squamous MIBC, resulting in the creation of a ‘GLI2-
high basal/squamous’ subset group, consisting of the ten basal/squamous tumours 
with the highest GLI2 expression alongside two GLI2-high stroma-rich tumours 
which were most closely correlated with the basal/squamous classification centroid 
(Samples # AA6Q, A3IB, A3OS, A42Q, A3WC, AA4N, A871, AATQ, A1AE, A3IQ, A5RI 
and A5ZZ; Fig. 5.23).  Ten other stroma-rich tumours that most closely correlated 
with the basal/squamous centroid when compared to all other subtypes were 
combined with the remaining basal/squamous tumours to create the GLI2-low 













































Figure 5.22: GLI2 overexpression in a subset of basal/squamous MIBC and bladder 
cancer cell lines, independent of stromal or immune infiltration  
A-B) Basal/squamous MIBC samples (n=165) were separated based on their expression 
of stromal-specific gene DES (A) or immunocyte-specific gene PTPRC (B) and their 
expression of Log
2 
transformed GLI2 subsequently compared to normal urothelium in 
situ, with tumours with DES TPM values <40 (median DES TPM in subtype) or PTPRC 
TPM values <9.5 (median PTPRC TPM in subtype) designated as being ‘DES-low’ or 
‘PTPRC-low’, respectively. C) Log
2 
transformed expression of GLI2 in NHU cells in an 
undifferentiated or ABS/Ca
2+ 
differentiated state (n=28) compared to a cohort of 
bladder cancer cell lines (n=30). Significance between groups was determined by a 
Kruskal-Wallis ANOVA with Dunn’s multiple comparisons post-hoc test (A-B) or a Mann-



















Figure 5.23: Stratification of basal/squamous MIBC into GLI2-high and GLI2-low 
subsets 
Visualisation of unlogged GLI2 expression in samples of basal/squamous (n=153) and 
stroma-rich MIBC (with closest correlation to the basal/squamous centroid; n=12), 
with the bars representing the median and interquartile range values. The two 
sample sets were combined and split based on GLI2 expression into GLI2-high (n=12) 
and GLI2-low (n=153) basal/squamous tumour subsets, with the triangular icons 
representing GLI2-high samples and the circular icons representing GLI2-low 
samples. The 1.5 x interquartile range rule was applied to confirm that the GLI2 TPM 
values of each tumour in the GLI2-high basal/squamous subset were outliers of the 
overall pattern of distribution. 
336 
 
5.4.6.4 Mutation status of GLI2-high basal/squamous MIBC  
To predict what mutations were potentially contributing to the overexpression of 
GLI2 observed in the GLI2-high basal/squamous subset, analysis of the mutated 
genes inherent to these tumours was performed. GLI2 itself with not mutated in 
any of the tumours in the subset, while PTCH1 was the only SHH pathway gene 
found to be mutated, with a single missense mutation at the Q1285H site found in 
the A3IB sample. In total, 18 genes were found to be mutated in at least 3 of the 
tumours in the subset (25%), with TP53 found to be the most common alteration 
(7/12 tumours; Table 5.7). However, this gene was found to be mutated at the 
same frequency in both GLI2-high and GLI2-low basal/squamous groups. A binomial 
test was subsequently performed on each frequently mutated gene to determine 
whether any of the aforementioned genes were significantly overrepresented in 
the GLI2-high subset compared to the GLI2-low subset. Interestingly, key genes of 
the oxidative stress response KEAP1-NRF2 pathway were found to be mutated at a 
significantly higher frequency in the GLI2-high subtype when compared to both the 
GLI1-low subset (p ≤0.01) and the entire MIBC cohort, with 18.5% of all NFE2L2-
mutated tumours and 37.5% of all KEAP1-mutated tumours in TCGA cohort also 
found within the GLI2-high basal/squamous group.  
Analysis of the mutational signature of the 12 individual tumours comprising the 
GLI2-high basal/squamous subset revealed that the only mutation common to the 
two tumours with the highest expression of GLI2 (#AA6Q and #A42Q) was loss-of-
function mutations of CDKN2A (Table 5.8). Activating mutations in NFE2L2 and loss-
of-function mutations in KEAP1 were found to be mutually exclusive in the GLI2-
high subset, meaning that 8/12 tumours in the subset carried mutations that would 
be predicted to induce aberrant NRF2 activity. This analysis therefore identified the 



























TP53 58.3% 58.8% 47.9% 58.2% 0.2286 
KMT2D 50% 30.1% 28.3% 31.5% 0.0933 
NFE2L2 41.7% 7.8% 6.3% 10.2% 0.0041 
PIK3CA 33.3% 22.9% 22% 23.6% 0.1782 
KDM6A 33.3% 19% 25.9% 20% 0.1329 
CSMD3 33.3% 13.1% 13.8% 14.6% 0.0632 
OLFM3 33.3% 0.7% 2.4% 3% 0.0003 
TTN 33.3% 46.4% 47.2% 45.4% 0.1661 
ARID1A 25% 22.9% 24.5% 23.1% 0.2549 
CDKN2A 25% 7.8% 6.5% 9% 0.0686 
FAT1 25% 12.4% 12.3% 13% 0.1380 
KEAP1 25% 0.7% 1.7% 2% 0.0015 
MUC16 25% 25.5% 28.3% 25.4% 0.2579 
MYT1 25% 2% 2.2% 3.6% 0.0074 
NUP188 25% 3.9% 4.8%   5.4% 0.0210 
SCN1A 25% 3.9% 7% 5% 0.0173 
SF3B1 25% 4.6% 5.6% 7% 0.0393 
XIRP2 25% 11.1% 12.1% 12% 0.1277 
 
Table 5.7: Overrepresented mutations in GLI2-high basal/squamous MIBC tumours 
Point mutation data for the tumours in the GLI2-high basal/squamous subset (n=12) and 
the GLI2-high J82 bladder cancer cell line were collated to determine the most common 
mutations inherent to these tumours. A predicted mutation frequency for each gene (in a 
random selection of n=12 basal/squamous tumours) was calculated based on the 
frequency of mutations of the genes across all basal/squamous samples. A binomial test 
was performed to determine whether the observed mutation frequency of any of the 
genes enriched in the subset was statistically significant, with significant p values 
338 
 
highlighted in bold.  The percentage of somatic mutations present in TCGA cohort for each 
gene was obtained from cBioPortal (https://www.cbioportal.org/). 
 
 AA6Q A42Q A3IB A3OS A3WC AA4N A871 AATQ A1AE A3IQ A5RI A5ZZ 
TP53 X  X X X X     X X 
KMT2D   X  X X   X  X X 
NFE2L2 X  X     X X  X  
PIK3CA X    X X  X     
KDM6A       X  X  X  
CSMD3      X  X X X   
OLFM3     X  X  X  X  
TTN X    X    X X   
ARID1A       X  X   X 
CDKN2A X X  X         
FAT1 X    X     X   
KEAP1  X   X X       
MUC16 X  X        X  
MYT1 X    X       X 
NUP188 X    X       X 
SCN1A   X   X    X   
SF3B1       X  X   X 
XIRP2   X     X    X 
 
Table 5.8: Matrix of overrepresented mutations in the GLI2-high basal/squamous subset  
The 12 tumours of the GLI2-high basal/squamous subset were arranged in order of GLI2 
expression, with sample #AA6Q displaying the highest GLI2 TPM value and #A5ZZ displaying 






Investigation of underrepresented mutations in the GLI2-high basal/squamous 
subset revealed six genes commonly mutated in basal/squamous tumours that 
exhibited no mutations in any of the GLI2-high tumours, including tumour 
suppressor RB1 and ERBB2 (Table 5.9). However, none of the six genes examined 
















Table 5.9: Underrepresented mutations in GLI2-high basal/squamous MIBC tumours 
The most common point mutations in the basal/squamous MIBC group were collated to 
determine if any genes were not mutated in the GLI2-high basal/squamous subset (n=12). 
Only mutations found in at least 15% of the total basal/squamous group and none of the 



























FLG 0% 20.9% 16.5% 19.4% 0.0754 
RB1 0% 19.6% 17.4% 18.1% 0.0911 
EP300 0% 19% 15.3% 17.6% 0.0980 
HMCN1 0% 18.3% 18.4% 17% 0.1075 
AHNAK2 0% 17.6% 12.1% 16.3% 0.1179 
ERBB2 0% 17% 12.1% 15.8% 0.1277 
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5.4.6.5 Phenotype of GLI2-high basal/squamous MIBC  
Differential expression analysis of the GLI2-high versus GLI2-low basal/squamous 
subgroups revealed 389 genes that experienced an absolute log2 fold change in 
expression ≥ 2 and had a q value ≤0.001 when comparing the two groups (Fig. 
5.24A). Alongside GLI2, some of the most upregulated genes in the GLI2-high 
subtype included genes involved in inhibiting WNT pathway signalling, such as SOST 
(sclerostin) and WIF1 (WNT inhibitory factor 1); in addition to ATP-binding cassette 
transporters ABCC1 and ABCC6 (multidrug resistance protein 1 and 6, respectively). 
Genes that have previously been inferred to have NRF2 transcriptional binding sites 
in the GeneHancer database, such as ADH1C (alcohol dehydrogenase 1c) and 
GSTM2/GSTM3 (glutathione S-transferase mu 2 and 3, respectively) were found to 
be some of the most upregulated genes in the GLI2-high basal/squamous subset. 
Furthermore, the two downregulated genes with the smallest q values in the 
comparison were determined to be KEAP1 paralog KLHDC7B and its associated 
lncRNA U62317.1, granting further credence to the possibility that the KEAP1-NRF2 
pathway is dysregulated in the GLI2-high basal/squamous subset. Notable other 
examples of the most downregulated genes in the GLI2-high subset included genes 
involved in apoptosis (CASP14; caspase 14), immune cell recruitment (ACKR2; 
atypical chemokine receptor 2), suppression of metastasis (KISS1; kisspeptin) and 
several genes associated with a differentiated urothelial phenotype (VGLL1, PPARG, 
UPK2, UPK3B, KRT20). GSEA analysis of the differentially expressed genes 
supported these observations, as the analysis revealed a significant enrichment of 
genes associated with the reactive oxygen species (ROS) pathway and a suppression 
of various pathways involved in inflammatory responses in the GLI2-high subset 
(Fig. 5.24B). Overall, the preceding results potentially suggest that GLI2-high subset 
of basal/squamous tumours exhibit a less differentiated, more highly invasive and 
reduced chemo-sensitive phenotype than other basal/squamous tumours.  
Expression of previously identified neuroendocrine-like tumour markers SOX2, 
SOX21, ENO2, CHGA, CHGB, SYP, SGC2 and SCG3 were analysed to confirm that the 
GLI2-high basal/squamous subset did not exhibit features of the neuroendocrine-
like phenotype. Of these genes, only CHGA (chromogranin A) was found to be 
341 
 
altered between groups, with a log2 fold increase of 3.39 in the GLI2-high subtype. 
To confirm that the overexpression of GLI2 in this context was independent of the 
canonical SHH pathway, changes in expression of SHH, PTCH1, SMO, GLI1, GLI3 and 
HHIP were analysed. It was determined that none of the above genes experienced a 
significant change in expression when comparing GLI2-low and GLI2-high 
basal/squamous subsets.  
To determine whether the observed phenotype resulted in a reduced overall 
survival of GLI2-high tumours compared to other basal/squamous tumours, a 
Kaplan-Meier survival analysis was performed. Strikingly, 75% of GLI2-high patients 
had died within 18 months of diagnosis compared to 37% of GLI2-low patients. This 
resulted in a reduced median survival time and a significantly reduced overall 
survival of GLI2-high basal/squamous tumours when compared to GLI2-low 
















































Figure 5.24: GLI2–high Basal/Squamous tumours have significantly increased 
expression of NRF2 target genes  
A) Volcano plot of the most differentially expressed genes in GLI2-high basal/squamous 
tumours (n=12) in comparison to GLI2-low basal/squamous tumours (n=153). Genes that 
pass the criteria of having a q value ≤0.001 and a log
2
 fold change in expression ≥ 2 or ≤-2 
are represented as red dots. Notable genes that pass the criteria set above are 
highlighted on the plot. A complete list of genes with a q value ≤0.001 and a log
2
 fold 
change in expression ≥ 2 or ≤-2 can be found in Appendix xiv. B) GSEA analysis of 
signalling pathways that are differentially expressed between GLI2-high and GLI2-low 
basal/squamous subsets. Each pathway analysed is assigned a normalised enrichment 
score, with only pathways that have a significant q value ≤0.05 displayed. 
Figure 5.25: GLI2–high Basal/Squamous MIBC patients have  reduced overall survival 
Kaplan-Meier survival plot of the groups created by separating basal/squamous 
tumours into GLI2-high and GLI2-low subtypes. The Log-Rank (Mantel-Cox) test was 
used to determine significance between the overall survival of groups. Median survival 
time of GLI2-high basal/squamous subset (n=12) = 385 days, GLI2-low basal/squamous 




5.5.1 Canonical and non-canonical SHH pathway signalling in urothelium 
SHH-mediated paracrine signalling between the urothelium and stroma has 
previously been implicated in human (Jenkins et al., 2007) and mouse (Haraguchi et 
al., 2007; Shiroyanagi et al., 2007; Caubit et al., 2008; Cheng et al., 2008; Cao et al., 
2010; DeSouza et al., 2013) fetal bladder development, in addition to the regulation 
of tissue homeostasis (and subsequent inhibition of hyperplasia) in adult murine 
bladders (Shin et al., 2011; Shin et al., 2014a; Shin et al., 2014b). This study provides 
evidence that the same directional paracrine signalling relationship could also exist 
in adult human bladder through confirmation of expression (and targeted 
induction) of pathway components in urothelial and stromal cell types.  
5.5.1.1 In situ expression of SHH and PTCH1 in urothelium 
Urothelial-specific expression of SHH was validated through both transcriptomic 
analysis and a preliminary study of its protein localisation in native urothelium. Of 
the SHH pathway genes examined, SHH was the only gene that exhibited significant 
differential expression when comparing in situ urothelium of bladder and ureter 
derivation, or comparing expression in ureter-derived in situ urothelium to NHU 
cells. The urothelia of bladder and ureter are derived from separate embryological 
origins but have been confirmed to share striking similarities in morphology (Hicks, 
1965) and gene expression profile (Böck et al., 2014). A significantly higher 
expression of SHH in bladder urothelial cells may therefore indicate a tissue-specific 
differential response to signals received by the underlying stroma that could 
regulate SHH expression. Further examination of the potential differences in 
signalling phenotype of bladder and ureter-derived stromal cells are discussed in 
Section 5.5.3.2.   
A significant reduction in SHH expression in ABS/Ca2+ differentiated cells when 
compared to native urothelium would also seem to suggest that inductive factors 
from stromal or other cell types that are absent from the in vitro culture 
environment are important to induce expression of the gene. The SHH ligand 
undergoes a series of post-translational modifications such as palmitoylation and 
cholesterol binding to generate its mature, active N-terminal state (Porter et al., 
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1996b; Pepinsky et al., 1998). Palmitic acid is not a constituent component of 
KSFMc; thus highlighting a probable scenario where NHU cells are unable to 
correctly synthesise SHH without exogenous administration of the fatty acid, 
meaning its effect on urothelial phenotype (if any) is not normally observed in vitro.  
Aside from its expression in both native and in vitro cultured stromal cells, PTCH1 
was also found to be intensely expressed at the apical membrane of superficial 
ureter urothelium, indicative of a receptor that readily receives secreted molecules 
from the lumen. This raises the question of why urothelial cells would express 
PTCH1 if autocrine downstream pathway signalling (as mediated by SHH/PTCH1 
binding) is not found in this cell type. Due to its known status as a tumour 
suppressor gene in other cell types (Gailani et al., 1996), the function of PTCH1 in 
urothelial cells may therefore be to provide a constitutive inhibitor of SMO (and 
subsequent downstream GLI) activity. How urothelial-secreted SHH morphogen 
would fail to bind to urothelial PTCH1 to activate autocrine pathway signalling (yet 
is able to bind to PTCH1 receptor in the surrounding stroma) may result from a lack 
of PTCH1-presenting primary cilium organelle structures, although studies to 
confirm the absence of primary cilium in urothelium have not been undertaken.  
5.5.1.2 Non-canonical induction of GLI1 expression in undifferentiated NHU cells 
Expression of downstream pathway effector GLI1 has been described in urothelial 
cells in vitro in studies of MIBC cell lines T24, 5637 and VM-CUB-1 (Fei et al., 2012; 
Kitagawa et al., 2019), whilst an initial study into SHH signalling in undifferentiated 
NHU cells concluded that expression of downstream components of the pathway 
were present due to an increase in luciferase activity using a GLI-dependent 
promoter (Thievessen et al., 2005). Thievessen et al. speculated that expression of 
GLI1 may be a result of crosstalk with active signal transduction pathways, which 
was confirmed in this study through the inhibition of EGFR and/or PI3K/AKT (but 
not SMO) signalling, thereby implicating a non-canonical mechanism of pathway 
activation. PI3K/AKT pathway signalling has been implicated in the activation of 
non-canonical GLI signalling in other epithelial cell types (Zhou et al., 2016; Kasiri et 
al., 2017), with AKT postulated to mediate the inhibition of PKA-regulated GLI-A 
degradation and thus allowing for the induction of GLI1 (Riobo et al., 2006). Future 
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work with GLI1-expressing undifferentiated NHU cells treated with a GLI-specific 
inhibitor such as GANT61 (Lauth et al., 2007) may prove to elucidate the specific 
effect that GLI1 expression has on downstream EGFR and PI3K/AKT-mediated 
processes such as proliferation.   
5.5.2 Paracrine canonical SHH pathway activation in urothelial stroma 
Both bladder and ureter-derived stromal cells were demonstrated to not express 
SHH, yet possessed canonical, SMO-mediated SHH signalling responses following 
activation with natural (rSHH) and synthetic (SAG) agonists, as demonstrated by a 
significant increase in GLI1 transcript and a striking increase in nuclear protein 
expression.    
The specific rod-like expression pattern of PTCH1 in untreated, serum-starved NuHS 
cells observed in this study was speculated to indicate the localisation of PTCH1 to 
the primary cilium of these cells. In order to verify this, a dual-labelling 
immunofluorescence approach that visualises both PTCH1 and a marker of primary 
cilium, such as acetylated α-tubulin (Cambray-Deakin et al., 1987), would need to 
be performed. A study in NIH-3T3 fibroblast cells revealed that while Shh/Ptch1 
binding was required for Smo ciliary accumulation, the subsequent ejection of 
Ptch1 from the primary cilium is independent from the process of Smo activation 
(Kim et al., 2015b), perhaps explaining why the localisation of PTCH1 was not 
observed to have changed following 24h SAG treatment. A subsequent loss of 
PTCH1 labelling observed in GDC-0449 treated cells is likely to signify a breakdown 
of the existing PTCH1 protein following inhibition of its transcript.  
5.5.3 RNAseq analysis of SHH pathway-active stromal cells 
5.5.3.1 Troubleshooting data 
RNAseq analysis of SAG-treated NbHS and NuHS cells suggested that minimal 
consistent transcriptional changes occurred within the stromal cultures following 
agonist treatment, other than induction of GLI1. Some potential explanations for 
this observation are discussed below.  
One conclusion that could be made from the data is that GLI1 activation in 
NuHS/NbHS cells is inducible but has little effect on downstream signalling 
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processes, although the possibility that a fully functional signal transduction 
pathway exists in these cells but has no physiological relevance seems unlikely. 
Alternatively, the induction of GLI1-specific targets may optimally take place at a 
later time-point than the times in which the RNAseq samples were harvested, 
despite the relatively rapid induction of GLI1 protein observed in the nuclei of SAG-
treated NuHS cells. The most probable explanation however stems from the use of 
a NuHS/NbHS cell model that currently lacks clarity as to the identity of the specific 
cell types it contains.   
As demonstrated in previous studies of cultured stromal cells, isolation of NuHS 
cells from ureter-derived stromal explants results in a highly heterogeneous cell 
population that express markers specific to various stromal cell types (Kimuli et al., 
2004; Baker et al., 2008). Considering previous reports that demonstrated 
differential responses of mouse bladder mesenchymal cells to Shh signalling based 
on their stromal cell type (Cheng et al., 2008; DeSouza et al., 2013), it is therefore 
possible that a mixed population of adult human stromal cells would also possess a 
differential capability to respond to SHH pathway agonism. This would thus account 
for the large variation in GLI1 induction observed between stromal cell lines from 
different donors that contained, for example, a low ratio of lamina propria-
originating fibroblast cells in the total cell population.  
5.5.3.2 Candidate genes of GLI1-mediated transcription in NbHS cells  
GLI1-mediated transcriptional changes may also be tissue-specific, as demonstrated 
by notable fold change increases in expression of laminin genes LAMA3, LAMB3 and 
LAMC2 and laminin receptor ITGB4 (Integrin β4) in NbHS cells (n=1) only. A 
relationship between GLI1 activation and integrin β4 expression has previously 
been implicated in a model of ovarian cancer, where inhibition of GLI1 resulted in a 
significant reduction in ITGB4 expression in SK-OV-3 cells (Chen et al., 2014). 
Integrin proteins have known roles in regulating epithelial cell polarity (W. Yu et al., 
2005) and remodelling of the basement membrane following shear stress (Béguin 
et al., 2020), while low expression of integrin β4 has previously been implicated in 
the propensity for high-grade MIBC cell lines to exhibit a highly migratory 
phenotype when implanted into mouse bladder (Harabayashi et al., 1999). That 
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NbHS cells upregulate ITGB4 and various laminin genes in this context would 
suggest potentially fascinating implications for the role of canonical SHH signalling 
in the regulation of urothelial organisation, assembly of basement membrane and 
protection against a migratory, invasive phenotype in bladder, but this observation 
would need to be further validated in vitro.  
To conclude, one or more of the aforementioned variables may account for the 
overall lack of a consistent gene upregulation response observed in the pathway-
activated stromal transcriptome, but due to the potential importance of this 
signalling axis in human bladder, it would be worth further study.  
5.5.3.3 Human urothelial stromal cell data resource 
Beyond its original intended use, this RNAseq cohort is seemingly the first curation 
of a human bladder/ureter-derived stromal cell transcriptome dataset, and may 
therefore prove to be a valuable resource for use in future studies that examine 
bladder/ureter stromal cell phenotype. For example, analysis of expression of genes 
encompassing the FGF family of ligands in NuHS/NbHS cells revealed that FGF7 was 
the predominantly expressed FGF gene, exhibiting high expression in both control 
and treated samples. Fgf7 has previously been shown to be vital for the complete 
stratification of mouse urothelium (Tash et al., 2001), making it an ideal candidate 
ligand to study in regards to its effect on FGFR3 signalling, a receptor whose natural 
ligand in urothelium has yet to be identified.   
5.5.4 SHH pathway dysregulation in MIBC 
5.5.4.1 Abrogation of SHH expression in MIBC 
The pattern of gene expression of canonical SHH pathway components in MIBC 
supports the hypothesis that aberrant expression (i.e. an inhibition of SHH 
expression in all but luminal papillary MIBC) is indicative of a progression to a more 
aggressive and invasive disease state. A recent study by Kim et al. implicated 
hypermethylation of the CpG shore upstream of the Shh promoter as a potential 
causative factor behind the loss of Shh expression in high-grade murine MIBC. 
Inhibition of DNA methyltransferase activity using 5’-azacitidine was observed to 
halt the development of murine MIBC, a phenotype postulated to occur as a result 
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of reactivated Shh expression and a corresponding increase in stromal Gli activity 
(Kim et al., 2019b). Studies that have analysed the efficacy of treatments that target 
DNA methyltransferase activity in MIBC are currently limited (Dhawan et al., 2013; 
Wang et al., 2015), but may prove to be beneficial in tumours with aberrant SHH 
expression based on the current evidence.  
5.5.4.2 GLI2-high phenotype in basal/squamous MIBC 
The overexpression of previously absent GLI2 in a subset of basal/squamous 
tumours was unexpected, but provides a potentially interesting insight into the 
molecular basis behind a highly aggressive, poor survival phenotype. Examination of 
GLI2 expression in a cohort of MIBC cell lines previously determined that high basal 
expression of GLI2 in a cell line such as UM-UC-3 correlated with invasiveness 
(Mechlin et al., 2010). Mechlin et al. observed that this GLI2-high phenotype was 
neither correlated with high expression of canonical SHH pathway genes, or was 
amenable to treatment by inhibitors of autocrine SHH activity, yet were unable to 
identify a potential source of the GLI2 expression that they observed.  
Analysis of the GLI2-high basal/squamous subgroup revealed enriched mutations in 
both NFE2L2 and KEAP1 genes, alongside significantly increased expression of 
multiple NRF2-KEAP1 pathway target genes such as GSTM2, GSTM3, GCLC and 
ABCC1. In normal, unstressed cells, the transcription factor NRF2 is bound to the 
adapter protein KEAP1 which mediates its ubiquitination and continual degradation 
(Kobayashi et al., 2004). In response to endogenous or exogenous stresses such as 
reactive oxygen species or electrophiles, NRF2 is able to circumvent KEAP1 
inhibition and induce a battery of target genes involved in cellular detoxification 
(Itoh et al., 1997), thus implicating KEAP1-NRF2 signalling as a pivotal pathway in 
the oxidative stress response. Inactivating mutations to KEAP1 or activating 
mutations to NFE2L2 therefore induce aberrant NRF2 activity and result in cancers 
with a chemo-resistant phenotype (Shibata et al., 2008). Previous studies using 
mouse embryonic fibroblast cells have identified Gli2 as a Nrf2 transcriptional 
target (Malhotra et al., 2010; Martin-Hurtado et al., 2019), yet this is the first study 
to potentially identify such a signalling relationship in human cells. It is currently 
unclear as to the specific effect that the aberrant GLI2 expression observed in the 
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NRF2 pathway-active, GLI2-high subgroup is having on cell phenotype. However, a 
recent study that inhibited GLI2 in the GLI2-high MIBC cell lines UM-UC-3 and 253J-
BV demonstrated that these cells exhibited reduced viability and increased 
apoptosis, thereby providing evidence that expression of the protein in MIBC 
contributes to an anti-apoptotic phenotype (Raven et al., 2019). 
5.5.4.3 GLI2 expression in NHU cells 
Expression of GLI2 was undetectable in all NHU cell lines assayed, regardless of 
differentiation state. Currently unpublished work from the laboratory has identified 
a NRF2-mediated oxidative stress response in NHU cells treated with plant-derived 
antioxidant sulforaphane, with sulforaphane-treated cells exhibiting a higher 
viability to control when cultured in the presence of toxic unsaturated aldehyde 
acrolein. It would therefore be interesting to observe whether activation of NRF2 
signalling induces expression of previously absent GLI2 in normal urothelium, and if 
so, determine what effect that this activation has on NHU cell phenotype. A 
summary diagram of the potential mechanisms of non-canonical GLI1 and GLI2 
activation in urothelial cells is provided in Figure 5.26. 
5.5.5 Chapter conclusions 
To summarise, the findings in this chapter confirm that urothelial and stromal-
derived cells express the necessary components of the SHH pathway in order to 
participate in a directional paracrine signalling axis, with urothelium in situ 
expressing SHH and the underlying stromal cells expressing PTCH1 and GLI1, with 
transcript expression of both genes exhibiting a significant induction upon 
treatment of said cells with SHH pathway agonists. Analysis of proliferating, 
undifferentiated NHU cells revealed an induction of GLI1 expression through a non-
canonical mechanism, with PI3K/AKT signalling postulated to play a key role. 
Examination of MIBC tumours identified that a loss of SHH and a gain of previously 
absent GLI2 expression is indicative of a highly aggressive basal/squamous MIBC 
subtype that exhibits dysregulation of KEAP1-NRF2 signalling, a chemo-resistant 
phenotype and a poor survival rate.  
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Figure 5.26: Potential mechanisms of non-canonical GLI1 and GLI2 induction in 
urothelium 
Nuclear GLI1 was observed to be expressed in undifferentiated NHU cells, with this 
expression abrogated following blockade of EGFR and/or PI3K/AKT signalling. GLI2 was 
not found to be expressed by NHU cells in the observed contexts of this study, but a 
subset of basal/squamous MIBC tumours exhibited high expression of the gene 
following aberrant activation of NRF2 signalling. Outstanding questions include whether 
AKT-mediated expression of GLI1 is dependent on PKA inhibition and confirming if 
RAS/RAF/MEK/ERK signalling additionally plays a role in expression of the protein. 
Based on previous reports that demonstrated that active GSK3β contributes to GLI 
degradation (Price et al., 2002), it would be predicted that dephosphorylation of GSK3β 
following PD153035 treatment (Georgopoulos et al., 2014) would additionally influence 
expression of GLI1 in NHU cells, although this hypothesis was not tested. Confirmation 
of GLI2 expression in NHU cells with activated NRF2 signalling and elucidation of its 
specific downstream target genes would help to reveal its potential role in mediating 




5.6 Summary of results   
 Urothelial cells expressed the necessary components of the SHH pathway 
(SHH, PTCH1) to both produce and receive a SHH signal, but had absent 
expression of downstream components of the pathway (GLI1, GLI2), 
suggesting that this cell type does not participate in autocrine SHH 
signalling.  
 
 Ureter and bladder-derived stromal cells did not express SHH but were both 
found to induce PTCH1 and GLI1 expression upon treatment with SHH 
pathway agonists, implicating this cell type as a receiver of SHH ligand as 
part of a paracrine signalling loop. However, treatment of stromal cells with 
SAG resulted in no significant alterations to global gene expression other 
than GLI1.  
 
 Despite being absent in urothelium in situ, expression of GLI1 was 
upregulated in undifferentiated NHU cells. Treatment of NHU cells with 
agonists and antagonists of canonical SHH signalling had no effect on the 
expression of GLI1, suggesting that this occurrence was a result of non-
canonical, SMO-independent GLI activation. Expression of this gene was 
instead found to be modulated through inhibition of both EGFR and 
PI3K/AKT signalling axes.  
 
 
 Cases of MIBC were found to exhibit reduced expression of SHH and PTCH1 
in comparison to normal urothelium, but mutations in the genes was 
relatively rare. A subset of the highly aggressive basal/squamous tumours 
were found to exhibit SHH-independent overexpression of GLI2, which 
resulted a downregulation of genes associated with differentiation, an 
upregulation of genes involved in anti-chemosensitivity and a reduced 
overall survival rate. This subgroup may arise through mutations in key 





6.1 Thesis overview   
This thesis has provided the first evidence that VGLL1, a previously unstudied 
transcriptional co-activator in urothelium, is an important protein in the regulation 
of urothelial tissue homeostasis. This function does not appear to arise through a 
traditional Hippo pathway role of inhibition of proliferation/migration-associated 
YAP/TAZ signalling, as initially hypothesised following a review of previous studies 
that examined the role of VGLL1 in other human tissues (Section 3.1.3). Instead, 
this study has demonstrated that expression of VGLL1 serves to inhibit cellular 
proliferation in both undifferentiated NHU and T24 cells, whilst helping to maintain 
a mitotically-quiescent phenotype once NHU cells have entered a late 
differentiation state. When differentiated urothelial tissues are wounded, evidence 
in this study suggests that VGLL1 plays an important role in regulating both the 
initial wound healing response and controlling the proportion of cells that re-enter 
the cell cycle to repopulate the damaged tissue. Analysis of a publically-available 
MIBC cohort resource determined that overexpression of the gene in a subset of 
tumours was potentially as a consequence of inactivating mutations to the 
chromatin remodelling gene ARID1A and related processes. MIBC tumours that 
exhibited VGLL1 overexpression expressed genes involved in anti-apoptotic 
processes and exhibited a poor survival rate, indicative of a loss of normal VGLL1 
function.   
Additionally, this study has also confirmed the capability of adult human urothelium 
and stroma to communicate via a paracrine SHH signalling axis, as hypothesised 
based on previous studies that demonstrated the same axis in adult murine and 
developing human bladders (Section 5.1.4). A loss of SHH expression observed in a 
majority of MIBC tumours not subtyped as luminal papillary was suggestive of an 
abrogation of this signalling in high-grade MIBC.  In an undifferentiated state, NHU 
cells were demonstrated to induce expression of GLI1 through a SHH/PTCH1/SMO-
independent, PI3K-AKT-mediated non-canonical mechanism. This activation of GLI1 
appears to be independent of GLI2, a gene not found to be expressed in NHU cells 
in any contexts studied here. However, GLI2 was discovered to be aberrantly 
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expressed in a subset of basal/squamous MIBC, potentially as a novel target gene of 
KEAP1-NRF2 signalling dysregulation.    
Collectively, the evidence provided in this thesis has successfully achieved the initial 
aim of this study, which was to understand how Hippo and SHH signalling, two 
previously little-studied pathways in adult human normal urothelium, affected 
urothelial tissue physiology through regulation of individual cell phenotype.   
6.2 Use of experimental urothelial models    
The unique, specialised function of the urothelium is an ideal cell type to investigate 
the mechanisms of tissue homeostasis due to its innate plasticity to rapidly switch 
between a mitotically-quiescent and a wound-healing migratory phenotype in vivo 
(Levi et al., 1969; Lavelle et al., 2002). This phenotype is recapitulated in vitro, as 
demonstrated by the functional differentiation and ability to self-repair exhibited 
by ABS/Ca2+ differentiated NHU cells (Cross et al., 2005; Fleming et al., 2012), a cell 
state that confers a morphology and protein expression profile comparable to that 
found in urothelium in situ (Cross et al., 2005; Smith et al., 2015). Use of non-
transformed NHU cells in a differentiated (by two independent methods), 
regenerating or actively proliferating undifferentiated state thus granted an 
extensive in vitro resource in which to investigate context-specific alterations to 
phenotype. This, allied with in silico analysis of normal and malignant urothelial 
phenotype through the use of both published (Fishwick et al., 2017; The Cancer 
Genome Atlas Research Network, 2014) and as-of-yet unpublished RNAseq 
datasets, therefore allowed for a more holistic inference of the role of signalling 
pathways in urothelial tissue homeostasis than can be achieved when studying 
immortalised or established cancer-derived cell lines (that have by definition 
evaded tissue regulatory mechanisms), or tissue types with a constitutive turnover 
rate.  
As previously stated, the comparative cell types of the human bladder and ureter 
exhibit extensive similarities in morphology and transcriptomic profiles (Hicks, 
1965; Böck et al., 2014). However, as the bladder and ureter arise from two 
separate embryological derivations, this inevitably results in subtle differences 
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between the tissues of the two organs, as demonstrated by the results collated in 
Chapter 5. Due to the logistical difficulties involved in acquiring normal human 
bladder tissue, all NHU cell lines used in this thesis (aside from select bladder NHU 
cell lines that were processed for RNAseq analysis) were derived from ureter. It 
would therefore be of great interest, if possible, to directly compare the 
phenotypes of bladder and ureter-derived NHU cells in regards to the observations 
made on VGLL1 function in this study, in a manner similar to the comparisons 
performed between NuHS and NbHS cells in Chapter 5. This approach would also 
potentially grant a further insight into the predicted mechanisms behind the 
dysregulation of VGLL1-high MIBC, a disease that overwhelmingly arises in bladder 
urothelium (Siegel et al., 2019). 
 A key assay used in this study that facilitated inferences about the phenotype of 
proteins in certain physiological contexts (particular following urothelial scratch 
wounding) was immunofluorescence labelling. While this technique was imperative 
in establishing the predicted function and potential relationship to other proteins 
that VGLL1 possesses in differentiated NHU cells, these conclusions were often 
based on the subjective interpretation of single, representative, high magnification 
immunofluorescence images from each cell line/condition. Quantification of the 
aforementioned immunofluorescence labelling using established image analysis 
methodology (referenced below) would therefore strengthen the conclusions made 
in this study. Examples of this would include the quantification of VGLL1, p63 and p-
SMAD3 nuclear positivity (using a macro similar to that performed on Ki67/MCM2 
labelled images in Figures 3.38 and 3.43), a quantification of the mean nuclear-to-
cytoplasmic ratio of YAP and PPARγ expression (as demonstrated by Grune et al., 
2018), or a comparison of the number of dissolved layers of ZO-3 at the wound 
edge of scratched urothelial cultures (using an analysis similar to that described by 




6.3 Hippo pathway regulation of YAP/TAZ signalling   
6.3.1 Relationship of VGLL1 to YAP/TAZ 
Analysis of YAP activity and induction of downstream gene targets in NHU and MIBC 
cell lines with modified VGLL1 expression revealed little to suggest that VGLL1 
functions in an antagonistic capacity to YAP/TAZ, inconsistent with reports of VGLL1 
function in other human cell types (Pobbati et al., 2012). Four reasons supporting 
this conclusion on VGLL1 function are detailed below. 
1. Preferential binding of VGLL1 and YAP/TAZ to different TEAD proteins in 
urothelium 
Transcriptomic analysis of TEAD transcription factors in normal urothelium revealed 
that TEAD1 and TEAD3 were the predominantly expressed TEAD family members in 
this cell type, while principal component analysis of Hippo pathway components in 
MIBC revealed striking associations of VGLL1 (TEAD3) and YAP1 and YAP 
downstream target genes (TEAD1) to different TEAD genes. Human TEAD1 protein 
has previously been demonstrated to bind to Vg and substitute for Sd function 
when expressed in Drosophila (Deshpande et al., 1997), while the core VxxHF TEAD 
binding motif is retained in all four VGLL proteins (Pobbati et al., 2012). The 
evolutionary divergence from a single Vg and Sd protein in Drosophila to four VGLL 
and TEAD proteins in mammals does however raise the question as to the level of 
functional redundancy that may or may not exist between the various VGLL and 
TEAD proteins. Does mammalian VGLL1 possess a similar binding affinity to each of 
the four TEAD proteins? A recent study undertaken using a synthetic peptide 
derived from mouse Vgll1 suggests this to be true (Bokhovchuk et al., 2019), but a 
comprehensive interrogation of whether preferential binding of human VGLL1 to a 
specific TEAD is dependent on tissue specificity or a cell signalling-specific context 
has yet to be performed.  
2. Lack of effect on YAP/TAZ-mediated activity in urothelial cells with 
manipulated VGLL1 expression 
Overexpression of VGLL1 had no effect on the amount of inactive, phosphorylated 
YAP in NHU cells, which appeared consistent between undifferentiated and 
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differentiated cell states. Knockdown of VGLL1 was observed to have no effect on 
the nuclear:cytoplasmic ratio of total YAP in wounded differentiated cells. 
Subsequent validation of the aforementioned observations in MIBC cell lines 5637, 
T24 and ScaBer revealed that these cells additionally did not exhibit changes to YAP 
activation, localisation or expression of commonly cited YAP/TAZ target genes.  
3. VGLL4-specific inhibitory function of YAP/TAZ signalling? 
Various studies have implicated mammalian VGLL4 as having a direct role in 
inhibiting YAP/TAZ signalling through competitive binding to TEAD1 (Zhang et al., 
2017), TEAD2 (Koontz et al., 2013) or TEAD4 (Jiao et al., 2014). However, unique to 
the structure of VGLL4 compared to other members of the VGLL family is a second 
VxxHF TEAD binding domain (Chen et al., 2004). This second binding domain was 
demonstrated to be vital for VGLL4-mediated inhibition of downstream YAP/TAZ 
target genes (Zhang et al., 2017), thus perhaps offering an additional explanation as 
to why the forced expression of VGLL1 in urothelial cells fails to confer a similar 
effect.   
 
4. Lack of evidence for role of VGLL1 in YAP/TAZ competitive inhibition in other 
cell models 
Currently the only evidence for the existence of VGLL1 and YAP mutual antagonism 
was obtained from a transformed human cell model by Pobbati et al. Through site-
directed mutagenesis of H44 and F45 in the VxxHF region of VGLL1, Pobbati et al. 
demonstrated a significant reduction in the amount of co-immunoprecipitated 
VGLL1 to TEAD4 in HEK293 cells, confirming the ability of the transcription factor 
and transcriptional co-activator to bind to one another. However, the study claims 
that a 55% reduction in YAP/TEAD4 co-immunoprecipitation is observed when 
VGLL1 is overexpressed in the HEK293 cell line, which appears to be an exaggerated 
figure based on the accompanying immunoblot image displayed. Furthermore, this 
observation is not validated in the prostate cancer cell lines PC-3 and LnCAP, with 
the increase in anchorage-independent cell proliferation observed in said lines 
following VGLL1 overexpression offering little conclusive evidence to support the 
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main stated conclusion of the study that VGLL1 directly antagonises YAP/TEAD 
binding (Pobbati et al., 2012). 
Through the evidence provided in this thesis, it can be thus be concluded that there 
is an overall lack of compelling evidence for the assumed role of VGLL1 in Hippo 
pathway signalling, as defined as a restriction of tissue growth through the 
inhibition of YAP/TAZ signalling.  
6.3.2 Phenotype of YAP/TAZ in urothelium 
While seemingly unrelated to VGLL1 activity in urothelium, experimental evidence 
in this study suggested a shift in the proportion of nuclear and cytoplasmic YAP in 
NHU cells that was sensitive to both inhibition of autocrine EGFR signalling and cell-
cell contact. Expression of YAP/TAZ target genes AXL and CYR61 were additionally 
found to be significantly downregulated in differentiated NHU cells when compared 
to their matched sub-confluent, undifferentiated state. Investigation into the role 
that YAP/TAZ plays in the urothelial tissue homeostatic phenotype may therefore 
warrant its own separate study. Genomic analysis of a pan-cancer cohort revealed 
that cases of MIBC collectively exhibited one of the highest copy number 
amplification frequencies of YAP1/WWTR1 in human cancer (Wang et al., 2018). 
Use of the benzoporphyrin derivative verteporfin has previously been shown to 
block the interaction between YAP/TAZ and TEAD and thus inhibit YAP/TAZ-
mediated signalling (Liu-Chittenden et al., 2012), with this drug later demonstrated 
to successfully inhibit the proliferation of MIBC cell lines 5637 and UM-UC-3 (Dong 
et al., 2018). Treatment of proliferating and/or regenerating NHU cells with 
verteporfin or YAP siRNA could therefore help to elucidate the role that activation 
of YAP/TAZ signalling (independent of VGLL1) plays in regulating tissue homeostasis 
in normal urothelium, and provide a greater understanding as to whether aberrant 




6.4 Concluding remarks and future work 
6.4.1 Hippo pathway signalling and VGLL1 
In this study the predicted transcriptional co-activator VGLL1 was identified as 
being associated to differentiation in NHU cells and as such, was designated as a 
candidate regulator of Hippo signalling in urothelium. VGLL1 expression was found 
to be induced in NHU cells following differentiation, contact inhibition, formation of 
E-cadherin-mediated cell-cell adherens junctions and/or blockade of the 
EGFR/RAS/RAF/MEK/ERK signalling axis. Genetic manipulation of VGLL1 revealed a 
likely role for the protein in the maintenance of urothelial tissue homeostasis, as 
knockdown of the gene resulted in reduced barrier tightness, inhibition of 
differentiation-associated proteins and increased re-entry into the cell cycle in 
differentiated NHU cells following scratch wounding. Conversely, overexpression of 
VGLL1 in undifferentiated NHU cells and T24 cells resulted in cell cycle arrest and an 
inhibition of proliferation in a YAP/TAZ signalling-independent mechanism. In MIBC, 
the VGLL1 gene was not mutated and expression was retained in a majority of 
cases, although specific subgroups of tumours that exhibited a complete loss or 
overexpression of the gene were observed. Examination of the VGLL1-high subtype 
of MIBC revealed an enrichment of ARID1A mutations and a patient group that 
exhibited a significantly increased mortality rate, indicative of a physiological 
redundancy of VGLL1 function and a dysregulation of its expression in these 
tumours. 
The cumulative observations made of VGLL1 in urothelial cells in this study have led 
to the following hypothesis as to its function in urothelium, as depicted in Figure 
6.1. The evidence collated collectively points to a potential binding relationship 
between VGLL1 and the transcription factor TEAD3. Co-immunoprecipitation 
and/or proximity ligation assay studies would confirm binding between the two 
proteins, whilst Chromatin Immunopreciptation sequencing of TEAD3-bound DNA 
sequences in control versus VGLL1 knockdown differentiated NHU cells would 
provide a comprehensive list of genes upregulated through this interaction. In 
differentiated urothelium, a reduction or inhibition of VGLL1/TEAD3-mediated 
transcriptional targets such as PAR6 and PLEKHG6 results in the production of a 
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faulty tissue barrier, thus accounting for the weaker barrier tightness observed in 
VGLL1 knockdown cells. PAR6 and PLEKHG6-associated RHOA signalling has 
additionally been implicated in the TGFβR-mediated dissolution of tight junctions 
that occurs following wounding, meaning that reduced expression of these proteins 
results in dysregulated TGFβR signalling and an impaired wound response. Loss of 
genes transcribed through VGLL1 transcriptional co-activity subsequently cause an 
increase in p-AKT activity and a loss of control regarding re-entry into the cell cycle. 
To verify the preliminary link established in this study between VGLL1 and a 
negative regulation of PI3K/AKT signalling, further NHU cell lines would be 
transduced with VGLL1 overexpression constructs to confirm this phenomenon. In 
differentiated urothelium, ARID1A functions to allow access of the VGLL1/TEAD3 
transcriptional complex to specific regions of the DNA, possibly through direct 
binding to the complex. To test this phenotype in vitro, Rapid Immunoprecipitation 
Mass spectrometry of Endogenous proteins would be performed to confirm the 
presence or absence of bound ARID1A to VGLL1/TEAD3 in NHU cells, followed by 
observing cell phenotype in cells with manipulated (through either site-directed 
mutagenesis or shRNA knockdown) ARID1A. Analysis of the viability of HT1376 and 
HT1197 cells following treatment with inhibitors against PI3K/AKT, HDAC, FGFR3 
and ATR would thus identify potentially viable treatment options  against the 
















Figure 6.1: Proposed mechanisms of VGLL1 function in urothelium 
A revision of the diagram presented in Figure 3.44, with opaque icons designating genes 
and/or proteins that were further investigated through in vitro or in silico analysis in 
Chapter 4. In a similar manner to undifferentiated NHU cells, forced expression of VGLL1 
in T24 cells resulted in G0/G1 cell cycle arrest and an inhibition of phosphorylated AKT 
(1), a signalling pathway that is potentially activated in EGFR-blockaded NHU cells 
through FGFR3 signalling (2). In differentiated urothelium, VGLL1 is predicted to bind to 
constitutively expressed TEAD3, with the VGLL1/TEAD3 transcriptional complex possibly 
requiring wild-type function of the ARID1A-containing SWI/SNF complex in order to 
access target gene promoter regions (3). Expression of VGLL1/TEAD3 target genes, 
potential examples of which being PARD6B, PLEKHG6 and CGN (4), help to maintain a 
quiescent phenotype and tight barrier in unwounded cells, but are also required to 
indirectly regulate AKT inhibition and mediate phosphorylation of SMAD3 upon TGFβR 
heterodimerisation (5), as predicted through their previously analysed functions in other 
cell types. Activation of SMAD3 in wounded urothelium subsequently results in a 
dissolution of tight junctions, effective wound repair and subsequent return to 
quiescence. Manipulation of VGLL1 was consistently observed to have no effect on YAP 





6.4.2 SHH pathway signalling 
Urothelium in situ and differentiated NHU cells were found to express SHH but not 
downstream pathway activators GLI1 or GLI2, suggesting that the human 
urothelium does not participate in canonical, autocrine SHH signalling but instead 
potentially participates in a paracrine signalling relationship with a surrounding cell 
type. Cultured NuHS/NbHS cells were confirmed to engage in canonical SHH 
pathway activation following treatment with both natural and synthetic agonists of 
the pathway, yet determination of the GLI1-specific target genes expressed by 
stromal cells following treatment was inconclusive. A group of tumours from the 
highly aggressive basal/squamous subtype (in addition to basal/squamous MIBC cell 
lines) exhibited an inhibition of SHH expression but increased expression of 
previously undetectable GLI2, with this subgroup marked by aberrant activation of 
genes associated with NRF2 signalling and a significantly decreased survival rate 
compared to other basal/squamous tumours.  
To interrogate the reasoning behind a lack of a reproducible GLI1-mediated 
response in stromal cells, a more comprehensive characterisation of NuHS/NbHS 
cell population identity would be performed. Separation of NuHS/NbHS cells into 
different populations (i.e. lamina propria and smooth muscle-derived cells) by 
immunoisolation using specific cell surface antigens would elucidate whether the 
different stromal subtypes exhibited differential responses to SAG treatment. Once 
a highly SAG-responsive cell population was identified, single-cell RNAseq of 
samples would be performed to identify whether specific stromal subtypes exhibit a 
consistent GLI1-mediated gene expression profile. Exogenous administration (or 
manipulation of) identified candidate proteins from the RNAseq analysis on NHU 
cells would subsequently be performed to determine whether said molecules affect 
in vitro urothelial cell phenotype in processes such as differentiation and wound 
repair. To examine the role of the potential NRF2-mediated GLI2 induction in 
normal urothelium, the ability of sulforaphane-treated NHU cells to survive 






Appendix i: List of suppliers 
Company name Company website 
Abcam https://www.abcam.com/  
Agilent Technologies https://www.agilent.com/  
American Type Culture Collection https://www.atcc.org/  
Atlas Antibodies https://www.atlasantibodies.com/  
BD Bioscience https://www.bdbiosciences.com/  
BioIVT https://bioivt.com/  
Bioline https://www.bioline.com/  
Bio-Rad https://www.bio-rad.com/  
Cambridge Bioscience https://www.bioscience.co.uk/  
Cayman Chemical https://www.caymanchem.com/  
Cellpath https://www.cellpath.com/ 
Cell Guidance Systems https://www.cellgs.com/  
Cell Signalling Technology https://www.cellsignal.co.uk/  
Developmental Studies Hybridoma 
Bank 
https://dshb.biology.uiowa.edu/  
Eurofins Genomics https://www.eurofinsgenomics.eu/  
Formedium https://www.formedium.com/ 
Fisher Scientific https://www.fishersci.co.uk/  
Greiner https://www.gbo.com/  
Hendley Essex http://www.hendley-essex.com/  
Leica Biosystems https://www.leicabiosystems.com/  
Li-Cor https://www.licor.com/  
Melford Laboratories https://www.melford.co.uk/  
Merck Milipore https://www.merckmillipore.com/  
nanoAnalytics https://www.nanoanalytics.com/  
New England Biolabs https://www.neb.uk.com/  
Novus Biologicals https://www.novusbio.com/  
Olympus https://www.olympus-lifescience.com/ 
PanReac Applichem https://www.itwreagents.com/  
Promega https://www.promega.co.uk/  
Proteintech https://www.ptglab.com/  
Qiagen https://www.qiagen.com/  
R&D Systems https://www.rndsystems.com/  
Rockland https://rockland-inc.com/  
Santa Cruz Biotechnology https://www.scbt.com/  
Sarstedt https://www.sarstedt.com/  
Selleck Chemicals https://www.selleckchem.com/  
Sigma-Aldrich https://www.sigmaaldrich.com/  
Takara Bio https://www.takarabio.com/ 
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Thermo Fisher https://www.thermofisher.com/  
Tocris https://www.tocris.com/  
Vector Laboratories https://vectorlabs.com/  
VWR https://uk.vwr.com/  
 






























 10x PBS tablets (Thermo Fisher; pH 7.3)/L dH2O. Solution was autoclaved 
prior to storage at ambient temperature.  
TBS 
  1.21 g (10 mM) Tris-HCl (pH 7.6) and 8.18 g (140 mM) NaCl in 1 L dH2O, with 
final solution equilibrated to pH 7.4.  0.1% Tween-20 was added to 1 L TBS 
to make TBST (pH 7.4). Both solutions were stored at ambient temperature. 
Tissue culture solutions 
EDTA 
 0.1% (w/v) EDTA in PBS. Solution was autoclaved before storage at ambient 
temperature. 
Transport medium  
 500 mL Hank’s Balanced Salt Solution (Thermo Fisher; contains Ca2+/Mg2+) 
containing 10 mM HEPES (pH 7.6) and 20 kallikrein inactivating units 
(KIU)/mL Aprotinin (Sigma-Aldrich). Solution stored at 4 oC.  
10% (v/v) formalin 
 100 mL 10% Richard-Allan Scientific™ Neutral Buffered Formalin (Thermo 
Fisher) in 900 mL PBSc (PBS + 0.5 mM MgCl2 + 0.9 mM CaCl2). Solution 
stored at ambient temperature. 
Stripper medium  







 Collagenase (Sigma-Aldrich) diluted to a working concentration of 100 U/mL 
in transport medium. Solution filter sterilised into 5 mL aliquots and frozen 
at -20 oC.  
TV 
 10% trypsin (Sigma-Aldrich; isolated from porcine pancreas) and 2% (w/v) 
EDTA in Hank’s Balanced Salt Solution. Solution was kept in 5 mL aliquots 
and stored at -20 oC. 
Trypsin inhibitor 
 100 mg tryspin inhibitor (Sigma-Aldrich; derived from soybean) in 5 mL PBS. 
Solution was filter sterilised into 100 µL aliquots and stored at -20 oC. 
Enterokinase buffer 
 2.5 mL 1 M Tris-HCl (pH 8.0), 3.3 mL 3 M NaCl, 100 µL 1 M CaCl2 and 0.1% 
Tween-20 made up to 50 mL in sterile dH2O. Buffer stored at 4 
oC. 
Molecular biology solutions 
10x TBE buffer 
 108 g Tris, 55 g boric acid and 20 mL 1 M EDTA made up in 1 L dH2O and 
stored at ambient temperature. Further 1:10 dilution in dH2O makes 
working 1x solution.   
Lysogeny broth (LB) medium 
 10 g bacto-tryptone, 10 g NaCl and 5 g yeast extract made up in 1 L dH2O 
(pH 7.0). Medium aliquotted into glass bottles and autoclaved immediately 
following generation and stored at ambient temperature.  
LB agar 
 1 L LB medium supplemented with 15 g agar. Solution aliquotted into glass 
bottles, autoclaved and stored at ambient temperature. Before use, the 
solid LB agar was melted in the microwave and poured into plastic Petri 
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dishes (under aseptic conditions) before allowing solution to solidify. Agar-
containing Petri dishes were stored at 4 oC for up to a month.  
 
Histology solutions 
Citric Acid Buffer pH 6.0 
 2.4 g citric acid (10 mM) in 1050 mL dH2O, pH adjusted to 6.0 using NaOH. 
Solution kept at ambient temperature. 
Immunoblotting solutions 
SDS sample buffer 
 10 mL glycerol (20% v/v), 6.25 mL 125 mM Tris-HCl (pH 6.8), 1 g SDS (2% 
w/v), 0.446 g Na4P2O7, 0.42 g NaF and 18.4 mg Na3PO4 made up to 50 mL in 
dH2O. Solution was mixed vigorously before aliquotting into 1.5 mL 
microfuge tubes and stored at -20 oC. 
Transfer buffer 
 1.45 g (12mM) Tris, 7.2 g (96mM) glycine and 200 mL methanol made up to 
1 L in dH2O. Solution made at time of use and stored on ice.   
Ponceau Red 











Appendix iii: List of patient samples 




Sex Operation Date 
Y499 Bladder Urothelial 3 Unknown Ureteric 
reimplantation 
27/01/2004 
Y499 Ureter Urothelial 3 Unknown Ureteric 
reimplantation 
27/01/2004 
Y719 Bladder Urothelial Unknown Unknown Unknown 25/01/2006 
Y719 Ureter Urothelial Unknown Unknown Unknown 25/01/2006 
Y732 Bladder NbHS 38 M Nephrectomy  23/02/2006 
Y781 Bladder NbHS 65 M Radical 
prostaectomy  
Unknown 
Y815 Bladder Urothelial Unknown Unknown Ureteric 
reimplantation 
06/09/2006 
Y815 Ureter Urothelial Unknown Unknown Ureteric 
reimplantation 
06/09/2006 
Y836 Bladder Urothelial 10 M Ureteric 
reimplantation 
01/11/2006 





NuHS 9 Unknown Pyeloplasty 23/05/2007 
Y879 Bladder NbHS Paediatric Unknown Unknown 05/06/2007 




Y896 Ureter NHU 74 F Nephrectomy  14/08/2007 
Y919 Ureter NuHS 67 M Nephrectomy  08/01/2008 
Y929 Bladder NbHS Paediatric Unknown Ureteric 
reimplantation 
15/04/2008 
Y929 Ureter Urothelial Paediatric Unknown Ureteric 
reimplantation 
15/04/2008 
Y929 Ureter NuHS Paediatric Unknown Ureteric 
reimplantation 
15/04/2008 
Y967 Ureter NHU Unknown Unknown Pyeloplasty 05/03/2009 
Y1026 Ureter NHU 38 M Unknown 10/10/2009 
Y1027 Ureter NuHS 54 F Unknown 10/10/2009 
Y1077 Ureter NHU 76 M Nephrectomy  29/10/2010 
Y1108 Ureter NHU 57 M Nephrectomy  15/03/2011 
Y1171 Ureter Urothelium 
in situ 
67 M Unknown 10/10/2011 
Y1174 Ureter Urothelium 
in situ 
49 F Nephrectomy  25/10/2011 
Y1178 Ureter Urothelium 
in situ 
57 F Nephrectomy  02/11/2011 
Y1192 Ureter NHU 27 M Nephrectomy  20/02/2012 
Y1214 Ureter NHU 76 F Nephrectomy  23/05/2012 
Y1226 Ureter NHU 78 M Nephrectomy  26/07/2012 
Y1237 Ureter NHU 73 M Nephrectomy  22/10/2012 
















Y1588 Ureter  57 F Renal 
transplant 
06/11/2014 
Y1601 Ureter  22 Unknown Renal 
transplant 
19/11/2014 
Y1651 Ureter  Unknown Unknown Unknown 21/01/2015 
Y1652 Ureter NHU 0 M Renal 
transplant 
23/01/2015 
Y1696 Ureter NHU 63 M Nephrectomy 25/03/2015 
Y1756 Ureter NHU 42 M Nephrectomy 03/07/2015 
Y1811 Ureter NHU 66 F Renal 
transplant 
14/10/2015 
Y1837 Ureter NHU 54 F Renal 
transplant 
13/11/2015 
Y1858 Ureter NHU 72 F Nephrectomy 04/01/2016 
Y1866 Ureter NHU 23 F Renal 
transplant 
29/01/2016 
Y1870 Ureter IHC 0 F Nephrectomy 03/02/2016 
Y1897 Ureter NHU 66 Unknown Lap 
nephrectomy 
10/03/2016 
Y1898 Ureter NHU 65 Unknown Renal 
transplant 
16/03/2016 
Y1914 Ureter NHU 61 F Nephrectomy 20/04/2016 
Y1946 Ureter NHU 37 M Nephrectomy 09/06/2016 
Y1947 Ureter NHU 90 F Nephrectomy 15/06/2016 
Y2055 Ureter NHU 42 F Renal 
transplant 
07/12/2016 
Y2145 Ureter NHU 58 M Nephrectomy 16/05/2017 
Y2167 Ureter NHU 58 M Renal 
transplant 
05/07/2017 
Y2303 Ureter NHU 50 F Transplant 07/03/2018 
Y2318 Ureter NHU Unknown M Pyeloplasty 24/03/2018 
Y2324 Ureter NHU 76 F Nephrectomy 28/03/2018 
Y2340 Bladder Urothelium 
in situ 
66 F Cystoscopy 17/04/2018 
Y2351 Ureter NHU Unknown M Transplant 27/04/2018 
Y2361 Bladder Urothelium 
in situ 
Unknown F Cystoscopy 11/05/2018 
Y2366 Bladder Urothelium 
in situ 
73 F Cystoscopy 15/05/2018 
Y2391 Ureter Urothelium 
in situ 
49 F Renal 
transplant 
21/06/2018 
Y2392 Ureter Urothelium 
in situ 
43 F Renal 
transplant 
21/06/2018 
Y2396 Ureter Urothelium 
in situ 
Unknown M Renal 
transplant 
05/07/2018 
Y2397 Ureter IHC 78 F Nephrectomy 10/07/2018 
Y2425 Ureter NHU 58 M Renal 
transplant 
05/09/2018 




Y2444 Ureter IHC 42 M Renal 
transplant 
24/10/2018 
Y2467 Ureter NHU 17 F Renal 
transplant 
30/11/2018 
Y2640 Ureter Urothelium 
in situ  
54 M Renal 
transplant 
25/10/2019 




Table 7.2: List of normal bladder/urinary tract samples used in study 
Rows in italics indicate NHU samples that were previously processed by RNAseq and used 
as a transcriptomic resource in this study. Boxes labelled ‘unknown’ refers to information 






















Appendix iv: List of PCR, RT-PCR and RT-qPCR primer sequences 









CYR61 RT-qPCR CACACCAAGGGGCTGGAATG CCCGTTTTGGTAGATTCTGG 
EGFR RT-PCR CCAGGAGGTGGCTGGTTATG TGCAGGTTTTCCAAAGGAATT
C 
ELF3 RT-qPCR TCAACGAGGGCCTCATGAA TCGGAGCGCAGGAACTTG 
FABP4 RT-qPCR GCGTCATGAAAGGCGTCACT GTCAACGTCCCTTGGCTTATG 
FGFR3 RT-PCR ACTGTCTGGGTCAAGGATGG TGTGTCCACACCTGTGTCCT 




GATA3 RT-qPCR   




GLI2 RT-PCR CATGGAGCACTACCTCCGTTC CGAGGGTCATCTGGTGGTAAT 





MKI67 RT-PCR TTGAAAAGAAGGCGTGTGTC TCTTCAGGACAGGTGGAGTG 
PTCH1 RT-PCR TCAGCAATGTCACAGCCTTC GTCGTGTGTGTCGGTGTAGG 
PTCH1 RT-qPCR CCGCGCAGAGACGCTTT  CAGCGGGCCCTATTGCTA 





PCR N/A CGATTTAGGTGACACTATAG 
T7 (Cloning; 
Fwd) 
PCR TAATACGACTCACTATAGGG N/A 
U6 (Cloning; 
Fwd) 
PCR GGGCAGGAAGAGGGCCTAT N/A 
VGLL1 RT-qPCR GGCAACCCTGGCCAGATAG CGGGAGGCAGGTTGAAGA 
 







Appendix v: RT-qPCR primer set dissociation curves 
RT-qPCR primers specific to ELF3, FAPB4, GAPDH and GATA3 had been validated for 
their ability to give a single peak when assessing the dissociation curve (indicative of 
the primers producing a single amplified product) and a linear response over a 
dilution range of control cDNA prior to their use in this study. Primers specific to 
ANKRD1, CTGF, CYR61, GLI1, PTCH1 and VGLL1 were similarly validated and the 















































































Figure 7.1: RT-qPCR primer set dissociation curves 
Primers specific to ANKRD1 (A), CTGF (B), CYR61 (C), GLI1 (D), PTCH1 (E) and VGLL1 (F) were 








Appendix vi: Validation of commercially available VGLL1, YAP and TEAD 
antibodies  
Commercial rabbit polyclonal antibodies against VGLL1 were tested by comparing 
their efficacy in various immunolabelling assays. VGLL1 antibodies procured from 
Proteintech (10124-2-AP) and Atlas Antibodies (HPA042403) had both previously 
been used in publications pertaining to VGLL1 (Castilla et al., 2014; Soncin et al., 
2018), with HPA042403 also in use as part of the Human Protein Atlas.  
Due to the observation in Section 3.4.1.3 that VGLL1 transcript was associated to 
differentiation, validation of both VGLL1 antibodies was first performed on NHU 
cells grown in the presence or absence of TZ/PD by immunoblotting. This approach 
demonstrated that both of the tested VGLL1 antibodies produced a band at the 
correct molecular weight of 29 kDa that correlated with the expression pattern 
found at the transcript level (Fig. 7.2A-B). However, the 10124-2-AP antibody 
produced intense bands above the 25 kDa mark and light bands in the 37 kDa and 
~60 kDa areas which did not appear to be affected by cell treatment, while 
HPA042403 was found to produce light bands in both lanes at the 75kDa size. These 
extraneous bands were not found on the blots when imaged after application of the 
rabbit secondary antibody alone (Fig. 7.2C-D), suggesting that both affinity-purified 
mono-specific antibodies were also found to produce additional non-specific bands.  
 Visualisation of VGLL1 expression in formalin-fixed TZ/PD differentiated NHU cells 
by immunofluorescence determined that both antibodies produced primarily 
nuclear labelling, as expected through its previously cited role as a transcriptional 
co-activator (Fig. 7.2E-F). Additional weak cytoplasmic expression in differentiated 
cells was observed when labelled with 10124-2-AP, while DMSO treated NHU cells 
were also found to exhibit weak nuclear labelling of VGLL1 when labelled with 
HPA042403.  
Use of both antibodies on FFPE sections of ureter resulted in similar expression 
patterns in the urothelium, which consisted of a combination of strong labelling in 
the nuclei of cells with additional weaker cytoplasmic labelling (Fig. 7.2G-H). 
Labelling of the Y1870 ureter with 10124-2-AP additionally labelled some cells of 
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the lamina propria, whereas no such labelling was observed with application of 
HPA042403. Despite the aforementioned limitations of each reagent, through 
validation of both antibodies in each immunoassay it was concluded that 
HPA042403 was the superior antibody for immunoblotting and 
immunohistochemistry purposes and 10124-2-AP was preferable for use by 
immunofluorescence. Each antibody was therefore used for their highlighted assays 










































Figure 7.2: Evaluation of VGLL1 protein expression in NHU cells and native 
urothelium using two different antibodies  
The efficacy of two rabbit polyclonal VGLL1 antibodies, 10124-2-AP (Proteintech) and 
HPA042403 (Atlas Antibodies), was examined in a variety of immuno-based assays. 
Panels (A-B) visualise VGLL1 expression in Y1858 cells treated with or without TZ/PD 
for a period of 72h, with 10124-2-AP (A) and HPA042403 (B) both demonstrating 
induction of a band at the correct molecular weight  of VGLL1 in cytodifferentiated 
samples. Despite this, both antibodies produced additional, unknown bands in both 
lanes of lysate. Panels (C-D) display images of blots (A-B) when bound to rabbit 
secondary antibodies alone, confirming that the non-specific bands observed in (A-B) 

























Figure 7.2: Evaluation of VGLL1 protein expression in NHU cells and native urothelium 
using two different antibodies  
Panels (E-F) represent immunofluorescence micrograph images of Y1858 (E) and Y1651 
(F) cells treated using the same conditions as (A-D), with 10124-2-AP used to visualise 
VGLL1 in (E) and HPA042403 used in (F). For each condition, cells were labelled with no 
primary antibody as a negative control. Images were all taken at same exposure, with 
the accompanying overlaid Hoechst 33258 DNA stain shown in the bottom left corner of 
























Figure 7.2: Evaluation of VGLL1 protein expression in NHU cells and native urothelium 
using two different antibodies  
Panels (G-H) demonstrate the localisation of VGLL1 expression in FFPE sections of 
Y1870 ureter, using antibodies 10124-2-AP (G) and HPA042403 (H). Note the absence 
of lamina propria labelling in the images of VGLL1 labelling (top row) in panel (H) 
compared to the corresponding images in (G). Sections that were labelled with rabbit 
monoclonal GATA3 (bottom left) or no primary antibody (bottom right) were used as 
positive and negative controls, respectively. Scale bar= 100 µm (top left images) or 20 
µm (all other images).  
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Expression of total and phosphorylated (S127) forms of YAP expression was 
analysed by immunoblotting in epidermoid carcinoma A431 cells lysed in a sub-
confluent state or left to grow to visual confluence due to this cell line previously 
demonstrating a density-dependent induction of p-YAP activity (Li et al., 2016b). 
Each cell condition was found to be specifically labelled as a doublet band by the 
total YAP (63.7) antibody, with one band of the doublet found at the 65 kDa region 
that YAP protein resides in (Fig. 7.3A). The 63.7 antibody additionally labels bands in 
the 49 kDa region, potentially relating to re-association of YAP with the lower MW 
protein TAZ that is expressed by the cell type. Labelling of the same lysates with an 
antibody specific to phosphorylated (S127) YAP expression (#4911) revealed strong 
bands at the same molecular weight as total YAP, while bands also appeared in the 
49 kDa region but were very weak (Fig. 7.3B), perhaps indicating limited binding of 
p-YAP to p-TAZ in this context. Expression of p-YAP increased in A431 cells lysed at 
visual confluence compared to cells at sub-confluence, an observation in line with 
findings reported by Li et al.  
Immunofluorescence labelling of A431 cells with the 63.7 antibody revealed a 
primarily nuclear expression pattern in A431 cells, with additional weak cytoplasmic 
labelling (Fig. 7.3C). Despite previous reports that concluded that expression of 
inactive YAP was solely localised to the cytoplasm of cells (Section 3.1.1), labelling 
with the #4911 antibody determined a primarily nuclear expression of p-YAP in 
A431 cells, although expression appeared to be more heterogeneous amongst the 
culture in comparison to total YAP/TAZ expression. This observation, alongside the 
fact that the #4911 antibody had not been validated for use in immunofluorescence 
by Cell Signalling, meant that the antibody was used for immunoblotting purposes 






























Figure 7.3: Expression of total and phosphorylated (S127) YAP in A431 cells  
Antibodies targeting the total and phosphorylated forms of YAP where titrated on 
endometroid carcinoma cell line A431 to confirm specific labelling of each antibody. 
Image (A) depicts expression of Total YAP (and additional bands in the 49 kDa region 
which potentially denote Total TAZ expression) in an immunoblot analysis of A431 
cells lysed in both a subconfluent and confluent state. Expression of Total YAP was 
found to be consistent between conditions. Image (B) demonstrates expression of p-
YAP in the same conditions as (A), with an increase of p-YAP visualised in cells left to 


























Figure 7.3: Expression of total and phosphorylated (S127) YAP in A431 cells  
C) Immunofluorescence analysis of total and phosphorylated YAP expression in 
A431 cells. Both antibodies were found to primarily label nuclei of cells, with weak 
cytoplasmic labelling also observed. Cells receiving no primary antibody were used 
as a negative control. Images were all taken at same exposure and are shown with 
or without overlaid Hoechst 33258 DNA staining. Scale bar= 50µm. 
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Transcription factors TEAD1 and TEAD3 had previously been demonstrated to be 
expressed at the transcript level by NHU cells (Section 3.4.1.2). 
Immunofluorescence analysis of Y1756 NHU cells treated with or without TZ/PD for 
72h was therefore used to confirm the validity of a rabbit “pan-TEAD” mAb that 
recognised all four TEAD proteins. The analysis revealed a predominantly nuclear 
localisation of TEAD proteins in both conditions, although some weak cytoplasmic 
expression was additionally visualised in TZ/PD differentiated cells (Fig. 7.4). Due to 
the nature of the antibody and assay used, identification of what specific TEAD 
proteins were being expressed by either cell type was not possible as part of this 





































Figure 7.4: Nuclear-localised expression of TEAD in undifferentiated and 
differentiated NHU cells 
Immunofluorescence analysis of TEAD expression using the pan-TEAD antibody in 
Y1756 cells treated with vehicle control or TZ/PD for 72h (A). TEAD expression is 
expressed in both conditions in a predominantly nuclear localisation, although 
expression appears weaker in TZ/PD differentiated cells. The white arrows also 
indicate the appearance of weak cytoplasmic labelling of a subset of cells that 
were treated with TZ/PD. Cells receiving no primary antibody (B) for each 
condition were used as negative controls. Images were all taken at same exposure 




Appendix vii: EGFR-mediated induction of FGFR3 expression in urothelium  
To determine if modulation of signal transduction pathways downstream of EGFR 
was able to initiate the induction of FGFR3 (in a similar manner to VGLL1) in FGFR3-
absent NHU cells, expression was examined at both the transcript and protein level 
in undifferentiated Y1237 cells treated with PD153035, LY294002 or a combination 
of both drugs. RT-PCR analysis of the above samples revealed that FGFR3 
expression was upregulated in samples treated with PD153035 compared to 
control, where no expression was visualised at the cycle amplification number used 
(Fig. 7.5A). Little difference in FGFR3 expression was observed when cells were 
treated concurrently with PD153035 alongside LY294002, while LY294002 alone 
was unable to induce FGFR3. Immunoblot analysis of the donor-matched protein 
lysates confirmed this observation, with FGFR3 induced only when Y1237 cells were 
treated with PD153035 (Fig. 7.5B). Immunoblotting with the FGFR3-specific mouse 
mAb (B-9) revealed a strong induction of doublet bands in the 85-100 kDa area, 
consistent with the molecular weight of the FGFR3b isoform in a glycosylated and 
non-glycosylated state observed in previous studies (Tomlinson et al., 2005a). 
Expression of FGFR3 protein was additionally assayed in immunoblot analysis of 
Y1226 cells treated with PD153035, with expression compared to that in various 
bladder cancer cell lines. As before, FGFR3 expression was strongly induced in cells 
treated with PD153035 compared to control (Fig. 7.5C). A comparison of FGFR3 
expression in five bladder cancer cell lines to EGFR-blockaded NHU cells determined 
that none of the cell lines assayed expressed FGFR3 in the manner found in 
PD153035-treated NHU cells. However, the B-9 antibody was found to display 
expression of a single band at a larger molecular weight in RT4 cells, a cell line that 
was previously cited to express the FGFR3-TACC3 fusion gene commonly found in 


































Figure 7.5: Induction of FGFR3 transcript and protein expression in undifferentiated 
NHU cells in response to EGFR blockade 
A) RT-PCR analysis of FGFR3 and housekeeping gene GAPDH transcript expression in 
Y1237 undifferentiated NHU cells. Cells were treated with 1 µM PD153035 or 5 µM 
LY294002 (or a combination of the above) for a period of 24h compared to a vehicle 
control. Each cDNA synthesis used 1 µg starting template RNA, with cDNA undergoing PCR 
amplification up to 30 cycles. The primers used for FGFR3 expression were intron-
spanning and therefore did not produce positive gDNA bands of the same size. B) 
Immunoblot image of FGFR3 and p-ERK expression in Y1237 undifferentiated NHU cells 
treated with the same conditions as above for 48h. FGFR3 expression was blotted using a 
mouse monoclonal antibody from Santa Cruz (B-9) which gave a doublet band at 
approximately 85 and 100 kDa. Expression of β-Actin was used to confirm equal loading of 






























Figure 7.5: Induction of FGFR3 transcript and protein expression in 
undifferentiated NHU cells in response to EGFR blockade 
C) Immunoblot image of FGFR3 expression in Y1226 undifferentiated NHU cells 
treated with 1 µM PD153035 for a period of 24h compared to five MIBC cell lines. 
Y1226 cells gave a similar labelling pattern of FGFR3 as that visualised in (B) while 
RT4 was the only cancer cell line to express FGFR3, with a single band found in the 
175 kDa region, indicative of expression of an altered version of the protein. 
Conditions marked with a red asterisk are not relevant to the figure. 
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Appendix viii: Titration of UO126 and PD98059 on NHU cultures  
MEK inhibitors U0126 and PD98059 were titrated prior to their use in Section 
3.4.7.3. Treatment of proliferating, undifferentiated NHU cells with different 
concentrations of U0126 determined that 5 µM of drug was required to inhibit p44 
phosphorylated ERK1/2 expression at a similar rate to PD153035 (Fig. 7.6A). 
Similarly, administration of 5 µM PD98059 was also found to be sufficient to block 
phosphorylated ERK1/2 activation at both 30 minutes (Fig. 7.6B) and 2h (Fig. 7.6C) 
post-treatment, confirming the ability of both reagents to effectively inhibit 
canonical EGFR/MEK/ERK signalling through inhibition of MEK1/2 (U0126) or MEK1 
(PD98059). Jack Birch Unit member Mr Zhen Liu additionally titrated the ERK1/2 
inhibitor FR180204 (FR180) for use in this study, with the optimum concentration of 






































Figure 7.6: Effective concentrations of U0126 and PD98059 activity on NHU cells 
UO126 and PD98059 were titrated on sub-confluent, actively proliferating NHU cells to 
determine the optimum concentration to use to inhibit MEK1/2 or MEK1, respectively. 
Inhibition of p-ERK expression by immunoblotting analysis was used as a proxy for 
effective inhibition. Y1866 cells were treated with U0126 for a period of 2h to analyse its 
downstream effect (A), while Y1356 cells were treated with PD98 for periods of 30 
minutes (B) and 2h (C). Treatment of cells with PD153035 was used in each case as a 
positive control for inhibition of p-ERK. Both drugs were found to effectively reduce 
activation of ERK in all time points assayed at a concentration of 5 µM. Expression of 
Total ERK1/2 was used as a loading control in each experiment.   
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Appendix ix: Generation of a VGLL1-overexpressing retroviral vector 
Specific details on methodology can be found in Section 2.7.2.2. Primers specific to 
the full length VGLL1 coding sequence (Ensembl Transcript ID- ENST00000370634.8) 
were designed to incorporate the forward and reverse strands alongside the 
inclusion of restriction enzyme sites and a Kozak sequence (Table 7.4). 
 
Direction Sequence 
Forward primer AAAAAAGTTAACACCATGGAAGAAATGAAGAAGAAGACTGCC 
Reverse primer AAAAAAGGATCCCTAAAAGATGCTGCAGGTATCGATGTGG 
 
Table 7.4: Primer sequences for amplification of full length VGLL1 coding sequence  
Poly-A tails were added at the 5’ end of both primers in order to aid ligation into the pGEM-
T Easy vector. Sequences in red and green designate the HpaI and BamHI restriction sites, 
respectively. Sequence in orange designates the Kozak sequence in the forward strand. 
Sequences in blue match the VGLL1 cDNA sequence (forward and reverse).  
 
RNA from NHU cells (Y1858) that had been TZ/PD treated for a period of 144h was 
used to synthesise 2 µg of cDNA containing the VGLL1 coding sequence by RT-PCR 
(Fig. 7.7).  
The amplified VGLL1 sequence was purified, concentrated and ligated with 
linearised pGEM-T Easy vector before being introduced into XL1-blue E. coli via 
bacterial transformation. The identity of successfully transformed bacteria was 
confirmed using gel electrophoresis of colony PCR products (Fig. 7.8).  
Plasmids were extracted from positive bacterial cultures and sequenced for 
validation that they contained the VGLL1 sequence in the correct orientation. 
Restriction digests were used to cut out and isolate the VGLL1 sequence from the 
subcloning vector pGEM-T Easy (Fig. 7.9), allowing for ligation of said sequences 



























Figure 7.7: Amplified VGLL1 sequence from NHU cells 
Verification by gel electrophoresis that a product of the correct molecular size 
(777bp) had been produced by PCR before undergoing purification of the 
product. 
Figure 7.8: Colony PCR of transformed XL1-Blue colonies  
Verification of XL1-Blue bacteria successfully expressing pGEM-T Easy vector 


























Figure 7.9: Restriction digests of pLXSN and pGEM-T Easy plasmids   
Verification of digestion of the VGLL1 coding sequence from the pGEM-T Easy 
plasmid backbone. Linearised pLXSN plasmid and the VGLL1 sequence were 
extracted from the gel, purified and ligated together.  
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Appendix x: Generation of VGLL1 shRNA retroviral vectors 
Specific details on methodology can be found in Section 2.7.2.3. Bioinformatic 
analysis of the full length coding sequence of VGLL1 was used to select three 
sequences that were predicted to possess siRNA activity against the VGLL1 gene. 
Three 69bp hairpin sequences were created that contained the siRNA sequences 
alongside restriction digest sites, a terminator sequence and a hairpin loop 
sequence (Table 7.5).  









































Table 7.5: Oligonucleotide sequences used to produce shRNAs specific to VGLL1 
The BamHI (GATCC) and EcoRI (AATTC) sites are in red, the MluI site is in blue and the 
hairpin loop sequence is in green. 
The shRNA oligonucleotide strands were annealed together and ligated into the 
pSIREN-RetroQ retroviral vector. Following bacterial transformation and colony 
PCR, restriction digest analysis using the MluI enzyme was used to confirm that the 



























Figure 7.10: Restriction digests of pSIREN plasmids 
Verification of a single enzymatic cut in the pSIREN plasmid using the MluI site 
downstream of the shRNA terminator sequence.  
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Appendix xi: Quality control of NuHS/NbHS cell RNAseq samples 
To determine what genes were being upregulated by the canonical SHH pathway in 
stromal cells treated with inducing reagents, RNAseq analysis was performed. RT-
qPCR analysis of the three cell lines treated with SAG demonstrated a ≥ 2-fold 
induction of PTCH1 and GLI1 for each cell line and at each time point, and were thus 
considered suitable candidate samples to sequence (Fig. 7.11A). Three NbHS cell 
lines were additionally treated with rSHH, with two lines (Y879 and Y886) found to 
induce GLI1 expression to a similar degree as observed with SAG treatment. 
However, Y732 cells treated with rSHH were found to not induce GLI1 expression 
and were therefore not sequenced (Fig. 7.11B). The quality of the raw sequencing 
reads from the SAG treatment experiment was confirmed using FastQC (Fig. 7.12); 
meaning that no trimming of reads was required. The total number of mapped 
reads was greater than 22 million for each sample, resulting in a minimum of 3.4 


































Figure 7.11: Validation of canonical SHH pathway signalling in ureteric and bladder 
stromal RNAseq samples 
Stromal cell lines Y875, Y879 and Y1027 were treated with 100 nM SAG for 24h and 48h, 
while Y732, Y879 and Y886 cells were treated in the presence and absence of 1 µg/mL 
rSHH for 24h. Graph (A) details qRT-PCR analysis of PTCH1 and GLI1 expression in the 
three independent stromal cell lines treated with SAG, while graph (B) displays GLI1 
expression in the three NbHS cell lines treated with rSHH. Values shown represent the 
fold change in expression between DMSO control and treatment conditions after 
normalisation against GAPDH expression. Icons of the same shape represent fold change 
values from donor-matched stromal samples. NbHS cells treated with rSHH were not 


















Figure 7.12: FastQC sequencing read analysis of stromal cell RNA 
The base quality of raw 75 bp paired-end sequencing reads of Y875, Y879 and Y1027 
cells treated with and without SAG was confirmed using FastQC. This figure 




Table 7.6: Total numbers of mapped reads (top number) and read bases (bottom 
number) for each RNAseq sample  
Sequencing reads from the SAG treatment experiment were considered to be of a high 




Sample Total mapped reads and sequences (bases) 
Y875 24h DMSO 27.3 million 
4.1 billion 
Y875 24h SAG 26 million 
3.9 billion 
Y875 48h DMSO 26.7 million 
 4.0 billion 
Y875 48h SAG 24.7 million 
 3.7 billion 
Y879 24h DMSO 24 million 
 3.6 billion 
Y879 24h SAG 26 million 
 3.9 billion 
Y879 48h DMSO 28 million 
 4.2 billion 
Y879 48h SAG 24.7 million 
 3.7 billion 
Y1027 24h DMSO 22.7 million 
 3.4 billion 
Y1027 24h SAG 28.7 million 
 4.3 billion 
Y1027 48h DMSO 30.7 million 
 4.6 billion 
Y1027 48h SAG 25.3 million 
 3.8 billion 
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Gene Comparison Significant? Summary  pval 
PPARG Urothelium in situ vs. Differentiated 
NHU cells 
No ns 0.9331 
PPARG Urothelium in situ vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
PPARG Differentiated NHU cells vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
GATA3 Urothelium in situ vs. Differentiated 
NHU cells 
No ns 0.156 
GATA3 Urothelium in situ vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
GATA3 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
FOXA1 Urothelium in situ vs. Differentiated 
NHU cells 
No ns 0.304 
FOXA1 Urothelium in situ vs. 
Undifferentiated NHU cells 
Yes ** 0.0014 
FOXA1 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
ELF3 Urothelium in situ vs. Differentiated 
NHU cells 
Yes * 0.0152 
ELF3 Urothelium in situ vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
ELF3 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
TP63 Urothelium in situ vs. Differentiated 
NHU cells 
No ns 0.1359 
TP63 Urothelium in situ vs. 
Undifferentiated NHU cells 
Yes ** 0.0031 
TP63 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
UPK2 Urothelium in situ vs. Differentiated 
NHU cells 
Yes *** <0.0001 
UPK2 Urothelium in situ vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
UPK2 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
 







Gene Comparison Significant? Summary pval 
YAP1 Urothelium in situ vs. Differentiated 
NHU cells 
No ns >0.9999 
YAP1 Urothelium in situ vs. 
Undifferentiated NHU cells 
No ns 0.1406 
YAP1 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
No ns 0.1439 
WWTR1 Urothelium in situ vs. Differentiated 
NHU cells 
No ns 0.6764 
WWTR1 Urothelium in situ vs. 
Undifferentiated NHU cells 
No ns 0.072 
WWTR1 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
No ns 0.3482 
ANKRD1 Urothelium in situ vs. Differentiated 
NHU cells 
No ns 0.9961 
ANKRD1 Urothelium in situ vs. 
Undifferentiated NHU cells 
No ns >0.9999 
ANKRD1 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
No ns 0.9969 
AXL Urothelium in situ vs. Differentiated 
NHU cells 
No ns 0.9835 
AXL Urothelium in situ vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
AXL Differentiated NHU cells vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
CTGF Urothelium in situ vs. Differentiated 
NHU cells 
Yes *** <0.0001 
CTGF Urothelium in situ vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
CTGF Differentiated NHU cells vs. 
Undifferentiated NHU cells 
No ns 0.3967 
CYR61 Urothelium in situ vs. Differentiated 
NHU cells 
Yes *** <0.0001 
CYR61 Urothelium in situ vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
CYR61 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
Yes *** <0.0001 
TEAD1 Urothelium in situ vs. Differentiated 
NHU cells 
Yes * 0.0342 
TEAD1 Urothelium in situ vs. 
Undifferentiated NHU cells 
Yes * 0.0335 
TEAD1 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
No ns >0.9999 
TEAD2 Urothelium in situ vs. Differentiated 
NHU cells 
No ns 0.7664 
TEAD2 Urothelium in situ vs. 
Undifferentiated NHU cells 
No ns 0.7656 
TEAD2 Differentiated NHU cells vs. No ns >0.9999 
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Undifferentiated NHU cells 
TEAD3 Urothelium in situ vs. Differentiated 
NHU cells 
No ns 0.9142 
TEAD3 Urothelium in situ vs. 
Undifferentiated NHU cells 
No ns 0.0562 
TEAD3 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
No ns 0.1339 
TEAD4 Urothelium in situ vs. Differentiated 
NHU cells 
No ns 0.9957 
TEAD4 Urothelium in situ vs. 
Undifferentiated NHU cells 
No ns 0.8752 
TEAD4 Differentiated NHU cells vs. 
Undifferentiated NHU cells 
No ns 0.8308 
 
















































Figure 7.13: VGLL1 expression in native urothelium  
Biological replicate from Figure 3.8 of VGLL1 expression and localisation in Y2444 
ureter (A). Sections that were labelled with no primary antibody (B) were used as 






























Figure 7.14: VGLL1 in TZ/PD differentiated NHU cells following PPARγ inhibition 
Biological replicates from Figure 3.15 of VGLL1 expression Y1226 (A) and Y1947 (B) 
NHU cells treated with a combination of TZ, PD and T0070907 over a time-course 
of 144h. Densitometry analysis of the above immunoblots in addition to the 
immunoblot displayed in Figure 3.15 was used to calculate the mean expression of 
VGLL1 for each condition (Fig. 3.15B).  
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Gene Comparison Significant? Summary pval 
GATA3 Ctrl siRNA DMSO vs. Ctrl siRNA TZ/PD Yes *** <0.0001 
GATA3 Ctrl siRNA DMSO vs. GATA3 siRNA #1 
TZ/PD 
No ns 0.4489 
GATA3 Ctrl siRNA DMSO vs. GATA3 siRNA #2 
TZ/PD 
Yes *** 0.0007 
GATA3 Ctrl siRNA TZ/PD vs. GATA3 siRNA #1 
TZ/PD 
Yes *** <0.0001 
GATA3 Ctrl siRNA TZ/PD vs. GATA3 siRNA #2 
TZ/PD 
Yes *** <0.0001 
GATA3 GATA3 siRNA #1 TZ/PD vs. GATA3 siRNA 
#2 TZ/PD 
Yes * 0.0142 
VGLL1 Ctrl siRNA DMSO vs. Ctrl siRNA TZ/PD Yes *** <0.0001 
VGLL1 Ctrl siRNA DMSO vs. GATA3 siRNA #1 
TZ/PD 
Yes *** <0.0001 
VGLL1 Ctrl siRNA DMSO vs. GATA3 siRNA #2 
TZ/PD 
Yes *** <0.0001 
VGLL1 Ctrl siRNA TZ/PD vs. GATA3 siRNA #1 
TZ/PD 
Yes ** 0.0012 
VGLL1 Ctrl siRNA TZ/PD vs. GATA3 siRNA #2 
TZ/PD 
Yes *** 0.0003 
VGLL1 GATA3 siRNA #1 TZ/PD vs. GATA3 siRNA 
#2 TZ/PD 
No ns 0.8948 
 















Gene  Comparison Significant? Summary pval 
VGLL1 Subconfluent DMSO vs. Confluent 
DMSO 
No ns 0.7863 
VGLL1 Subconfluent DMSO vs. Confluent 
TZ 
No ns 0.9789 
VGLL1 Subconfluent DMSO vs. Confluent 
PD 
No * 0.0424 
VGLL1 Subconfluent DMSO vs. Confluent 
T007 
No ns 0.8656 
VGLL1 Subconfluent DMSO vs. Confluent 
TZ/T007 
No ns 0.9453 
VGLL1 Subconfluent DMSO vs. Confluent 
PD/T007 
Yes ** 0.0013 
VGLL1 Subconfluent DMSO vs. Confluent 
TZ/PD 
Yes ** 0.0045 
VGLL1 Confluent DMSO vs. Confluent TZ No ns 0.9984 
VGLL1 Confluent DMSO vs. Confluent PD No ns 0.5595 
VGLL1 Confluent DMSO vs. Confluent T007 No ns >0.9999 
VGLL1 Confluent DMSO vs. Confluent 
TZ/T007 
No ns 0.9999 
VGLL1 Confluent DMSO vs. Confluent 
PD/T007 
Yes * 0.0252 
VGLL1 Confluent DMSO vs. Confluent 
TZ/PD 
No ns 0.0821 
VGLL1 Confluent TZ vs. Confluent PD No ns 0.257 
VGLL1 Confluent TZ vs. Confluent T007 No ns 0.9998 
VGLL1 Confluent TZ vs. Confluent TZ/T007 No ns >0.9999 
VGLL1 Confluent TZ vs. Confluent PD/T007 Yes ** 0.0079 
VGLL1 Confluent TZ vs. Confluent TZ/PD Yes * 0.0268 
VGLL1 Confluent PD vs. Confluent T007 No ns 0.4619 
VGLL1 Confluent PD vs. Confluent TZ/T007 No ns 0.3371 
VGLL1 Confluent PD vs. Confluent 
PD/T007 
No ns 0.5661 
VGLL1 Confluent PD vs. Confluent TZ/PD No ns 0.895 
VGLL1 Confluent T007 vs. Confluent 
TZ/T007 
No ns >0.9999 
VGLL1 Confluent T007 vs. Confluent 
PD/T007 
Yes * 0.0182 
VGLL1 Confluent T007 vs. Confluent TZ/PD No ns 0.0603 
VGLL1 Confluent TZ/T007 vs. Confluent 
PD/T007 
Yes * 0.0114 
VGLL1 Confluent TZ/T007 vs. Confluent 
TZ/PD 
Yes * 0.0383 
VGLL1 Confluent PD/T007 vs. Confluent 
TZ/PD 
No ns 0.9978 
 














Figure 7.15: ERK1/2 expression in NHU cells grown in high Ca2+ alongside treatment 
with PD153035 or LY294002 
Labelling of total and phosphorylated (Thr202/Tyr204) ERK1/2 expression in Y1336 
cells treated as described in Figure 3.23. p-ERK expression was reduced compared to 
control when treated with high Ca2+ or PD153035, but increased following LY294002 






























Figure 7.16: Negative controls for Figure 3.23 
Cells receiving no primary antibody were used as a negative control. Images were all 
taken at same exposure and are shown with or without overlaid Hoechst 33258 DNA 












































Figure 7.17: VGLL1 knockdown in TZ/PD differentiated NHU cells 
Biological replicates from Figure 3.30 depicting expression of VGLL1, PPARγ, GATA3, 
FOXA1 and ELF3 in Y1811 (A) and Y2318 (B) cells following VGLL1 knockdown and 72h 
TZ/PD differentiation.  Analysis of the above immunoblot images was used to produce 
the densitometry quantification found in Figure 3.30. Expression of β-Actin was used to 















































Figure 7.18: Analysis of TEER in VGLL1 knockdown ABS/Ca
2+
 differentiated NHU 
cells 
Biological replicate from Figure 3.31 of barrier impedance in Y2425 cells following 
VGLL1 knockdown and ABS/Ca
2+ 
differentiation.  As seen in Figure 3.31, VGLL1 
knockdown results in a consistently (and significantly) weaker barrier when 
compared to control in an unwounded state. Significance in barrier tightness 
between conditions was determined using a two-way repeated measure ANOVA 













































Figure 7.19: p-SMAD3 expression in VGLL1 knockdown differentiated NHU cells 
Biological replicate from Figure 3.35 of wounded Y2324 cells following VGLL1 
knockdown and ABS/Ca
2+ 
differentiation.  As seen in Figure 3.35, p-SMAD3 
expression is inhibited at the wound edge of VGLL1 knockdown cells 4h post-
















































Figure 7.20: Total YAP expression in VGLL1 knockdown differentiated NHU cells 
Biological replicate from Figure 3.36 of wounded Y2425 cells following VGLL1 
knockdown and ABS/Ca
2+ 
differentiation.  As seen in Figure 3.36, YAP localisation 
does not appear to change based on VGLL1 inhibition or upon wounding of 
















































Figure 7.21: Negative controls for Figures 3.33- 3.36 
Y2324 (A) and Y2425 (B) cells receiving no primary antibody at all time points were 
used as negative controls. Images were all taken at same exposure and are shown 


































Figure 7.22: p-SMAD3 expression in TGFβ agonist and antagonist-treated 
differentiated NHU cells 
Biological replicate from Figure 3.39 of Y2696 cells following ABS/Ca
2+ 
differentiation and pretreatment with TGFβ or SB431542 and prior to wounding.  
Panel (A) depicts p-SMAD3 expression in cells in either an unwounded state or 4h 
post-wound. As seen in Figure 3.39, p-SMAD3 is intensely expressed at the wound 
edge of TGFβ treated cells but is inhibited at the wound edge of SB431542 treated 

























Figure 7.22: p-SMAD3 expression in TGFβ agonist and antagonist-treated 
differentiated NHU cells 
Biological replicate from Figure 3.39 of Y2696 cells following ABS/Ca
2+ 
differentiation and pretreatment with TGFβ or SB431542 and prior to wounding.  
Panel (B) depicts p-SMAD3 expression in cells in either an unwounded state or 72h 
post-wound. As seen in Figure 3.39, p-SMAD3 is lost in control cells following 


























Figure 7.23: PPARγ expression in TGFβ agonist and antagonist-treated 
differentiated NHU cells 
Biological replicate from Figure 3.41 of Y1837 cells following ABS/Ca
2+ 
differentiation and pretreatment with TGFβ or SB431542 and prior to wounding.  
As seen in Figure 3.41, PPARγ exhibits a cytoplasmic localisation at the wound 
edge of control and TGFβ treated cells but is nuclear in SB431542 treated cells. 


















Figure 7.24: VGLL1 expression in TGFβ agonist and antagonist-treated 
differentiated NHU cells 
Biological replicate from Figure 3.42 of Y1837 cells following ABS/Ca
2+ 
differentiation and pretreatment with TGFβ or SB431542 and prior to wounding.  
As seen in Figure 3.42, treatment with TGFβ or SB431542 before wounding of 



























Figure 7.25: Ki67/MCM2 expression in TGFβ agonist and antagonist-treated 
differentiated NHU cells 
Biological replicate from Figure 3.43 of Y2696 cells following ABS/Ca
2+ 
differentiation and pretreatment with TGFβ or SB431542 and prior to wounding.  
As seen in Figure 3.43, treatment with TGFβ inhibited the increase in Ki67 and 
MCM2 expression observed in control cells following wounding, while SB431542 































Figure 7.26: Negative controls for Figures 3.39- 3.43 
Y1837 (A) cells receiving no primary antibody at all time points were used as 
negative controls. Images were all taken at same exposure and are shown with 































Figure 7.26: Negative controls for figures 3.39- 3.43 
Y2696 (B) cells receiving no primary antibody at all time points were used as 
negative controls. Images were all taken at same exposure and are shown with 
overlaid Hoechst 33258 DNA staining. Scale bar= 50µm. 
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Table 7.11: Mutational status of commonly mutated MIBC genes in bladder cancer cell 
lines 
Cells highlighted in red indicate a previously identified alteration to a gene in a specific cell 
line. HD= homozygous deletion, LOH= loss of heterozygosity. Table adapted from a 













HT1376 RT112 RT4 SCaBER  T24 UM-
UC-9 
TERT Mut. Mut. Mut. Mut. Mut. Mut. Mut. Mut. 







WT WT WT 
PIK3CA WT E545K WT WT WT WT WT WT 
AKT WT Unk. Unk. WT Unk. Unk. WT WT 




H-RAS WT WT WT WT WT WT G12V WT 
K-RAS WT WT WT WT WT WT WT Unk. 
N-RAS WT Q61R WT WT WT WT WT Unk. 
CDKN2
A 
































































Figure 7.27: Cell cycle analysis of T24 eGFP and VGLL1 overexpressing cells 
Technical replicates from Figure 4.12 of flow cytometry analysis of T24 cells pulsed 
with BrdU and labelled with a BrdU-specific antibody.  (A) and (B) represent 
propidium iodide versus BrdU scatter plots of transfected T24 cells fixed 
independently, with both occasions demonstrating a G0/G1 arrest in T24 VGLL1 
cells compared to control, as seen in figure 4.12.  
 

















































Figure 7.28: Cell cycle analysis of 5637 eGFP and VGLL1 overexpressing cells 
Technical replicate from Figure 4.13 of flow cytometry analysis of 5637 cells 
pulsed with BrdU and labelled with a BrdU-specific antibody.  As seen in figure 
4.13, overexpression of VGLL1 in 5637 cells has little effect on the proportion of 








Gene Comparison Significant? Summary pval 
VGLL1 Urothelium in situ vs. Luminal 
Papillary 
No ns >0.9999 
VGLL1 Urothelium in situ vs. Luminal Non-
Specified 
No ns 0.1021 
VGLL1 Urothelium in situ vs. Luminal 
Unstable 
Yes * 0.0426 
VGLL1 Urothelium in situ vs. 
Basal/Squamous 
No ns >0.9999 
VGLL1 Urothelium in situ vs. 
Neuroendocrine 
No ns >0.9999 
VGLL1 Urothelium in situ vs. Stroma-Rich No ns >0.9999 
VGLL1 Luminal Papillary vs. Luminal Non-
Specified 
No ns 0.1077 
VGLL1 Luminal Papillary vs. Luminal 
Unstable 
Yes *** 0.0006 
VGLL1 Luminal Papillary vs. 
Basal/Squamous 
Yes *** <0.0001 
VGLL1 Luminal Papillary vs. 
Neuroendocrine 
Yes ** 0.0023 
VGLL1 Luminal Papillary vs. Stroma-Rich No ns >0.9999 
VGLL1 Luminal Non-Specified vs. Luminal 
Unstable 
No ns >0.9999 
VGLL1 Luminal Non-Specified vs. 
Basal/Squamous 
Yes *** <0.0001 
VGLL1 Luminal Non-Specified vs. 
Neuroendocrine 
Yes *** <0.0001 
VGLL1 Luminal Non-Specified vs. Stroma-
Rich 
No ns 0.1799 
VGLL1 Luminal Unstable vs. 
Basal/Squamous 
Yes *** <0.0001 
VGLL1 Luminal Unstable vs. 
Neuroendocrine 
Yes *** <0.0001 
VGLL1 Luminal Unstable vs. Stroma-Rich Yes ** 0.0079 
VGLL1 Basal/Squamous vs. 
Neuroendocrine 
No ns >0.9999 
VGLL1 Basal/Squamous vs. Stroma-Rich Yes *** 0.0001 
VGLL1 Neuroendocrine vs. Stroma-Rich Yes ** 0.0058 
 














Copy # Predicted effect 
A9KW X1367_splice Splice Shallow del. Likely loss-of-function 
A2LD Y500Lfs*123 FS Ins Shallow del. Likely loss-of-function 
A3SR Q605E Missense Gain Unknown 
A3JV Q1363* Nonsense Shallow del. Likely loss-of-function 
A9KI S740_Q743delins* Nonsense WT Likely loss-of-function 
A3PH E2035* Nonsense WT Likely loss-of-function 
A40G Unknown Unknown Unknown Unknown 
A3IT Unknown Unknown Unknown Unknown 
 
Table 7.13: Information on ARID1A mutations in VGLL1-high MIBC subtype 
Information was downloaded from cBioPortal. 5/8 tumours with ARID1A mutations were 
predicted to have loss of function of ARID1A, with the predicted phenotype caused by the 






Zygosity Validated Type Position 
ARID1A p.S2264L c.6791C>T Heterozygous Unverified Missense 1:26780689.. 
26780689 
ARID1A p.S2256* c.6767C>A Heterozygous Unverified Nonsense 1:26780665.. 
26780665 
 
Table 7.14: Information on ARID1A mutations in HT1197 cells 
Information was downloaded from the COSMIC database 
(https://cancer.sanger.ac.uk/cosmic). The list of mutations inherent to T24 cells revealed 
that no mutations in the ARID1A gene have been discovered in that cell line. 
 




Zygosity Validated Type Position 
ARID1A p.S186fs*209 c.557_570 
del14 




ARID1A p.T1302S c.3905C>G Heterozygous Unverified Missense 1:26773618.. 
26773618 
 
Table 7.15: Information on ARID1A mutations in HT1376 cells 




Gene Log2 fold change pval qval 
FTHL17 -21.69129073 1.58E-23 4.71E-19 
LIN28A 5.575709122 1.71E-22 2.56E-18 
NR6A1 2.17491435 1.30E-16 1.30E-12 
CLEC1A 3.078366756 8.70E-16 6.50E-12 
HTR7 -5.006224837 2.47E-15 1.48E-11 
GCM1 4.525459814 6.75E-15 2.88E-11 
DSG3 -7.724638095 1.58E-14 5.90E-11 
HMGA2 -6.653485821 1.81E-14 6.00E-11 
MMP10 -5.728936107 2.21E-13 6.00E-10 
KRT4 -6.829501743 2.10E-13 6.00E-10 
PMEL 2.484728939 3.41E-13 8.49E-10 
BNC1 -7.839103133 4.56E-13 1.05E-09 
KRT6B -7.906156579 6.29E-13 1.34E-09 
CD55 2.231098495 1.30E-12 2.59E-09 
IRX3 -4.099034614 2.11E-12 3.95E-09 
MMP12 -4.801547591 2.46E-12 4.32E-09 
CLCA2 -5.406682884 6.17E-12 9.70E-09 
SERPINB4 -6.76221952 6.05E-12 9.70E-09 
LINC00519 -3.945129041 1.00E-11 1.50E-08 
KRT13 -5.446432666 1.31E-11 1.80E-08 
DAPL1 -5.983756554 1.44E-11 1.80E-08 
TENM2 -6.390382891 1.38E-11 1.80E-08 
KRT6C -7.631061725 1.35E-11 1.80E-08 
KLK10 -6.185783258 1.56E-11 1.86E-08 
S100A2 -4.430455423 1.80E-11 1.99E-08 
KRT5 -5.641261736 1.76E-11 1.99E-08 
SERPINB3 -6.272218417 1.90E-11 2.03E-08 
LINC01960 3.730352562 2.73E-11 2.81E-08 
BRWD1-AS1 2.889343023 3.62E-11 3.61E-08 
KRT6A -6.286607315 4.03E-11 3.89E-08 
VSNL1 -4.641258846 6.91E-11 6.45E-08 
KRT75 -8.225238623 8.36E-11 7.57E-08 
GJA5 2.978216748 9.21E-11 8.10E-08 
AC011374.1 -4.866299647 1.12E-10 9.54E-08 
CYP1A1 -7.311626923 1.16E-10 9.61E-08 
SRGAP3 -2.495949863 1.43E-10 1.15E-07 
LINC01752 -4.064161117 1.58E-10 1.25E-07 
FOXE1 -5.353626756 1.64E-10 1.26E-07 
KRT17 -3.557700016 1.82E-10 1.36E-07 
MIR222HG -2.490666644 1.91E-10 1.39E-07 
C1orf105 5.149508172 2.64E-10 1.79E-07 
ATP7B 2.672310082 2.59E-10 1.79E-07 
PI3 -5.770410685 2.81E-10 1.86E-07 
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CDH3 -3.273657984 3.03E-10 1.97E-07 
MYOSLID -4.411910467 3.81E-10 2.37E-07 
MMP13 -4.635516684 3.78E-10 2.37E-07 
WDR66 -3.433476093 4.01E-10 2.40E-07 
SERPINB13 -6.001910175 3.99E-10 2.40E-07 
AC103746.1 2.209384493 4.68E-10 2.64E-07 
CA12 -3.128413505 4.68E-10 2.64E-07 
FGFBP1 -5.341334682 4.61E-10 2.64E-07 
PPP2R2C -4.601084692 4.81E-10 2.66E-07 
AIM2 -3.933089062 5.21E-10 2.83E-07 
WNT10A -3.712551401 6.54E-10 3.49E-07 
KLK11 -5.642509116 7.10E-10 3.72E-07 
KRT1 -6.076054801 8.00E-10 4.12E-07 
KRT16 -4.775957096 9.51E-10 4.82E-07 
PKP1 -3.764757525 1.59E-09 7.80E-07 
NCF4-AS1 5.054246856 1.75E-09 8.42E-07 
C12orf54 -4.009991739 1.96E-09 9.28E-07 
CRTAC1 -5.089708224 2.10E-09 9.80E-07 
SLC38A5 -3.327043157 2.17E-09 9.82E-07 
CLCA4 -5.185819704 2.14E-09 9.82E-07 
LGALS7B -5.534561733 2.30E-09 1.03E-06 
AC018553.1 -3.407003029 3.52E-09 1.52E-06 
EPO 3.5552921 4.05E-09 1.73E-06 
BAALC -3.767534123 4.23E-09 1.78E-06 
ERVW-1 3.747899777 4.41E-09 1.83E-06 
CYP27C1 -3.370878003 4.65E-09 1.91E-06 
KRT74 -5.415434136 6.97E-09 2.78E-06 
TAC4 2.664669727 7.30E-09 2.87E-06 
ALDH3A1 -4.369161067 8.10E-09 3.14E-06 
ATP6V1C2 2.006335017 8.25E-09 3.16E-06 
GNLY -3.561956062 8.34E-09 3.16E-06 
LINC00900 -3.42352445 8.79E-09 3.20E-06 
SLC47A2 -4.18437741 8.68E-09 3.20E-06 
KRT31 -5.823715935 8.70E-09 3.20E-06 
DUSP13 3.638181043 1.32E-08 4.70E-06 
SHOX 4.235141495 1.44E-08 5.02E-06 
EN1 -5.114578156 1.43E-08 5.02E-06 
KLRC1 -3.244654777 1.52E-08 5.23E-06 
SFTPB -4.815174074 1.59E-08 5.41E-06 
SPOCD1 -3.215192645 1.62E-08 5.45E-06 
GRAMD2 3.25049971 1.72E-08 5.71E-06 
AKR1C1 -3.707499051 2.31E-08 7.57E-06 
KRT17P3 -4.060028145 2.45E-08 7.96E-06 
PTPRZ1 -5.413696849 2.49E-08 7.99E-06 
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CDKN1C 2.369823682 2.63E-08 8.36E-06 
CSF3R 2.689029093 3.09E-08 9.54E-06 
SDR16C5 -4.756253808 3.13E-08 9.56E-06 
TMEM45A -3.27685897 3.30E-08 9.97E-06 
AC041040.1 -3.342613077 3.45E-08 1.02E-05 
LINC01314 -4.47997102 3.44E-08 1.02E-05 
CPA4 -4.072905344 3.50E-08 1.03E-05 
KRT15 -3.654913424 3.64E-08 1.05E-05 
S100A7 -5.599701824 3.63E-08 1.05E-05 
BCL11B -2.375461711 3.73E-08 1.06E-05 
LINC01503 -2.020969935 3.91E-08 1.09E-05 
LINC00707 -4.858530131 4.26E-08 1.18E-05 
IDO1 -3.975204407 4.61E-08 1.26E-05 
CLEC2B -2.62251103 5.49E-08 1.45E-05 
ZFPM2-AS1 -3.070048277 5.33E-08 1.45E-05 
GSC -3.856182952 5.42E-08 1.45E-05 
ALDH1L1-AS2 -3.998178733 5.42E-08 1.45E-05 
S100A3 -2.84082339 5.68E-08 1.49E-05 
AC099796.1 -5.40706202 6.28E-08 1.63E-05 
SCGB1A1 -7.24921193 6.72E-08 1.70E-05 
HEPHL1 -4.159280971 6.86E-08 1.72E-05 
SLC22A11 5.067930662 7.06E-08 1.73E-05 
MED12L 2.060002868 7.13E-08 1.73E-05 
CALML3 -4.769825217 7.05E-08 1.73E-05 
KLK13 -5.334404816 7.11E-08 1.73E-05 
HIC2 2.305329786 7.35E-08 1.77E-05 
POU3F1 -3.568577604 7.50E-08 1.78E-05 
PTHLH -3.859522433 7.47E-08 1.78E-05 
KRT17P6 -4.081871842 7.78E-08 1.81E-05 
IL36G -4.563702847 7.76E-08 1.81E-05 
KRTDAP -5.313360858 7.81E-08 1.81E-05 
AC080013.4 2.575150954 8.42E-08 1.94E-05 
CD44 -2.297397445 9.23E-08 2.06E-05 
COLCA1 -3.461605968 9.15E-08 2.06E-05 
MMP1 -3.711827106 9.10E-08 2.06E-05 
NMRAL2P -4.599336682 9.14E-08 2.06E-05 
PLA2G4A -2.070981851 9.65E-08 2.14E-05 
ADH7 -5.99178322 1.02E-07 2.24E-05 
AC018647.1 2.212886671 1.06E-07 2.29E-05 
AC002401.4 -3.632861258 1.06E-07 2.29E-05 
LINC00460 -5.041793477 1.09E-07 2.33E-05 
PICSAR -4.903903911 1.12E-07 2.40E-05 
TMPRSS11D -5.626454291 1.13E-07 2.40E-05 
ZNF812P -3.286259243 1.16E-07 2.45E-05 
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ADCY10 2.660973686 1.26E-07 2.61E-05 
LINC00704 -4.179539581 1.34E-07 2.76E-05 
NPBWR1 -3.798221989 1.39E-07 2.85E-05 
KRT16P6 -4.905872467 1.44E-07 2.94E-05 
SPRR1B -4.601312586 1.52E-07 3.06E-05 
IFI16 -2.135829946 1.53E-07 3.08E-05 
M1AP -3.565151187 1.65E-07 3.27E-05 
LINP1 -4.404182261 1.65E-07 3.27E-05 
UGT1A8 -5.425135369 1.90E-07 3.71E-05 
PGLYRP3 -4.79651469 1.94E-07 3.76E-05 
KRT77 -4.799645677 2.01E-07 3.87E-05 
CP -4.009238513 2.03E-07 3.90E-05 
FOLR1 4.146258211 2.17E-07 4.10E-05 
AC012501.2 -5.117726066 2.15E-07 4.10E-05 
FAM26F -2.541177675 2.20E-07 4.13E-05 
LY6G6C 3.538214275 2.36E-07 4.36E-05 
TNFRSF18 -2.512554438 2.36E-07 4.36E-05 
KLK5 -6.754695498 2.33E-07 4.36E-05 
SEZ6L -4.654205319 2.52E-07 4.59E-05 
MUC2 -4.722024027 2.51E-07 4.59E-05 
L1CAM -4.023889052 2.58E-07 4.68E-05 
CA9 -3.419588657 2.84E-07 5.08E-05 
SLURP1 -3.93751084 2.83E-07 5.08E-05 
PNMA5 -5.799924186 2.86E-07 5.09E-05 
CCNA1 -4.524737898 2.97E-07 5.23E-05 
FABP4 -4.200874145 3.09E-07 5.37E-05 
CTAGE3P 3.105878376 3.32E-07 5.68E-05 
ADSSL1 -2.155273374 3.34E-07 5.68E-05 
BBOX1 -3.222458447 3.32E-07 5.68E-05 
LINC02154 -4.913882573 3.30E-07 5.68E-05 
LINC01587 -4.927318822 3.43E-07 5.79E-05 
ACHE 2.739802714 3.60E-07 6.05E-05 
ECHDC3 -3.157976356 3.72E-07 6.15E-05 
NKAIN2 -3.818076595 3.71E-07 6.15E-05 
CASP1 -2.098048972 4.12E-07 6.66E-05 
TMEM246 -2.500800394 4.11E-07 6.66E-05 
IGFBP6 -2.660060843 4.15E-07 6.66E-05 
CSMD1 -4.333907791 4.19E-07 6.70E-05 
IL31RA -4.081686937 4.32E-07 6.83E-05 
KIR2DL4 -3.383611505 4.49E-07 7.06E-05 
KRT14 -4.78755817 4.71E-07 7.29E-05 
CARD17 -4.38899694 4.80E-07 7.40E-05 
AL354766.2 -5.466534774 4.96E-07 7.60E-05 
SHISA2 -3.369196869 5.04E-07 7.68E-05 
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SERPINA1 -3.094356448 5.14E-07 7.76E-05 
KRT79 -4.092978523 5.13E-07 7.76E-05 
AL365356.3 -4.074546304 5.50E-07 8.22E-05 
AC024940.1 -2.772850725 5.74E-07 8.53E-05 
ADGRE1 -3.1358715 5.79E-07 8.57E-05 
LGR5 -3.851270392 6.24E-07 9.14E-05 
CHRM5 2.275437127 6.50E-07 9.47E-05 
SUN3 2.901943649 6.60E-07 9.58E-05 
S100A7A -6.392424693 6.69E-07 9.67E-05 
ERVMER34-1 2.203708858 6.96E-07 1.00E-04 
LCMT1-AS2 2.387500049 7.12E-07 0.000102 
LINC00540 -4.177998039 7.28E-07 0.000104 
CALB2 -3.477352387 7.53E-07 0.000107 
LINC02446 -3.960769561 7.78E-07 0.00011 
BRINP1 -3.939335136 8.02E-07 0.000112 
NELL2 -2.984685834 8.61E-07 0.00012 
SBSN -4.317450565 8.70E-07 0.00012 
BMS1P8 -5.701133966 9.58E-07 0.000131 
PROC -2.392241384 9.83E-07 0.000133 
NTS -4.174938708 9.75E-07 0.000133 
LINC01686 2.064680282 1.01E-06 0.000136 
KRT42P -2.700485055 1.03E-06 0.000138 
DEC1 -4.331219522 1.12E-06 0.000149 
KRT78 -3.124657093 1.14E-06 0.000152 
AC068987.4 2.674090608 1.17E-06 0.000154 
GKN1 -5.864174347 1.18E-06 0.000155 
PPP4R4 -3.903869829 1.28E-06 0.000166 
MROH2A -3.748667563 1.28E-06 0.000166 
RNY3P8 -3.083470778 1.37E-06 0.000176 
AC108751.5 2.085160587 1.44E-06 0.000181 
RYR1 -2.742677817 1.43E-06 0.000181 
KLK12 -6.011363636 1.44E-06 0.000181 
SOX2 -3.639979686 1.50E-06 0.000188 
SOSTDC1 -4.194435 1.60E-06 0.000198 
AP000424.1 -3.788824386 1.61E-06 0.000198 
B3GAT1 -3.379793518 1.69E-06 0.000207 
MT1X -2.472672118 1.74E-06 0.000212 
PLA2G4E -3.865825658 1.77E-06 0.000214 
GBP5 -3.232310228 1.78E-06 0.000215 
TGFBI -2.603609923 1.81E-06 0.000216 
KRT17P1 -3.09246939 1.83E-06 0.000219 
AL354919.2 -3.094876921 1.89E-06 0.000224 
AP001505.1 -5.203510915 1.95E-06 0.00023 
SHH -4.086354701 2.05E-06 0.000241 
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LINC01871 -2.879112493 2.07E-06 0.000241 
AC022182.2 -3.730176396 2.07E-06 0.000241 
MEFV -2.640085589 2.16E-06 0.000251 
NEFM -4.405980203 2.21E-06 0.000254 
UGT2B28 -4.737730649 2.26E-06 0.000258 
AL122017.1 3.220121926 2.34E-06 0.000266 
COL22A1 -3.20966787 2.38E-06 0.00027 
MAGEA4 -5.727745263 2.41E-06 0.000271 
GZMB -2.831560344 2.46E-06 0.000276 
CALB1 -4.15852608 2.51E-06 0.000279 
GJB2 -2.77292457 2.58E-06 0.000285 
BCL11A -2.393098114 2.87E-06 0.000311 
LINC01121 -2.752371955 2.87E-06 0.000311 
NHLH2 -3.721545253 2.88E-06 0.000311 
GDPD4 2.535468009 2.92E-06 0.000314 
CHP2 -3.739072654 2.96E-06 0.000318 
VIM-AS1 -2.327696881 3.07E-06 0.000327 
PRF1 -2.573041653 3.12E-06 0.00033 
SYT14 -3.370745458 3.36E-06 0.000352 
FLG -3.492303461 3.41E-06 0.000357 
SPNS2 2.165466078 3.44E-06 0.000358 
AC078788.1 -3.613836793 3.48E-06 0.000362 
CADM1 -2.448115532 3.54E-06 0.000363 
ATOH8 -2.829044687 3.53E-06 0.000363 
SLCO1B3 -6.05324827 3.74E-06 0.000382 
AC113383.1 -2.900501067 3.76E-06 0.000382 
MTND1P23 -3.584521391 3.86E-06 0.000391 
RTBDN 2.971724018 3.87E-06 0.000391 
TRBC2 -2.30934756 4.01E-06 0.000403 
LAMA3 -3.029452223 4.04E-06 0.000404 
RASSF10 -2.540690882 4.10E-06 0.000405 
KRT81 -3.794270714 4.07E-06 0.000405 
AL135818.2 -2.669888733 4.32E-06 0.000423 
ERVFRD-1 2.994795051 4.35E-06 0.000425 
DACH2 -3.576471673 4.42E-06 0.000429 
AC008011.2 -4.066071794 4.41E-06 0.000429 
SULT4A1 -4.35967906 4.49E-06 0.000433 
AC005035.1 -3.712216269 4.50E-06 0.000433 
HSPA7 -2.089868963 4.54E-06 0.000435 
AC011997.1 -2.328132674 4.68E-06 0.000446 
COL17A1 -3.166917926 4.73E-06 0.000448 
AL133330.1 -2.695318114 4.86E-06 0.00046 
ALB -4.603637111 4.99E-06 0.000469 
BEGAIN -2.266942007 5.09E-06 0.000477 
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AKR1B10 -3.759414956 5.27E-06 0.000492 
AL356215.1 -2.73659178 5.42E-06 0.000502 
TMEM72-AS1 2.015120942 5.50E-06 0.000508 
NRG1 -3.115516149 5.56E-06 0.00051 
SPOCK3 -3.594736965 5.57E-06 0.00051 
AFAP1-AS1 -3.737675601 6.17E-06 0.00056 
ST8SIA2 -3.418928704 6.23E-06 0.000565 
AC011453.1 3.058315573 6.33E-06 0.000572 
LINC02323 -2.586427415 6.62E-06 0.000596 
KRT16P2 -3.756751728 6.91E-06 0.000618 
ADGRD2 -3.899522523 6.94E-06 0.000619 
RBP1 -2.343519706 7.11E-06 0.000628 
FRMPD4 -4.089699477 7.35E-06 0.000646 
G0S2 -2.431726051 7.46E-06 0.000654 
LAMB3 -2.176652414 7.49E-06 0.000655 
BMPER -2.31737868 7.55E-06 0.000656 
LINC00643 3.449975434 7.85E-06 0.000678 
AC130686.1 -2.159521765 8.12E-06 0.000699 
SMOC1 -3.0896068 8.26E-06 0.000709 
C11orf53 -2.829367747 8.62E-06 0.000736 
MTCYBP18 -3.135402166 8.68E-06 0.000737 
XDH -2.163041879 8.84E-06 0.000749 
PINLYP -2.038587587 9.12E-06 0.000764 
AK4 -2.178262408 9.10E-06 0.000764 
FAM83A-AS1 -2.833141772 9.08E-06 0.000764 
VGLL1 2.427341053 9.22E-06 0.00077 
ZP1 -2.61580685 9.29E-06 0.000773 
RAD51AP2 -3.512851566 9.44E-06 0.000782 
DKK4 -3.403875137 9.63E-06 0.000793 
AMTN -4.678779508 9.66E-06 0.000793 
SERPINA5 -2.80510705 9.70E-06 0.000794 
ATP13A4 2.853522812 9.84E-06 0.000799 
DPYD -2.058037367 9.80E-06 0.000799 
AACSP1 -4.223458456 9.83E-06 0.000799 
GFI1 -2.093938181 9.99E-06 0.00081 
GRP -3.985914427 1.02E-05 0.00082 
IL12RB2 -2.720026552 1.05E-05 0.000842 
SLPI -2.929776292 1.06E-05 0.000842 
CLEC4G -3.087704022 1.05E-05 0.000842 
FGG -5.771079569 1.06E-05 0.000842 
MIR205HG -2.141534633 1.08E-05 0.000858 
STAR -2.354407611 1.09E-05 0.00086 
KBTBD12 -3.605749318 1.09E-05 0.00086 
AADAC -3.723907169 1.12E-05 0.000882 
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AC069366.1 2.68138141 1.13E-05 0.000883 
CACNA1B -3.725992841 1.13E-05 0.000884 
FGF19 -6.100637039 1.18E-05 0.000918 
SPRR2E -5.307338853 1.18E-05 0.000919 
ASS1 2.170787768 1.20E-05 0.000928 
TMEM31 2.161268506 1.21E-05 0.000931 
LSP1 -2.198845741 1.31E-05 0.000997 
TRBJ2-3 -3.51844333 1.31E-05 0.000997 
AC078883.4 -2.644135071 1.33E-05 0.00101 
ARID3A 2.004034568 1.37E-05 0.001036 
LGR6 -2.692040217 1.39E-05 0.001046 
AL160408.1 -3.445237962 1.47E-05 0.001093 
LINC01249 -6.199710775 1.49E-05 0.00111 
SPINK4 -3.915561217 1.53E-05 0.001133 
ADGRG5 -2.290866541 1.56E-05 0.001154 
RHCG -3.235306101 1.58E-05 0.001159 
COX6B2 -2.203097728 1.60E-05 0.001175 
S100A8 -3.504543415 1.62E-05 0.001186 
MUCL1 -3.507556505 1.69E-05 0.001224 
HAS2 -2.36731517 1.73E-05 0.001253 
PLCH2 -2.216283161 1.78E-05 0.001279 
KLRC2 -3.357536855 1.80E-05 0.001289 
MCF2 -2.481791994 1.81E-05 0.001295 
AL118508.1 -3.002401028 1.89E-05 0.001329 
KRT17P2 -3.064496006 1.90E-05 0.001337 
HP -3.81741461 1.96E-05 0.001371 
KRT84 -5.260117588 1.96E-05 0.001371 
IFNG -3.213234679 1.98E-05 0.00138 
SOST -4.796476699 1.98E-05 0.00138 
CCR3 2.144887908 2.04E-05 0.001409 
CAGE1 -2.740288126 2.04E-05 0.001409 
WNT3A -3.040121098 2.04E-05 0.001409 
NKX2-1 -5.548537478 2.05E-05 0.001412 
RGS9BP 2.161096297 2.16E-05 0.001475 
LGALS9C -3.091427922 2.19E-05 0.001492 
PAX7 -5.876108883 2.19E-05 0.001492 
CGB3 3.414581035 2.22E-05 0.001502 
MOGAT2 -3.574893348 2.22E-05 0.001502 
AL035446.1 -3.267201488 2.25E-05 0.00152 
MT1G -2.373078807 2.32E-05 0.001559 
VAX1 -5.142383939 2.39E-05 0.001603 
MYLK4 -2.370553387 2.42E-05 0.001616 
DPY19L2P1 -2.824846592 2.41E-05 0.001616 
S100A12 -2.976297018 2.43E-05 0.001617 
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TPTEP1 -2.868495013 2.50E-05 0.001654 
FOXG1 -5.851647518 2.52E-05 0.001664 
TMPRSS11A -3.338869379 2.53E-05 0.001666 
CLDN6 3.39486995 2.54E-05 0.001667 
SST -5.9593918 2.57E-05 0.00168 
GDNF -2.395388803 2.61E-05 0.001701 
EFHD1 2.290675754 2.63E-05 0.00171 
CASP1P2 -3.27073107 2.67E-05 0.001729 
SLC30A10 -3.547641401 2.68E-05 0.001729 
ROS1 -3.89145916 2.68E-05 0.001729 
B4GALNT2 -4.143023017 2.68E-05 0.001729 
KEL -2.428544829 2.72E-05 0.001748 
WARS -2.003260858 2.74E-05 0.001756 
ARSJ -2.183696268 2.78E-05 0.001757 
ADGRB1 -2.25297352 2.79E-05 0.001757 
CDH2 -2.61626594 2.79E-05 0.001757 
TMPRSS11E -3.095261742 2.82E-05 0.001769 
KLK6 -4.375023412 2.84E-05 0.001777 
AC108136.1 -2.693638205 2.88E-05 0.001803 
IGFL3 -5.195190716 2.90E-05 0.001806 
SPRR2F -4.772274344 2.91E-05 0.001808 
BARX1 -3.262121908 3.03E-05 0.001863 
KRT32 -4.14105293 3.02E-05 0.001863 
DNAI1 2.62151024 3.05E-05 0.001873 
AC097478.1 -3.343422612 3.13E-05 0.001915 
CDH12 -4.875518101 3.14E-05 0.001919 
DUOX2 -2.646471759 3.17E-05 0.001932 
SPINK5 -2.434765821 3.20E-05 0.001936 
CLEC12A-AS1 -3.993949979 3.20E-05 0.001936 
MT1H -2.702155741 3.23E-05 0.001951 
OCA2 -4.170782675 3.29E-05 0.001977 
TKTL1 -4.318271001 3.53E-05 0.002108 
SLC35F3 -3.231436534 3.57E-05 0.002128 
ADD2 -2.831637763 3.61E-05 0.002143 
LINC02195 -2.692525731 3.65E-05 0.002154 
SIGLEC12 -2.592140858 3.67E-05 0.002166 
RN7SL684P -3.084411846 3.68E-05 0.002168 
WIF1 -4.590117189 3.71E-05 0.002179 
FLG-AS1 -2.236460218 3.73E-05 0.002183 
CD209 -2.338856831 3.75E-05 0.002185 
AL671277.1 -2.386190378 3.75E-05 0.002185 
LINC01550 -2.345107428 3.83E-05 0.002221 
TUSC5 -5.243279461 3.83E-05 0.002221 
SFTPD -2.254820543 3.84E-05 0.002223 
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FAM131B -2.060506839 3.89E-05 0.002243 
LINC00520 -3.434303917 3.94E-05 0.002269 
CASP5 -2.731656235 3.98E-05 0.002285 
WNT5A -2.115988321 4.02E-05 0.002296 
ALOXE3 2.306080183 4.08E-05 0.002322 
AC023906.2 -4.175428023 4.08E-05 0.002322 
MMP9 -2.582671135 4.10E-05 0.002331 
LGALS7 -4.832441389 4.38E-05 0.00247 
LINC01268 -2.281167908 4.40E-05 0.002478 
AC131097.3 -2.542190505 4.44E-05 0.002494 
LEMD1 -3.101577461 4.46E-05 0.002501 
AL357833.1 2.8808956 4.47E-05 0.002503 
LDHAL6A -3.549487376 4.48E-05 0.002503 
AC091182.2 -2.805996974 4.51E-05 0.002512 
NKG7 -2.258020851 4.55E-05 0.002528 
AMOT 2.228553688 4.59E-05 0.002543 
CTLA4 -2.05810334 4.61E-05 0.002549 
FXYD2 -2.333390466 4.62E-05 0.002549 
BLACAT1 -2.592450532 4.63E-05 0.00255 
LRRC38 -4.209845379 4.66E-05 0.002559 
TRDC -2.303893023 4.75E-05 0.002602 
CYP4X1 -2.204944299 4.78E-05 0.002612 
UTS2 -2.840021232 4.81E-05 0.00262 
IL1A -2.619513427 4.85E-05 0.002634 
ACVR1C -2.133499553 4.98E-05 0.002693 
TM4SF19 -2.895994657 4.98E-05 0.002693 
HLA-U -2.145427329 5.15E-05 0.002779 
APCDD1L-AS1 -2.941195892 5.17E-05 0.002779 
LGSN -4.440051147 5.16E-05 0.002779 
MT2A -2.280543713 5.25E-05 0.002811 
SCIN 2.141074006 5.41E-05 0.002863 
HR -2.011124713 5.40E-05 0.002863 
NDUFA4L2 -2.289554643 5.39E-05 0.002863 
MARCO -2.913708148 5.41E-05 0.002863 
AL096829.2 -2.666948613 5.53E-05 0.002913 
DCAF4L2 -8.492541663 5.56E-05 0.002917 
AC090409.1 -2.239804378 5.58E-05 0.002923 
FAM181B -2.283654619 5.59E-05 0.002923 
ISM2 2.353028795 5.63E-05 0.002928 
LILRP2 -3.113867177 5.62E-05 0.002928 
LBP -2.917029877 5.82E-05 0.003017 
EDN2 -2.545039683 5.85E-05 0.003018 
GREB1L 2.655310767 5.97E-05 0.003068 
CCL20 -2.761489105 5.97E-05 0.003068 
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LYPD1 -2.073640835 6.08E-05 0.003111 
LINC00479 2.110585104 6.13E-05 0.003132 
S100B -2.009676078 6.15E-05 0.003136 
SELL -2.507884352 6.16E-05 0.003136 
LAMC2 -2.398771908 6.37E-05 0.003232 
GZMA -2.301238976 6.50E-05 0.003291 
FGA -5.95181005 6.72E-05 0.003394 
LRP2 2.649493299 6.77E-05 0.003408 
STEAP1B -2.811579644 6.77E-05 0.003408 
AC004687.1 -2.138520765 6.85E-05 0.003435 
NTSR1 -3.275369338 6.86E-05 0.003435 
AK5 -2.280890138 6.89E-05 0.003442 
CXCL11 -2.876488231 6.96E-05 0.003469 
NPW -2.290096443 7.07E-05 0.003504 
CD70 -2.507222808 7.11E-05 0.003519 
MT2P1 -2.490416168 7.16E-05 0.00353 
TDRD9 -2.882206985 7.17E-05 0.003531 
LINC00944 -2.763067215 7.28E-05 0.00358 
USP30-AS1 -2.090049005 7.46E-05 0.003647 
DMBT1 -3.256035127 7.47E-05 0.003647 
AC100801.1 -5.074731115 7.50E-05 0.003656 
UCHL1 -2.617883871 7.51E-05 0.003656 
CCL4 -2.090568106 7.70E-05 0.003726 
MSTN -2.608274745 7.74E-05 0.003736 
EREG -3.141934464 7.77E-05 0.003745 
AC112251.1 -4.827046051 7.86E-05 0.003777 
LINC00327 -2.52203689 7.90E-05 0.003789 
CALR4P 2.085896931 7.95E-05 0.003802 
FASLG -2.35952689 7.94E-05 0.003802 
FIGNL2 2.511678841 8.00E-05 0.00382 
GABRG2 -5.524845148 8.03E-05 0.00382 
GFI1B -3.484130957 8.06E-05 0.003823 
NPPC -2.982353859 8.09E-05 0.003825 
CNR1 -2.672332004 8.34E-05 0.003927 
IGKV1-12 -3.559685548 8.36E-05 0.003931 
OSBPL6 -2.248799725 8.40E-05 0.003941 
LINC01564 -2.457041623 8.50E-05 0.003977 
AL034346.1 -2.476012724 8.50E-05 0.003977 
SPAG6 -2.876547823 8.64E-05 0.004024 
PRTG 2.023740454 8.68E-05 0.004033 
CD44-AS1 -2.008560434 8.76E-05 0.004068 
MIA -2.933358664 8.96E-05 0.004121 
AC226118.1 -3.324619362 9.09E-05 0.004165 
C16orf54 -2.202908441 9.10E-05 0.004166 
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LYPD2 -3.622130376 9.16E-05 0.004183 
SPINK6 -4.227773418 9.16E-05 0.004183 
PCDHA1 -3.259314162 9.42E-05 0.004285 
WNT5A-AS1 -2.113452335 9.45E-05 0.004293 
AC010735.2 -2.118534077 9.47E-05 0.004295 
AL033381.2 -4.373260936 9.50E-05 0.004303 
CROCC2 -2.917803834 9.57E-05 0.00432 
CHRNA9 -3.680609968 9.56E-05 0.00432 
ARC -2.231234199 9.74E-05 0.004394 
FAT2 -2.47550085 9.83E-05 0.004419 
MTCO1P40 -2.446596776 0.0001 0.00449 
RASSF9 -2.416473049 0.000102 0.004539 
AC036176.3 -3.16939908 0.000102 0.004539 
DPP10-AS1 -5.931053882 0.000103 0.00457 
AL033519.3 2.631073924 0.000103 0.004573 
CCL23 -2.452243614 0.000105 0.00462 
LAG3 -2.110224594 0.000109 0.004778 
AC026782.2 -3.240779178 0.000109 0.004778 
AC002384.1 -2.777926382 0.000109 0.004788 
IL20RB -2.565726449 0.00011 0.004794 
FDCSP -3.840551838 0.00011 0.004794 
CTSE -3.287671773 0.000111 0.004843 
RARRES1 2.526014731 0.000117 0.005051 
CXCL2 -2.343978087 0.000119 0.005115 
AC005722.2 -3.709461606 0.000121 0.005185 
NEFH -2.191305665 0.000122 0.005234 
CCL13 -2.375278828 0.000123 0.005247 
AP005117.1 -3.872890084 0.000124 0.00526 
CDH8 -2.18781003 0.000124 0.00526 
ASPG -2.437292387 0.000124 0.00526 
RAET1L -2.731597101 0.000124 0.00526 
NLRP3P1 -2.295143606 0.000128 0.005382 
AC005532.1 2.158341359 0.000128 0.005383 
ALDOB -2.941779659 0.00013 0.005434 
PLA2G4D -2.279414184 0.000132 0.00551 
AL683807.1 -2.375847683 0.000135 0.005606 
GSTM1 -3.78522604 0.000137 0.005641 
TGM3 -2.877530452 0.000139 0.005703 
KLK14 -2.581278178 0.00014 0.005718 
NGFR -2.403102406 0.00014 0.005727 
AL161630.1 -4.744423159 0.000141 0.005736 
AC011473.4 -5.52506497 0.000142 0.005785 
KIT -2.188992785 0.000143 0.005791 
RPSAP52 -2.812100918 0.000143 0.005791 
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AC099066.2 -2.382618352 0.000145 0.005846 
GPR15 -2.841406133 0.000146 0.00585 
UGT2A1 -4.11955576 0.000146 0.00585 
AC011632.1 -3.655829248 0.000147 0.005903 
PGLYRP4 -2.911869437 0.000149 0.005947 
AP000439.3 -4.127922117 0.000149 0.005947 
TTC4P1 4.200277063 0.00015 0.005987 
LINC00456 2.677610792 0.000151 0.005987 
SERPINB7 -3.399459231 0.00015 0.005987 
AC023794.3 -2.510559002 0.000153 0.006049 
CYP11A1 2.76944053 0.000154 0.006057 
SULF2 -2.014164903 0.000154 0.006057 
DNAI2 -2.596800432 0.000154 0.006057 
LGALS17A -3.24452801 0.000153 0.006057 
DSCAM -3.832774362 0.000157 0.00618 
CD69 -2.070715999 0.00016 0.006245 
SERPINB11 -4.064933119 0.000162 0.006286 
GRIN2A -2.80169566 0.000163 0.006316 
AC010307.4 -3.047872246 0.000164 0.006367 
TMSB15A -2.2757969 0.000165 0.006378 
PNCK -2.613090501 0.000165 0.00639 
ART3 -2.376236879 0.000166 0.006395 
ADH4 -2.761438399 0.000166 0.006395 
AC021218.1 -2.912986827 0.000167 0.006404 
BPIFB4 -3.863353261 0.000168 0.006431 
GPR25 -2.649041732 0.000169 0.006454 
ADIPOQ -5.902584602 0.000172 0.006495 
CYP26B1 2.063969736 0.000175 0.006566 
LINC02159 -2.783315633 0.000174 0.006566 
HSD3B1 4.107666237 0.000177 0.006625 
LINC00923 -3.229811329 0.000178 0.006652 
BMPR1B -2.588897934 0.000183 0.006799 
AC013264.1 -2.939230381 0.000184 0.006807 
EYA1 -2.212068585 0.000185 0.00682 
AC010275.1 -3.951680283 0.000185 0.00682 
LCE3E -5.531217635 0.000185 0.00682 
C8orf74 -2.969085792 0.000187 0.006852 
LINC00973 -5.160908505 0.000191 0.006981 
AC006058.1 -2.52277978 0.000193 0.007055 
LINC01807 -4.160438551 0.000196 0.007152 
CHODL -2.39550201 0.000198 0.007192 
KCNQ5 -2.899086267 0.000198 0.007192 
MICD -3.423705844 0.0002 0.007263 
RBMS3-AS3 -3.15723637 0.000201 0.007266 
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C2orf72 2.670235117 0.000202 0.007289 
PLEKHG4B 2.636775161 0.000205 0.007349 
AC113346.1 -3.0106194 0.000204 0.007349 
CYP1A2 -4.701803217 0.000207 0.007404 
TM4SF4 3.72584061 0.000208 0.007424 
SLCO5A1 -2.225919991 0.00021 0.007453 
PLA2G2A -2.79637978 0.000211 0.007498 
AC007991.2 -4.082310733 0.000214 0.007575 
LHX9 -2.772562952 0.000215 0.007614 
CSF2 -2.499033494 0.000216 0.00763 
TSGA10IP -2.655692998 0.000219 0.007709 
HTR3A -3.600246635 0.000221 0.007739 
TREML2 2.12314735 0.000221 0.007746 
AL499606.1 -2.800562684 0.000221 0.007747 
OTOF -2.124604335 0.000228 0.007953 
UBD -2.621199469 0.000228 0.007953 
SAA1 -2.961223929 0.000236 0.008203 
IGLC7 -3.163716424 0.000239 0.008288 
ANKUB1 -2.834693747 0.000241 0.00831 
CLCA3P -2.539420124 0.000247 0.008496 
CHGB -2.464475082 0.000247 0.008505 
CDSN -4.258521882 0.000252 0.00865 
AC112206.3 -3.241972976 0.000253 0.008666 
ALDH1A1 -2.274880452 0.000257 0.008742 
AC092384.2 -2.463485392 0.000257 0.008752 
LINC01901 -4.121086079 0.000262 0.008874 
IGHV2-70 -3.218511814 0.000263 0.008902 
PAX5 -2.425533713 0.000265 0.008975 
PRKAG3 -3.225095535 0.000267 0.009001 
APOA1 -2.633835727 0.000272 0.00913 
SOAT2 -2.404775553 0.000275 0.009202 
AC010735.1 -2.711923517 0.000279 0.00928 
PTX3 -2.316679002 0.000284 0.009416 
SLCO6A1 -3.017635274 0.000289 0.009531 
PIWIL3 4.143800326 0.000297 0.009776 
LINC01139 -3.571626937 0.000297 0.009776 
ARHGEF4 -2.029145158 0.000303 0.009894 
AC023157.1 -2.508828523 0.000302 0.009894 
KRT3 -2.632006967 0.000302 0.009894 
AL160408.4 -3.331728811 0.000302 0.009894 
WFDC12 -4.423277806 0.000304 0.009896 
FABP5P7 -2.118041447 0.000306 0.009969 
IL13RA2 -2.281999003 0.000307 0.009976 
AC078993.1 -2.585081902 0.000308 0.009984 
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ZNF385B -2.727871412 0.000309 0.009984 
C6orf15 -4.448935157 0.000309 0.009984 
CD1A -2.204181093 0.000312 0.010031 
SMIM2 2.15031704 0.000313 0.01004 
DUSP27 -3.481219971 0.000314 0.010074 
RPTN -4.351627163 0.000317 0.010141 
IQCA1 -2.103696661 0.000318 0.010154 
PRRT4 -2.062532316 0.000321 0.010205 
TRGC2 -2.064472685 0.000324 0.010289 
STMN2 -2.768206868 0.000324 0.010305 
ZFHX4-AS1 -2.974464603 0.000327 0.010342 
TMEM82 2.687808838 0.000329 0.010386 
JPH3 -2.485384147 0.000339 0.010666 
TNIP3 -2.214671859 0.000341 0.010699 
SCN2A -2.452538231 0.000342 0.010723 
CD38 -2.024347484 0.000344 0.010775 
NAA11 -4.937315577 0.000346 0.010806 
TBX18 -2.255829348 0.000347 0.010813 
LCE1C -4.291021459 0.000347 0.010813 
TAGLN3 -2.718031616 0.000351 0.010908 
SERPINA3 -3.041961748 0.000357 0.011053 
HRASLS2 2.723920991 0.000357 0.011062 
SLCO1A2 -2.863250472 0.000358 0.01107 
AL023754.1 -4.17119933 0.000364 0.011185 
FAM9C 4.164361946 0.000365 0.01119 
AC106865.1 -2.279145256 0.000367 0.011205 
AC018552.3 -2.919190862 0.000369 0.011241 
AL033384.1 -2.992511811 0.000368 0.011241 
SSTR5-AS1 -4.116227336 0.00037 0.011241 
DDX53 -5.304465043 0.000369 0.011241 
CES1 -2.660528766 0.000373 0.011285 
PROKR2 4.975652203 0.000375 0.011332 
BTG4 -3.439804063 0.000383 0.011439 
NNAT -2.530886608 0.000385 0.011447 
NTRK2 -2.29005608 0.00039 0.01151 
AC016717.2 -2.930230469 0.000393 0.011577 
PEG10 2.497191753 0.000396 0.011606 
AC007384.1 -2.130348639 0.000396 0.011606 
SFTA1P -2.648212852 0.000404 0.011838 
AC128709.1 -2.88692417 0.000417 0.012135 
ALDH1L1 -2.152528383 0.000419 0.012148 
AC106799.3 -4.621008677 0.000419 0.012153 
CSF3 -2.942516727 0.000425 0.012276 
DLX2 -2.511700594 0.000427 0.012296 
440 
 
MYL7 -3.951400592 0.000429 0.012328 
UGT1A1 -2.839740463 0.000432 0.012391 
PROX1-AS1 -3.238741339 0.000434 0.012417 
LEFTY1 -2.342774508 0.000435 0.012448 
AC004870.2 -5.090194783 0.000436 0.012451 
SLC6A14 -2.760519622 0.000437 0.012476 
PCDHA10 -2.295216525 0.000438 0.012482 
SPRR2A -3.446489781 0.000438 0.012486 
SIGLEC14 2.414498535 0.00044 0.012524 
AC078880.3 -3.069369753 0.00044 0.012525 
ORM1 -3.902661073 0.000442 0.012563 
DLX3 2.23304294 0.000445 0.012629 
AADACP1 -2.989117149 0.000448 0.012664 
PTPRN -2.288977936 0.000448 0.012672 
C11orf87 -3.661616498 0.000451 0.012741 
SH2D5 -2.374800516 0.000452 0.012753 
AL390755.1 -4.175162427 0.000454 0.012766 
GJB6 -2.053419075 0.00046 0.012891 
AC040174.2 -3.257158225 0.000467 0.012993 
SMLR1 2.790485732 0.000471 0.013069 
AC073115.1 3.150676691 0.000473 0.013095 
CEACAM4 -2.007535662 0.000472 0.013095 
MIR221 -2.404799119 0.000473 0.013095 
RNF17 -2.4298492 0.000483 0.013231 
PPARGC1A -2.547206323 0.000483 0.013231 
AC007991.4 -3.763515208 0.000486 0.013278 
PRODH -2.02123723 0.000488 0.013317 
DPP10 -4.069329733 0.000489 0.013341 
PAX3 -4.078254266 0.000492 0.013373 
AC016397.2 -2.414852465 0.000495 0.013441 
LINC00942 -2.178037456 0.000497 0.01345 
VTA1P1 -3.399990172 0.000506 0.013657 
SORCS2 -2.07738025 0.000508 0.013682 
AC087783.2 -3.029227162 0.000508 0.013687 
KRT82 -3.523355605 0.000511 0.013738 
LINC01714 2.279108976 0.000512 0.013761 
GNG4 -2.416559004 0.00052 0.013845 
KHDC1L -3.615941801 0.00052 0.013845 
OR2I1P -2.506981021 0.000525 0.013928 
C14orf39 -2.847764971 0.000525 0.013928 
ARHGDIG -2.955263949 0.000533 0.014078 
FMO3 -2.006835214 0.000538 0.014148 
ZNF683 -2.207189203 0.000546 0.014295 
LINC01615 -2.205693314 0.000551 0.014427 
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TMPRSS4 -2.093949503 0.000558 0.014524 
LINC01088 -2.161233582 0.000574 0.014905 
AP003174.1 -4.754438798 0.000575 0.014909 
C5orf66-AS1 -2.150958499 0.000576 0.014914 
CNTNAP5 -3.670108683 0.000578 0.014935 
MTND4P24 -2.662105367 0.000579 0.014948 
HSPB3 -3.163992678 0.000582 0.015001 
TMEM179 -2.950972145 0.000584 0.015036 
MTCO3P12 -2.004723602 0.000586 0.015048 
HLA-V -2.065795798 0.000593 0.015181 
TLL1 -2.172648734 0.000596 0.015237 
LINC01583 -3.555156022 0.000616 0.015607 
CCL24 -2.350944623 0.000619 0.015633 
TNFRSF19 -2.107151752 0.00062 0.015653 
TPRXL -2.281232639 0.000623 0.015687 
CXCL10 -2.327885285 0.000625 0.015717 
SLC6A10P -4.643165337 0.000626 0.015717 
SCN5A -2.075366013 0.000628 0.015742 
TTC24 -2.272032146 0.000629 0.01576 
KIF1A -2.945025369 0.000631 0.015787 
DTHD1 -2.145785077 0.000636 0.015903 
PTPN20CP -2.829174383 0.000646 0.016069 
AC068647.2 -3.586063925 0.000647 0.016089 
LINC02345 -2.013276199 0.00065 0.016105 
GJA3 -2.254784457 0.000649 0.016105 
LINC00930 -2.919831666 0.000655 0.016197 
NGB -3.239320309 0.00066 0.0163 
PCYT1B -2.197392293 0.000673 0.016492 
LINC00943 -2.745309865 0.000679 0.016608 
EGOT -2.411562153 0.00068 0.016614 
BPIFA1 -4.480019881 0.000688 0.016758 
CFHR1 -3.420363582 0.000691 0.016826 
LINC01115 -3.565036449 0.000692 0.016826 
SYT12 -2.077149111 0.000698 0.016917 
SPANXB1 -6.324343505 0.000698 0.016917 
ALOX12B -2.209491452 0.000702 0.016974 
FTLP15 3.464269373 0.00071 0.017115 
AC005064.1 -3.628388653 0.000712 0.017142 
AL357507.1 -4.49703446 0.000714 0.017173 
IGFN1 -2.602933208 0.000718 0.017208 
CAPN6 2.928906569 0.000721 0.017229 
MSLN -2.771378798 0.000728 0.017359 
AP000696.1 -2.708275708 0.00073 0.017406 
UGT1A9 -2.896353918 0.000731 0.017408 
442 
 
SERPINA9 -3.962578776 0.000737 0.017509 
TBC1D3D -4.861244717 0.000754 0.017839 
KCNJ18 -4.177834455 0.000785 0.018339 
IGHV2-5 -2.771669251 0.000788 0.018362 
PAK5 -3.219461608 0.000789 0.018378 
SLC19A3 2.098494251 0.000794 0.018445 
AC122710.3 -2.150159181 0.000799 0.018491 
SPINK7 -2.890234712 0.000801 0.018497 
LURAP1L-AS1 -3.222787205 0.0008 0.018497 
CT83 -5.755865453 0.000804 0.018549 
TF -2.177163563 0.000823 0.018916 
TRBV30 -2.272530471 0.000828 0.018987 
AC022274.1 -2.545460904 0.000829 0.018988 
MPPED1 -3.630186263 0.000833 0.019028 
SLC13A5 -2.046312188 0.000837 0.019065 
FGF20 -4.042670438 0.000838 0.019065 
CTCFL -4.205133855 0.000839 0.019065 
HKDC1 -2.363067764 0.000861 0.019475 
GZMH -2.027690147 0.000864 0.019514 
GBP6 -2.443929703 0.000882 0.019811 
CA8 -2.235051537 0.000886 0.019868 
BX324167.1 -2.909637899 0.000889 0.019903 
AC093627.6 -2.853609829 0.000894 0.019969 
AC019171.1 -2.00314279 0.000897 0.020017 
OR9A4 -3.815901455 0.000902 0.020073 
AC005009.1 -2.485985253 0.000907 0.020151 
DNER -2.700440762 0.000911 0.020216 
MT1M -2.101774376 0.000914 0.020232 
LINC01215 -2.147973316 0.000921 0.020325 
IL22RA2 -2.390230732 0.000921 0.020325 
DUOXA2 -2.39468372 0.000921 0.020325 
RPS4XP23 -2.369597255 0.000925 0.020338 
LINC01854 -5.043544796 0.000931 0.020452 
SCN11A -2.033078927 0.000956 0.020855 
AC020922.1 -2.862616098 0.00096 0.020901 
LINC01546 -2.184114032 0.000973 0.021145 
IL33 -2.052444648 0.000981 0.021218 
SGCG -2.568777855 0.000979 0.021218 
PYDC1 -3.502470347 0.000997 0.02148 
AP000904.1 -3.701718137 0.00101 0.02165 
C15orf53 -2.680153743 0.001012 0.02169 
MED15P9 -4.547171036 0.00102 0.021817 
FAM83A -2.073891931 0.001028 0.021953 
U8 -2.129827763 0.001029 0.021953 
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LINC00221 -6.104305706 0.001035 0.022004 
FCGR3B -2.077639354 0.001045 0.022162 
AC010754.1 -2.364486876 0.001054 0.022284 
AC002454.1 -2.400210725 0.001074 0.022575 
AL157931.1 -4.011689286 0.001097 0.022899 
AC104078.1 -2.880726345 0.001101 0.022947 
SAGE1 -4.832578738 0.001115 0.023116 
LRP1B -2.517881658 0.00112 0.023174 
KNG1 -4.145317246 0.001128 0.023269 
LINC01998 -3.234959836 0.001132 0.02333 
EEF1DP5 -3.886933066 0.001134 0.023371 
FGF5 -2.628291395 0.001141 0.02345 
TCN1 -2.769403933 0.001141 0.02345 
GAL3ST1 2.058629083 0.001142 0.023454 
AC243829.4 -2.288474679 0.001153 0.023598 
LGALS9B -2.799105077 0.00116 0.023725 
CXCL1 -2.087383272 0.001191 0.024172 
AP005264.1 -2.307841266 0.001191 0.024172 
SPRR2C -5.694033218 0.00119 0.024172 
SLC27A6 2.626284615 0.001194 0.024208 
PNLIPRP3 -4.723733517 0.001196 0.024224 
AP005131.2 -2.220388287 0.00121 0.024384 
AC078880.5 -2.81369498 0.001213 0.024384 
SAA2-SAA4 -3.21467226 0.001215 0.024384 
CES1P1 -3.343941333 0.00121 0.024384 
AC010894.5 -2.361984437 0.00122 0.024465 
MESP1 2.065763465 0.001227 0.024516 
GAP43 -2.315361694 0.001228 0.024516 
MIR3681HG -2.521616619 0.001245 0.024753 
SH3GL2 -2.863609857 0.001247 0.024768 
C1orf68 -4.557211476 0.001248 0.024768 
AC126768.2 -3.016196415 0.001252 0.024796 
PHACTR3 -2.005128507 0.001255 0.024804 
LINC02086 -2.077544089 0.001261 0.024873 
AC017048.3 -2.22287428 0.001263 0.024903 
LINC02242 -3.638575721 0.001264 0.024903 
AL591468.1 -3.27541953 0.001277 0.025082 
PTCHD3 -3.704990025 0.001279 0.025103 
MTCO2P16 -3.026755706 0.001292 0.025205 
MIR27B -3.07009666 0.001297 0.025267 
AC000032.1 -4.454225176 0.001297 0.025267 
CRNN -4.566652309 0.001301 0.025288 
LINC02152 -5.146498055 0.001306 0.025298 
AC022872.1 2.154584857 0.001308 0.025316 
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AC012501.1 -3.234709724 0.001313 0.025378 
MRGPRX3 -3.860190882 0.001315 0.025389 
AC083805.1 -2.478101707 0.001329 0.025593 
C8orf89 -2.475150707 0.00135 0.025872 
AC004241.4 -2.05733952 0.001366 0.026108 
CLDN10 -2.437749977 0.00138 0.026325 
CXCR2P1 -2.278832818 0.001388 0.02642 
TRPM8 -2.05690014 0.001389 0.026433 
ATP12A -2.722551922 0.00139 0.026433 
AP001999.1 -3.377098213 0.001403 0.026627 
TRGV10 -2.099963354 0.001408 0.026678 
AL021877.2 -3.185478727 0.001431 0.027006 
AL035252.2 -3.242637995 0.001431 0.027006 
AP003486.1 -2.036031874 0.001433 0.027026 
ERVH48-1 3.074584993 0.001442 0.027124 
LINC01338 -2.19407131 0.001446 0.027187 
RPRM -2.049382292 0.001491 0.027729 
IGLV3-27 -2.671929349 0.001503 0.027888 
AL645939.5 -3.01897623 0.001504 0.027897 
AC092769.1 2.633686769 0.001515 0.027981 
IRX6 -2.982863267 0.001514 0.027981 
BEND4 -2.186600726 0.001522 0.028038 
DLX1 -2.190179097 0.00152 0.028038 
AC010998.3 -2.979089029 0.001519 0.028038 
KRT72 -2.815173815 0.001533 0.0282 
IGKV1OR2-6 -3.141036558 0.001538 0.028244 
FAM19A4 -3.517239962 0.001549 0.028377 
KLRC4 -2.502795572 0.001552 0.02841 
PROK2 -2.197958782 0.001567 0.028554 
WFDC5 -2.56995252 0.001569 0.028554 
AC055854.1 -2.748400555 0.001565 0.028554 
AC114786.3 -3.30674798 0.001562 0.028554 
AL139246.4 -2.15979804 0.001585 0.028783 
SLC2A2 -3.849144184 0.001595 0.028877 
GUCA1A -2.212504427 0.001601 0.028932 
CFAP77 -2.352578634 0.001604 0.028932 
FAM133A -3.264086508 0.001602 0.028932 
SLITRK4 -2.150879745 0.001609 0.028966 
CCDC185 -2.244157146 0.001626 0.029237 
PIWIL1 -2.720090889 0.001628 0.029257 
AL772337.1 -3.11229497 0.00163 0.029264 
HMP19 -2.66265529 0.001642 0.029409 
LINC00626 -3.627922349 0.001649 0.029503 
NAP1L6 -2.852970069 0.001659 0.029614 
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C20orf166-AS1 -2.348056567 0.001674 0.029773 
AC010280.2 -2.412794475 0.001678 0.029778 
TFPI2 -2.103567256 0.001686 0.029863 
PTPRT -2.340193378 0.001703 0.030089 
DNAH11 -2.296247633 0.001713 0.030167 
NYAP2 -2.562052013 0.001711 0.030167 
C7orf65 -2.853930504 0.001715 0.030173 
LCE3D -4.975246654 0.001723 0.030225 
AL136088.1 -2.904753996 0.001733 0.030388 
AF106564.1 -3.359400127 0.00174 0.030477 
KRT34 -2.673873177 0.001755 0.030592 
LINC02029 -2.462951148 0.001766 0.030708 
BCHE -2.043495909 0.001774 0.030824 
PRAME -3.264233492 0.001776 0.030847 
UGT2B17 -2.663056319 0.00178 0.030903 
AF274855.1 -3.743314763 0.001798 0.031112 
CGA 2.761665289 0.001802 0.03115 
AC026495.1 -3.267938261 0.001807 0.031209 
PPY 2.578306048 0.001812 0.031269 
ELFN2 -2.301846293 0.001826 0.031432 
AC022075.2 -2.277066219 0.001829 0.031453 
TM4SF19-TCTEX1D2 -2.057788564 0.001832 0.031463 
MS4A8 -3.623454128 0.001834 0.031463 
TUBA3E -3.872424005 0.001832 0.031463 
XIST -3.590899771 0.001837 0.031493 
CXCL13 -2.125770406 0.00185 0.031673 
AC105460.1 -4.633704537 0.001854 0.031688 
AL355601.1 -3.607074322 0.001863 0.031794 
C11orf44 -3.232783217 0.001874 0.031914 
ELANE -2.371844915 0.001877 0.031947 
AL391704.1 -4.35343115 0.001902 0.032232 
AC012498.2 -3.608795 0.001906 0.032263 
BOK-AS1 -3.528100575 0.001916 0.032358 
AKR1C2 -2.037094798 0.001944 0.032759 
CALML5 -3.04998459 0.001981 0.033212 
VSTM2L 2.018537637 0.002003 0.033467 
DEFB1 -2.151400118 0.002013 0.033586 
MT1A -2.192072549 0.002016 0.033617 
C20orf141 -3.68061537 0.002022 0.033696 
SPRR4 -3.279271782 0.002025 0.033697 
AL355596.1 -2.33196447 0.002032 0.033766 
CPB1 -3.199263939 0.00203 0.033766 
CD36 -2.0449001 0.002067 0.034248 
GPR142 -2.677664964 0.002069 0.034248 
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AL139095.3 -3.24302511 0.002069 0.034248 
SLC22A31 -2.274606048 0.002074 0.034278 
AC234772.3 -2.132363547 0.002076 0.03429 
C1orf186 -2.1607558 0.00208 0.03434 
AC110618.1 -2.089401194 0.002091 0.034494 
SGK2 2.052175716 0.002098 0.034555 
IGLV1-51 -2.064534816 0.0021 0.03457 
LINC00504 -2.612009996 0.00211 0.034628 
MIR23B -3.3179136 0.002111 0.034628 
AFP -3.434022606 0.00211 0.034628 
CALHM3 -2.281459843 0.00212 0.03473 
AC009955.2 -2.322060601 0.002139 0.034964 
CTAGE12P -2.566392107 0.002142 0.034984 
AL022342.1 -2.288214303 0.002151 0.035045 
KLK7 -3.581456291 0.00221 0.035757 
PRSS33 -3.0109695 0.00222 0.035851 
CHL1 -2.164389566 0.002224 0.035871 
AP000943.2 -3.076703738 0.002223 0.035871 
PIGR -2.550495839 0.002234 0.035987 
MUC21 -2.855304318 0.002241 0.036002 
FGB -4.078684959 0.002244 0.03602 
AC120036.2 -2.007587943 0.002254 0.036067 
FAM163B -2.256908711 0.002261 0.036067 
AC025016.1 -4.901165626 0.002265 0.036072 
CLRN3 -2.348531893 0.002285 0.036306 
AC079630.2 -3.110543564 0.002288 0.036306 
IGKV1D-33 -3.673576048 0.002296 0.036411 
LINC02450 -2.213810905 0.002303 0.036457 
ZFP57 -2.76325187 0.00231 0.036561 
TGFB2-AS1 -2.082252694 0.002322 0.03669 
SDR9C7 -2.28576258 0.002334 0.036796 
VCX3A -2.9238814 0.002334 0.036796 
MT1P3 -3.167606008 0.002353 0.03698 
ACTBL2 -2.83079711 0.002363 0.037087 
TMPRSS11F -3.774737603 0.002376 0.03722 
AGMO -2.344736763 0.002382 0.037274 
LINC01698 -2.809265813 0.002411 0.037561 
AC025884.1 -2.726311824 0.002415 0.037589 
BCAR4 2.852891994 0.00243 0.037717 
IGLV1-40 -2.27405514 0.00245 0.037948 
PI16 -2.346533126 0.00246 0.038067 
FLJ42969 2.240854592 0.002465 0.038103 
CYP4Z1 -2.001050141 0.002479 0.038217 
DBET -2.875626509 0.002501 0.038418 
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FOXN1 -2.105651499 0.002506 0.038422 
RTL1 -4.366691696 0.002511 0.038456 
CCAT1 -3.171071714 0.002518 0.038517 
NFE4 -2.781668169 0.002531 0.038648 
IFNK -4.810385681 0.002543 0.038798 
AC087672.3 -2.031383764 0.002546 0.038836 
AC091173.1 -2.948306777 0.00255 0.038862 
AL121949.1 -3.98013946 0.002558 0.038914 
AC092811.1 -2.417286837 0.002566 0.038957 
AC007907.1 -3.490686389 0.002565 0.038957 
KLK8 -3.586291633 0.002571 0.038994 
FCRL5 -2.05554166 0.002583 0.039121 
IGHV4-4 -2.65673949 0.002584 0.039121 
KCNA1 -3.454988932 0.002633 0.039563 
MIR548XHG -4.012679706 0.002634 0.039563 
AC024337.1 2.776634605 0.002638 0.03958 
KC6 -2.643713248 0.002647 0.039623 
MUC16 -2.647970979 0.002654 0.039691 
PENK -2.670613156 0.002653 0.039691 
AL136018.1 -3.78779298 0.002693 0.040106 
AC015656.1 -2.794219883 0.0027 0.040194 
RPE65 -3.37055988 0.002711 0.04029 
RPS16P9 2.785560189 0.002726 0.040357 
CHRNA4 -3.274137138 0.002735 0.040479 
IGKV3D-15 -2.522969235 0.002762 0.040809 
LOR -3.024709153 0.002782 0.040967 
AC012174.1 -2.417505106 0.002804 0.041174 
AC122685.1 -4.30721626 0.002815 0.041244 
AC016769.3 -2.626151786 0.002829 0.041409 
TTLL11-IT1 -2.131544199 0.002841 0.041563 
AIPL1 -2.906691293 0.002857 0.041665 
SERPINA10 -2.854826012 0.002876 0.041831 
AC093833.1 -2.780668837 0.00288 0.041861 
LUCAT1 -2.042351162 0.0029 0.042006 
GABRG3 -2.774947062 0.00291 0.042046 
AC037486.1 -2.696172146 0.002921 0.042141 
GOLGA6L7P -3.315384229 0.002932 0.042261 
LPA -2.374788335 0.002941 0.042302 
SPRR2B -4.641805409 0.002938 0.042302 
LINC01792 -2.641584576 0.002943 0.042321 
AC021723.1 -2.189413131 0.002978 0.04267 
SSX1 -4.79886094 0.002976 0.04267 
PNLDC1 -2.12162452 0.002984 0.042714 
VIL1 -2.484749543 0.002996 0.042837 
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AC025881.1 -3.648383573 0.003008 0.042927 
IGHV3-43 -2.387355112 0.003027 0.043126 
TCAM1P -2.383177747 0.003051 0.043374 
AC079209.1 -2.000776411 0.003076 0.043638 
AC015908.2 2.167351464 0.003098 0.043874 
NUTM2E -2.526015455 0.003118 0.044068 
LINC02432 -2.543005434 0.003118 0.044068 
SYNPR -3.876299494 0.003133 0.044242 
PRAC1 -3.969744007 0.003137 0.044281 
IGHV3-48 -2.310441374 0.003143 0.044343 
IGKV1-9 -2.271687064 0.003162 0.044444 
AC105384.2 -2.168437187 0.003166 0.044478 
AC114776.1 -2.95905246 0.003172 0.0445 
NBEAP1 -2.113650698 0.003207 0.044864 
AC090578.1 -2.78816597 0.003229 0.045015 
THEG -2.804316794 0.003249 0.045168 
PSG9 2.837300554 0.003287 0.045407 
AC093063.1 -3.508187517 0.003331 0.045868 
AC010343.3 -3.321640182 0.003339 0.045925 
IGLV5-37 -3.267137169 0.003347 0.045996 
SERPINA11 -3.767240282 0.00335 0.046022 
ABCC13 -2.193243579 0.003364 0.046193 
CIDEA -2.03618672 0.003367 0.046213 
AC023310.4 -2.571734362 0.003436 0.046862 
LRRC3B -2.973391151 0.003458 0.047021 
MMP7 -2.040002507 0.003536 0.047874 
AL445531.1 -2.753373887 0.003568 0.048148 
SLC7A11-AS1 -2.392557606 0.003577 0.048234 
ZG16 2.459406132 0.003684 0.049164 
AL445437.1 -2.228800546 0.003686 0.049164 
AL390334.1 -2.848271613 0.003691 0.049196 
ELAVL3 -2.341692571 0.003708 0.049313 
ALG1L3P -2.318885338 0.003734 0.049546 
AC128709.2 -2.793682188 0.003772 0.049876 
PSAT1P1 2.049320551 0.003783 0.049996 
 
 
Table 7.16: List of significantly altered genes between VGLL1-high and VGLL1-low MIBC 

































Figure 7.29: PTCH1 expression in native urothelium 
Biological replicate from Figure 5.4 of PTCH1 expression and localisation in Y2444 
ureter (A). Sections that were labelled with no primary antibody were used as 
















































Figure 7.30: NuHS cell morphology before and following SAG treatment 
Phase micrograph images of Y875 NuHS cells in sparse (top image) and confluent 
(bottom images) cultures. Once confluent, cells were serum starved for 24h before 
subsequent treatment with either vehicle DMSO (bottom left image) or 100 nM SAG 
(bottom right image) for a period of 24h before the image was captured.  
Figure 7.31: GLI1 induction by SAG in NuHS cells 
Biological replicate from Figure 5.8 of GLI1 expression in Y929A NuHS cells following 24h 
100 nM SAG treatment. Cells that were labelled with no primary antibody were used as 
negative controls. An accompanying Hoechst 33528 DNA staining image is provided in 
the left hand corner of each immunofluorescence image. Scale bar= 20 µm.  
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Gene  Comparison Significant? Summary pval 
PTCH1 DMSO vs. PD153035 Yes ** 0.0043 
PTCH1 DMSO vs. PD/SAG No ns 0.6366 
PTCH1 DMSO vs. PD/SAG/GDC Yes ** 0.0095 
PTCH1 DMSO vs. GDC-0449 No ns 0.6083 
PTCH1 PD153035 vs. PD/SAG No ns 0.9756 
PTCH1 PD153035 vs. PD/SAG/GDC No ns >0.9999 
PTCH1 PD153035 vs. GDC-0449 No ns 0.0853 
PTCH1 PD/SAG vs. PD/SAG/GDC No ns 0.9974 
PTCH1 PD/SAG/GDC vs. GDC-0449 No ns 0.2196 
GLI1 DMSO vs. PD153035 Yes *** 0.0001 
GLI1 DMSO vs. PD/SAG Yes *** 0.0002 
GLI1 DMSO vs. PD/SAG/GDC Yes *** 0.0002 
GLI1 DMSO vs. GDC-0449 No ns >0.9999 
GLI1 PD153035 vs. PD/SAG No ns >0.9999 
GLI1 PD153035 vs. PD/SAG/GDC No ns >0.9999 
GLI1 PD153035 vs. GDC-0449 Yes *** 0.0009 
GLI1 PD/SAG vs. PD/SAG/GDC No ns >0.9999 
GLI1 PD/SAG vs. GDC-0449 Yes ** 0.0019 
GLI1 PD/SAG/GDC vs. GDC-0449 Yes ** 0.0016 
 



































































Figure 7.32: Negative controls for Figure 5.15 
Y1483 cells receiving no primary antibody at all time points were used as negative 
controls. Images were all taken at same exposure and are shown with overlaid 
Hoechst 33258 DNA staining. Scale bar= 50µm. 
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Gene  Comparison Significant? Summary pval 
SHH in situ vs. Luminal Papillary No ns >0.9999 
SHH in situ vs. Luminal Non-Specified No ns 0.0974 
SHH in situ vs. Luminal Unstable Yes * 0.0176 
SHH in situ vs. Basal/Squamous Yes *** 0.0006 
SHH in situ vs. Neuroendocrine No ns 0.5169 
SHH in situ vs. Stroma-Rich No ns 0.0831 
SHH Luminal Papillary vs. Luminal Non-
Specified 
Yes *** 0.0002 
SHH Luminal Papillary vs. Luminal 
Unstable 
Yes **** <0.0001 
SHH Luminal Papillary vs. 
Basal/Squamous 
Yes **** <0.0001 
SHH Luminal Papillary vs. 
Neuroendocrine 
No ns 0.2903 
SHH Luminal Papillary vs. Stroma-Rich Yes **** <0.0001 
SHH Luminal Non-Specified vs. Luminal 
Unstable 
No ns >0.9999 
SHH Luminal Non-Specified vs. 
Basal/Squamous 
No ns >0.9999 
SHH Luminal Non-Specified vs. 
Neuroendocrine 
No ns >0.9999 
SHH Luminal Non-Specified vs. Stroma-
Rich 
No ns >0.9999 
SHH Luminal Unstable vs. 
Basal/Squamous 
No ns >0.9999 
SHH Luminal Unstable vs. 
Neuroendocrine 
No ns >0.9999 
SHH Luminal Unstable vs. Stroma-Rich No ns >0.9999 
SHH Basal/Squamous vs. 
Neuroendocrine 
No ns >0.9999 
SHH Basal/Squamous vs. Stroma-Rich No ns 0.0875 
SHH Neuroendocrine vs. Stroma-Rich No ns >0.9999 
 
 








Gene  Comparison Significant? Summary pval 
PTCH1 in situ vs. Luminal Papillary Yes ** 0.0018 
PTCH1 in situ vs. Luminal Non-Specified Yes * 0.0172 
PTCH1 in situ vs. Luminal Unstable Yes * 0.0151 
PTCH1 in situ vs. Basal/Squamous Yes *** 0.0006 
PTCH1 in situ vs. Neuroendocrine No ns >0.9999 
PTCH1 in situ vs. Stroma-Rich Yes * 0.0339 
PTCH1 Luminal Papillary vs. Luminal Non-
Specified 
No ns >0.9999 
PTCH1 Luminal Papillary vs. Luminal 
Unstable 
No ns >0.9999 
PTCH1 Luminal Papillary vs. 
Basal/Squamous 
No ns >0.9999 
PTCH1 Luminal Papillary vs. 
Neuroendocrine 
Yes * 0.0189 
PTCH1 Luminal Papillary vs. Stroma-Rich No ns >0.9999 
PTCH1 Luminal Non-Specified vs. Luminal 
Unstable 
No ns >0.9999 
PTCH1 Luminal Non-Specified vs. 
Basal/Squamous 
No ns >0.9999 
PTCH1 Luminal Non-Specified vs. 
Neuroendocrine 
No ns 0.1094 
PTCH1 Luminal Non-Specified vs. Stroma-
Rich 
No ns >0.9999 
PTCH1 Luminal Unstable vs. 
Basal/Squamous 
No ns >0.9999 
PTCH1 Luminal Unstable vs. 
Neuroendocrine 
No ns 0.1114 
PTCH1 Luminal Unstable vs. Stroma-Rich No ns >0.9999 
PTCH1 Basal/Squamous vs. 
Neuroendocrine 
Yes ** 0.0079 
PTCH1 Basal/Squamous vs. Stroma-Rich No ns 0.5654 
PTCH1 Neuroendocrine vs. Stroma-Rich No ns 0.2176 
 









Gene  Comparison Significant? Summary pval 
GLI1 in situ vs. Luminal Papillary No ns 0.8105 
GLI1 in situ vs. Luminal Non-Specified Yes ** 0.0087 
GLI1 in situ vs. Luminal Unstable No ns 0.9572 
GLI1 in situ vs. Basal/Squamous No ns 0.0525 
GLI1 in situ vs. Neuroendocrine No ns 0.7044 
GLI1 in situ vs. Stroma-Rich Yes **** <0.0001 
GLI1 Luminal Papillary vs. Luminal Non-
Specified 
Yes * 0.0219 
GLI1 Luminal Papillary vs. Luminal 
Unstable 
No ns >0.9999 
GLI1 Luminal Papillary vs. 
Basal/Squamous 
Yes * 0.0197 
GLI1 Luminal Papillary vs. 
Neuroendocrine 
No ns >0.9999 
GLI1 Luminal Papillary vs. Stroma-Rich Yes **** <0.0001 
GLI1 Luminal Non-Specified vs. Luminal 
Unstable 
No ns 0.0567 
GLI1 Luminal Non-Specified vs. 
Basal/Squamous 
No ns >0.9999 
GLI1 Luminal Non-Specified vs. 
Neuroendocrine 
No ns >0.9999 
GLI1 Luminal Non-Specified vs. Stroma-
Rich 
No ns >0.9999 
GLI1 Luminal Unstable vs. 
Basal/Squamous 
No ns 0.267 
GLI1 Luminal Unstable vs. 
Neuroendocrine 
No ns >0.9999 
GLI1 Luminal Unstable vs. Stroma-Rich Yes **** <0.0001 
GLI1 Basal/Squamous vs. 
Neuroendocrine 
No ns >0.9999 
GLI1 Basal/Squamous vs. Stroma-Rich Yes **** <0.0001 
GLI1 Neuroendocrine vs. Stroma-Rich No ns >0.9999 
 













Gene  Comparison Significant? Summary pval 
GLI2 in situ vs. Luminal Papillary No ns 0.3866 
GLI2 in situ vs. Luminal Non-Specified Yes **** <0.0001 
GLI2 in situ vs. Luminal Unstable Yes * 0.0204 
GLI2 in situ vs. Basal/Squamous Yes **** <0.0001 
GLI2 in situ vs. Neuroendocrine Yes ** 0.0022 
GLI2 in situ vs. Stroma-Rich Yes **** <0.0001 
GLI2 Luminal Papillary vs. Luminal Non-
Specified 
Yes **** <0.0001 
GLI2 Luminal Papillary vs. Luminal 
Unstable 
No ns 0.1547 
GLI2 Luminal Papillary vs. 
Basal/Squamous 
Yes **** <0.0001 
GLI2 Luminal Papillary vs. 
Neuroendocrine 
No ns 0.0543 
GLI2 Luminal Papillary vs. Stroma-Rich Yes **** <0.0001 
GLI2 Luminal Non-Specified vs. Luminal 
Unstable 
Yes * 0.0115 
GLI2 Luminal Non-Specified vs. 
Basal/Squamous 
No ns >0.9999 
GLI2 Luminal Non-Specified vs. 
Neuroendocrine 
No ns >0.9999 
GLI2 Luminal Non-Specified vs. Stroma-
Rich 
No ns >0.9999 
GLI2 Luminal Unstable vs. 
Basal/Squamous 
Yes ** 0.0035 
GLI2 Luminal Unstable vs. 
Neuroendocrine 
No ns >0.9999 
GLI2 Luminal Unstable vs. Stroma-Rich Yes **** <0.0001 
GLI2 Basal/Squamous vs. 
Neuroendocrine 
No ns >0.9999 
GLI2 Basal/Squamous vs. Stroma-Rich Yes *** 0.0002 
GLI2 Neuroendocrine vs. Stroma-Rich No ns >0.9999 
 










Gene         log2 fold change                     pval                      qval 
KLHDC7B -5.556864704 2.11E-21 5.79E-17 
GSTM2 4.042492238 7.80E-20 1.07E-15 
U62317.1 -5.5999835 1.23E-18 1.12E-14 
GLI2 3.448127657 1.63E-17 1.12E-13 
AP000688.1 2.786853663 1.14E-16 6.26E-13 
FGFBP2 5.463622964 4.07E-15 1.86E-11 
PSD2 3.486184918 1.85E-14 7.27E-11 
ABCC1 2.072706781 7.94E-14 2.72E-10 
TREML3P 3.912880726 3.96E-13 1.21E-09 
F2RL2 3.480595587 4.45E-13 1.22E-09 
CABYR 2.78654588 1.52E-12 3.79E-09 
LTF -5.955470485 5.38E-12 1.07E-08 
IGLV6-57 -5.151473665 5.27E-12 1.07E-08 
SOX11 3.295994639 5.46E-12 1.07E-08 
AL355303.1 4.021524635 6.94E-12 1.24E-08 
U8 4.334193506 7.22E-12 1.24E-08 
ANXA3 -2.769645751 8.83E-12 1.43E-08 
ADH1C 5.469687727 1.52E-11 2.31E-08 
IGLV3-21 -4.781074286 4.33E-11 5.40E-08 
MZB1 -4.002502823 4.23E-11 5.40E-08 
IGLC2 -4.387943721 4.67E-11 5.58E-08 
ACKR2 -4.422559767 5.19E-11 5.93E-08 
CXCL5 -4.712743982 6.28E-11 6.89E-08 
IGLV2-23 -4.632817248 7.09E-11 7.49E-08 
IGLC3 -4.217846703 7.50E-11 7.62E-08 
FCRLA -4.121992113 7.82E-11 7.66E-08 
IGHV4-31 -4.749990056 8.79E-11 8.32E-08 
IGKV1-5 -4.361328065 9.89E-11 9.05E-08 
IGLV1-36 -4.867918687 1.18E-10 9.74E-08 
SAA2 -4.606693751 1.21E-10 9.74E-08 
IGKV1-16 -4.491579718 1.12E-10 9.74E-08 
FCRL5 -4.289303387 1.14E-10 9.74E-08 
IGKV3-11 -4.243587806 1.27E-10 9.97E-08 
IGHV3-21 -4.545267431 1.38E-10 1.00E-07 
IGLV1-44 -4.084995431 1.72E-10 1.21E-07 
IGKC -4.068257789 1.86E-10 1.25E-07 
FCGR3B -4.037251516 1.82E-10 1.25E-07 
PTGR1 2.455970946 2.41E-10 1.52E-07 
GSTM4 2.567564661 2.46E-10 1.52E-07 
SLC47A1 3.21398786 2.49E-10 1.52E-07 
NECAB2 3.449092113 3.25E-10 1.94E-07 
MT-TH -6.393174329 3.54E-10 1.96E-07 
IGKV1-9 -4.602012883 3.43E-10 1.96E-07 
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IGHV4-34 -4.232039564 3.62E-10 1.96E-07 
AC004889.1 2.069718635 3.63E-10 1.96E-07 
STXBP5L 4.360664941 3.40E-10 1.96E-07 
IGLV3-10 -4.909376391 3.83E-10 2.01E-07 
IGHG1 -4.028745432 3.91E-10 2.01E-07 
SLC35G1 2.003232314 3.95E-10 2.01E-07 
IGLV4-69 -5.041918009 4.13E-10 2.01E-07 
SRXN1 2.171467981 4.18E-10 2.01E-07 
SOST 6.437246464 4.04E-10 2.01E-07 
CALML5 -5.970795598 4.95E-10 2.34E-07 
IGLV10-54 -5.104517793 5.10E-10 2.37E-07 
IGLV3-27 -5.158433766 5.18E-10 2.37E-07 
IGLV1-40 -4.255499539 6.34E-10 2.76E-07 
IGHV3-30 -4.231736045 6.32E-10 2.76E-07 
LINC02010 3.080405746 6.75E-10 2.89E-07 
AL121758.1 2.542330631 7.45E-10 3.14E-07 
FDCSP -6.002171448 7.85E-10 3.18E-07 
IGHV3-73 -4.815599993 7.80E-10 3.18E-07 
IGHV4-39 -4.420081974 7.87E-10 3.18E-07 
IGHV1-46 -4.359243517 8.06E-10 3.20E-07 
SVIP -2.005780552 8.20E-10 3.22E-07 
IGHG2 -4.126642567 8.63E-10 3.34E-07 
IGHGP -3.967366264 9.45E-10 3.60E-07 
MDGA1 2.776465447 9.84E-10 3.70E-07 
GLDC -4.268608911 1.01E-09 3.76E-07 
IGKV3-15 -4.192738873 1.10E-09 3.97E-07 
IGHV3-48 -4.519585287 1.23E-09 4.39E-07 
GCLM 2.30944184 1.37E-09 4.81E-07 
HECW1 2.530760705 1.38E-09 4.81E-07 
AC108865.1 4.445714392 2.08E-09 7.12E-07 
AFAP1-AS1 -4.933630537 2.15E-09 7.27E-07 
IGLV10-67 -4.307159081 2.25E-09 7.51E-07 
CIDEC -5.966849362 2.46E-09 7.80E-07 
KISS1 -4.875145929 2.47E-09 7.80E-07 
IGHV3-66 -4.744111922 2.44E-09 7.80E-07 
JCHAIN -3.571384715 2.46E-09 7.80E-07 
NAT16 3.352228189 2.45E-09 7.80E-07 
AC245369.3 -4.460620794 2.61E-09 8.15E-07 
IGHV5-51 -4.190415774 2.67E-09 8.25E-07 
IGHV3-53 -4.285604523 2.83E-09 8.64E-07 
Z98257.1 -4.611997509 3.12E-09 9.40E-07 
IGHV3-13 -4.559220279 3.23E-09 9.63E-07 
IGHV3-74 -3.798569278 3.51E-09 1.03E-06 
IGKV1-8 -4.511649081 3.59E-09 1.04E-06 
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BATF -2.233504043 3.89E-09 1.10E-06 
MS4A1 -4.594789441 4.66E-09 1.31E-06 
IGHV1-69 -4.740351055 4.92E-09 1.36E-06 
IGHV3-33 -4.088673951 5.17E-09 1.42E-06 
IGHG4 -3.915188757 5.24E-09 1.42E-06 
IGHA1 -3.662656219 5.33E-09 1.44E-06 
PSORS1C2 -5.07718539 5.50E-09 1.45E-06 
IGLV2-11 -4.057478571 5.47E-09 1.45E-06 
TNFRSF17 -4.229034664 6.62E-09 1.71E-06 
ADAM8 -2.079057105 6.78E-09 1.74E-06 
IGKV1-27 -4.122472455 7.04E-09 1.77E-06 
AKR1C7P 3.519539221 7.01E-09 1.77E-06 
IGHV1-24 -4.223449976 7.44E-09 1.86E-06 
IGLV3-19 -4.125197608 7.53E-09 1.86E-06 
CASP14 -4.920166264 8.14E-09 1.99E-06 
MARCO -3.415982922 8.53E-09 2.07E-06 
IGHV3-15 -3.983471793 1.07E-08 2.56E-06 
HSD3B1 -8.686495164 1.18E-08 2.77E-06 
IGKV1D-8 -4.16993594 1.27E-08 2.93E-06 
IGLV2-14 -3.951523807 1.27E-08 2.93E-06 
CCL19 -3.872539929 1.29E-08 2.95E-06 
IGHV2-70 -4.777530223 1.32E-08 2.99E-06 
IGLC7 -4.784907278 1.39E-08 3.10E-06 
IGHG3 -3.760030035 1.49E-08 3.30E-06 
GSTM3 2.852639311 1.55E-08 3.41E-06 
CYP11A1 -4.364993228 1.63E-08 3.55E-06 
IGHM -3.848529616 1.68E-08 3.63E-06 
IGLON5 2.760245865 1.77E-08 3.79E-06 
IGKV1-17 -4.080905114 1.98E-08 4.21E-06 
IGKV4-1 -3.800526858 2.05E-08 4.29E-06 
PLA2G2D -4.401004745 2.25E-08 4.54E-06 
IGLV3-25 -3.959741974 2.25E-08 4.54E-06 
IGKV3-20 -3.781655209 2.26E-08 4.54E-06 
AKR1C3 3.685421864 2.22E-08 4.54E-06 
TCL1A -4.767287124 2.28E-08 4.54E-06 
IGLV3-9 -4.542915403 2.33E-08 4.60E-06 
PURG 2.504599315 2.35E-08 4.60E-06 
IGHD -4.537242165 2.75E-08 5.28E-06 
IGLV3-1 -4.091498122 2.73E-08 5.28E-06 
WNT5A 2.666281297 3.11E-08 5.92E-06 
IGLV2-8 -3.804384929 3.30E-08 6.21E-06 
GCLC 2.191739574 3.36E-08 6.27E-06 
IGLV7-43 -4.31551621 3.44E-08 6.37E-06 
IGHV2-26 -4.575212452 3.51E-08 6.47E-06 
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AKR1C1 4.015195925 3.59E-08 6.57E-06 
RDH16 -3.057532904 3.85E-08 6.99E-06 
SLC6A15 -4.482555654 3.92E-08 7.08E-06 
DCC 2.657676922 4.09E-08 7.34E-06 
CLDN9 -4.464375129 4.72E-08 8.35E-06 
OLR1 -3.307594025 4.70E-08 8.35E-06 
ADGRB1 2.918830918 4.84E-08 8.51E-06 
CXCL11 -3.676896029 5.28E-08 9.24E-06 
IGLV8-61 -3.916609122 5.34E-08 9.28E-06 
MRAP2 3.135527411 5.50E-08 9.44E-06 
SLC1A3 -2.269572772 5.80E-08 9.89E-06 
PNMA5 -5.808211324 6.20E-08 1.04E-05 
CALB1 -5.445055205 6.26E-08 1.04E-05 
AC145207.8 2.589246254 6.19E-08 1.04E-05 
OSGIN1 2.572477271 6.32E-08 1.04E-05 
SPP1 2.905648472 6.47E-08 1.06E-05 
AC099329.2 -4.261058083 6.65E-08 1.08E-05 
IGHV1-18 -3.828580817 6.86E-08 1.10E-05 
ABCC6 2.045702066 6.94E-08 1.11E-05 
IGHV4-61 -3.974252899 7.23E-08 1.14E-05 
AC243965.2 2.285957141 7.25E-08 1.14E-05 
CCL18 -3.122827201 7.82E-08 1.23E-05 
IGKV1OR2-11 -3.853121871 8.29E-08 1.27E-05 
IGLV5-45 -3.853033151 8.27E-08 1.27E-05 
LINC02476 -6.331594411 8.80E-08 1.32E-05 
IGHV2-5 -4.431663787 8.76E-08 1.32E-05 
NUDT10 3.158042403 8.79E-08 1.32E-05 
IGHV1-2 -4.032902281 9.21E-08 1.37E-05 
IGKV3D-20 -4.089709997 9.31E-08 1.38E-05 
IGKV2D-29 -4.193834518 1.02E-07 1.48E-05 
TRIM16L 2.200077972 1.03E-07 1.49E-05 
ZNF350-AS1 -3.667678541 1.04E-07 1.50E-05 
CDH4 2.24592075 1.11E-07 1.59E-05 
CHI3L2 -3.154296253 1.16E-07 1.66E-05 
TSPAN7 3.474874076 1.18E-07 1.68E-05 
IGKV5-2 -4.900695335 1.26E-07 1.73E-05 
IGHV3-20 -4.545289391 1.25E-07 1.73E-05 
CR2 -4.451356831 1.25E-07 1.73E-05 
IGKV1D-16 -4.090914477 1.36E-07 1.86E-05 
ADAM23 3.15238359 1.36E-07 1.86E-05 
UNC13D -2.025552847 1.38E-07 1.87E-05 
IGHA2 -3.44484748 1.40E-07 1.89E-05 
CD79A -3.393291359 1.41E-07 1.89E-05 
IGKV2-24 -3.683189365 1.42E-07 1.91E-05 
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ALPP -4.528818271 1.46E-07 1.94E-05 
U62317.2 -2.519633091 1.46E-07 1.94E-05 
SERPINA1 -2.831313136 1.66E-07 2.17E-05 
IGHV4-28 -4.082377622 1.68E-07 2.19E-05 
MEG9 3.1557138 1.71E-07 2.21E-05 
MIA -4.307857977 1.73E-07 2.22E-05 
LINC01217 -3.463209984 1.78E-07 2.28E-05 
IGKV1-6 -3.904685601 1.79E-07 2.28E-05 
SLC17A7 2.5466855 1.81E-07 2.30E-05 
LINC01510 4.971065592 1.90E-07 2.40E-05 
AC104024.2 -3.119675821 1.94E-07 2.43E-05 
CYSRT1 -2.722138201 1.95E-07 2.43E-05 
AL158206.1 -2.366120914 1.98E-07 2.46E-05 
IGKV3D-15 -4.255807882 2.12E-07 2.63E-05 
IGHV3-23 -3.65185603 2.36E-07 2.90E-05 
FAM30A -3.388262596 2.44E-07 2.98E-05 
JAKMIP3 3.239657502 2.44E-07 2.98E-05 
DHRS2 -3.670406363 2.71E-07 3.29E-05 
FOXJ1 -4.249645248 2.77E-07 3.34E-05 
COLCA1 3.659015226 2.82E-07 3.39E-05 
FCRL2 -3.769788284 2.83E-07 3.40E-05 
U62317.5 -2.342949961 2.95E-07 3.52E-05 
HLA-DQB1 -2.42754085 3.00E-07 3.56E-05 
PDZD4 2.390140527 3.06E-07 3.62E-05 
ALDH3A1 4.406257915 3.11E-07 3.66E-05 
SNCB 2.746166015 3.15E-07 3.69E-05 
FMO1 -2.257838419 3.22E-07 3.76E-05 
WIF1 5.339570193 3.25E-07 3.78E-05 
ZBP1 -2.781142182 3.36E-07 3.89E-05 
HMCN1 2.605673032 3.56E-07 4.10E-05 
IGKV1-39 -4.88667974 3.88E-07 4.44E-05 
AKR1C6P 2.79456123 4.00E-07 4.55E-05 
IGHV4-55 -3.865513931 4.12E-07 4.65E-05 
IGHJ3 -3.978510246 4.17E-07 4.69E-05 
MAFA-AS1 3.616933709 4.27E-07 4.79E-05 
PELI2 2.037901701 4.38E-07 4.89E-05 
AXDND1 3.098808147 4.41E-07 4.90E-05 
IGHV3-43 -3.748578599 4.68E-07 5.18E-05 
AC245369.1 -5.047694076 4.80E-07 5.29E-05 
S100A7 -4.789957997 4.83E-07 5.30E-05 
AC002401.4 -3.224334541 5.33E-07 5.83E-05 
EPYC -3.857963738 5.40E-07 5.88E-05 
IGHV3-64 -4.663354455 5.49E-07 5.90E-05 
NETO1 -3.900694596 5.45E-07 5.90E-05 
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AL589765.4 -2.031764913 5.47E-07 5.90E-05 
KRT7 -3.117695751 5.74E-07 6.15E-05 
XDH -2.456116724 6.08E-07 6.50E-05 
UCA1 -3.709735465 6.15E-07 6.54E-05 
MC4R 4.060506937 6.32E-07 6.70E-05 
AC008760.2 -2.919388044 6.35E-07 6.70E-05 
HLA-DQA1 -2.441186406 6.50E-07 6.81E-05 
OASL -2.143376214 6.70E-07 6.99E-05 
IGKV3D-11 -3.854491869 6.73E-07 7.00E-05 
TDRKH-AS1 -2.135567015 6.90E-07 7.15E-05 
ADRA2C 3.09714452 7.13E-07 7.32E-05 
IGHV6-1 -3.819575394 7.40E-07 7.58E-05 
ACKR3 2.228141088 7.67E-07 7.80E-05 
RORC -3.002175362 7.75E-07 7.85E-05 
IGKV1D-43 -4.980553933 8.22E-07 8.21E-05 
IGLL5 -3.310875072 8.23E-07 8.21E-05 
JSRP1 -2.771611329 8.27E-07 8.23E-05 
HLA-DRB1 -2.160113346 8.51E-07 8.38E-05 
PRSS2 -5.463202261 8.65E-07 8.45E-05 
MEG3 2.522739914 8.68E-07 8.45E-05 
LILRA5 -2.175798862 8.89E-07 8.62E-05 
MAP2 2.644599616 8.96E-07 8.66E-05 
SHC3 -2.495696843 9.01E-07 8.68E-05 
LEP -4.232114608 9.26E-07 8.86E-05 
CHI3L1 -2.557061024 9.58E-07 9.09E-05 
RNASE7 -3.342775421 9.64E-07 9.13E-05 
SAMD5 2.510022122 9.75E-07 9.20E-05 
TFF1 -4.431231031 1.01E-06 9.45E-05 
IGHV3-49 -3.647023259 1.03E-06 9.65E-05 
RNF223 -2.396561802 1.04E-06 9.66E-05 
IGKV2D-40 -4.420189754 1.10E-06 0.000101 
IGLV9-49 -4.03216802 1.11E-06 0.000102 
IGKV2-28 -5.413517447 1.13E-06 0.000104 
IGHV1OR15-2 -4.32137214 1.14E-06 0.000104 
IGLV2-18 -3.656096422 1.16E-06 0.000105 
AC005481.1 3.140699355 1.16E-06 0.000105 
FAM43B 2.705416616 1.21E-06 0.00011 
SAA1 -3.556609461 1.24E-06 0.000112 
GCK 2.130385994 1.28E-06 0.000115 
FAM189A1 3.808996804 1.30E-06 0.000117 
HHIPL2 3.343226919 1.33E-06 0.000118 
SP9 4.707113362 1.33E-06 0.000118 
IFIT2 -2.059645199 1.41E-06 0.000125 
C4BPB -4.001179458 1.56E-06 0.000137 
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IGLV1-50 -4.164943431 1.57E-06 0.000138 
TNFRSF13B -3.365084153 1.62E-06 0.000142 
IGLV4-60 -3.999755816 1.67E-06 0.000145 
AC097478.1 -3.920026207 1.79E-06 0.000154 
CHGA 3.219022991 1.81E-06 0.000154 
CCDC189 2.040241829 1.83E-06 0.000155 
AC108865.2 4.07207284 1.83E-06 0.000155 
AL512488.1 -2.864639392 1.96E-06 0.000165 
BLK -3.49231898 2.00E-06 0.000168 
XK -2.321419741 2.01E-06 0.000169 
NOTUM 2.557089401 2.04E-06 0.000171 
NAA11 -7.19357506 2.11E-06 0.000175 
OLFM1 2.530691885 2.11E-06 0.000175 
IL2RG -2.284692837 2.19E-06 0.000182 
KRT71 -2.860784412 2.22E-06 0.000183 
AC004233.3 -2.888803083 2.26E-06 0.000185 
ART4 -4.26111962 2.30E-06 0.000188 
MACROD2 -2.70670238 2.31E-06 0.000188 
SPIB -3.117959117 2.34E-06 0.000189 
ACER2 -2.461444367 2.40E-06 0.000194 
IFNG-AS1 -4.536727253 2.44E-06 0.000196 
IGHV4-59 -3.500234613 2.45E-06 0.000196 
IFNL1 -3.828043162 2.49E-06 0.000198 
TRPV6 -3.352466475 2.52E-06 0.000201 
LINC02364 -2.569387711 2.60E-06 0.000206 
AL353150.1 -2.559225587 2.71E-06 0.000213 
FCRL3 -2.653941528 2.91E-06 0.000228 
NMRAL2P 3.764391752 2.91E-06 0.000228 
CXCL9 -2.809712227 2.98E-06 0.000233 
PLA2G2F -3.790653271 3.02E-06 0.000235 
IGKV2-30 -3.509969824 3.15E-06 0.000244 
TH -3.607600334 3.19E-06 0.000245 
AL354798.1 2.052380851 3.21E-06 0.000246 
SAA2-SAA4 -3.770883799 3.24E-06 0.000247 
VGLL1 -3.295312002 3.46E-06 0.000261 
CHRNA1 -2.692618896 3.45E-06 0.000261 
RSAD2 -2.15195298 3.64E-06 0.000269 
TMEM155 2.426861618 3.74E-06 0.000276 
IGLV3-16 -4.370871874 3.84E-06 0.000282 
DPYSL4 2.724756024 3.99E-06 0.000291 
IL27 -2.29419433 4.00E-06 0.000292 
LINC00520 -3.33690998 4.11E-06 0.000299 
LINC01699 3.917989925 4.21E-06 0.000304 
NAT8B -2.715175274 4.22E-06 0.000304 
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LINC02006 -2.771046541 4.25E-06 0.000305 
TBC1D27 -3.276295749 4.30E-06 0.000308 
AC107294.2 2.005776291 4.53E-06 0.000324 
NTRK2 3.346105561 4.69E-06 0.000335 
AC133644.2 -2.791104145 4.87E-06 0.000347 
C4orf26 -3.50961947 5.10E-06 0.000361 
TMPRSS3 -2.744700775 5.35E-06 0.000376 
ART3 -2.934830961 5.38E-06 0.000377 
HLA-DRB5 -2.144356022 5.45E-06 0.000379 
NPR3 2.381435421 5.45E-06 0.000379 
AC107294.1 2.175279368 5.56E-06 0.000385 
CFAP46 2.435183197 5.59E-06 0.000386 
GPAT2 -2.972212805 5.85E-06 0.000401 
C20orf144 -3.863455642 5.88E-06 0.000402 
IGHV3-11 -3.246511133 6.07E-06 0.000413 
STEAP4 -2.391226269 6.11E-06 0.000415 
AC093865.1 2.939426835 6.17E-06 0.000418 
KRT20 -4.313072903 6.23E-06 0.000421 
CYP2A6 3.736515844 6.30E-06 0.000423 
TRHDE-AS1 -4.012900415 6.47E-06 0.000431 
DMBT1 -3.787239899 6.45E-06 0.000431 
DYNLL1P4 2.788290055 6.54E-06 0.000435 
SYT12 -2.688442626 6.64E-06 0.00044 
KRT18P8 -2.243560277 6.76E-06 0.000446 
AC105118.1 3.323294677 6.82E-06 0.000447 
ADIPOQ -6.988353189 6.88E-06 0.00045 
CTSE -3.671316797 6.97E-06 0.000454 
FOLR1 -3.476689768 7.21E-06 0.000466 
KRT7-AS -3.230311027 7.41E-06 0.000478 
TRHDE -3.755523413 7.51E-06 0.000483 
IGHV1OR15-9 -4.1715302 7.56E-06 0.000484 
CATSPER1 -2.530524808 7.57E-06 0.000484 
SLC7A11 2.914189747 7.93E-06 0.000504 
COL11A1 -2.714937965 8.04E-06 0.00051 
AL512625.3 -3.134474695 8.08E-06 0.000511 
IL24 -2.441989635 8.49E-06 0.000531 
CRCT1 -4.042030662 8.60E-06 0.000537 
LINC01423 -5.691929294 8.71E-06 0.000542 
MCHR1 -2.264697885 9.02E-06 0.00056 
IGLV5-37 -5.255888548 9.08E-06 0.000562 
AC103563.3 -4.461730996 9.24E-06 0.000569 
IGHV3-7 -3.549841812 9.24E-06 0.000569 
IGLV1-41 -3.590897066 9.40E-06 0.000575 
CYP4F11 3.126450534 9.54E-06 0.000582 
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NCF1B -2.403315486 9.66E-06 0.000587 
AC023301.1 -3.79656028 9.87E-06 0.000598 
IGLV2-28 -4.467610722 1.03E-05 0.000621 
AL162414.1 -4.389585577 1.06E-05 0.000634 
SMIM6 -2.840453254 1.07E-05 0.000638 
LINC00462 -2.722934429 1.08E-05 0.000642 
LINC00944 3.7688567 1.11E-05 0.000659 
UPK2 -3.329143445 1.12E-05 0.000661 
HMGB2P1 -2.818504083 1.15E-05 0.000674 
TMEM53 -2.725976123 1.20E-05 0.000699 
ADTRP -2.230311494 1.20E-05 0.0007 
IGHV3-72 -3.115045697 1.24E-05 0.000718 
C11orf87 4.495360229 1.28E-05 0.00074 
RARRES3 -2.199135859 1.30E-05 0.000749 
AC012414.5 2.594067044 1.34E-05 0.000769 
LILRB4 -2.079000594 1.36E-05 0.000777 
EXOC3L4 -2.538895026 1.40E-05 0.000795 
IGKV1D-13 -4.176212316 1.43E-05 0.000809 
NR0B1 6.062678099 1.46E-05 0.000822 
ZSCAN4 -3.141519179 1.47E-05 0.000827 
AC090826.2 -3.561683743 1.51E-05 0.000845 
PRSS27 -2.128996309 1.52E-05 0.000848 
PLIN1 -3.241143938 1.53E-05 0.000849 
RARRES2 -2.106966613 1.53E-05 0.000849 
AL391427.1 3.038048781 1.55E-05 0.000857 
TRBV10-3 -3.531245199 1.56E-05 0.000858 
SALL1 2.498939369 1.59E-05 0.000871 
NRIR -2.154233013 1.60E-05 0.000872 
NCF1 -2.053745213 1.60E-05 0.000872 
LINC00518 -2.875492657 1.60E-05 0.000872 
UBD -2.83076893 1.65E-05 0.000896 
MIR3945HG -2.627557766 1.65E-05 0.000896 
CCL17 -2.226654069 1.67E-05 0.000902 
NMNAT2 -2.192891291 1.70E-05 0.000915 
AL355796.1 3.038633732 1.73E-05 0.000926 
UPK3B -2.837833778 1.82E-05 0.00097 
RXFP1 -2.640101022 1.87E-05 0.00099 
PLPPR3 3.131927707 1.87E-05 0.00099 
 
Table 7.22: List of significantly altered genes between GLI2-high and GLI2-low 




Appendix xv: Unix shell/R scripts  
FastQC script (Unix) 
#!/bin/sh 
## qsub –N submission_name ./RNAseq_fastqc.sh /path/fastq 
# Grid Engine options 
#$ -cwd 
#$ -l h_rt=1:00:00 
#$ -l h_vmem=2G 
#$ -V 
#$ -R y 
#$ -pe smp 4 
#$ -j y 
#$ -o /dev/null 
Export MALLOC_ARENA_MAX=4 
# Load modules 
Module load fastqc/0.11.5 
# Generate outname variable  
Outname=`echo $1 | rev | cut –d’/’ –f1 | rev | cut –d. –f1` 
Outdir=`pwd` 
# run fastqc 





Trimmomatic script (Unix) 
#!/bin/sh 
## qsub –N submission_name ./RNAseq_trimming.sh 
/path/read1.fastq.gz/path/read2.fastq.gz 
# Grid engine options  
#$ -cwd 
#$ -l h_rt=8:00:00 
#$ -l h_vmem=2G 
#$ -R y 
#$ -pe smp 9 
#$ -j y 
#$ -V 
## -o /dev/null 
Export MALLOC-ARENA_MAX=4 
vmArgs=” -Xmx1G –XX:ParallelGCThreads=9” 
# Load modules 
module load fastqc/0.11.5 
# Generate outname variable 
outname=`echo $1  | rev  | cut –d’/’ –f1  | rev  | cut –d. –f1  | sed ‘s/_read1//g’  | sed 
‘s/_read2//g’’ 
# Run trimmomatic  
# generate output files for the paired data, and also the reads which were binned, 
resulting in their pairs being binned (UP, orphan reads) 
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#Use a given file of adapters etc taken from from the FASTQC output and use palindromic 
trimming to get contamination on the other read in the pair 
# enabling 2 mismatches, match must get a score of 30 
# use a sliding window approach to check quality, average in 4bp windows if the quality 
drops below 20, trims the read 
# remove read if length drops below 49 (arbitrary threshold, mapping should still work 
down to ~25bp) 
java $vmArgs –jar $TRIMMOMATIC-JAR PE –phred33 $1 $2 ${outname}_read1-PE.fastq.gz 
${outname}_read1=UP.fastq.gz ${outname}_read2-PE.fastq.gz 
${outname}_read2.UP.fastq.gz \ ILLUMINACLIP:/scratch/RNAseq_adapters_list.fa:2:30:10 \ 
SLIDINGWINDOW: 4 :20 MINLEN : 49 
#for i in ${outname}_read1-PE.fastq.gz ${outname}_read1-UP.fastq.gz ${outname}_read2-
PE.fastq.gz ${outname}_read2.UP.fastq.gz; do echo”`zcat $i | wc -1` /4” | bc; done 
# perform new fastqc of PE read 1 to confirm improvement  













Pseudo read assignment script (Unix) 
#!/bin/sh 
##qsub –N submission_name ./RNAseq_05_pre-kallisto_read_manipulation_GE.sh 
/path/sample 
# Grid Engine options 
#$ -cwd 
#$ -l h_rt=3:00:00 
#$ -l h_vmem=2G 
#$ -R y 
#$ -j y 
#$ -V 
# -o /dev/null 
# define outnames – those from the original read1 file which are now unpaired, need 
pseudo mates (which will be read2 reads) and vice versa 
read1UPmatch=`echo $1 | rev | cut –d’/’ –f1 | rev`”_pseudo_read2.fastq” 
read2UPmatch=`echo $1 | rev | cut –d’/’ –f1 | rev`”_pseudo_read1.fastq” 
# iterate through headers in read1UP and generate pseudoread2 





# iterate through headers in read2UP and generate pseudoread1 







# create composite read1 then read2 files  
samplename=`echo $1  | rev  | cut –d’/’ –f1  | rev` 
cat $1”_read1-PE.fastq.gz” $1”_read1-UP.fastq.gz” $read2UPmatch”.gz” > $samplename”-
merged_read1.fastq.gz” 
cat $1”_read2-PE.fastq.gz” $1read1-UPmatch”.gz” $1”_read2-UP.fastq.gz” > 
$samplename”-merged_read2.fastq.gz” 
# remove the pseudo files 















Kalisto script (Unix) 
#!/bin/sh 
## qsub –N submission_name ./RNAseq_kallisto_mapping.sh 
/path/read_pseudo/path/index_file 
# Grid Engine options 
#$ -cwd 
#$ -l h_rt=08:00:00 
#$ -l h_vmem=2G 
#$ -R y 
#$ -j y 
#$ -V 
#$ -pe smp 9 
# -o/dev/null 
# Load modules 
module load kallisto/0.44.0 
# Generate outname variable 
basename=`echo $1 | sed ‘s/-merged//g’ | rev | cut –d’/’ –f1 | rev` 
# Run kallisto quantification 
# 100 bootstraps given for technical repeats when analysing by sleuth 
# also the – fusion flag for detecting fusion genes 
kallisto quant --index $2 –fusion –output-dir=${basename} –threads 8 –bootstrap-









>mart <- useEnsembl(biomart="ensembl", dataset="hsapiens_gene_ensembl") 
>t2g <- biomaRt::getBM(attributes = c("ensembl_transcript_id", "transcript_version", 
"ensembl_gene_id", "external_gene_name"), mart = mart) 
>t2g2 <- dplyr::select(t2g, ensembl_transcript_id, external_gene_name) 
 
>setwd("path") 
>files <- list.files(".","tsv$") 
>names(files) <- gsub("_abundance.tsv", "", files) 
 


















# create gene level database 
>mart <- biomaRt::useMart(biomart = "ENSEMBL_MART_ENSEMBL", dataset = 
"hsapiens_gene_ensembl", host = 'ensembl.org') 
>t2g <- biomaRt::getBM(attributes = c("ensembl_transcript_id", "transcript_version", 
"ensembl_gene_id", "external_gene_name"), mart = mart) 
>t2g <- dplyr::select(t2g, target_id = ensembl_transcript_id, ens_gene = ensembl_gene_id, 
ext_gene = external_gene_name) 
 
# set working directory (directory where the individual file folders are) and load sample 
file 
>setwd(PATH) 
>s2c <- read.table("sample_info.txt", header=TRUE, stringsAsFactors=FALSE) 
 
# one variable (group vs group - "express") 
>so <- sleuth_prep(s2c, ~express, extra_bootstrap_summary=TRUE, num_cores=1, 
target_mapping=t2g, transformation_function = function(x) log2(x+1.5), gene_mode=TRUE, 
aggregation_column = 'ext_gene') 
>so <- sleuth_fit(so, ~express, 'full') 
>so <- sleuth_wt(so, 'express') 
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# two variables (group vs group but control for donor - "biorep") 
>so <- sleuth_prep(s2c, ~express + biorep, extra_bootstrap_summary=TRUE, num_cores=1, 
target_mapping=t2g, transformation_function = function(x) log2(x+1.5), gene_mode=TRUE, 
aggregation_column = 'ext_gene') 
>so <- sleuth_fit(so, ~express + biorep, 'full') 
>so <- sleuth_fit(so, ~biorep, 'reduced') 
>so <- sleuth_lrt(so, 'reduced', 'full') 














DESeq2 script (R) 
>if (!requireNamespace("BiocManager", quietly = TRUE)) 




#Read in TCGA counts "cts" data 
>cts <- as.matrix(read.csv("counts_data.txt" ,sep="\t",row.names="gene_id")) 
>head(cts) 
#Read in new groupings 
>groups = read.table("DESeq_groups_file.txt", header = FALSE) 
>colnames(groups) = c("id", "variable") 
# head(groups) to check correct format 
>groups$id <- as.factor(groups$id) 
>groups$variable <- as.factor(groups$variable) 
>coldata <- groups[,c("id","variable")] 
>rownames(coldata) = coldata$id 
>head(cts,2) 
>head(coldata) 
#Check if all row/col names in cts and coldata match - should return "TRUE" 




#Check if all row/col names in cts and coldata are sorted in the same way – may return 
“TRUE/FALSE” 
>all(rownames(coldata) == colnames(cts)) 
#If needed (ie FALSE above): Sort cts based on rownames in coldata 
>cts <- cts[, rownames(coldata)] 
# If needed: Re-check if all row/col names in cts and coldata are sorted in the same way - 
must return "TRUE" 
>all(rownames(coldata) == colnames(cts)) 
#Build a DESeqDataSet 
>library("DESeq2") 
>dds <- DESeqDataSetFromMatrix(countData = cts, 
                              colData = coldata, 
                              design = ~ variable) 
>dds 
#Pre-filtering - remove rows with fewer than 404 counts (ie 1 per sample) 
>keep <- rowSums(counts(dds)) >= 404 
>dds <- dds[keep,] 
>dds 
#Choose reference or "control" group - default is group 1 which from the 
dendrogram_cut might be a hi/lo group 
>dds <- dds[, dds$variable %in% c("0","1")] 





# Differential expression analysis 
>dds <- DESeq(dds) 
>res <- results(dds) 
>res 
#Write results table for Excel 
>write.table(res, "results_file_name.txt", sep="\t") 
 
EnhancedVolcano script (R) 
#complete DEG analyses by DESeq2 then run this code on res function 
>if (!requireNamespace('BiocManager', quietly = TRUE)) 




                lab = rownames(res), 
                x = 'log2FoldChange', 
                y = 'pvalue', 
                xlim = c(-10, 10),  
                title = 'name_of_analysis', 
                FCcutoff = 2, 
                pCutoff = 0.0038, 
                pointSize = 1.0, 
                labSize = 4.0, 
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                col=c('grey', 'black', 'blue', 'red3'), 
                legendPosition = 'bottom', 
                legendLabSize = 16, 
                legendIconSize = 5.0, 
                boxedLabels = TRUE, 
                drawConnectors = TRUE, 
                widthConnectors = 0.2, 
                colConnectors = 'black', 
                gridlines.major = FALSE, 
                gridlines.minor = FALSE, 














fgsea script (R) 
#complete DEG analyses by DESeq2 then run this code on res function 
>res <- results(dds, tidy = TRUE) 
>readr::write_csv(res, path="deseq2_results_file.csv") 
>library(tidyverse) 
>res <- read_csv("deseq2_results_file.csv") 
>res 
# remove other data from res function, leaving only row and stat columns 
>res2 <- res %>%  
  >dplyr::select(row, stat) %>%  
  na.omit() %>%  
  distinct() %>%  
  group_by(row) %>%  
  summarize(stat=mean(stat)) 
>res2 
#install and load fgsea 
>if (!requireNamespace("BiocManager", quietly = TRUE)) 




#create tibble of named vector of test statistics 




# load pathways downloaded from MsigDB website 
>pathways.hallmark <- gmtPathways(“c2.cp.biocarta.v7.2.symbols.gmt”) 
#Show first few pathways with first few genes only 
>pathways.hallmark %>%  
  head() %>%  
  lapply(head) 
# run fgsea algorithm with 1000 permutations and tidy results 
>fgseaRes <- fgsea(pathways=pathways.hallmark, stats=ranks, nperm=1000) 
>fgseaResTidy <- fgseaRes %>% 
  as_tibble() %>% 
  arrange(desc(NES)) 
# install DT table package 
>install.packages(‘DT’) 
#Display results in DT table 
>fgseaResTidy %>%  
  dplyr::select(-leadingEdge, -ES, -nMoreExtreme) %>%  
  arrange(padj) %>%  
  DT::datatable() 
# Plot normalised enrichment scores 
>ggplot(fgseaResTidy, aes(reorder(pathway, NES), NES)) + 
  geom_col(aes(fill=padj<0.05)) + 
  coord_flip() + 
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  labs(x="Pathway", y="Normalized Enrichment Score", 
       title="Hallmark pathways NES from GSEA") +  
  theme_classic() 
#display tibble showing gene q values and what hallmark gene set they enrich 
>pathways.hallmark %>%  
  enframe("pathway", "row") %>%  
  unnest() %>%  
  inner_join(res, by="row") %>% 
  arrange(padj)  
#plot GSEA table plot 
>topUp <- fgseaResTidy %>%  
  filter(ES > 0) %>%  
  top_n(10, wt=-padj) 
>topDown <- fgseaResTidy %>%  
  filter(ES < 0) %>%  
  top_n(10, wt=-padj) 
>topPathways <- bind_rows(topUp, topDown) %>%  
  arrange(-ES) 
>plotGseaTable(pathways.hallmark[topPathways$pathway],  
              ranks,  
              fgseaResTidy,  




prcomp/ggbiplot script (R) 
>library(“devtools”) 
# Load programs 
>install_github("vqv/ggbiplot") 
>library(ggbiplot) 
# Run PCA on dataset (change number of columns to number of genes being analysed) 
>genes.pca <- prcomp(file_name[, c(2:10)], center = TRUE, scale = FALSE) 
#Show % of principle components in data 
>summary(genes.pca) 
# Create group of sample subtypes  
>Subtype <- as.factor(file_name$Subtype[1:21]) 
# Add classifications and ellipses to PCA 
>g <- ggbiplot(genes.pca, obs.scale = 1, var.scale = 1, groups = Subtype, ellipse = TRUE, 
label.repel = TRUE)  
# Assign specific colours to Subtypes 
>cols <- c("group1" = "green", "group2" = "darkgreen", "group3" = "violet", "group4" = 
"red", "group5" = "yellow3", "group6" = "blue") 
>g <- g + scale_color_manual(values = cols) 
>g <- g + theme(legend.direction = 'horizontal', legend.position = 'top') 
# Display PCA and remove grey background 






List of used acronyms 
Acronym Full name 
ABS Adult Bovine Serum 
ACTA2  α-Smooth muscle actin 
ANOVA One-way Analysis of Variance 
ARID1A AT-rich interactive domain-containing 
protein 1A 
AUM Asymmetric Unit Membrane 
Ba/Sq Basal/Squamous 
BCG  Bacillus Calmette-Guérin 
BCS Bovine calf serum 
BrdU Bromodeoxyuridine 
cDNA complementary DNA 
CGN Cingulin 
CIS Carcinoma in situ 
CK Cytokeratin 
Ct Cycle threshold 
DAB 3,3'Diaminobenzidine 
DBD DNA-Binding Domain 
DEPC Diethylpyrocarbonate 
DES Desmin 
DMEM Dulbecco’s Modified Eagle’s Medium  
DTT Dithiothreitol 
ECM Extracellular Matrix 
EDTA Ethylenediaminetetra-acetic acid  
EGF Epidermal Growth Factor 
EGFR EGF Receptor 
ELF3 ETS-related transcription factor 3 
ER Endoplasmic Reticulum 
ERK1/2 Extracellular signal-regulated kinase 
FAIREseq Formaldehyde-Assisted Isolation of 
Regulatory Elements coupled with next-
generation sequencing 
FBS Fetal Bovine Serum 
FFPE Formalin-Fixed, Paraffin-Embedded 
FGF Fibroblast Growth Factor 
FGFR FGF Receptor 
FOXA1 Forkhead Box A1 
FR180 FR180204 
GaM Goat anti-Mouse 
GaR Goat anti-Rabbit 
GLI Glioma-associated oncogene 
GSEA Gene Set Enrichment Analysis 
GSK3β Glycogen Synthase Kinase 3 Beta 
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HIER Heat-Induced Epitope Retrieval 
hpo Hippo 
IGF-1 Insulin Growth Factor-1 
IHC Immunohistochemistry 
IRF-1 Interferon Regulatory Factor-1 
KSFMc Keratinocyte Serum-Free Medium 
(complete) 
LDS Lithium Dodecyl Sulfate  
lncRNA long non-coding RNA 
LTR Long terminal repeat 
LumNS Luminal Non-Specific 
LumP Luminal Papillary 
LumU Luminal Unstable 
LY LY294002 
MEK1/2 Mitogen-activated protein kinase kinase 
MIBC Muscle-Invasive Bladder Cancer 
MW Microwave method (IHC) 
NbHS Normal (bladder-derived) Human Stromal 
NE Neuroendocrine-like 
NHU Normal Human Urothelial 
NMIBC Non-Muscle-Invasive Bladder Cancer 
NuHS Normal (ureter-derived) Human Stromal 
PAGE Polyacrylamide Gel Electrophoresis 
PBS Phosphate-Buffered Saline 
PC Pressure cooker method (IHC) 
PD PD153035 
PD98 PD98059  
PI3K Phosphoinositide 3-Kinase 
POU5F1 OCT4 
PPARγ Peroxisome proliferator-activated receptor 
gamma 
PPRE PPAR Response Elements 
PTCH1 Patched 1 
PTPRC CD45 
PVDF Polyvinylidene Difluoride  
RB Retinoblastoma protein 
RHOA Ras homolog family member A 
RNAseq RNA sequencing 
ROS Reactive Oxygen Species 
RT+/- Reverse Transcriptase  
RTK Receptor Tyrosine Kinase 
RT-PCR Reverse Transcription Polymerase Chain 
Reaction  
RT-qPCR Quantitative Reverse Transcription 
Polymerase Chain Reaction  
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RXRα Retinoid X Receptor Alpha 
sav Salvador 
sd Scalloped 
SDS Sodium Docecyl Sulfate 
SHH Sonic Hedgehog 
shRNA short hairpin RNA 




TBS Tris-Buffered Saline 
TEER Transepithelial Electrical Resistance 
TGFβ Transforming Growth Factor Beta 
Tm Primer melting temperature 






wts  Warts 
WWTR1 Taz; transcriptional co-activator with PDZ 
binding motif 
YAP Yes-associated protein 
yki  Yorkie 
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